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Human Cytomegalovirus (HCMV), the prototypic β-herpesvirus, is the most 
common cause of congenital infections as well as morbidity and mortality in 
immunocompromised patients. The anti-HCMV drugs currently available have a 
number of drawbacks (i.e. detrimental side-effects and/or the appearance of drug-
resistant strains), which limit their clinical usefulness. Therefore, a better 
understanding of host-virus interactions is important to develop new, safe and 
effective ways to treat HCMV. HCMV has evolved various strategies to make the 
host cell more conducive for the replication process, many of these involve 
modulation of host signalling pathways through proteins or non-coding RNAs. The 
focus of this thesis is on the regulation of one class of non-coding RNA, microRNAs 
(miRNA) by HCMV as well as murine CMV (MCMV). miRNAs are short ~22 
nucleotide RNA sequences, which negatively regulate the stability and translational 
efficiency of specific target messenger RNAs (mRNAs). It has been previously 
shown that three host-encoded miRNAs, miR-199-3p, miR-199-5p and miR-214, are 
down-regulated in both MCMV and HCMV infected cells. Despite the biological and 
genomic differences between the two viruses, this down-regulation occurs in both 
infections, suggesting a possible conserved antiviral role of the miRNAs in mouse 
and human cells. Consistent with this, miR-199-3p and miR-214 manifest antiviral 
properties against MCMV and HCMV when over-expressed in vitro. This thesis 
investigates two hypotheses: 1) CMV down-regulates the expression of these host 
miRNAs through a mechanism involving viral factors, 2) The down-regulation of 
miR-199-3p leads to the up-regulation of its targets and this influences the cell in a 
way that favours some aspect of the viral life cycle. The first part of this project 
examined the regulation of miR-199-3p, miR-199-5p, and miR-214, which derive 
from a single primary transcript (pri-miRNA). The down-regulation of all three 
miRNAs was found to occur at the transcriptional level by 4 hours post infection. 
The promoter of the miR-199a/214 cluster was therefore cloned into a reporter vector 
in order to interrogate the factors regulating transcription of pri-miRNA in infection; 
this was carried out in the murine model based on availability of reagents. The 
reduction in the pri-miRNA was found to correlate with a decrease in the 




revealed the presence of a sequence between -421 to -273 relative to the transcription 
start site (TSS) that was critical for promoter activity. This sequence contains a 
putative serum response element (SRE), which includes two binding sites for the 
SRF dimer (serum response factor) and a binding site for a molecule of TCF (ternary 
complex factor), ELK-1. Initial knock-down studies suggest that these transcription 
factors are required for basal activity but it remains unknown whether they are 
involved in the differential expression of miR-199a/214 observed during infection. 
Another binding site for the transcription factor TWIST-1 was found outside this 
region, which is known to regulate the miR-199a/214 cluster in other cell types. 
Western blot analysis showed reduced expression of TWIST-1 in cells infected with 
HCMV and MCMV infections, by 24 and 48 hours, respectively, suggesting a role of 
TWIST-1 in regulating miR-199a/214 cluster during these infections. This regulation 
seems to be dependent on viral gene expression, as a replication deficient viral 
mutant fails to repress the promoter function and subsequent pri-miRNA production. 
Taken together, these results suggest an active viral mechanism for transcriptional 
repression of the miR-199a/214 promoter. To understand the antiviral function of 
miR-199-3p, the second part of this thesis examined whether miR-199-3p regulates 
host signalling pathways important for CMV replication and/or the life cycle. A 
microarray analysis was carried out with samples from cells transfected with miR-
199-3p mimic versus inhibitor. This revealed 198 genes significantly down-regulated 
by the miRNA. From the 198 genes, Ingenuity pathway analysis (IPA) software 
identified several host pathways with a potential role in HCMV infection including: 
PI3K/AKT signalling, the ERK-MAPK cascade, and prostaglandin production. This 
thesis examined the role of miR-199-3p in regulating the PI3K/AKT pathway in 
HCMV infection. It was found that miR-199-3p modulates the phosphorylation of 
the central regulator of PI3K/AKT signalling, AKT. Transfection of miR-199-3p 
before the infection impedes the complete phosphorylation of AKT, which is known 
to be required for the immediate early viral gene expression and replication. This 
provides an explanation for the antiviral function of miR-199-3p, through its ability 
to modulate AKT phosphorylation. An open question, however, is how the natural 
down-regulation of miR-199-3p from 24 to 72 hours post infection naturally affects 




ITGA3, and ITGA6 were shown to be up-regulated at these late time points, 
correlating with the miR-199-3p down-regulation. The interaction of miR-199-3p 
with target sites in the 3′UTRs of PIK3CB and ITGA3 was validated by luciferase 
reporter assays and western blotting and qRT-PCR results indicated that protein and 
mRNA levels of ITGA6 were regulated by miR-199-3p mimic transfection. 
However, the knock-down of these three targets did not result in a significant 
decrease of the viral growth, and thus cannot alone explain the antiviral function of 
miR-199-3p. Overall, this study suggests that the transcriptional repression of miR-
199a/214 is likely a strategy employed by CMV to support its own growth through 
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1 General Introduction  
1.1 Herpesviridae ‘Family of Herpes viruses’: overview  
Herpesviridae are a significant cause of human diseases worldwide and are amongst 
the most disseminated and successful human pathogens, with specific viruses 
infecting more than 90% of the population (Tanaka-Taya et al. 1996). The 
Herpesviridae virus family is believed to have arisen from a common ancestral virus, 
at least 300 million years ago (Davison 1993). These viruses are relatively large 
(approximately 130-250 nm diameter), with an envelope surrounding the icosahedral 
capsid, enclosing a linear dsDNA genome (from 130 to 250 kb). In addition to these 
characteristics, Herpesviridae encode a group of enzymes involved in DNA 
replication (e.g. DNA-polymerase, DNA helicase-primase complex), nucleic acid 
metabolism (e.g. thymidine kinase), and protein processing and modification (e.g. 
protein kinases). Herpesviridae can also establish latent infections, enabling them to 
reside life-long in their hosts, during which time the virus enters a dormant phase. Its  
genome exists in a circular configuration within the cell nucleus and viral gene 
expression is almost suspended (Davison 2007). The family of Herpesviridae contain 
eight known human-pathogenic members, Herpes Simplex viruses 1 and 2 
(HSV1/HHV-1 and HSV2/HHV-2), Varizella Zoster virus (VZV/HHV-3), 
Cytomegalovirus (CMV/HHV-5), Human Herpes virus-6 (HHV-6), Human Herpes 
virus-7 (HHV-7), Epstein-Barr virus (EBV/HHV-4), and Karposi Sarcoma-
associated Herpes virus (KSHV/HHV-8) (Table 1.1). The current classification of 
Herpesviridae (2011) by the International Committee for the Taxonomy of Viruses 
(ICTV) has further divided this family into three subfamilies Alphaherpesvirinae, 
Betaherpesvirinae and Gammaherpesvirinae (http://www.ictvonline.org/index.asp) 
based on their specific biological properties, genetic content, genomic organisation 
and sequence alignment (Alba et al. 2001; Hannenhalli et al. 1995; Karlin et al. 1994; 
McGeoch et al. 1995; Montague and Iii 2000). The biological properties include the 
specificity of host and target cells for productive and latent infection in vivo, host cell 
tropism in vitro, the duration of virus replication and spread of infection (Roizman et 
al. 1992) (Table 1.2). The genome-wide sequence comparison between the 
subfamilies reveals at least 26 conserved open reading frames (ORFs) that encode 
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diverse genes required for replication, transcription or packaging of the viral genome, 
as well as those ORFs involved in the formation of virus structure, such as the 
nucleocapsid and glycoprotein spikes. The conserved ORFs comprise approximately 
a third of the identified viral proteins of Alpha and Gamma-herpes viruses, but not 
Beta-herpes viruses, owing to their larger genomes. This is particularly true in the 
case of Human Cytomegalovirus (HCMV), which encodes more than 200 ORFs 
(Table 1.1) (Alba et al. 2001). The Betaherpesvirinae HCMV belongs to the genera 
Cytomegalovirus and is the central focus of this thesis. 
  




SubFamily Virus  Acronyms ORF Length 
(Kb) 
Alphaherpes viruses     
α1 Human herpes virus 1 HSV-1/HHV1 77 152 
α1 Human herpes virus 2 HSV-2/HHV2 77 154 
α2 Human herpes virus 3 VZV/HHV3 71 124 
Betaherpes viruses     
β1 Human herpes virus 5 HCMV/HHV5 203 229 
β2 Human herpes virus 6a HHV6 A 121 159 
β2 Human herpes virus 6B HHV6 B 105 161 
β2 Human herpes virus 7 HHV7 107 144 
Gammaherpes viruses     
γ1 Human herpes virus 4 HHV-4/EBV 86 172 
γ2 Human herpes virus 8 HHV8/KSHV 82 137 
 
Table 1:1: The genomic characteristics and number of open reading 
frames (ORFs) of all human herpes viruses.  
 
Alphaherpesvirinae Betaherpesvirinae Gammaherpesvirinae 





Variable host range Limited host range Tend to be specific for either 
T or B lymphocytes 
Relatively short cycle Long cycle Short replication cycle 
Rapid spread of infection  Slow spread of 
infection  
 
Latent infection is maintained 
in sensory ganglia 
Site of latency is 
myeloid progenitor 
cells  
Site of latency is lymphoid 
tissue 
 
Table 1:2: A summary of biological characteristics used to define 
members of the three subfamilies of herpes viruses.   
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1.2 Biology of Human Cytomegalovirus  
Betaherpesvirinae includes two genera, Cytomegalovirus and Roselovirus, which 
includes HHV-6A, HHV-6B, and HHV-7. All exhibit a restricted host range and 
slow replication mechanism. Several species of Cytomegalovirus have been 
identified in distinct mammalian hosts, namely human, primates, and rodents. 
However, no cross-species infection has been identified, so a human virus cannot 
infect a mouse, or vice versa. The first isolation of HCMV was reported in 1956, 
from a dead infant with cytomegalic inclusion disease (Smith 1956). The virus was 
also subsequently isolated in two other laboratories, one from a patient with 
suspected varicella (Rowe et al. 1957) and another with suspected toxoplasmosis 
(Weller et al. 1957). In 1960, Weller et al. proposed that the virus be named 
‘Cytomegalovirus’ (Brennan 2001; Ho 2008).  
1.2.1  Virion Structure  
The structural properties of HCMV resemble that of the classic herpes viruses 
(Figure 1.1a,b). 
1. The envelope comprises a phospholipid bilayer derived from the infected cell 
that is impregnated with viral glycoproteins. The HCMV envelope includes a 
set of glycoprotein homologues, gB, gH, gL, gM and gN. These are essential 
for initial virus-host attachment, virus internalisation, and cell to cell viral 
transmission (Navarro et al. 1993; Gicklhorn 2003; Kinzler and Compton 
2005; Shimamura et al. 2006; Shen et al. 2007; Hobom et al. 2000; Keay and 
Baldwin 1991). Virion envelopes also contain another glycoprotein, gO. A 
gO gene deletion mutant of HCMV is viable but forms smaller plaques in 
fibroblast cells (Hobom et al. 2000). In addition, there are multiple HCMV 
specific glycoproteins, gp48, gpTRL10, gpTRL11, gpTRL12 and gpUL132, 
which are not considered essential for productive infection (Dunn et al. 
2003). HCMV also encodes a number of receptors known as G-protein-
coupled receptors (GPCRs) that are homologous to human chemokine 
receptors. These receptors (GPCRs), encoded by the ORFs, US27, US28, 
UL33, and UL78, are able to activate multiple cell signaling networks in a 
ligand-independent manner (Vischer et al. 2006). Some of these GPCRs, such 
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as UL78 and US27, have been shown to be important for viral entry in 
epithelial cells and its efficient extracellular spread, respectively (O’Connor 
and Shenk  2011; 2012).  
2. The capsid or nucleocapsid packages and maintains the viral genomic 
dsDNA. It has an icosahedral geometry shape and each icosahedral lattice is 
composed of pentons, hexons, and triplexes arranged in a triangulation 
number = 16 (T=16) (Butcher et al. 1998; Chen et al. 1999).  
3. The tegument is defined as the compartment between the capsid and the lipid 
envelope. Currently, 20 viral tegument proteins are known to assist with 
important functions in multiple events during the viral life cycle (Kalejta 
2008). For example, pp71, ppUL35, and pUL69 transactivate viral gene 
expression (Liu and Stinski 1992; Winkler et al. 1994; Schierling et al. 2004), 
pp65 and pIRS1/pTRS1 facilitate immune evasion (Browne and Shenk 2003; 
Abate et al. 2004; Child et al. 2004; Marshall et al. 2009), and  pp150 
supports the egress of viral particles at the final envelopment stage (AuCoin 
et al. 2006; Tandon and Mocarski 2008). This compartment also contains a 
total of 71 host cellular proteins, with cytoskeletal proteins, translational 
protein factors, signaling transduction protein 14-3-3 and intracellular 
vesicular trafficking proteins (Varnum et al. 2004). Moreover, cellular and 
viral mRNAs appear to be incorporated within the tegument domain 
presumably through non-specific interactions with several viral proteins such 
as tegument pp28 (Terhune et al. 2004). The proportions of different host 
RNAs within tegument are similar to those expressed in host cells, it 
therefore seems to be independent of either signal-specific or sequence-
specific mechanisms. A similar situation has been described for retroviruses, 
where RNA is packaged in virus particles and acts as a structural component 
promoting the integrity of the virion (Muriaux et al. 2001; Wang and 
Aldovini 2002).  
4. The HCMV genome, which consists of one molecule of linear dsDNA, ~ 220 
to ~ 240 kb in length, is the longest genome identified among animal viruses. 
The complete genome of nine strains of HCMV have been sequenced: 3157, 
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HAN13, HAN20, HAN38, JP and 3301, AD169, Towne, and Merlin 
(Cunningham et al. 2010; Dolan 2004; Bradley et al. 2009). The HCMV 
AD169 strain, isolated from a child’s adenoids in 1956 (Montague and Iii 
2000), is the virus strain used in this study. There are 208 ORFs in the 
prototypic reference strain of HCMV AD169 (Chee et al. 1990), however, 
extensive propagation in different laboratories over time has resulted in 
multiple mutations. In comparison to a low-passage strain virus, AD169 has 
mutation in genes TRL5A, TRL13, TRL14, UL36, UL131A, UL140, UL141, 
UL142, and UL144 ( Skaletskaya et al. 2001; Yu et al. 2002; Akter 2003; 
Davison 2003; Bradley et al. 2009). One of multiple changes is a substitution 
in gene UL36 rendering this protein non-functional (Skaletskaya et al. 2001). 
Those mutations do not exist in HCMV strains that have a wider cell tropism 
than AD169, therefore it has been speculated that these genes are critical for 
determining cell tropism (Cha et al. 1996; MacCormac and Grundy 1999). 
ORFs in the HCMV strain AD169 have been assigned into three major 
classes functionally: (i) 41 essential (ii) 27 augmentative and (iii) 88 
nonessential genes. This was based upon the generation of a library of ORF 
mutations in this strain, which were analysed for their growth properties in 
fibroblasts (Yu et al. 2003).   
1.2.2 Genome structure of HCMV  
Like many other herpes viruses, the HCMV genome is organised into two unique 
regions: unique long (UL) and unique short (US) regions (Figure 1.1c). Each unique 
region is flanked by a terminal repeat component (TRL or TRS) at one end and an 
inverted repeat component (IRL or IRS) at the other end, which results in the overall 
genome arrangement TRL–UL–IRL–IRS–US–TRS. These unique sequences can be 
inverted, giving rise to equimolar populations of four isomeric variants of the HCMV 
genome (Kilpatrick and Huang 1977) (Figure 1.1c). The four isomers have basically 
the same DNA sequences but vary in the orientation and position of the inverted ends 
relative to the rest of the DNA molecule (Kilpatrick and Huang 1977). It is unclear 
whether the organisation of the isomeric forms have an inherent biological 
importance in terms of the infection and propagation of HCMV as studies have 
shown that the circular isomeric forms of the HCMV genome in the form of bacterial 
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artificial chromosome (BAC) are infectious (Borst et al. 1999). The nomenclature 
used to designate the ORFs of HCMV depends on their position within the unique or 
repeat segments, with the ORF within this segment being given numbers in 
sequential order (Chee et al. 1990).  
 
Figure 1.1: Structure of CMV virion and genome.  A) electron micrograph 
image showing two HCMV particles (Mettenleiter et al. 2009). B) Schematic 
representation of a cytomegalovirus virion showing the lipid bilayer that is 
studded with at least 10 glycoproteins (gB-gN), l inear double-stranded DNA 
(dsDNA) is encased by an icosahedral capsid , and tegument proteins. C) The 
genome of HCMV is composed of a unique long (U L) and a unique short (US) 
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1.2.3 HCMV life cycle  
1.2.3.1 Attachment and entry  
HCMV initiates infection through multi-step sequential interactions with cellular 
receptors. The viral envelop glycoproteins gB and gCII (gM/gN) mediate low-
affinity interaction with heparan sulfate proteoglycans (HSPGs) present in the cell 
membrane of host cells, as treatment of cultured fibroblasts with heparin, heparinise, 
and other sulfated polysaccharides reduces viral attachment and plaque titer (Kari 
and Gehrz 1992; Neyts et al. 1992). This reduction was also seen in a CHO cell line 
harbouring mutations in HSPGs or all GAGs suggesting this interaction occurs via 
the glycosaminoglycans (GAGs) portion of the HSPGs (Figure 1.2a) (Neyts et al. 
1992; Compton et al. 1993; Boyle and Compton 1998).  
In the response to the initial binding of HCMV gBs with HSPGs, more stable 
interactions between one or more viral and cellular receptors appear to take place. 
Several cellular receptors have been studied in this context, but whether they are 
essential for virus entry has not been confirmed. For example, (i) Annexin II on the 
host cell membrane binds to the viral envelope protein gB, promoting virus and cell 
membrane fusion (Pietropaolo and Compton 1997; Raynor et al. 1999). However, 
treatment of cells with anti-annexin II antibody suggests that Annexin II is not 
required for virus entry into fibroblasts (Pietropaolo and Compton 1999). (ii) HCMV 
mediates the phosphorylation of host cell epidermal growth factor receptor (EGFR) 
briefly upon infection. The rapid phosphorylation of EGFR results in the activation 
of Ca
++
 fluxes and phosphorylation of the regulatory subunit of the PI3K, p85 and 
AKT (Wang et al. 2003). However, polyclonal antibodies directed against human 
EGFR or blocking its kinase activity have no effect on HCMV entry or levels of 
infectivity in fibroblast, epithelial, or endothelial cell lines (Isaacson et al. 2007), 
further EGFR is not expressed by all cells permissive to HCMV infection. (iii) 
HCMV infection has also been associated with host cell expression of CD13 
(Aminopeptidase N). Antibodies against CD13 or compounds known to block its 
enzymatic properties can inhibit the binding of HCMV to susceptible cells 
(Söderberg et al. 1993), suggesting CD13 is essential. A more recent report has 
shown that CD13 antibodies interact directly with the virus and neutralise HCMV 
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impeding viral entry. However, HCMV has also been shown to successfully enter 
CD13 depleted cells (Giugni et al. 1996), suggesting it is not essential. (iv) The effect 
of neutralising antibodies against integrins on HCMV entry has also been assessed 
by Feire et al. (2004). Anti-α2β1, α6β1, and αvβ3 antibodies caused a pronounced 
decrease in HCMV infectivity. The integrin antibodies did not block attachment of 
virus to the host cells but blocked internalisation of the virus. Viral glycoprotein B 
disintegrin-like domain was shown to mediate interactions between the virus and 
integrins and HCMV gB disintegrin-like peptide inhibits CMV infection (Feire et al. 
2004). However, it remains important to confirm the role of integrins as cellular co-
receptors for HCMV, as well as to identify the cellular receptors essential for 
infection.  
Upon the attachment, there are three main routes by which the virus enters into the 
host cells.  
1- Fusion: direct pH-independent fusion was demonstrated between the HCMV 
envelope and host cell membrane in permissive fibroblasts (Compton et al. 
1992) (Figure 1.2a).  
2- Endocytosis: viral internalisation into epithelial and endothelial cells occurs 
through the low-pH-dependent endosomal pathway. Acidification of the 
endosome promotes the fusion of the viral and endosomal membranes and the 
subsequent release of the nucleocapsid particles (Ryckman et al. 2006) 
(Figure 1.2b). Most internalised viruses (AD169 and Towne laboratory 
strains) appear to be sequestrated and degraded within the endosomes, 
resulting in a low level of infection, and a delay in DNA synthesis and virus 
replication (Bodaghi et al. 1999). However, the epithelial and endothelial 
cells are permissive for replication of clinical strains of HCMV (Toledo, 
Merlin, and TR). It might be because the clinical isolates retain a cluster of 
genes located between UL128 to UL150 that are lost by natural deletion in 
laboratory strains (Cha et al. 1996; Murphy et al. 2003). Recent reports show 
that individual genes within this cluster (UL128, UL-130, UL-131) are 
required for HCMV replication in epithelial and endothelial cells (Hahn et al. 
2004; Patrone et al. 2005; Wang and Shenk 2005).  
Introduction   Chapter 1 
10 
 
3- Macropinocytosis: Haspot et al., (2012) reported that HCMV enters dendritic 
cells by promoting the formation of membrane ruffles within the cholesterol-
enriched domain of the membrane of dendritic cells through an actin-driven 
mechanism. Viruses are then internalized into a large macropinosome-like 
vesicle, which has endosomeal-features, protecting the virus particles from 
degradation. The membranes of the macropinosome and enveloped virus fuse 
to release the nucleocapsid in close proximity to the nuclear envelope of the 
infected dendritic cells (Figure 1.2c). 
4- Combined entry methods: in a study on the infection of macrophages by 
HCMV, it has been found that the entry of virus into M2 anti-inflammatory 








Figure 1.2: Models of the different mechanisms of HCMV entry into the 
host cell. HCMV is init ially attached to host cells through an interaction 
between heparan sulfate proteoglycans (HSPGs) and virus glycoproteins. This 
is followed by a stable interaction with un identif ied cellular receptors. One or 
more of these interactions induces fusion that leads to the internalization of 
virion nucleocapsid (A). At least one of these interactions activates the 
endocytosis (B) or macropinocytosis (C) that result in endocytic internalization 
of the vir ion particle.  Adapted from (Compton et al. 1992)  
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1.2.3.2 The translocation  
Interaction of the virion with cellular receptors is followed by the fusion of the virus 
envelope with the host cellular membrane, which results in release of the 
nucleocapsid into the cytoplasm of the infected cell, along with free or capsid bound 
tegument proteins. In case of viral entry via endocytosis and macropinocytosis, the 
viral envelope fuses with the endocytic vesicle and the viral nucleocapsid and 
tegument proteins are then released into the cytoplasm of the host cell. Some 
disassociated tegument proteins are sequestered in the cytoplasm, while others such 
as pp65 and pp71 migrate to the nucleus. The mechanisms that mediate capsid 
disassembly and the delivery of viral DNA into the nucleus through the nuclear pore 
complexes are poorly understood in herpes viruses. Tegument proteins that are 
associated with the nucleocapsid, such as pUL48 have been shown to mediate 
interactions between the nucleocapsid and cellular microtubule-associated motor 
proteins during intracellular transport into the nucleus, through p180, an endoplasmic 
reticulum protein (Figure 1.3) (Ogawa-goto et al. 2007; Irie et al. 2002). Also, a 
complex of tegument proteins maybe formed from interaction of pUL47 with 
pUL48, pUL69, and major capsid protein (MCP or pUL86) (Bechtel and Shenk 
2002). A constructed mutant HCMV strain AD169 lacking pUL47 displays deficits 
in the protein expression of pUL48 and IE gene expression (Bechtel and Shenk 
2002). Studies from HSV-1 support that the homologs of HCMV pUL47 and pUL48 
(named UL37/VP1 and UL36/VP2, respectively) form a complex with the capsid 
(Klupp et al. 2002; Vittone et al. 2005; Coller et al. 2007) that directs the trafficking 
of HSV-1 nucleocapsids toward the nucleus (Luxton et al. 2005; Wolfstein et al. 
2006).  
1.2.3.3 Gene expression  
Once the viral genome enters the host nucleus, transcription is initiated in a cascade 
manner. Consequently, HCMV proteins are characterised according to their temporal 
expression pattern, namely (i) immediate-early ‘IE’, (ii) early ‘E’, and (iii) late 
proteins (Wathen and Stinski 1982).  
The first stage in the expression involves the transcription of IE1 (IE-72) and IE2 
(IE-86). This happens within the first 3 hours of HCMV infection (Stinski et al. 
Introduction   Chapter 1 
13 
 
1983), and utilises host cell RNA-Polymerase II together with viral tegument 
proteins pp71 and pUL69 (Cantrell and Bresnahan 2006; Preston and Nicholl 2006). 
The expression of IE genes is therefore independent of de novo-synthesised viral 
proteins. Tegument pp71 interacts directly with a death domain-associated protein 
(Daxx) to counteract its repressive function through the recruitment of histone 
deacetylase (HDAC) to the IE promoter (Hofmann et al. 2002; Cantrell and 
Bresnahan 2005). pp71 induces proteasome-dependent degradation of Daxx at the 
start of productive infection (Saffert and Kalejta 2006) (Figure 1.3). Similarly, pp71 
interacts with and degrades the hypophosphorylated forms of retinoblastoma proteins 
(pRB, p107 and p130) in a proteasome-dependent manner (Kalejta and Shenk 2002) 
leading to the activation of the transcription factor E2F, which is involved in DNA 
replication and cell cycle progression from G0/G1 toward G1/S phase (Kalejta and 
Shenk 2003). However, the latter degradation is not essential for efficient HCMV 
replication, as HCMV has other mechanisms to control the RB-E2F pathway, such as 
viral UL97 (Hume et al. 2008) or IE-2 (Song and Stinski 2002). Binding of viral 
protein pUL69 to UAP56-URH49 regulates the export of viral mRNA and supports 
translation (Lischka et al. 2006; Aoyagi et al. 2010; Zielke et al. 2011). The 
transcription and translation of the viral immediate early gene products, IE-1 and IE-
2 initiates viral gene expression. These IE proteins also play a role in suppressing 
cellular immune responses, for example, IE1 disrupts interferon (IFN) signaling 
cascades. The IE1 protein interacts directly with signal transducer and activator of 
transcription 2 (STAT2), inhibiting the formation of STAT1:STAT2 heterodimers 
which in turn impedes the formation of the STAT1:STAT2:IRF9 trimeric 
transcription factor complex known as interferon stimulated gene factor 3 (ISGF3). 
ISGF3 is able to bind to IFN-stimulated response elements (ISREs) within the 
promoter of ISGs and subsequently activate their transcription (Paulus et al. 2006; 
Krauss et al. 2009; Huh et al. 2008). IE-1 protein also has multiple inductive and 
repressive interactions with other host proteins (Hayhurst et al. 1995; Hwang et al. 
2009; Iwamoto et al. 1990; Kline et al. 1994.; Koh et al. 2009; Lee et al. 2005; Lukac 
et al. 1997; Margolis et al. 1995; Murayama et al. 2000; Nevels et al. 2004; Poma et 
al. 1996; Strååt et al. 2009; Yurochko et al. 1997; Iwamoto and Konicek 1997). In 
HCMV strains where IE1 has been  deleted,  the expression of the late early genes 
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are reduced and this causes a severe growth deficiency in fibroblasts infected at low 
multiplicities of infection (MOI), though at high MOI, replication is normal, negating 
the absence of IE1 (Mocarski et al. 1996; Greaves and Mocarski 1998; Gawn and 
Greaves 2002). IE-2 protein is essential for productive infection. A deletion in the 
IE-2 gene in recombinant HCMV results in total absence of viral gene expression 
and the subsequent failure of DNA replication and virus production (Marchini et al. 
2001; Sanders et al. 2008). IE2 is a crucial trans-activator for viral early and late 
genes. Activation occurs through the interaction of IE2 with specific DNA motifs 
(Arlt et al. 1994; Scully et al. 1995), which may include RNA polymerase II 
transcription initiation complexes such as TBP, TFIIB (Caswell et al. 1993; Lukac et 
al. 1994; Sommer et al. 1994), transcription factors such as Rb, p53, CREB (Lang et 
al. 1995; Bonin and McDougall 1997; Fortunato et al. 1997), and histone 
acetyltransferase, such as PCAF and CBP (Schwartz et al. 1996; Bryant et al. 2000).  
The second stage of viral gene expression involves the early genes, whose expression 
is controlled by the immediate early genes (Fortunato and Spector 1999). The 
products of early genes include the proteins required for transcription and DNA 
replication, which are expressed between 3 and 36 hours following infection. DNA 
synthesis, which starts from the replication origin (oriLyt) (Zhu et al. 1998; Borst and 
Messerle 2005), occurs by the rolling circle-mechanism to generate concatemeric 
viral DNA of head-to-tail-linked genomes (McVoy and Adler 1994).  
The final step of viral gene expression starts with the expression of viral late proteins 
from 36 to 72 hours. These mainly include the structural proteins such as envelope 
glycoproteins, teguments, and capsids.  
  




Figure 1.3: Tegument proteins aid the translocation of HCMV nucleocapsid 
to the nucleus upon viral entry and assist the initiation of the 
transcription of the immediate early viral genes.  (1) Capsid-associated 
tegument proteins UL47 and UL48 (and possibly pp150) are involved in the 
traff icking of the viral nucleocapsids along the microtubule toward the nucleus. 
(2) Some of tegument proteins (such as pp71) are transported to the nucleus 
independently of capsids. (3) Capsids ult imately detach from microtubules, 
dock at nuclear pores, and release their DNA into the nucleus.  (4) pp71 
interacts with Daxx in the nucleus to  induces Daxx degradation and 
transcription of viral IE genes, and thus starts the lytic cycle of HCMV. Adapted 
from (Compton et al. 1992; Kalejta 2008).  
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1.2.3.4 Formation of capsid and DNA packaging 
The processes of HCMV capsid maturation and viral DNA genome packaging occur 
exclusively in the nucleus of infected cells. Capsid formation starts with the 
construction of a spherical procapsid in the cytoplasm through a series of interactions 
between MCP and the two alternatively translated gene products of UL80, 
scaffolding protein (preAP) and proteinase precursor (pPR) (Beaudet-Miller et al. 
1996; Oien et al. 1997; Wood et al. 1997). These interactions, together with the 
complex of the minor capsid protein (mCP or pUL85) and its binding protein (mC-
PB or UL46) (Gibson et al. 1996), are also required for nuclear translocation of the 
procapsid (Plafker and Gibson 1998). Simultaneously, the portal protein pUL104 is 
incorporated at one end to form the channels for DNA import into the capsid 
(Dittmer and Bogner 2005; Holzenburg et al. 2009). The complete assembled capsid 
includes two protein layers: structural components are located in the outer layer, and 
scaffold elements are located the inner layer. Before DNA can be imported, the 
capsid has to be matured through the cleavage of the scaffold proteins by the 
proteolytic activity of the pPR derived protease, PR (Welch et al. 1991; Rixon 1993). 
The correct formation of mature capsid is believed to be dependent on the overall 
time and speed of scaffold protein digestion and binding of DNA. Variations in these 
factors  determine the final outcome of capsid formation (Welch et al. 1991; Yu et al. 
2005). The accurate timing of digestion of scaffold proteins enables efflux of 
digested products from the capsid and DNA packaging to proceed concurrently 
before angularization and sealing of the capsid occurs, resulting in capsid C 
formation which can develop into infectious particles (Figure 1.4) (Yu et al. 2005). 
Two other defective forms of capsids can arise if a failure occurs during scaffold 
protein processing, neither of which are infectious as they fail to import DNA 
(Gibson and Roizman 1972): 1) Capsid A will release the digested proteins and be 
sealed before importation of DNA; 2) Capsid B, where sealing occurs before efflux 
of all  digested scaffold products occurs (Yu et al. 2005). HCMV infected cells 
therefore not only release infectious virions (capsid C), but also non-infectious 
enveloped particles (NIEPs) and dense bodies (DBs) believed to be A and B capsids, 
respectively (Figure 1.4). The biological importance of these non-infectious particles 
is not well-studied, however, it has been shown that these particles can stimulate the 
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immune response in the absence of viral gene expression in vivo (Pepperl et al. 
2000). The viral DNA concatamer has to be processed for entry into the capsid. Viral 
terminase subunits pUL56 and pUL89 recognise and bind to two specific packaging 
sequences of viral DNA (pac1 and pac2) (Bogner et al. 1998) and their endonuclease 
activity cleaves the concatemers into unit-length viral genomic DNA strands 
(Scheffczik et al. 2002; Thoma et al. 2006). The terminase subunits also have ATP 
activity producing sufficient energy for packaging through ATP-hydrolysis (Scholz 
2003; Hwang and Bogner 2002). The terminase translocates the DNA through the 
capsid channel into the capsid (Dittmer and Bogner 2005; Welch et al. 1991).  
 
Figure 1.4: HCMV capsid assembly and maturation.  HCMV capsid proteins 
come together into an inner circular capsid, which angularizes to generate A, 
B, or C capsids, depending on the packaging of DNA and timing of scaffold 
protein cleavage by PR.  The failure of proper formation of C capsids leads to 
non-infectious enveloped particles (NIEPs) and dense bodies (DBs). Adapted 
from (Yu et al.  2004).  
 
 




Once the unit-length viral genomic DNA packaging into the capsid is completed, the 
nucleocapsids will be exported from the host cell nucleus into the cytoplasm where 
the mature virions are assembled. HCMV nucleocapsids cannot simply exit though 
the nuclear pore as they are larger (~120nm) than the nuclear pore (~39nm) (Pante 
and Kann 2002). Therefore, the nucleocapsids penetrate the nuclear envelope in a 
process known as a perinuclear budding. The budding of nucleocapsids at the inner 
nuclear membrane leads to the acquisition of the first temporal envelope, which is 
lost in the perinuclear space when this envelope fuses with the outer nuclear 
membrane before leaving the nucleus (Figure 1.5) (Mettenleiter 2002; 2004; 
Mettenleiter et al. 2006). The inner nuclear membrane is normally stabilized by 
attachment to the nuclear lamina, however, in mitosis the association is disrupted by  
phosphorylation of the lamina by specific cellular kinases (Peter et al. 1990; Buendia 
et al. 2001; Otto et al. 2001). Therefore, during budding the nucleocapsid engages a 
complex mixture of cellular and viral proteins including, pUL50, pUL53, UL97, 
protein kinase C (PKC) and PKC-binding protein p32 to access and disassemble the 
inner nuclear membrane (Milbradt et al. 2010). It is proposed that the morphogenesis 
of HCMV, specifically the tegumentation and final envelopment of the infectious 
particle, is largely acquired within a cytoplasmic virion assembly complex (cVAC). 
The cVAC is a compartment adjacent to the nucleus, which contains abundant 
structural and nonstructural HCMV proteins (Hensel et al. 1995; Sanchez et al. 2000; 
Theiler and Compton 2002; Das and Pellett 2007; Seo and Britt 2008) with 
endoplasmic reticulum at its periphery, around which concentric arrangements of 
Golgi, trans-Golgi network (TGN) are  formed. At the centre, the  cVAC contains 
early endosomal vesicles (Figure 1.5) (Das and Pellett 2007; 2011; Das et al. 2007). 
It is believed that HCMV pp150 (pUL32) (AuCoin et al. 2006; Tandon and Mocarski 
2008; Indran et al. 2010; Indran and Britt 2011) and pUL71 (Womack and Shenk 
2010; Schauflinger et al. 2011) are critical for efficient trafficking of the partially 
tegumented nucleocapsids during the maturation in the cVAC and for egress from 
infected cells. The inhibition of the interaction between pp150 and the cellular 
protein Bicaudal D1, a trafficking protein that associates with dynein motor protein 
and the Rab6 GTPase, interrupts the localization of pp150 and results in a reduction 
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in the production of infectious virions. Whereas infection with a virus in which 
pUL71 is mutated causes marked accumulation of mutant virions (Womack and 
Shenk 2010) . Other mutations can also affect egress, infection with a virus in which 
UL103 ORF is deleted prevents release of enveloped virions and dense bodies 
(Ahlqvist and Mocarski 2011). The proposed model for the final envelopment of 
HCMV hypothesizes that the viral envelope is acquired from the cisternal membrane, 
which has features of the vesicles derived from the TGN as well as endosomes 
(Cepeda et al. 2010). Therefore, it appears that the endosomes are recruited to TGN 
in order to incorporate their endosomal proteins into the viral envelop (Cepeda et al. 
2010). Upon the completion of morphogenesis, mature enveloped virions are 
released by exocytosis at the plasma membrane of host cells (Figure 1.5) 
(Mettenleiter 2004).  




Figure 1.5: Schematic representation of HCMV envelopment and egress.  
The nucleocapsid is released from the nucleus through the nuclear membrane. 
In the cytoplasm, tegumentation and envelopment occur during migration from 
the periphery of cVAC {known as vir ion assembly complex} to the exit in a 
vesicle, which occur close from the plasma membrane. Virus is released from 
host cells by exocytosis. The cVAC is composed of endoplasmic reticulum 
(ER), trans-Golgi network (TGN) and endosomal vesicles (EV).  
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1.2.4 Mouse cytomegalovirus (MCMV) provides a model for HCMV 
infection  
β-herpes viruses exhibit a strict host specificity, with the result that HCMV is 
incapable of infecting species other than humans. This fact prohibits experimental 
studies of HCMV infection in an animal model and limits them to in vitro studies 
using human cells. MCMV is a close relative of HCMV that provides a good in vivo 
model for the following reasons. 1) MCMV and HCMV share 80 conserved ORFs, 
representing ~40% of encoded ORFs in these viruses (Rawlinson et al. 1996; 
Brocchieri et al. 2005). 2) The pathological outcomes of MCMV infection of mice 
resemble those of HCMV in its host. It has been reported that infection with MCMV 
leads to the establishment of latent MCMV infection in immunocompetent mice 
(Hudson 1979), whereas the infection of immunosuppressed mice is lethal 
(Reddehase et al. 1985; Krmpotic et al. 2003). 3) MCMV can be reactivated from its 
latent phase (Anon 1977; Jordan et al. 1978; Shanley et al. 1979; Reddehase et al. 
1994; Krmpotic et al. 2003) and transmitted during transplantation and blood 
transfusion (Hamilton and Seaworth 1985; Roback et al. 2006) 4) MCMV is also 
similar to HCMV in terms of the structure, kinetics of gene expression, dynamics of 
the replication cycle (Mocarski and Kemble 1996), and the host immune response to 
infection (Mocarski 2004). MCMV has been proven to be an invaluable model for 
the investigation of responses to potential antiviral drugs, host susceptibility to 
infection, and the identification of host resistance genes. This MCMV model also 
enables the study of MCMV-mutants in intact physiological system (Scalzo et al. 
2007). However, it is important to consider that conserved modulation of host 
proteins performed by HCMV and MCMV could be mediated through different viral 
products of the two viruses as well as mechanisms.  
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1.3 microRNAs (miRNAs)  
1.3.1 Introduction to small non-coding microRNAs (miRNAs)  
The insights resulting from the sequence-profiling of the full-mammalian 
transcriptome have challenged the traditional view that the majority of genes code 
for proteins and that the more complex the organism, the greater the number of 
protein-coding genes. It is now quite evident that the number of protein-coding genes 
in human and mice are comparable to those in the nematode, Caenorhabditis elegans 
(C. elegans) (Carninci et al. 2005). A possible explanation is that the complexity of 
organism correlates with the proportion of non-protein-coding RNAs, whilst only 2% 
of the mammalian genome encodes mRNAs, the vast majority is transcribed as 
ncRNAs, some, if not many, of which have been shown to have biological functions 
(Taft et al. 2007; 2010). 
Non-coding RNAs (ncRNAs) are defined as classes of functional regulator RNAs 
that do not encode protein sequences. ncRNAs can be categorised into small, mid-
size and long ncRNA. The focus of this thesis is the most-studied class of small non-
coding, microRNAs (miRNAs) (originally called short temporal RNAs (stRNAs)). 
miRNAs are single-stranded RNAs between 19 to 24 nt in length, which function to 
regulate protein expression at the post-transcriptional level (Bartel et al. 2004). The 
first miRNA, lin-4, was identified in the nematode C. elegans in 1993 by Ambros 
and Ruvkun. They observed an inverse correlation between the lin-4 gene product 
and the protein level of lin-14 in C. elegans. lin-4 was shown to produce two short 
non-coding RNAs of 22 nt and 60 nt, rather than a protein. These RNAs of lin-4 have 
complementary sequences to the 3′ untranslated region (3′UTR) of lin-14 mRNA and 
able to reduce the translation of lin-14 through the formation of a lin-4:lin-14 RNA 
duplex (Lee et al. 1993; Wightman et al. 1993). Through a similar mechanism, lin-4 
also seems to repress the translation of lin-28, a cold-shock-domain protein that is 
involved in regulation of the developmental transition between the L2 and L3 larval 
stages of C. elegans (Moss et al. 1997). Almost seven years after these reports on lin-
4, Reinhart et al. (2000) identified a second small RNA in C. elegans named let-7 
RNA. This RNA contributes to the transition from the larval to adult stage through 
its interaction with the 3′UTR of lin-41 and hbl-1 (lin-57), which results in inhibition 
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of their translation (Slack et al. 2000; Abrahante et al. 2003; Lin et al. 2003; Vella et 
al. 2004). The let-7 RNA was found to be conserved in several species, including 
Homo sapiens, resulting in the assumption that more short RNA molecules were 
likely to exist (Pasquinelli et al. 2000). The number of miRNAs identified continues 
to increase, and online miRNA database was established to publish and categorise 
miRNA sequences (Griffiths-Jones 2004): (http://www.mirbase.org/). To date, more 
than 1500 miRNAs in the human genome have been annotated in the latest version of 
miRBase (version 19.0) (Kozomara and Griffiths-Jones 2011).  
1.3.2 Biogenesis of mammalian miRNAs 
Biogenesis of miRNAs involves two sequential processing reactions: pri-miRNA 
processing in the nucleus and subsequent pre-miRNA maturation in the cytoplasm 
(Figure 1.6).  
1) Pri-miRNA processing in the nucleus  
 Transcription of the pri-miRNA 
The majority of the miRNAs are transcribed by RNA polymerase II (also called 
RNAP II and RNA Pol II), while RNA polymerase III mediates the transcription of a 
relatively small proportion (Lee et al. 2002; Cai et al. 2004; Borchert et al. 2006; 
Monteys et al. 2010). miRNAs are transcribed as single primary transcripts (pri-
miRNA) ranging from hundreds to thousands of nucleotides in length. The pri-
miRNAs that are synthesised by RNA Pol II have been shown to be capped at their 
5′-ends and polyadenylated at their 3′-ends (Cai et al. 2004). Independent 
transcription units within introns, exons, or intergenic regions can host either 
monocistronic miRNA, dicistronic, or polycistronic clusters of miRNAs that are 
transcribed from the same promoter (Lee et al. 2002), or they can also be transcribed 
and regulated independently of each other (Song and Wang 2008). Pri-miRNAs 
contains at least one region of imperfectly paired double-stranded RNA (dsRNA) 
known as the stem-loop structure that is required for the expression of mature 
miRNAs. This stem-loop is flanked by single-stranded RNA (ssRNA) (Figure 1.6).  
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 pri-miRNA cleavage by the Drosha-DGCR8 microprocessor complex 
The RNAse III enzyme Drosha interacts with its co-factor anchor protein, DiGeorge 
syndrome critical region gene 8 (DGCR8) to form the microprocessor complex, 
which recognises the stem-loop structure of  the pri-miRNA (Lee et al. 2003; Denli 
et al. 2004; Gregory et al. 2004; Han et al. 2004; Landthaler et al. 2004; Zeng et al. 
2005). DGCR8 guides Drosha to cleave the base of the stem-loop structure and 
release a precursor miRNA (pre-miRNA) of ~60 to 70nt in length having a 5′-
phosphate and 3′-OH with 2nt overhang (Zeng 2003; Zeng et al. 2005; Zeng and 
Cullen 2005). Few miRNAs that have been found to be processed independent of 
Drosha-DGCR8 microprocessor complex as the two ends of their precursors reside at 
the splice sites of the intron. These miRNAs are known as mirtron (Figure 1.6) 
(Okamura et al. 2007; Ruby et al. 2007).  
 Pre-miRNA export mediated by Exportin 5-RanGTP 
The 3′ overhang of pre-miRNA facilitates its interaction with Exportin 5 and 
RanGTP molecules, producing a stabilized heterotrimer that allows efficient nuclear 
export to occur (Yi et al. 2003; Bohnsack 2004; Lund et al. 2004; Zhang et al. 2004; 
Okada et al. 2009). Once the heterotrimer arrives in the cytoplasm, the pre-miRNA is 
released from Exportin 5 following hydrolysis of RanGTP to RanGDP, promoted by 
RanGAP and other cofactors (Kehlenbach et al. 1999; Wang et al. 2011).   
2) pre-miRNA maturation in the cytoplasm 
pre-miRNA processing  
Following export of pre-miRNA from the nucleus, RNaseIII nuclease Dicer and its 
cofactors, TAR DNA-binding protein (TRBP) and protein activator of PKR (PACT) 
form the RISC loading complex (RLC) that subsequently associates with the core 
component Argonaute-2 (Ago2) (Gregory et al. 2005; Haase et al. 2005; Maniataki 
and Mourelatos 2005; Lee et al. 2006; MacRae et al. 2008). Dicer’s PAZ domain and 
two RNase III domains (RIIIa and RIIIb) are involved in the recognition and binding 
of RLC to the exported pre-miRNA (Lingel et al. 2003; Song et al. 2003; Yan et al. 
2003; Ma et al. 2004; MacRae and Doudna 2007). A single RNase domain is 
required in order to cleave pre-miRNA at the base of the stem loop, producing an 
Introduction   Chapter 1 
25 
 
imperfect miRNA:miRNA* duplex with a 5′ phosphate and 3′ OH with 2nt overhang 
(Zhang et al. 2004). While neither TRBP nor PACT is important for the pre-miRNA 
cleavage reaction stage, PACT facilitates the RLC formation and TRBP contributes 
to the stabilization of Dicer (Lee et al. 2006; Kok et al. 2007) and the recruitment of 
Ago2 to the RLC (Chendrimada et al. 2010). Although Dicer seems to be the 
predominant molecule for pre-miRNA processing, a Dicer-independent miRNA 
biogenesis pathway has been identified in which there is an Ago2-mediated cleavage 
reaction of pre-miRNA. An unusual pre-miRNA, pre-miR-451, is relatively short 
(~39nt) for loading into Dicer, instead Ago2 is used (Figure 1.6) (Cheloufi et al. 
2010; Cifuentes et al. 2011; Yang et al. 2010).  
miRNA duplex unwinding and loading 
Following Dicer cleavage, the miRNA duplex is separated into the functional guide 
strand and the subsequently degraded passenger strand (Gregory et al. 2005). The 
guide strand incorporates into the RNA-induced silencing complex (RISC). The 
selection of the mature strand from the duplex is partially based on the 
thermodynamic stabilities of the two terminal base pairs. The miRNA strand with the 
less stable base pair at its 5' end in the duplex is incorporated into RISC and becomes 
the mature miRNA, whereas the miRNA strand with the more stable base pair is 
generally discarded (Khvorova et al. 2003; Schwarz et al. 2003).  
RISC complex  
The minimal efficient RISC complex includes the mature miRNA in combination 
with at least one Ago protein (Ago 1-4). Four Ago proteins hAgo1-4 are expressed in 
humans, all contain a PAZ domain required for the binding of the 3′OH of loaded 
miRNA (Song et al. 2003; Lingel et al. 2003; Sasaki et al. 2003; Yan et al. 2003; Ma 
et al. 2004), and a MID domain that has an important role in anchoring the 5′ 
phosphate end of the miRNA (Yuan et al. 2005). Amongst the Ago proteins, Ago2 
exhibits endonuclease “slicer” activity that is capable of cleaving target mRNA 
strands that are perfectly complementary to the mature miRNA (Liu et al. 2004; 
Meister et al. 2004; Song et al. 2004). Once the mature miRNAs have become 
associated with the RISC complex, these miRNAs are able to bind to their target sites 
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through base complementarity on the 3′UTR of mRNA transcripts. Most miRNAs 
have their targets pair at position 2–7 or 2–8 nt of the 5′ end of the mature miRNA 
(called the seed site). It is possible that interactions between the 3-end of an miRNA 
and an mRNA could support a seed match (supplementary pairing) or compensate 
for mismatch in the seed region (compensatory pairing) (Doench and Sharp 2004; 
Kiriakidou et al. 2004; Kloosterman et al. 2004; Grimson et al. 2007). Furthermore, 
few miRNAs naturally have extensive interaction with their target mRNAs, examples 
include miR-196, which leads to repression of mouse HOXB8 through perfect 
complementarity with its 3′UTR sequence in myeloid differentiation of HL 60 cells 
(Kawasaki and Taira 2004; Yekta et al. 2004).  
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Figure 1.6: Schematic overview of canonical and non-canonical pathways 
of miRNA biogenesis and regulation in animals. The canonical miRNA 
biogenesis produces pri-miRNA transcripts, which are transcribed by RNA 
polymerase II in the nucleus. The pri-miRNA transcript is capped and 
polyadenylated. It can harbour either a single pre-miRNA (monocistronic) or 
multiple pre-miRNA (polycistronic). Splicing of short intron without the 
microprocessor complex, Drosha and DGCR8, produces pre-miRNA of the non-
canonical mirtron pathway. Both pre-miRNAs produced by the canonical and 
non-canonical pathways are exported through the nuclear pore complex via 
Exportin-5 into cytoplasm where the stem of the precursor is cleaved by Dicer 
within the RISC loading complex (RLC) in the canonical pathway or by Ago in 
the non-canonical pathway. The miRNA/miRNA* duplex is separated and 
loaded into Ago protein within RLC, where one strand of the duplex is 
preferentially retained. This strand is associated with Ago and GW182, which 
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1.3.3 Modes of miRNA-mediated regulation of target mRNAs  
Besides the cleavage of mRNA, the miRNA-associated with RISC affects the 
expression of target mRNA by two modes of regulation: inhibition of translation 
and/or destabilisation and degradation of the target transcript.   
1) miRNA-mediated mRNA degradation   
 
A) Deadenylation 
The miRNAs guide the RISC complex to mRNAs bearing imperfectly 
complementary sequences in the 3′ UTR of target mRNAs. This requires the CCR4-
CAF1-NOT1 deadenylation complex and to a lesser extent PAN2-PAN3 
deadenylation complex to mediate the deadenylation of target mRNAs. GW182 
protein is able to recruit both complexes, CCR4-CAF1-NOT1 complex through 
direct interaction with NOT1 and PAN2-PAN3 complex through direct and/or 
indirect interactions with PAN3 and PABP, respectively (Jakymiw et al. 2005; 
Yamashita et al. 2005; Behm-Ansmant et al. 2006; Eulalio et al. 2008; Fabian et al. 
2009; Braun et al. 2011; Chekulaeva et al. 2011; Fabian et al. 2011). Thus, the 
interaction between GW182 and CCR4-CAF1-NOT1complex seems critical for the 
removal of the poly (A) tail, as well as for the degradation of mRNA in a 3′-to-5′ 
direction (Figure 1.7).  
B) Decapping  
The next critical step in the degradation of target mRNA is the decapping and 5′ to 3′ 
exonuclease activities. The 5′ terminal cap (m
7
GpppG) of target mRNA is removed 
by the DCP1:DCP2 decapping complex catalyses and is degraded by the XRN1 5′- 3′ 
exonuclease (Sheth and Parker 2003; Cougot et al. 2004; Rehwinkel et al. 2005; 








Figure 1.7: A schematic model of miRNA-mediated mRNA degradation. (1)  
GW182 binds Argonaute (AGO) to form the RISC. GW182 interacts with two 
cytoplasmic deadenylase complexes, CCR4-CAF1-NOT1 and PAN2-PAN3. 
These interactions lead to the deadenylation of the poly(A) tail, which is a 
prerequisite to 3′-5′ degradation (2) Following deadenylation, The removal of 
the mRNA 5′ cap structure by the decapping enzyme DCP1:DCP2 causes a 
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C) miRNA-mediated translational repression  
The first known miRNA in C. elegans, lin-4, was shown to impair the translational 
level of its target gene lin-14 without a corresponding reduction in its transcript level 
(Lee et al. 1993; Wightman et al. 1993). Following this the initial studies of miRNAs 
focused on the inhibition of translation, as the primary mechanism by which 
miRNAs regulates their target genes. The translation process is initiated by the 
binding of the translation initiation factor eIF4E to the cap structure of mRNAs. 
eIF4E and other eukaryotic initiation factors (eIFs) are involved in the recruitment of 
ribosome to the 5′ end of mRNA and thus initiate the translation (Reviewed in 
Sonenberg and Hinnebusch 2009). RISC has been shown to repress the cap-
dependent translation at the initiation step by interfering with the recruitment of 
ribosome to the target mRNAs (Pillai et al. 2005; Chendrimada et al. 2007; 
Mathonnet et al. 2007; Wang et al. 2008; Ding and Grosshans 2009). RISC also 
could repress the translation at the post-initiation level by slowing down or inhibiting 
ribosome elongation (Petersen et al. 2006; Gu et al. 2009). The details of the 
molecular mechanisms of the translation repression, however, are still unclear.  
Results from recent reports suggest that translational repression, deadenylation and 
decay, molecular mechanisms employed by miRNAs to mediate gene expression, are 
all linked processes. miRNAs were first shown to repress the translation of the target 
mRNA and this was followed by induction of mRNA deadenylation and finally its 
degradation (Bazzini et al. 2012; Béthune et al. 2012; Djuranovic et al. 2012). 
D) miRNA-mediated the translational activation  
A small number of miRNAs, miR-122, miR-10a, and miR-369-3 have been reported 
to activate rather than repress mRNA translation under certain conditions. For 
instance, in G1/G0 arrested cells, miR369-3p was shown to target the 3′UTR of 
TNFα mRNA and mediate its translational upregulation but not in proliferating cells 
(Vasudevan et al. 2007; Vasudevan and Steitz 2007). In response to stress or amino 
acid starvation, miR-10a interacts with the 5′UTR of several ribosomal protein 
mRNAs downstream of their 5′-TOP motif (terminal oligopyrimidine tract), showing 
an increase in their translation (Ørom et al. 2008). Furthermore, miR-122, a liver-
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enriched miRNA was found to bind to two sites within the 5′UTR of HCV RNA in 
hepatic cells and to stimulate HCV RNA translation (Jopling et al. 2005; Henke et al. 
2008).  
E) miRNAs target the 5′UTR and coding sequence (CDS) of mRNA  
Besides the reports from Jopling et al. (2005) and Ørom et al. (2008), relatively few 
studies have shown possible miRNA interaction sites in the 5′-UTR of target mRNAs 
(Lytle et al. 2007).  A small number of studies have revealed functional miRNA sites 
located within the coding sequence of mRNAs, which mediated the translational 
repression. For example, the miR-148 target site in Dnmt3b1 CDS (Duursma et al. 
2008), the miR-134 site in Sox2 CDS, the miR-470 site in Oct4 CDS, and two sites 
for miR-296 and a site for miR-470 in Nanog CDS (Tay et al. 2008). Out of these 
identified sites, only two have canonical miRNA seed matches (Duursma et al. 2008; 
Tay et al. 2008). However, the impact of miRNA regulation on transcripts containing 
sites within their CDS appears to be smaller than those mRNAs with sites in 3′UTRs 
(Fang and Rajewsky 2011). To date, no studies have addressed whether the 
mechanism of miRNA regulation is the same for a transcript with a functional site 
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1.3.4 Studying the biological function of miRNA 
Understanding the biological functions of an miRNA relies to a large extent on the 
identification of their target genes. This has been addressed by the application of a 
combination of computational and experimental approaches.  
1) In silico miRNA target prediction  
A number of bioinformatic algorithms were developed to predict miRNA sites: 
miRanda (John et al. 2004), TargetScan (Ruby et al. 2007), Pictar (Lall et al. 2006), 
and PITA (Kertesz et al. 2007). These algorithms are based on well known miRNA-
mRNA interaction rules. The first of these rules is the pattern of base pairing 
between the miRNA and its target mRNA including 1) At least 6 nucleotides of 
consecutive match between the seed site of a miRNA and the 3′UTR of target mRNA 
(2-8 nt) with a preference for an ‘A’ at the first position in the target site; 2) The 
pairing between the 3′ end of an miRNA and its target mRNA ranging from no 
interaction to extensive compensatory interactions; and 3) The composition of AU 30 
nt up and downstream of the target site is associated with a more favourable site (Lee 
et al. 1993; Wightman et al. 1993; Brennecke et al. 2003; Grimson et al. 2007; 
Nielsen et al. 2007). The miRNA target sites in the 3′UTR are often conserved 
among vertebrates (Lewis et al. 2005; Friedman et al. 2009). However, some 
software programmes either do not include conservation as a criterion for target 
predication or they permit the examination of both conserved and non-conserved 
sites. Nonetheless, there is a concern that a significant proportion of false targets are 
predicted by these algorithms as the actual factors involved in making the target site 
accessible for miRNA binding are not fully understood (Lewis et al. 2005; Didiano 
and Hobert 2006). This means that relying on bioinformatic identification of miRNA 
targets is still problematic and requires validation through complimentary 
biochemical approaches. 
2) Biochemical target identification  
Given that miRNAs cause degradation of their mRNA targets, the inverse 
correlations between the expression levels of miRNAs and mRNAs can be used to 
further support the prediction of miRNA-target mRNA interactions (Lim et al. 2005; 
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Huang et al. 2007). The transcriptome experiments are based on the introduction or 
inhibition of a particular miRNA in cultured cells. It is expected that introduction of 
the miRNA leads to decreased mRNA and/or protein expression levels, while 
inhibition of an miRNA can result in increased levels. The set of regulated genes 
holding miRNA seed match sites in their transcripts are expected to be miRNA 
targets; however there are limitations to the application of transcriptome microarrays 
for the identification of miRNA targets. For example, miRNAs causing regulation at 
the translational levels with little or no change in the mRNA levels are undetectable 
using this approach. In order to overcome this condition, proteomics can be used to 
assess the impact of miRNA on protein levels through quantitative mass 
spectrometry using SILAC (Stable Isotope Labelling by Amino Acids in Cell 
Culture) (Baek et al. 2008). A key insight into the miRNA-mediated mRNA 
regulation obtained from the proteomic approach is that all proteins repressed by 
more than 30% also displayed down-regulation at the transcriptional levels. This 
strongly suggests that the effect of miRNA on gene expression involves repression at 
both transcript and protein levels. A drawback of quantitative mass spectrometry is 
that its application is limited to proteins whose solubility and abundance are 
sufficient for the approach to identify (Baek et al. 2008; Selbach et al. 2008). Both 
transcriptome and proteome-based approaches have identified targets that exhibit 
sites that match the miRNA seed(s) in their 3′UTRs and change in response to 
miRNA expression. A second limitation of these approaches is that a large number of 
genes that change in expression level in response to miRNA manipulation do not 
possess seed matches between the miRNA and the mRNAs of those genes. It is 
possible that regulation of these genes could result from secondary regulatory effect 
of miRNA overexpression or inhibition or interactions could occur through non-
canonical-seed sites. Several recent studies have observed that certain miRNAs bind 
to non-canonical sites at the 5′ end of mRNA, with a preference for positions 3-8 or 9 
nt or through the centred sites (from position 4 or 5 to position 14 or 15) instead of 
the canonical seed sequence (2-7 nt or 2-8 nt) (Wu and Belasco 2005; Didiano and 
Hobert 2006; Grimson et al. 2007; Selbach et al. 2008; Tay et al. 2008; Shin et al. 
2010).  
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Several groups have therefore developed biochemical methods for direct 
identification of miRNA:mRNA target pairs. These methods are based on the co-
immunoprecipitation of either mRNAs bound to a single biotin-tagged miRNA 
(Ørom et al. 2008) or mRNAs bound to the RISC complex through pulling down the 
Ago protein (Beitzinger et al. 2007; Easow et al. 2007; Karginov et al. 2007; 
Hendrickson et al. 2008; Chi et al. 2009). The purified target mRNAs can then be 
identified by means of microarray analysis or deep sequencing. The microarray study 
of immunoprecipitated mRNAs from biotin-tagged miR-10a revealed the interaction 
between miR-10a and the 5′UTR of ribosomal protein mRNAs (Ørom et al. 2008). 
The immunoprecipitation of a tagged Ago, which was over-expressed in cultured 
cells with a particular miRNA, also led to the detection of several potential target 
mRNAs. As an example of this, Hendrickson et al (2008) showed that the enrichment 
of the seed sequence within the 3′UTRs of purified target mRNAs was more than 
70% for miR-1 or miR-124 targets containing a 6 nt seed match. An advance in the 
Ago immunoprecipitation technique termed crosslinking immunoprecipitation (CLIP 
or HITS-CLIP) utilises UV cross-linking and RNase treatment to detect only 
miRNA:mRNA complexes directly protected by Ago (Chi et al. 2009; Zisoulis et al. 
2010). This improves the specificity in determining the sites of miRNA interactions 
within the target transcripts in both UTRs and CDS.  
Combining in silico prediction with one of the experimental approaches above has 
identified numerous potential miRNA-regulated mRNAs. A common tool for 
functionally validating the direct target of miRNA is the use of a luminescent or 
fluorescent reporter construct expressing the potential target sequence (Zeng et al. 
2002; Brennecke et al. 2003; Doench et al. 2003). The 3′UTR of an miRNA target 
gene is cloned and inserted downstream of a luciferase or fluorescent reporter gene. 
This construct is then transfected into the cultured cells, along with the miRNA of 
interest (or miRNA inhibitor). The degree of reporter gene expression is then 
measured 24 or 48 hours after transfection, in order to determine the effect of a 
particular miRNA on repressing the expression of reporter gene. The direct 
regulation of the reporter by a miRNA can be validated by mutating the sequence of 
the identified seed match. The mutation should abolish the interaction with the 
miRNA resulting in no repression.  
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1.4 miRNAs in host–virus interactions 
Given the diverse and important function played by miRNAs in gene regulation, it is 
not surprising that viruses express miRNAs and utilise host miRNAs to modulate the 
expression of both their own genes and those of the host cells. 
Pfeffer et al. (2004) discovered the first virus-encoded miRNA, which is expressed in 
the latent stage of EBV infected B cells. To date, about 143 viral miRNAs have been 
reported in the three subfamilies of human herpes viruses (α, β, and γ) (Reviewed in 
Kincaid and Sullivan 2012) and one or two miRNAs in each of the human retrovirus 
(Ouellet et al. 2008), polyomavirus (Seo et al. 2009) and adenovirus families 
(Andersson et al. 2005). These viral-encoded miRNAs were shown to contribute to 
the regulation of host cell functions, viral replication, to establishing/maintaining 
latency, immune evasion, or pathogenicity (Reviewed in Skalsky and Cullen, 2010; 
Cullen 2011).  
1.4.1 Host-encoded miRNAs  
In addition to the viral-encoded miRNAs, several studies have demonstrated 
modulation in the expression profile of host miRNAs during infection caused by 
viral genes or the host antiviral immune response. At the same time, host miRNAs 
have been directly or indirectly implicated in regulating viral gene expression, 
having either a positive or negative effect on virus replication and pathogenesis.  
1) Direct regulation of viral genes by host miRNAs 
Jopling et al. (2005) made the important discovery that the liver-specific miRNA, 
miR-122 interacts with the 5′ end of Hepatitis C virus genomic RNA (HCV). 
This interaction is required for virus replication as the inhibition of miR-122 led 
to a reduction in the viral RNA load and production of infectious virus in vitro 
(Randall et al. 2007). An miR-122 inhibitor was also reported to be successful in 
reducing the viral loads in vivo when administered to chimpanzees with chronic 
HCV infection (Lanford et al. 2010) and is presently undergoing phase II clinical 
trials (Broderick and Zamore 2011). Beyond the proviral effect of miR-122, 
many other cellular miRNAs have been reported to have antiviral effects against 
HCV. For example, interferon-mediates the upregulation of several miRNAs that 
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have imperfect complementarity to the HCV RNA genome including miR-196, 
miR-296, miR-351, miR-431, miR-448 (Pedersen et al. 2007). It was also shown 
that miR-199-3p targets both the HCV RNA genome and Hepatitis B virus 
(HBV) transcripts, thereby suppressing their replication (Murakami et al. 2009; 
Zhang et al. 2010). Further interactions have been reported between host 
miRNAs and human viruses from the Flaviviridae, Hepadnaviridae, 
Orthomyxoviridae and Rhabdoviridae families (Table 1.3). For example, several 
miRNAs in resting CD4+ T cells including miR-150, miR-125-5p, miR-28, miR-
223, miR-382, were found to target the 3′ end of human immunodeficiency virus 
type-1 (HIV-1) RNA to maintain the latent infection in those cells (Huang et al. 
2007).  
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Table 1:3: Direct interactions between host-encoded miRNAs and viruses. Adapted 
from (Laqtom and Buck 2011). HCV: hepatitis C virus, HBV: hepatitis B virus, H1N1: 
Influenza, HIV-1: human immunodeficiency virus-1, VSV: vesicular stomatitis virus.  
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2) miRNAs that influences viral infection through regulation of host genes 
miRNAs regulate many cellular processes (e.g. proliferation, survival, metabolism, 
immune response), therefore, their expression levels can affect the infection process. 
One of the earlier studies of miRNAs in this context demonstrated that the two 
cellular miRNAs, miR-17-5p and miR-20, were inhibited following HIV infection. 
This inhibition resulted in a corresponding increase in the target expression of 
p300/CBP-associated factor (PCAF), which is a cellular histone acetylase and co-
factor for the viral Tat protein (Triboulet et al. 2007). Another related example is the 
inhibition of miR-100, miR-101 (Wang et al. 2008), and all the mature members of 
miR-199a/214 cluster (Santhakumar et al. 2010) following the lytic HCMV 
infection. The ectopic expression of miR-100, miR-101, miR-199-3p or miR-214 
results in a significant inhibition of viral growth. Wang et al (2008) suggested that 
miR-100 and miR-101 target the mTOR signaling through direct interactions with 
two components within this signaling pathway, mTOR and Raptor. Similar to lytic 
HCMV infection, the expression of miR-92a in CD34+ haematopoietic progenitor 
cells is reduced during the latent infection of HCMV. A consequence of this 
reduction is an increase in the expression of GATA-2 and a corresponding increase 
in IL-10 production, supporting the maintenance of viral genomes in CD34+ cells the 
during latent infection (Poole et al. 2011). As the expression of anti-viral miRNAs 
can be inhibited, viruses also can cause significant increase in miRNAs could have 
proviral properties. For example, miR-132 is upregulated following KSHV infection 
and has a negative impact on the expression of interferon-stimulated genes through 
the direct regulation of P300 transcriptional co-activator, thus enhances viral 
replication (Lagos et al. 2010). miR-31 is also up-regulated by the expression of 
KSHV protein K15 to target FAT4, which is a tumor suppressor and thereby 
contributes to progression of malignant Kaposi sarcoma (Wu et al. 2011). An 
additional list of host-encoded miRNAs that manifests anti- or proviral properties by 
regulation of host genes is presented in Table 1.4. This thesis focuses on the 
regulation and function of an antiviral host miRNA, miR-199-3p, in HCMV and 
MCMV infections. 
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Table 1:4: Indirect interactions between host miRNAs and host targets, which are 
involved in the infection process. Adapted from (Laqtom and Buck 2011). HCMV: human 
Cytomegalovirus, KSHV: Kaposi's Sarcoma-associated Herpes virus, HSV-1: Herpes 
Simplex virus-1, HBV: Hepatitis B virus, EV71: Enterovirus 71, RV1B: Rhinovirus 1B, HIV-1: 
human Immunodeficiency virus-1, VSV: Vesicular Stomatitis virus, HPV: Human 
Papillomavirus, SFV: Semliki Forest virus, RSV: Respiratory Syncytial virus.  
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1.5 miR-199-3p is a member of miR-199a/214 cluster  
The miR-199a/214 cluster is encoded within the opposite strand of an intronic region 
of the dynamin 3 (DNM3) gene (GeneID: 100628315 in NCBI database, 
http://www.ncbi.nlm.nih.gov/pubmed/) (Figure 1.8). It comprises two miRNA 
precursors, miR-199a and miR-214, both of which are evolutionarily conserved 
among several species. The products of this cluster are number miR-199-5p, miR-
199-3p, miR-214-5p, and miR-214-3p (Accession number of miR-199a: MI0000281 
and miR-214: MI0000290 in miRBase, http://mirbase.org/) (Figure 1.8). Notably, the 
seed sequences (nucleotides 2–8) of miR-199-3p and miR-214-3p share significant 
similarity (Figure 1.9) and hence, presumably similar or overlapping functions. 
However, the seed sequence of miR-199-5p is distinct from these two miRNAs.  
 
Figure 1.8: A schematic diagram of human dynamin3 (DNMIII) gene 
showing that miR-199a/214 gene lies within the opposite strand of its 
intron. The pri-miR-199a/214 transcript encodes miR-199a and miR-214 
precursors.   
 
Figure 1.9: Alignment of miR-199-3p with the mature sequence of miR-214-
3p. Red indicates seed sequence.   




miRNA profiling studies have shown that in various cancers, the expression pattern 
of one or more member of the miRNA cluster, miR-199a/214, are deregulated (Table 
1.5). Although, their functional significance has not yet been elucidated in all 
cancers, the concurrent alteration in expression of miR-199-3p, miR-199-5p, and 
miR-214 indicates a possible cooperative and/or supportive role in the disease. At the 
same time, decrease or increase of an individual member of this cluster could point 
towards their specific or individual functions.  
 
MET and mTOR signaling pathways in hepatocellular carcinoma (HCC) 
It has been reported that compared to normal liver there is a simultaneous decrease of 
miR-199-3p, miR-199-5p, and miR-214 in hepatocellular carcinoma. The decrease in 
expression of miR-199-3p contributes to the increased expression of its targets, MET 
proto-oncogene (MET) (Fornari et al. 2010), p21-activated kinase 4 (PAK4) (Hou et 
al. 2011), and the cell surface glycoprotein CD44 (Henry et al. 2010). It is important 
to note these target genes, MET, PAK4, and CD44, are part of the MET signaling 
pathway, which act together to amplify the signaling cascade thereby regulating 
downstream effectors, such as mitogen-activated protein kinase-1 (MAPK1, Known 
as ERK2). Thus, decreased miR-199-3p expression can effectively enhance HCC cell 
proliferation and invasion. In addition to targeting MET signaling, miR-199-3p 
targets mTOR, the central kinase in the mammalian target of rapamycin (mTOR) 
signaling pathway. Therefore, attenuated level of miR-199-3p elevates mTOR 
signaling and enhances the survival and resistance to doxorubin-induced cell death of 
HCC cells (Fornari et al. 2010) (Figure 1.10).  
In agreement with the tumour suppressor function of  miR-199-3p, Fornari et al. 
(2010) observed that decreased miR-199-5p expression promoted survival of HCC 
by increasing expression of hypoxia inducible factor 1, alpha subunit (HIF-1α) 
(Fornari et al. 2010). HIF-1α is also a downstream gene of mTOR, which is a target 
of miR-199-3p (Land and Tee 2007). Besides HIF-1α, the discoidin domain receptor-
1 (DDR1) tyrosine kinase, implicated in cell invasion-related signaling pathway, is 
also a target of miR-199-5p (Shen et al. 2010) (Figure 1.10).  
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The suppression of miR-214 expression is associated with increased β-catenin 
signaling, enhanced cell growth and invasion of HCC cells. β-catenin is a direct 
target of miR-214, its suppression therefore results in modulation of several genes 
downstream of β-catenin such as, c-Myc, cyclinD1, TCF-1, and LEF-1 (Wang et al. 
2012; Xia et al. 2012) (Figure 1.10). These examples demonstrate that miR-199-3p, 
miR-199-5p, and miR-214 are important regulators of multiple signaling pathways 
and consequently, their functional outcomes in cancer cell proliferation, survival, and 
invasion. These miRNAs are able to effectively cooperate though targeting genes of 
the same pathway or genes of different pathways with related functions in the 
pathological states. This could account for their co-existence in one cluster and their 
simultaneous deregulation in disease states.  
1.5.2 Prostaglandin signaling.   
The clustered miRNAs, miR-199a-3p and miR-214 have been reported to be  
simultaneously decreased in the uterine myometrium of full-term pregnant humans 
and mice, as well as in a mouse model of pre-term labour (Williams et al. 2012). As 
expected, the expression of their direct target, PTGS2 (COX-2), is elevated and its 
associated functions such as prostaglandin production and labour are induced 
(Williams et al. 2012). Consistent with this,  increased expression of miR-199-3p has 
been shown to be associated with a decrease in the level of its target PTGS2 
(COX-2) in early pregnancy, during implantation (Chakrabarty et al. 2007a). The 
regulation of PTGS2 (COX-2) and subsequent prostaglandin production mediated by 
miR-199-3p has also been reported in chondrocytes in osteoarthritis (Akhtar and 
Haqqi 2012).  
Most studies on miRNAs examine one or a few cellular targets of a miRNA. 
However, miRNAs can simultaneously repress the expression of hundreds of 
proteins (Baek et al. 2008; Selbach et al. 2008) and the regulatory impact on most of 
these target genes is subtle ‘fine-tuning’ (Reviewed in Bartel and Chen 2004). 
Therefore, elucidating how a single miRNA induces observable functional 
consequences with such subtle regulation is complicated. It seems likely that miRNA 
can exert its functions by targeting several genes of host signaling pathway and/or 
genes of multiple functionally-related pathways. Consequently, the subtle regulation 
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of several target genes could produce a cumulative effect and contribute to 
observable functional changes (He et al. 2010). Most studies have also focused on 
one or two deregulated miRNAs but not the global picture of how the miRNAs in a 
cell act in concert with each other and with other regulatory proteins (e.g. 
transcription factors) to regulate the expression of their target genes and ultimately, 
changes in cellular functions.  
 
Table 1:5: The cancers in which miRNAs of miR-199a/214 cluster are 
dysregulated. (U:up, D:down, U/D: up in a study and down in  another).    
 
  
Cancer miR-199-3p miR-199-5p miR-214 Reference 
Ovarian cancer U/D U/D U/D (Zhang et al. 2006; Iorio 
et al. 2007; Dahiya et al. 
2008; Yang et al. 2008;  
Yin et al. 2010; He et al. 
2012) 
Breast cancer U - D (Derfoul et al. 2011; 
Shatseva et al. 2011) 
Hepatocellular 
carcinoma 
D D D (Murakami et al. 2006; 
Duan et al. 2012) 
Osteosarcoma D - - (Duan et al. 2011) 
Gastric cancer U U - (Song et al. 2010; 
Brenner et al. 2011) 
Testicular 
cancer 
D D - (Cheung et al. 2011) 
Colorectal 
cancer 




U - - (Shigehara et al. 2011) 
Pancreatic 
cancer 
- - U (Zhang et al. 2010) 
bladder 
carcinoma 
D D - (Ichimi et al. 2009; Su et 
al. 2012) 
Cervical cancer - - D (Peng et al. 2012) 




Figure 1.10: A summary diagram of the signaling pathways in 
hepatocellular carcinoma (HCC) modulated by miR-199a/214 cluster to 
regulate tumorigenicity. Pathways regulated by miR-199a/214 that are known 
to be important in l iver cancer. Direct targets genes of miR-199-3p are shown 
with red arrow, miR-199-5p with purple arrow, and miR-214 with blue arrow. 
Circles with dashed lines represent indirect targets , which were shown to be 
regulated by these miRNAs through direct targeting.   
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1.6 Central hypothesis and objectives of the thesis 
HCMV is an important virus for number reasons. Perhaps most importantly, HCMV 
infection is ubiquitous and affects 50% to 80% of the world’s populations (Odland et 
al. 2001; Alanen et al. 2005; Hannachi et al. 2011). In addition, the perinatal 
infection of HCMV causes congenital diseases that can lead to serious complications, 
such as mental retardation. The virus also establishes a life-long latent infection, with 
a high risk of malicious reactivation whenever the immune status of an infected 
individual is compromised. Finally, the available anti-HCMV drugs (Ganciclovir, 
Cidofovir and Foscarnet) do not cure the infection and can have serious side effects 
that include the emergence of drug resistant virus strains (Reviewed in Lurain and 
Chou 2010). Therefore, a better understanding of host-virus interactions is important 
to be able to design new, safe and effective ways to treat HCMV infection. The 
recent discovery of miRNAs playing a critical role in viral replication and 
pathogenesis reveals a new level of host-virus interactions and that could lead to 
novel preventive and therapeutic strategies. 
HCMV like the other viruses, modulates the profile of host-encoded miRNAs (Wang 
et al. 2008; Santhakumar et al. 2010) to suit its replication and other aspects of its life 
cycle. The host miRNA cluster, miR-199a/214 including three mature miRNAs, 
miR-199-3p, miR-199-5p and miR-214, are all down-regulated by both MCMV and 
HCMV in fibroblast cells. At least two mature members of this cluster have antiviral 
properties against MCMV and HCMV growth when over-expressed in vitro 
(Santhakumar et al. 2010). Interestingly, the antiviral properties of miR-199-3p 
extend to other herpes viruses including HSV-1 and mouse γ-herpes virus (MHV-68) 
as well as other unrelated viruses, such as Semliki Forest virus (SFV) (Santhakumar 
et al. 2010), HVB (Zhang et al. 2010) and HVC (Murakami et al. 2009). 
Therefore, the study presented in this thesis was designed to test the central 
hypothesis that MCMV and HCMV actively repress the expression of miR-199a/214 
transcript in order to evade the negative consequences of at least miR-199-3p on 
virus infection.  
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In order to test this hypothesis, 5 objectives were defined: 
 To determine at what stage of biogenesis the expression of miR-199a/214 is 
regulated by CMV infection.  
 To discover whether the observed down-regulation in miR-199a/214 expression 
requires viral gene expression. 
 To investigate what cellular elements are involved in the down-regulation of 
miR-199a/214 expression.  
 To ascertain which host signaling pathways are regulated by miR-199-3p which 
may relate to its antiviral properties. 
 To identify the direct targets of miR-199-3p and to investigate their role in the 
infection.
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2 Materials and Methods 
2.1 Tissue culture    
2.1.1 Cell lines  
NIH-3T3 cells and P53-null MEFs cell lines were purchased from American Type 
Culture Collection (Manassas, VA.). NIH-3T3 cells (ATCC CRL1658) are 
spontaneously immortalized fibroblast cells. They are established from a NIH Swiss 
mouse embryo. P53-null MEFs cells (ATCC CRL2645) are mouse embryonic 
fibroblasts obtained from mice with a null mutation in only the p53 gene. NIH-3T3-
BAM25 cells were derived by stable transfection of a plasmid bearing the MCMV 
IE1 and IE3 genes by Angulo et al. (2000), into NIH-3T3 cells. MRC-5 and HEF 
fibroblasts were also obtained from American Type Culture Collection (Manassas, 
VA.). MRC-5 cells (ATCC CCL-171) were derived from the normal lung tissue of a 
human foetus. HEF cells (ATCC SCRC-1041) are foreskin-derived human 
embryonic fibroblasts. All cell lines were maintained at 37°C in incubators that were 
supplied with 5% CO2 and a relative humidity of 95%.  
2.1.2 Cell media and tissue culture consumables 
NIH-3T3and NIH-3T3-BAM25 were grown in Dulbecco’s Modification of Eagle’s 
Medium (DMEM) (Lonza, Belgium), which was supplemented with 10% heat-
inactivated calf serum (HI-CS) (Sigma), 0.293 mg/ml of L-glutamine (Lonza, 
Belgium) and 50 U of Penicillin/Streptomycin (Lonza, Belgium) per ml. The 
sterilised media was stored at 4°C for up to six months. The same media was used 
for P53-null MEFs cells, but HI-CS was replaced with heat-inactivated fetal bovine 
serum (HI-FBS) (GIBCO, Invitrogen, UK). MRC-5 and HEF cells were cultured in 
Eagle's minimal essential medium (EMEM) (Lonza, Belgium), supplemented with 
10% HI-FCS, 0.293 mg/ml of L-glutamine (Lonza, Belgium), 50 U of 
Penicillin/Streptomycin (Lonza, Belgium) per ml and 0.1 mM non-essential amino 
acids (Lonza). All tissue culture flasks were obtained from Corning, USA.  
2.1.3 Passaging cell lines 
When the monolayer of cells reached 70-80% confluence, culture media was 
discarded and the adherent cells washed once with phosphate buffered saline (PBS). 
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The cells were then incubated with trypsin/EDTA (Lonza, Belgium) for 5-10 min at 
room temperature until they detached. The cells were then collected into 3-5 ml of 
appropriate serum supplemented medium (to inhibit further trypsin digestion) and 
centrifuged at 200 g-force at room temperature for 5 min. The supernatant was 
discarded and the pellet resuspended in fresh medium using an appropriate volume 
for a split ratio between 1:2 and 1:4, according to the cell line and experimental 
requirements. This process was repeated up to a maximum of 10 passages. Wherever 
possible, low passage cells were used for the experiments. 
2.1.4 Cell counts using a hemocytometer and trypan blue dye 
exclusion  
To determine the cell count, resuspended cells were diluted (1:2 or 1:10) with trypan 
blue stain, 0.4% (Lonza, USA). 10μl of this dilution was then introduced into a 
haemocytometer (HAUSSER Scientific, USA) under a cover slip, after which the 
viable cells were counted in the central 16 marked squares. Counts were repeated 6 
to 10 times from different replicates of the sample and an average count was then 
calculated. Cells per ml were calculated by means of the following equation: 
Number of viable cells per ml = Average number of counted cells * the relative area 




) * dilution factor. 
Cells were then diluted to appropriate seeding density. The seeding densities for 
NIH-3T3, NIH-3T3-Bam25, MRC-5, and HEF cells in different sized tissue culture 
plates (Costar, USA) were as follows;  
 96-well plates: 1.5x104 cells in 100μl medium per well.  
 48-well plates: 4x14 cells in 500μl medium per well.  
 24-well plates: 1x105 cells in 1ml medium per well.  
 6-well plates: 3x105 cells in 2ml medium per well.  
2.1.5 Cryopreservation of cells 
For the purposes of long-term preservation, cells were re-suspended after 
trypsinisation in a freezing medium containing 40% DMEM or EMEM, 50% CF or 
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FCS as appropriate, and 10% dimethyl sulfoxide (DMSO) (Sigma, UK). 1ml aliquots 
were placed in 2ml cryovials (SARSTEDT, Germany) containing 0.5-1x10
6
 
resuspended cells each. The cryovials were stored in a Nalgene Cryo 1ºC freezing 
container (USA) at –80°C overnight for 24 hours prior to long-term storage in a 
liquid nitrogen container (-170°C). 
2.1.6 Thawing cells from liquid nitrogen 
To effectively recover frozen cell lines from liquid nitrogen, cells should be thawed 
and the DMSO removed as rapidly as possible. For this reason, each vial was thawed 
in a 37°C water bath and the DMSO contained in the freezing medium then diluted 
with the addition of 5 ml of fresh growth media. Cells were then centrifuged at 200 
g-force at room temperature for 5 min. The supernatant was removed and the cell 
pellet resuspended in 10 ml of appropriate normal pre-warmed medium and placed in 
a 75cm
2
 tissue culture flask for propagation as previously described (2.1.2 and 2.1.3).  
2.1.7 Assessing cell culture contamination 
Tissue culture requires strict control measures to prevent contamination. The steps 
taken to avoid cell contamination were as follows: 
 Penicillin and Streptomycin were used as an antibiotic mix in the growth 
medium to prevent bacterial infection.  
 Incubators were disinfected weekly using antimicrobial agents (Aquasan 
from Guest Medical) and tissue culture hoods were also cleaned thoroughly 
with a disinfectant (Tecknon, Thermo Fisher) prior to and upon each use. 
 Cells were tested for the presence of mycoplasma contamination every three 
months using MycoSensor
TM
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2.2 General methods for virology 
2.2.1 Viruses  
 
2.2.1.1 MCMV  
The parental MCMV (Smith strain) was derived from bacterial artificial chromosome 
(BAC) clone pSM3fr (named C3X or MW97.01) which contained the complete 
MCMV genome, described in previous studies (Messerle et al. 1997; Wagner et al. 
1999). It is important to note that recent DNA sequencing of the complete BAC 
genome of MCMV found four differences compared to the sequence published for 
MCMV Smith strain. Three point mutations and a frameshift in MCK-2 ORF 
resulted in prematurely truncated MCK-2 protein (Jordan et al. 2011). It was also 
noted that the virus stock of MCMV Smith strain contains mixtures of viruses with 
or without the frameshift mutation, suggesting that the mutation originated from the 
clonal selection process (Jordan et al. 2011). However, the sequence of MCMV BAC 
plasmid pSM3fr appears largely comparable to the sequence of the Smith strain.  
2.2.1.2 MCMVdie3 
The IE1 and IE3 mRNAs share the same first three exons which are spliced either 
with a fourth exon into the mature IE1 mRNA (Keil et al. 1987) or with a fifth exon 
into the IE3 mRNA (Messerle et al. 1992). The IE2 mRNA is transcribed in the 
opposite direction and spliced from three separate exons (Messerle et al. 1991). 
Angulo and colleagues (2000) describe the construction of MCMVdie3, in brief: 
almost the entire fifth exon in IE1/IE3 gene transcriptional unit was deleted from the 
MCMV genome of BAC plasmid pSM3fr (details of the genome map of the MCMV 
and MCMdie3 virus are shown in Figure 2.1). This means that the gene expression of 
this virus is restricted to IE1 and IE2, causing deficiency in viral growth (Angulo et 
al. 2000; Lacaze et al. 2011). Replication can be rescued by growing the virus on the 












Figure 2.1: Schematic diagram of the structural organisation of the major 
immediate-early region (MIE) of MCMV and MCMVdie3 viruses.  Coding 
exons are shown as blue boxes while non-coding exons are white boxes, with 
the arrows in these boxes indicating the direction of transcription. The gray box 
denotes the MCMV enhancer IE1/IE3 promoter, while the end products are 
shown in yellow boxes. Starting with MCMV, f ive exons located downstream of 
MCMV enhancer IE1/IE3 promoter generate two alternatively spliced major 
transcripts, IE1 and IE3. The IE1 transcript of MCMV is composed of exons 1 to 
4, and the IE3 transcript consists of exons 1 to 3 and 5. MCMVdie3, the 
deletion of the fifth exon of the IE1 gene is marked by the delta (∆).  
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2.2.1.3 HCMV-eGFP  
The full-genome of the HCMV strain AD169 was cloned into BAC-pHB5 plasmid 
(Borst et al. 1999), which was then used to generate HCMV expressing enhanced 
green fluorescent protein (eGFP). AD169-derived recombinant virus additionally 
contain eGFP coding sequences, which was inserted as a separate ORF upstream of 
UL127 ORF but downstream of the UL127 promoter (Angulo et al. 2000) (The map 
of the HCMV and HCMV-eGFP genome are illustrated in Figure 2.2).  
 
Figure 2.2: Schematic representation of the major immediate-early region 
of HCMV and HCMV-eGFP viruses. Coding exons are shown as blue boxes 
and gray box represents the enhancer elements, which are flank ed by the 
promoters and transcription units IE1/2 and UL127. Beginning with HCMV, the 
region downstream from the promoter is conserved with MCMV, which gives 
rise to two transcripts IE1 and IE2 (known as IE3 in MCMV). Conversely, the 
genomic region on the other side of the regulatory elements is not conserved 
between MCMV and HCMV. In the recombinant HCMV-GFP virus, the coding 
sequence for enhanced green florescence protein (eGFP) was fused to UL127 
as it is placed downstream of the UL127 promoter sequence and upstream of 
its coding sequence. The GFP reporter sequence is i l lustrated in green.  
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2.2.2 Viral stock propagation 
In order to prepare a bulk viral stock of MCMV, confluent 150cm
2
 culture flasks of 
NIH-3T3 cells were infected at MOI of 0.01 in 20 ml of growth medium per flask. 
The cells and the supernatant were collected 5-7 days after infection when cytopathic 
changes were observed in the infected cells. The cells and supernatant were 
centrifuged for 15 min at 800 g-force, collected, and the pellet from the cell debris 
was discarded. The cell-free supernatant was stored at -70°C in sterile in 5-10 ml 
aliquots. The same method was utilised to propagate MCMVdie3, grown on the 
complementing cell line NIH-3T3-Bam25. HCMV was grown on HEF cells using 
the same procedure, although in this case the infection was at MOI of 1. In order to 
reduce the risk of viral mutations occurring over multiple rounds of infection, a 
master stock was produced in a T25 flask from seed viral stock of low passage 
number and was stored at -70°C in aliquots of appropriate volume. These aliquots 
were then used to make the working viral stocks.  
2.2.3 Titration of virus by plaque assay 
Plaque assays are the standard method for estimating the number of infective 
particles in a sample. These were performed on P53-null MEF cells for MCMV, 
NIH-3T3-BAM25 cells for MCMVdie3, and HEFs for HCMV. The cells were 
seeded at a density of 4x10
4
 cells in 500μl per well in 48 well plates, which were 
then incubated overnight in a 37°C incubator. A ten-fold serial dilution series of a 




. 100μl of each dilution for 
each virus was added to triplicate wells. After an hour of incubation with the virus at 
37°C, the cells were washed using warm growth media and then overlaid with a thick 
layer of a 0.25% agarose-medium mixture. This agarose-medium mixture was 
prepared by diluting a 2.5% agarose solution (2.5g of agarose dissolved in distilled 
water) 1:10 in a 3% serum supplemented medium. Agarose was used in order to 
prevent the spread of virus from infected cells to uninfected cells. Four to six days 
later, plaques were counted for each well and the viral titres were expressed as 
plaque forming units per ml (PFU/ml) using the following equation: 
PFU/ml = Average number of counted plaques * individual dilution factor * 10 (for 
case of 48 well plates)  
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Based on the above calculation, the titer of a given virus stock is determined and can 
be used to determine the multiplicity of infection (MOI) required for experiments. 
The MOI corresponds to the number of PFUs delivered into each cell. For the 
purpose of infecting cells, the necessary quantity of virus was combined with 
warmed growth media in order to produce an infectious inoculum. The total volume 
of infecting inoculum made for different cell culture plates is presented below: 
  96-well plates - 50μl of viral inoculum  
 48-well plates - 100μl of viral inoculum 
 24-well plates - 200μl of viral inoculum.  
 6-well plates - 1ml of viral inoculum 
In all experiments conducted in this study, cells were incubated with the viral 
inoculum for an absorption period of one hour at 37°C in the incubator. The cells 
were then washed twice with medium and replaced with normal growth medium. For 
MCMV, the hours post infection were counted starting at the end of the viral 
adsorption period; while in HCMV, it corresponds to the start of incubation with the 
virus. For mock infections the same volume of media was used but without virus. 
The mock infected wells were washed and the medium replenished as for the 
infected wells.  
2.2.4 Treatment of cells with kinase inhibitors 
2.2.4.1 Ly294002 
Ly294002 (Cell Signalling Technology) is a potent cell-permeable inhibitor of 
inhibitor of phosphoinositide 3-kinases (PI3Ks). It abolishes PI3K activity without 
affecting other lipid or protein kinases such as PI4 kinase, PKC, PKA, MAP kinase, 
EGFR, and c-Src (Mahoss et al. 1994). Ly294002 was resuspended in DMSO and 
used at a concentration of 10 μM and 25 μM.  
2.2.4.2 TGX-221 
TGX-221 (Cayman Chemical) is a selective ATP-competitive inhibitor of PIK3CB 
(aliases PI3Kβ, p110β) at concentration of (5 ~ 50 nM). However, TGX-221 can also 
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inhibit other isoforms of PI3K (i.e. p110α and p110δ) at higher concentrations. 
TGX-221 was resuspended in DMSO and used at 50 nM.  
2.2.4.3 Treatment of Cells  
For investigation of the effect of kinase inhibitors on viral growth, cells were pre-
treated with Ly294002 or TGX-221 inhibitors 2 hours prior to infection. Equal 
amount of DMSO was added to the control. The cells were washed after 2 hours of 
HCMV infection and the culture media replaced with normal growth media.  Another 
aliquot of kinase inhibitors or DMSO control was added to the cultured cells.   
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2.3 Transfection into cells 
2.3.1 DharmaFECT1 transfection  
DharmaFECT1 transfection reagent (Dharmacon, Thermo Scientific) is a lipid based 
reagent that is an efficient means of delivering synthetic RNA (siRNA, miRNA 
mimic or inhibitor) into cultured cells. The lipid reagent encapsulates the small RNA 
molecules with cationic lipids that mediate the transfection process into the cells. The 
method used for the purposes of transfecting both mouse NIH-3T3 or human MRC-5 
cells was a reverse transfection in which cells were simultaneously seeded and 
transfected. NIH-3T3 or MRC-5 cells were grown to a confluence of 70-80% or 85-
90% in tissue flasks. The cells were trypsinized, counted, and diluted in antibiotic-
free medium to an appropriate volume in order to ensure the desired seeding density 
per well, as mentioned above in 2.1.4. Cells were then incubated on ice until the 
transfection mixture had been prepared.  
The siRNAs (SMARTpools-ON-TARGETplus modification), miRNA mimics 
(miRIDIAN microRNA Mimics), miRNA inhibitors (Hairpin Inhibitors), and their 
negative controls were purchased from Thermo Scientific Dharamcon, USA. All of 
these were supplied in 5 nmol powder form and were dissolved in 1x siRNA buffer 
(Thermo Fisher) in order to produce a concentrated stock of 20 μM. This stock was 
used to prepare working stocks at 500 nM. For transfection of cells, an appropriate 
volume of the 500 nM stock was mixed with an equal volume of opti-MEM buffer 
(Gibco, Invitrogen) (for volumes see Table 2.1). In parallel, the lipid mixture was 
prepared by mixing the DharmaFECT1 reagent with opti-MEM buffer to give 
concentrations of 4% for NIH-3T3 and 3% for MRC-5 transfection. The lipid-opti-
MEM mixture was gently pipetted up and down, and incubated at room temperature 
for 5 min. The lipid-opti-MEM mixture was added to siRNA/miRNA-opti-MEM 
mixture and incubated for 20 min at room temperature. The appropriate volume of 
the transfection mix was then added into a well, followed by the addition of cells in 
antibiotics-free medium, see Table 2.1. The plate was then tapped every 10 min for 
30 min to ensure that the miRNA/siRNA liposomes mixed fully in the cells and that 
the cells were equally distributed in each well. Cells were incubated at 37°C for 48 
Materials and Methods Chapter 2 
57 
 
hours before samples were harvested or infected with a virus, depending on the 
experimental objective.  
Plate format Volume of 500 nM 










6-well plate 50µl 50µl 100µl 






24-well plate 12.5µl 12.5µl 25µl   






96-well plate 5µl 5µl 10µl   







Table 2.1: Parameters for siRNA and miRNA transfection with 
DharmaFECT1 in various multi-well plates. 
 
2.3.2 LipofectamineTM 2000 transfection  
Lipofectamine
TM
 2000 transfection reagent was used for the transfection of DNA 
plasmids (see Table 2.2) or for co-transfecting DNA plasmids with siRNA or 
miRNA into cultured cells. The number of cells, amount of DNA, and volume of 
transfection reagent differed according to the multi-well plate used in each 
experiment, as illustrated in Table 2.3 for DNA transfection and in Table 2.4 for the 
co-transfection of DNA and siRNA or miRNA. For each transfection reaction, DNA 
was diluted in opti-MEM to ensure the desired concentration in the appropriate 
volume. The lipofectamine-opti-MEM mixture was then prepared at 2.5% and 
incubated for 5 min at room temperature, after which it was added to the transfectent 
and incubated for 20 min at room temperature. The mixture was aliquoted into wells 
and cells were added, as shown in the Tables 2.3 and 2.4. The plates were then 
incubated at 37°C and, at 24 hours post transfection, the medium was replaced with 
standard culture media.  
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Plasmid DNA Supplier  
Firefly luciferase reporter  
PGL4.1 basic vector 
Progema (Kind Gift of Dr. Finn Grey) 
Renilla luciferase reporter  
PhRL-SV40  
 (Kind Gift of Dr. Anton Enright) 




Table 2.2: Plasmid DNAs used in transfection. 
 
Plate format DNA:Opti-MEM  Lipid-Opti-MEM 
mixture  
Lipofectamine% 
 Cells count 
in media 
















Table 2.3: Parameters for plasmid DNA transfection using Lipofectamin e
TM
 









 Cells count 
in media 
6 well-plate 1µg of DNA mixed with 50µl 
of 500nM miRNA/siRNA in 
100µl of opti-MEM 








250ng of DNA mixed with 
12.5µl of 500nM 










50ng of DNA mixed with 5µl 
of 500nM miRNA/siRNA in 








Table 2.4: Parameters for plasmid DNA and siRNA/miRNA co-transfection 
using Lipofectamine
TM
 in multi-well culture plates.  
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2.3.3 Cell viability  
The viability of cells was assessed using the cell titer-blue reagent (Promega). 20µl 
of the reagent was added to each well, which contained 100µl of media in a 96-well 
plate. The plate was tapped for 30 seconds and incubated for 2-4 hours at 37°C. Live 
cells will irreversibly reduce resazurin (non-fluorescent) in the blue reagent into the 
fluorescent molecule resorufin, whereas dead cells will have lost this capacity. The 
fluorescence was detected using the Varioskan Flash Multimode Reader 
(Thermofisher scientific) at 590nm. The cell viability was calculated by comparing 
the fluorescence signal from transfected cells to control cells.  
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2.4 RNA isolation and characterisation   
2.4.1 RNA extraction  
2.4.1.1 Extraction of total RNA using TRIzol  
For RNA extraction, cells were washed twice with warm PBS before lysing in tissue 
culture plates using 200µl (24-well plates) or 400µl (6-well plates) of TRIzol reagent 
per well (Invitrogen, USA). The plates were gently tilted in order to ensure the equal 
distribution of TRIzol reagent over the cells and after 5 min RNA samples were 
collected into sterile 1.5 ml microcentrifuge tubes. The lysed RNA samples were 
stored short-term at -20ºC or long term at -70ºC. TRIzol samples were then thawed 
and 80μl or 40 μl chloroform was added to 400μl or 200μl samples, respectively. The 
tubes were then capped and inverted 5 times to ensure that they were well-mixed. 
TRIzol samples were incubated at room temperature for 2-3 min and then 
centrifuged at 12,000 g-force at 4
o
C for 15 min, after which the clear aqueous phase 
harbouring the total RNA was carefully removed and transferred to a sterile 1.5 ml 
microcentrifuge tube, avoiding any aspiration of the white interface, which contains 
precipitated DNA and/or TRIzol containing cellular debris. The aqueous phase was 
approximately 180μl and 80μl of 400μl and 200μl RNA-TRIzol samples, 
respectively. The aqueous phase was then precipitated by adding 1/10 volume of 3M 
NaOAc (pH 5.7) (AppliChem, Germany), 0.5μl of 15 mg/ml glycogen blue 
(Ambion, USA), and 2x volumes of cold ethanol (100%). This was mixed by 
inversion, and incubated for an hour at -70
o
C or overnight at -20
o
C. To pellet the 
RNA, the samples were spun at 4
o
C for 30 min at 12,000 g-force. Then, 100% 
ethanol was carefully aspirated from the edge and close from the base of each tube 
without touching or disrupting the RNA pellet. Each RNA pellet was washed twice 
with one volume 70% cold ethanol. The samples were mixed by inversion and 
centrifuged at 12,000 g-force at 4
o
C for 10 min. The washed pellet was then air dried 
for 5-10 min and resuspended in 20-30μl of RNase/DNase free H2O (GIBCO, 
Invitrogen, UK) with 0.1 mM EDTA (Promega, USA). RNA samples were placed in 
a water bath that was maintained at 55
o
C for 10 min, and then transferred into ice.  
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2.4.1.2 Quality assessment of total RNA 
The concentration and degree of contamination of the acquired RNA samples was 
assessed on a Nanodrop ND-1000 spectrophotometer (Thermo scientific, USA), 
which operates by means of locating the sample between two optical pedestals 
(upper and lower). The level of UV absorption was measured at wavelengths of 230, 
260 and 280nm. 2μl of purified total RNA sample was used for spectrophotometry. 
All RNA samples in experiments have a A260:A280 ratio of >1.8. Protein 
contamination is likely to have occurred if the A260:A280 ratio is < 1.8, in which case 
samples were re-extracted with TRIzol. If the ratio at A260:A230 is <1.5, phenol or 
chloroform contamination is possible, these samples were re-precipitated. In order to 
assess RNA integrity, a 12% RNA gel was prepared using the SequaGel (UreaGel 
System), which consists of UreaGel Concentrate, UreaGel Diluent, and UreaGel 
Buffer (National Diganostic). To cast 2 small gels, 4.8 ml of UreaGel Concentrate, 
4.2 ml UreaGel Diluent, 1ml UreaGel Buffer, 4µl TEMED, and 80µl of APS were 
mixed, poured immediately into the space between the short and long slides, and the 
comb then fixed in place. 0.8~1µg of RNA samples were mixed with 2x RNA 
loading buffer and were then denatured at 95°C for 20 seconds, after which they 
were snap cooled on ice.  This RNA samples were loaded in the UREA-TBE gel and 
run in 0.5x TBE at 100-120 Volt for 1-2 hours. The gel was then stained with 
ethidium bromide (EtBr) (Invitrogen) and visualised on a UV transilluminator 
(SYNGENE). Intact total RNA is characterised by three distinct bands comprising 
5S, 5.8S rRNAs, and tRNAs. No smeared RNA is indication of good-quality.  
2.4.1.3 Extraction of total RNA using Qiagene   
The RNA samples used for microarray expression profiling were extracted using the 
miRNeasy Mini Kit (QIAGEN). The miRNeasy Mini Kit is designed to isolate 
miRNA and total RNA from tissue and cell samples using spin columns that having 
binding capacities for RNAs > 18 nt. Cultured cells were harvested from 6-well 
plates using 400µl of QIAzol lysis reagent and were transferred into sterile 1.5ml 
tubes and incubated at room temperature for 5 min before the addition of 80µl of 
chloroform to each sample. The tubes were then centrifuged at 12,000 g-force at 4°C 
for 15 min in order to separate the aqueous phase that contains the total RNA. The 
upper aqueous phase (~ 180µl) was transferred into a clean 1.5 ml tube and 1.5x 
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volume of 100% ethanol (270µl) was added and thoroughly mixed by pipetting up 
and down several times. This aqueous-ethanol mixture was transferred to a spin 
column in a collection tube, which was centrifuged at 12,000 g-force at room 
temperature for 1 min. The flow-through was discarded from the collection tube and 
the spin column was then washed for 1 min with 700μl of RWT buffer. Again the 
flow-through was discarded and the spin column was washed twice with 500μl RPE 
wash buffer by centrifugation at 12,000 g-force for 1 min. The flow-through and 
collection tube were discarded and the spin column was placed in a clean collection 
tube. Spin columns were then centrifuged for 1 min at 12,000 g-force to ensure that 
no residual RPE remained in the column, after which the columns were placed in 
clean 1.5 ml tubes and eluted with 30μl of 0.1 mM EDTA in RNase/DNase-free 
water. Purified RNA was collected in the flow through following centrifugation of 
the spin column in a fresh collection tube at 12,000 g-force. The 2100 Bioanalyzer 
(Agilent, CA, USA) was used for the assessment of the integrity of extracted RNA 
samples. This stage was performed by Dr. Amy Buck at the Division of Pathway 
Medicine, University of Edinburgh, UK. All RNA samples had RIN > 9.  
2.4.2 Reverse transcription polymerase chain reaction (RT-PCR) 
To determine the relative expression of miRNAs and mRNA transcripts between 
samples across multiple experiments, total RNA was reverse-transcribed into 
complementary DNA (cDNA) before being amplified and quantified by qRT-PCR. 
For the reverse transcription step, the miScript II RT Kit (QIAGENE) was used. The 
reaction components and their amounts were pipetted in a total reaction volume of 
10µl, in accordance with the manufacturer’s recommendations (see Table 2.5).  
Component Amount 
5x miScript HiFlex Buffer 2μl 
10x miScript Nucleics Mix 1μl 
miScript Reverse Transcriptase Mix 1μl 
Total RNA (template) 200ng  
Final volume  10μl 
 
Table 2.5: The components of the reaction mix of reverse transcription.  
After the addition of 200ng of total RNA to the PCR tube (Axygen Scientific) 
containing the reverse-transcription master mix, the tubes were gently tapped and 
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centrifuged for 5 seconds using a microcentrifuge (Starlabs). The PCR tubes were 
kept on ice during the preparation stage. The RT reaction was carried out on a 




The 10μl of cDNA produced in each RT reaction was diluted in RNase-free water 
(1:200 dilution), prior to qPCR reaction. The diluted cDNA samples were used for 
miRNA and mRNA quantification. For the efficiency verification of primers, 10-fold 
serial dilutions (1:10, 1:100, 1:1000, 1:10,000) of pooled cDNA were prepared from 
different samples and used to generate standard curves for each target and control 
RNA.  
2.4.3 Quantitative real-time polymerase chain reaction (qRT-PCR)  
2.4.3.1 Quantitative real-time PCR for mature miRNA  
The quantification of expression levels of mature miRNA was conducted using the 
miScript SYBR® Green PCR Kit, which includes a universal primer (reverse primer) 
and SYBR Green PCR master mix. The forward primers were purchased from 
(QIAGENE) for each miRNA of interest. The qRT-PCR reaction mix was prepared 
in accordance with the manufacturer’s recommendations, as shown in the Table 2.6 
below.   
Components  96-well plate 384-well plate 
2x QuantiTect SYBR Green 
PCR Master Mix 
4µl 2µl 
10x miScript universal primer 1µl 0.5µl 
RNase-free water 3µl 1.5µl 
10x miScript specific primer 1µl 0.50µl 
cDNA template (1:200 dilution) 1µl 0.50µl 
Total volume per well  10µl 5µl 
 
Table 2.6: The components of the reaction mix for detecting miRNAs by 
qRT-PCR. 
The initial qRT-PCR mix was prepared from SYBR Green PCR master mix, 
universal primer and RNase-free water, which were mixed together gently and 
Steps Temperature Time 
cDNA synthesis 37ºC 60 min 
Reverse transcriptase 
inactivation 
95ºC 5 min 
Cool 4ºC For ever 
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thoroughly. This initial qRT-PCR mix was then aliquoted into sterile 2 ml tubes and 
one of the specific forward primers added. This specific qRT-PCR mix was then 
pipetted into 96 or 384 well plates using multichannel pipettes in order to minimise 
the number of pipetting steps. In the case of 384-well plates, 4.5µl of the specific 
qRT-PCR mix was pipetted into each well, while in 96-well plates 9µl was pipetted 
per well. Each diluted cDNA sample (1:200) was then added to the well (two 
technical replicates were carried out). The qRT-PCR plate was then carefully and 
tightly sealed, after which it was centrifuged at 800 g-force for 2-3 min to ensure that 
all the cDNA was at the bottom of well, as well as to remove bubbles. The qRT-PCR 
plates and seal films were purchased from Roche. The following thermal profile was 





qRT-PCR was performed on the LightCycler® 480 Real-Time PCR instrument from 
Roche Applied Science and cycle threshold (CT) values were calculated using 
Roche’s LightCycler® 480 Software. The CT values of the amplified products in 
qRT-PCR analysis are based on the detection of the fluorescent SYBR Green dye, 
which is specific for double-stranded DNA (dsDNA). Target miRNA levels were 
normalized to the non-coding small nuclear RNA, U6 snRNA and miR-16. These 
non-coding RNAs have been found to be abundant in the examined cells and to be 
stable over a range of experimental treatments.   
2.4.3.2 Quantitative real-time PCR for pri-miRNA and mRNA 
The LightCycler® 480 SYBR Green I Master Kit (Roche Applied Science) was also 
used to quantify the expression of mRNAs and pri-miRNA in samples. The specific 
forward and reverse primers were designed for each RNA using the online 
ProbeFinder software (Roche Applied Science) at (http://qRT-
PCR.probefinder.com/roche3.html). Primers were produced by Invitrogen (see the 
Steps Temperature Time Cycle 
Initial denaturation   95ºC 15 min 1 cycle  
Amplification  
Denaturation 













Cooling  40ºC Hold 1 cycle 
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list of human primers in Table 2.8 and mouse primers in Table 2.9). Each tube 
containing lyophilised primer was briefly centrifuged, after which a 100 µM stock 
solution was made in DNase/RNase-free water and stored at –20°C. The 
concentrated stock solution was then further diluted to produce a working stock at a 
final concentration of 10 µM. The primers were also designed to have very similar 
melting temperatures, around 60°C, the temperature of the annealing step. All the 
primers were tested and experimentally validated as described below (2.4.3.3) before 
a qRT-PCR plate was run. As previously described (2.4.3.1), the kit components, 
primers, and diluted cDNAs were thawed on ice and the qRT-PCR mix was prepared 
in accordance with the manufacturer’s instructions, as shown in the Table 2.7 below.  
Components  96-well plate 384-well plate 
2x SYBR Green I Master  
 
5µl 2.5µl 
RNase-free water, PCR 
Grade 
3µl 1.5µl 
Forward primer (10 µM) 0.5µl 0.25µl 
Reverse primer (10 µM) 0.5µl 0.25µl 
Total volume per well  9.5µl 4.5µl 
 
Table 2.7: The components of the reaction mix for detecting mRNAs by 
qRT-PCR.  
This mix was aliquoted into sterile tubes to which a specific set of primers was 
added, after which a volume of 9µl or 4.5µl of the specific mix was pipetted into the 
wells of 96 or 384-well plate, according to the experiment’s layout. 0.5µl of cDNAs 
were added into the wells at the last in two repeats, the plate was sealed, centrifuged, 
and then run in the LightCycler® 480 Real-Time PCR instrument (Roche Applied 




Steps Temperature Time Cycle 
Initial denaturation 95ºC 5 min 1 cycle 
Amplification  
Denaturation 













Cooling  40ºC Hold 1 cycle 
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 Target mRNA and pri-miRNA levels were normalized to the housekeeping GAPDH 
mRNA, which maintains stable expression in various experimental conditions.  
 












































































Table 2.9: A list of the mouse primers used in qRT-PCR experiment. 
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2.4.3.3 qRT-PCR analysis 
2.4.3.3.1 Validation of qRT-PCR primers 
All designed primers should meet at least two important criteria to be validated: 1) 
amplification efficiency is between 80 and 110% and 2) a single amplicon is 
produced. The traditional method for assessing amplification efficiency requires a 
standard curve for each primer. Therefore, 10-fold serial dilutions were prepared 
from pooled cDNA samples (20ng/µl, 2ng/µl, 0.2ng/µl, 0.02ng/µl, 0.002ng/µl). The 
reverse transcription (RT) and qRT-PCR were then performed in accordance to the 
protocol outlined above (2.4.2 and 2.4.3), with three technical replicates for each 
dilution point. The average CT values were plotted versus the initial cDNA input (see 
an example in Figure 2.3) and the slope was calculated for each primer. The 
amplification efficiency (E value) can be determined from the slope as follows: E= 
(10
(-1/slope)
-1)*100%. Slopes between -3.8 and -3.1 correspond to amplification 
efficiencies between 80% and 110%. All primers used have shown amplification 
efficiency > 80 %. As for the second criterion, a default melting program was run on 
qRT-PCR instrument after the completion of cycling program. The melting curve 
analysis have shown a clean amplification of a single amplicon, which in some cases 
was also confirmed by a presence of a single band corresponding to the predicted 
length of the amplicon on the agarose gel.  
      Figure 2.3: Standard curves for primer used in qRT-PCR assay. 
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2.4.3.3.2 qPCR quantification method 
For the most reliable qPCR
 
results, the amplification efficiencies of the target and 
control RNAs should be approximately equal. To calculate the changes in the 
miRNA or mRNA expression levels, two strategies are widely used: absolute 
quantification, where the absolute numbers of RNA copies in a sample is calculated 
(this requires the generation of the standard curve for the known quantity of RNA) 
and relative quantification, where a comparison of the relative expression levels of 
the target miRNA or mRNA is carried out between samples over a period of time or 
during exposure to treatment. The relative quantification for the miRNA or mRNA is 
performed as follows: 
1. For each biological sample the CT values of the two technical replicates are 
averaged. 
2. The ∆CT relative change is then calculated for each biological sample using 
the comparative CT method, also known as the 2
-ΔCt
 method applying 
equation ∆CT = CT(Target RNA) – CT(Reference RNA), where reference RNA stands 
for a control small non-coding RNA or a housekeeping gene. 
3. The ∆CT values are then compared between the samples of interest and their 
experimental controls (calibrators), such as untreated or mock infected in 
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2.4.4 Northern blot analysis 
2.4.4.1 Buffers and solutions used for Northern method 
10x TBE Buffer (Tris-borate-EDTA): 109g Tris base, Boric acid 55.6g, 50 ml of 
500 mM of EDTA, which is made up to 1L using ddH2O.  
15% TBE-UREA gel: 6ml concentrate reagent (SequaGel, National diagnostics), 
3ml dilute reagent (Sequa gel, National diagnostics), 0.5 ml 10x TBE, 0.5 ml ddH2O, 
100µl of 10% ammonium persulfate (APS) (Sigma) and 4µl 
Tetramethylethylenediamine (TEMED) (Sigma) 
2x loading dye: 8 M urea (Sigma), 5 mM EDTA (Promega), 0.05 % bromophenol 
blue(Sigma), 0.05% xylene cyanol (Sigma). 
Cross-linking Solution: 245µl of 12.5M 1-methylimidazole, 9ml of ddH2O, adjust 
pH to 8, 0.753g EDC and then increase the volume to 25ml using ddH2O.  
Wash Buffer 1 (2x SSC, 0.1% SDS): 100 ml 20x SSC (Biosciences), 10 ml 10% 
SDS (Sigma), and 890 ml ddH2O. SSC and SDS stand for sodium chloride-sodium 
citrate buffer and sodium dodecyl sulfate.  
Wash Buffer 2 (1x SSC, 0.1% SDS): 50 ml 20x SSC (Biosciences), 10 ml 10% 
SDS (Sigma), and 940 ml ddH2O. 
Wash Buffer 3 (0.1x SSC, 0.1% SDS): 5 ml 20x SSC (Biosciences), 10 ml 10% 
SDS (Sigma), and 985 ml ddH2O. 
Stripping Buffer (0.1% SDS): 5 ml 10% SDS and 495 ml ddH2O.  
All the buffers were prepared with double-distilled water (ddH2O) from a Millipore 
system (>18 MΩ cm).  
2.4.4.2 RNA gel electrophoresis  
For each experimental condition, a pool of total RNA was prepared from the three 
technical repeats. Each pooled RNA sample (5µg in mouse/condition and 7µg in 
human/condition) was resuspended in a total volume of 7 or 8µl using 
DNase/RNase-free water. In cases where the total volume of pooled RNA exceeded 
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7 to 8µl, the samples were divided into approximately equal volumes and then 
concentrated in speedvac (Savant, USA) using a low drying rate. Following the 
speedvac step, RNA samples (7µl to 8µl) were mixed with an equal volume of 2x 
urea loading dye.  The RNA samples were denatured by heating them to 95°C for 20 
seconds, after which they were snap cooled on ice. The RNA samples were resolved 
on a denaturing 15% TBE-Urea gel, which had been made and allowed to set for >30 
min. The gel was pre-run in 0.5% TBE buffer for > 30 min at 100 Volt. The wells in 
the gel were also cleaned with a syringe in order to remove air bubbles and urea, 
which collected at the bottom of each well, before loading an equal amount of the 
RNA samples (14µl to 16µl). At the same time, a radiolabeled RNA decade marker 
(10 to 150 bases) (Ambion, Applied Biosystem) was loaded to serve as a nucleotide 
length standard. Samples were run at 120 Volt for ~1.5-2 hours until the 
bromophenol blue dye reached ¾ of the overall length of the gel.  
2.4.4.3 The synthesis of Northern γ-32P labelled oligonucleotides 
probes and RNA-labelled marker   
Reverse complement oligonucleotides for miR-199-3p, miR-199-5p, miR-214, 
miR-16, and tRNA sequences (Table 2.10) were produced by Invitrogen.  





tRNA (Gly) 5′-GGCGAGAATTCTACCACTGAACCACCAATGC-3′ 
 
Table 2.10: Primer sequences used for Northern blot.  
The radioactive labelling at the 5′- termini was carried out using [γ-
32
P]-dATP and 
T4 Kinase Kit (Invitrogen) with 20 µM of each oligonucleotide. The reaction was 
incubated at 37°C for 45 to 60 min in a thermocycler. The oligonucleotide probes 
were subsequently purified from the reaction components using microSpin™ G-25 
columns (GE Healthcare). The labelled probes were then diluted in 50µl of 3 mM 
EDTA. The date of labelling was written on the tube and then it was stored at -20°C 
in a protective radioactive box.  
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For the decade RNA ladder, 100ng of marker RNA, 1μl 10x Kinase buffer, 1μl [γ–
32
P]ATP, and 1μl T4 Polynucleotide Kinase were mixed in a total volume of 10 μl 
and incubated for one hour at 37°C. 2μl 10x cleavage reagent and 8μl of water was 
then added to the mixture and incubated at room temperature for 5 min. The labelled 
RNA marker was mixed with 20μl loading buffer and stored at -20°C. The required 
volume of RNA ladder was heated at 95°C for 5 min before use. 
2.4.4.4 Northern blotting, cross-linking and hybridisation using γ-32P 
labelled oligonucleotides probes  
To transfer RNA from a denaturing gel, a sheet of nylon membrane (Hybond N) (GE 
Healthcare, Fisher Scientific) and 4-6 sheets of Whatman filter paper (Whatman Ltd, 
UK) of similar size to the gel were soaked in cold 0.5% TBE. The blotting sandwich 
of pad, filter papers, gel, nylon membrane, filter papers and pad was assembled (from 
negative to positive electrodes) and immersed in cold 0.5% TBE. The transfer was 
conducted at 80 Volt for one hour in a cold room (4°C). To cross-link the transferred 
RNA, the nylon membrane was placed on a pad containing EDC cross-linking 
solution for 2 hours at 50°C in a Techne oven. After the cross-linking stage, the 
membrane was immersed in 4-5 ml of Perfect Hyb Plus Hybridisation buffer (Sigma) 
in a 15 ml falcon tube for 30 min at 42°C in a rotary oven. 10µl of the 
32
P-labeled 
probe was added to the hybridisation buffer and incubated for at least 6 hours or 
over-night at 42°C in a Techne hybridisation oven. The membrane was then washed 
successively at 42°C with increasingly stringent buffers: 1) 2x SSC, 0.1% SDS, 2) 1x 
SSC, 0.1% SDS, and 3) 0.1x SSC and 0.1% SDS. Following the washes, the 
membrane was kept in a sealed film and exposed to a phosphorimager screen 
(Molecular Dynamics, LabX, USA) for 24 to 48 hours. The screen was scanned 
using a Typhoon Trio variable mode imager (GE Healthcare) and blanked for 15 min 
with an imager eraser (BioSciences). The membrane was stripped to remove the 
radio-labelled probe to allow re-hybridisation with a new 
32
P-labelled probe. The 
stripping buffer was boiled in the microwave and the membrane was placed in this 
buffer. The membrane left for ~ 2 hours in the stripping buffer at room temperature. 
The membrane was re-exposed in phosphorimager for 6 to 24 hours to ensure that no 
bound probe remained before re-hybridisation with another probe. 
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2.4.5 Primer extension analysis 
2.4.5.1 Buffers and solutions used for Northern method 
10x annealing buffer: 200 mM Tris-HCL (pH 8.0), 300 mM KCl, 5 mM EDTA (pH 
8.0) 
6x reverse transcriptase buffer: 300 mM Tris-HCL (pH 8.0), 300 mM KCl, 5 mM 
EDTA (pH 8.0), 60 mM MgCl2, 60 mM DTT, 3 mM EDTA.  
2.4.5.2 Primer extension  
The primer extension technique was used to determine the transcription start site of 
the pri-miRNA. Two primers that have complementary sequences to different 
regions close to the 5′ end of the RNA transcript were designed and 
32
P-labelled (as 
described in 2.4.4.3). 20µg of total RNA from mouse liver and 0.5 pmol of each 
primer were mixed with annealing buffer in a total volume of 4µl. The primer was 
annealed to RNA by incubating tubes at 90°C for 2 min, then placing them at room 
temperature. During the incubation period, the reverse transcriptase mix was 
prepared (1.5µl of 6x RT buffer, 1.8µl dNTPs (2.5 mM), 0.2µl reverse transcriptase, 
0.2µl RNA inhibitor, 1.3µl DNase/RNase-free water per reaction). Following the 
cooling of annealed RNA primer, 5µl of the reverse transcriptase mix was added into 
each reaction tube to make 9µl. The reaction tubes were then incubated at 42°C for 
40min, after which 9µl of 2x loading dye was added to stop the reaction. Samples 
and radiolabeled RNA decade markers were loaded onto a TBE-UREA gel and run at 
120 Volt until the bromophenol blue dye reached ¾ of the gel. The top gel slide was 
carefully removed and the gel was wrapped in cling film. The wrapped gel was then 
exposed in the phosphorimger for 24 hours at 4
o
C, after which the screen was 
scanned in the Typhoon Trio variable mode imager (GE Healthcare).  
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2.5 DNA purification and cloning   
2.5.1 Buffers and solutions used for DNA techniques  
Lysis buffer: 100 mM Tris-Hcl (pH=8), 5 mM EDTA (pH=8), 200 mM NaCl, 0.2% 
SDS, 250 µg/ml of proteinase K.  
2.5.2 The extraction of genomic DNA 
In order to isolate genomic DNA from cultured NIH-3T3 cells, the cells were 
trypsinised and centrifuged for 10 min at 200 g-force. The supernatant was discarded 
and the pellet resuspended in 1ml of 1x PBS. After the pellet had been washed, it 
was lysed using 1 ml of lysis buffer (for 1x10
6
 cells) for 3-4 hours at 50°C. Phenol–
chloroform extraction was then used for purification of the DNA sample. An equal 
volume of phenol–chloroform was added to the cell lysates and then vortexed at 
room temperature for 15 seconds. The sample was centrifuged at 12,000 g-force for 
20 min. The aqueous phase was collected and phenol–chloroform step repeated twice 
more. The DNA in aqueous phase was precipitated using 60µl of 5M NaCl and 2.5x 
volume ice cold 70% ethanol at -70°C for an hour, then centrifuged at 12,000 g-force 
for 10 min. The supernatant was removed and the pellet washed twice with 70% 
ethanol, dried for 5min and finally resuspended in 50µl of DNase/RNase free water.  
2.5.3 Cloning the promoter into basic PGL4.10 vector 
2.5.3.1 The amplification of the pri-miRNA promoter sequences  
The mouse promoter sequence was obtained from Gene2Promoter, which is included 
in the Genomatix package (http://www.genomatix.de/). The basic PGL4.10 vector 
was kindly provided by Dr. Finn Grey (The Roslin Institute, University of 
Edinburgh, Edinburgh). Primers were manually designed with the help of 
oligonucleotide properties calculator software 
(http://eu.idtdna.com/analyzer/applications/oligoanalyzer/default.aspx). The 
annealing temperature and GC content (40 to 60%) for each pair of primer were 
similar. The forward and reverse primers contain restriction sites, for either XhoI or 
HindIII to allow cloning into the PGL4.10 vector as well as 3 nt (CCG) to act as a 
loading pad for the restriction enzyme (listed in Table 2.11). The primers were 
purchased from Invitrogen and resuspended at find concentration of 10 pmol/µl, as 
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described above (2.4.3.2). The PCR reactions were performed as described below 
(Table 2.12) using Phusion
®
 high-fidelity DNA polymerase (Finnzymes, New 
England Biolabs, UK). The PCR reactions were mixed gently and thoroughly, after 




Table 2.11: A list of the primer sets used in amplification of the promoter 
sequence. Restr iction sites are underlined and flanking cushion sequences are 
italic.  
 
Steps Temperature Time Cycle 
Initial denaturation 98ºC 2 min 1 cycle 
Amplification  
Denaturation 













Final extension 72ºC 7 min 1 cycle 
Cooling 4ºC Hold 1 cycle 
Primer Sequence Melting 
Temp 
Forward  primer  
Full-length  
(-596,+100) 
5′-CCGCTCGAGAAAAGAAAGGGGGGAGC -3′ 59.1°C 
Reverse primer   5′-CCGAAGCTTAGAGCCTGTCTTCCTGC -3′ 60.6°C 
Forward  primer  
(-421,+100) 
5′-CCGCTCGAGAGCCCAGATCAGGCAACAAATTTG-3′ 65.9°C 
Reverse primer   
 
  5′-CCGAAGCTT AGAGCCTGTCTTCCTGCACC -3′ 65.7°C 
Forward  primer  
(-273,+100) 
5′- CCGCTCGAG CTGCCCAGTTGAGGGAAAAAATCTG-3′ 65.7°C 
Reverse primer   
 
  5′-CCGAAGCTT AGAGCCTGTCTTCCTGCACC -3′ 65.7°C 
Forward  primer  
(-128,+100) 
5′- CCGCTCGAGCCCCAGGGTGACATCATCC -3′ 63.6°C 
Reverse primer   
 
  5′-CCGAAGCTTAGAGCCTGTCTTCCTGCAC-3′  63.6°C 
Forward  primer  
(-1000,+100) 
5′-CCGCTCGAGTAAACTTTTTAACATTTCC-3′ 63.8°C 
Forward  primer  




Reverse primer   
For sequencing 
5′- AATGGCGCTGGGCCCTTCTT -3′ 
 
 




Components Volumes Final 
concentration 
5x Phusion HF Buffer 5µl 1X 
10mM dNTPs (Invitrogen) 1µl 200µM 








1µl 1ng/ µl 
Phusion DNA 
Polymerase (2U/μl) 
0.5µl 0.02 U/μl 
DNase/RNase free-water 37.5µl  
Total volume  50µl  
 
Table 2.12: The components of the PCR reaction mix for the amplification 
of 3′UTRs or promoter. 
 
2.5.3.2 Purification of PCR product 
To check whether amplified DNA was the correct size, a sample of 5µl of PCR 
product was run in 2.5% TAE agarose gel electrophoresis and visualised in the UV 
transilluminator (described in more detail below). The remaining 45µl of the PCR 
product was purified using QIAquick PCR Purification Kit from QIAGENE, in 
accordance with the protocol stipulated by the manufacturer.  
2.5.3.3 Restriction digestion of the PCR products and PGL4.10 basic 
vector  
Restriction endonuclease reactions were conducted on all of the PCR products and 
PGL4.10, in compliance with the manufacturer’s recommendations. Briefly, 1.5μg of 
DNA plasmid or PCR products was digested for 2 hours with the appropriate buffer 
(defined by BioLabs) and temperature for XhoI and HindIII (BioLabs) using 10-20 U 
of the enzymes. Upon completion of the restriction digestion, the QIAquick PCR 
Purification Kit (QIAGENE) was used to clean up the digested DNA or vector.  
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2.5.3.4 Cloning the promoter sequences into PGL4.10 basic vector  
The amplified product (insert) was mixed with digested vector at a molar ratio of 3:1 
insert to vector, based on the following equation:  
Length of insert (Kb) / Length of vector (Kb) x ng of vector = ng of insert required 
for a 1:1 ratio 
Ligation reactions were carried out in 10μl volume comprising 5μl 2x Quick ligation 
buffer (BioLabs), and 1μl 5 U T4 DNA ligase (BioLabs), which was added to the 
mixture of insert and vector. The reaction tubes were mixed thoroughly and briefly 
centrifuged. After 15-30 min incubation at room temperature, 2µl of the ligation 
reaction was added directly to 50μl of pre-thawed chemically competent bacteria 
DHα5 (Invitrogen) and then incubated on ice for 30 min. The competent cells were 
heat shocked for 45 seconds in a 42°C water bath and then placed on ice for 2 min. 
450μl of pre-warmed S.O.C. medium (Invitrogen) was added to the transformed 
competent cells. After shaking for 1 hour at 225 rpm (37°C) in an orbital incubator, 
50-200μl of the transformed cells was spread on LB agar plates (Agar from Sigma 
and plates from Corning, USA) containing 100 μg/ml ampicillin (Sigma) and 
incubated overnight at 37°C (LTE laboratory incubator). A negative control ligation 
(ligation reaction without insert), was used to estimate the ‘background’.  
Background colonies are a consequence of the presence of undigested or re-ligated 
vector.  Ideally the results of this test should be few or no colonies in the control and 
tens to hundreds in the ligation. 5 to 10 single bacterial colonies were selected from 
each LB plate and transferred to 3 ml of LB broth (Sigma) with ampicillin. The 
cultures were incubated overnight at 37°C, with constant shaking in an orbital 
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2.5.3.5 Purification of the DNA plasmid  
P1 buffer: 50 mM Tris·HCl (pH 8.0), 10 mM EDTA 100 µg/ml RNase A (stored at 
4°C).  
P2 buffer: 0.2N NaOH, 1% SDS 
P3 buffer: 3M CH3CO2K  
1 ml of the incubated broth was centrifuged at 12,000 g-force for 2 min. The 
supernatant was then discarded and the pelleted bacteria resuspended in 200µl of 
buffer P1. An equal volume of Buffer P2 was added, mixed by gentle inversion (4-6 
times), and incubated at room temperature for 5 min. 200µl of ice cold buffer P3 was 
added, inverted 4 times to mix, and incubated on ice for 10 min. The mix was then 
centrifuged for 10 min at maximum speed in order to pellet the debris. Following 
centrifugation, the supernatant was transferred to a fresh tube and 500µl of 
isopropanol was added. The supernatant-isopropanol mix was then cooled in ice for 
at least an hour and then centrifuged at maximum speed for 30 min to pellet the 
plasmid DNA. The DNA was then washed with chilled ethanol (70%) and 
centrifuged for 10 min. Finally, the supernatant was removed and the pellet was air-
dried for 5-10 min and resuspended in 50µl of DNase/RNase-free water.  
2.5.3.6 Agarose gel electrophoresis 
Agarose (electrophoresis grade, Invitrogen) was dissolved in 1x TAE buffer (Tris-
Acetate-EDTA) (Fisher BioReagent) to the desired concentration based on the length 
of DNA fragments (1 to 2.5%) by boiling in a microwave oven. When the agarose-
TAE mixture cooled to approximately 60-70°C, ethidium bromide (Etbr) was added 
to a final concentration of 0.5μg/ml. The agarose mixture was then poured into a gel 
chamber (BioRad). After solidification, 0.8-1µg of digested DNA sample was mixed 
with 6x DNA loading dye at a ratio of 6:1 (Biolabs) and loaded. The gels were run in 
1x TAE buffer at 120 Volt and visualized on a UV transilluminator. Bands of the 
correct size were then sequenced.  
2.5.3.7 Sequencing of the inserted sequences 
Sequencing of the inserts was carried out commercially by GenePool (University of 
Edinburgh, Edinburgh, UK), using forward and reverse primers for the basic 
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PGL4.10 vector listed above. The raw sequencing files were uploaded into a freely 
available sequence analysis program (BioEdit Sequence Alignment Editor) (Hall., 
1999). The pairwise sequence alignment was performed in BioEdit software between 
the sequencing results and retrieved sequences from NCBI. This program was also 
utilised to view chromatograms of the GenePool sequencing results.  
2.5.3.8 Midi plasmid preparation 
To maintain stocks of plasmid DNA, the purification was conducted using the 
QIAprep Midiprep Kit in accordance with the manufacturer's instructions 
(QIAGENE). 
2.5.3.9 Preparation of glycerol stocks 
For maintenance of the correct DNA plasmids with the correct sequence, overnight 
LB broth bacterial cultures were mixed 1:1 with sterile 50 % glycerol (Sigma) and 
stored in 0.5 ml aliquots at –70°C. The bacteria were recovered by thawing the 0.5ml 
glycerol stock of bacterial cells and adding them into 150-200 ml LB overnight at 
37°C in an incubator with constant shaking.  
2.5.4 Cloning a miR-199-3p sensor and the 3′UTRs of target mRNAs 
into psi-CHECK2  
2.5.4.1 The amplification of the 3′UTR sequences   
The mouse 3′UTR sequences for PIK3CB, CD151, ITGA3, and ITGA6 mRNAs 
were obtained from NCBI (http://www.ncbi.nlm.nih.gov/) with ID numbers 
NM_029094, NM_001111049, NM_013565, and NM_008397, respectively. 
Although CD151 has three alternative spliced mRNA transcripts, the 3′UTRs are 
identical. The length of 3′UTR of PIK3CB and ITGA3 are ~1.3 kb, CD151 3′UTR is 
~0.7 kb and ITGA6 3′UTR is ~0.9 kb. The psiCHECK-2 plasmid DNA was 
purchased from Promega. Primers for cloning and sequencing the various 3′UTRs 
were designed (Table 2.13), ordered from Invitrogen and resuspended at a final 
concentration of 10 pmol/µl (as described in 2.4.3.2 and 2.5.3.1).  
 
 




Table 2.13: A list of the primer sets used in amplification and sequencing 
of the 3′UTR sequence. Restriction sites are underlined and flanking cushion 
sequences are italic.  
The PCR reactions were performed using 5ng of cDNA as a template and Phusion
®
 
high-fidelity DNA polymerase from Thermoscientific and amplified according to the 





























































































The amplified products were then subjected to the same steps described previously 
(2.5.3.2 to 2.5.3.9) in order to obtain the final cloned plasmids. 
2.5.4.2 The mutatgensis of the miR-199-3p binding sites in the PIK3CB 
3′UTR    
The plasmid psiCHECK-2 containing PIK3CB 3′UTR was subjected to mutagenesis 
using the QuikChange lightning site-directed mutagenesis kit (Aglient Technologies, 
UK Ltd). Three bases were chosen for substitution within the miR-199-3p binding 
sites in the PIK3CB 3′UTR. These mutants occur within nucleotides 2–4 of each 
mature miR-199-3p target site. The primers containing the desired mutation, flanked 
with intact nucleotide sequence, were designed using the QuikChange® Primer 
Design Program available online 
(https://www.genomics.agilent.com/CollectionSubpage.aspx?PageType=ToolandSub






Steps Temperature Time Cycle 







































Final extension 72ºC 7 min 1 cycle 
Cooling 4ºC Hold 1 cycle 




Table 2.14: A list of the primer sets used for the mutation of the miR-199-
3p site in the 3′UTR of PIK3CB. 
 
The PCR reaction contained 5μl of 10x reaction buffer, 100ng of psiCHECK-
PIK3CB 3′UTR template, 125ng of forward primer, 125ng of reverse primer, 1μl of 
dNTP mix, 1.5μl of QuikSolution reagent, 1μl of QuikChange lightning enzyme, and 
RNase/Dnase free water. The reaction was mixed thoroughly and amplified using the 






To ensure digestion of the parental strands, 2μl of the Dpn I restriction enzyme was 
then added after the amplification, centrifuged for 1 min, and incubated for 5 min at 
37°C. 2μl of the Dpn I treated DNA was then transformed into ultracompetent cells 
supplied with the kit and plated in LB agar overnight. Colonies were inoculated into 




Primer Sequence Melting 
Temp 















Steps Temperature Time Cycle 
Initial denaturation 95ºC 2 min 1 cycle 
Amplification  
Denaturation 













Final extension 68ºC 5 min 1 cycle 
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2.5.5 Dual luciferase reporter assay 
The dual luciferase system (Promega, UK) was used to measure reporter gene 
expression. This system relies on the use of a plasmid like psiCHECK-2 that contains 
two luciferase reporters: the Firefly reporter (Photinus pyralis) and Renilla gene 
(Renilla reniformis). Firefly represents the normalizing transfection control for 
Renilla, which harbours the cloned 3′UTR sequence downstream of its coding 
sequence. In the case of the PGL4.10 plasmid, which only carries the firefly gene, a 
second Renilla construct was included to serve as a transfection control. Dual 
luciferase reporter assays were performed as follows. Fibroblast cells were plated 
into 96 well plates at a density of 1.5x10
4
 cells per well for 48 hours, the plates were 
swiftly turned and flicked twice to remove the culture medium.  The cells were then 
lysed by the addition of 50μl of 1x passive lysis buffer, after which the plates were 
incubated for 20 min to ensure efficient lysis of the cells. 15μl of the total cell lysates 
were transferred into white opaque-walled 96 well-plates, which measure the output 
signal (NUNC, Denmark). Detection of luminescence was performed using a 
Varioskan Flash Multimode Reader (Thermofisher scientific). The two automatic 
dispensers of the instrument were cleaned with ethanol and then ddH2o each time 
prior to use. The first dispenser was primed with firefly reagent, while the second 
was primed with Stop and Glo reagent. Both dispensers were set to dispense 50µl per 
well. The plate was then shaken for 2 seconds and the luminescence measured twice 
at the wavelength 450–700 nm. Following this measurement, 50µl from the second 
dispenser primed with Stop and Glo reagent was injected into the same well to 
quench the firefly luciferase activity within 2 seconds. The Renilla luciferase signal 
was then read twice at wavelength area 400–600 nm. The background luciferase 
signal generated by the untreated cells was subtracted from the luciferase signal 
obtained either from the firefly or Renilla reporter. Relative luciferase activity was 
calculated by normalising the firefly luciferase value to that of the Renilla luciferase 
when PGL4.10 was used. For instances where psi-CHECK-2 vector was used, the 
relative luciferase activity was calculated by normalising the Renilla luciferase value 
to that of the firefly luciferase. In order to standardise the luciferase activity of 
samples within the same experiment set, the normalised luciferase values were 
divided by the value of the appropriate control sample.  
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2.6 Western blot analysis 
2.6.1 Buffers and solutions used for protein techniques 
NP-40 lysis buffer: 50 mM Tris-Cl (pH 7.5), 100 mM NaCl, 1% NP40 (IGEPAL) 
(Sigma). Before use, the required amount of lysis buffer was supplemented with 
protease inhibitors (Roche, UK) and phosphatase inhibitors (Roche, UK).  
4x SDS-PAGE sample loading buffer: 50 mM Tris-Cl (pH 6.8), 12.5mM EDTA, 
2% SDS, 10% glycerol, 1% β-mercaptoethanol, 0.02% bromophenol blue.  
Tris-buffered saline-Tween (TBS-T): 10 mM Tris-HCl, 100 mM NaCl, 0.2% 
Tween-20. 
10% Ammonium Persulfate (APS): 1g of APS dissolved into 10 ml ddH2O, aliquoted 
and stored at -20°C. 
Laemmli running buffer (10x): 30.3g Tris, 144.2g Glycine, 10g SDS dissolved in 
1L ddH2O and pH was adjusted to 8.3. 
Transfer buffer (10x): 29g Tris, 144g Glycine, 3.7g SDS dissolved in 1L ddH2O. In 
order to make the transfer buffer (1x), 100ml of 10x transfer buffer was added to 
200ml Methanol and 700ml ddH2O. 
Blocking buffer (5%): 5g of skimmed milk powder (Cell Signaling Technology, 
USA) was dissolved in 100ml TBS-T solution. This was made fresh before use.  
1 M Tris-HCl pH 6.8: 120g Tris dissolved in 800 ml of ddH2O, the pH was then 
adjusted with HCl and the total volume made up to 1L using ddH2O. 
1.5 M Tris- HCl pH 8.8: 181g of Tris dissolved in 800 ml of ddH2O, the pH was 
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2.6.2 Materials and supplements used in protein techniques 
2.6.2.1 Primary and secondary antibodies used: 














TWIST-1 (mAb) Mouse 1:500 4°C overnight Abcam (ab50887) 
PIK3CB (mAb) Rabbit 1:1000 4°C overnight Cell Signaling 
Technology (#3011) 
ITGA6 Rabbit 1:1000 4°C overnight Cell Signaling 
Technology (#3750) 
AKT Rabbit 1:1000 4°C overnight Cell Signaling 
Technology (#9272) 
Phospho-Akt (Ser473) Rabbit 1:1000 4°C overnight Cell Signaling 
Technology (#9271) 




















Table 2.15: Primary and secondary antibodies used for Western blot 
analysis. 
 
2.6.2.2 Ladder  
SeeBlue® Plus2 Pre-Stained Standard, ranging in molecular weight from ~3 to 198 
kDa, was purchased from Invitrogen. This was used to estimate the molecular weight 
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2.6.2.3  BCA protein assay reagent 
The BCA protein quantification kit was purchased from Thermo Scientific and 
carried out according to manufacturer's recommendations. 
2.6.3 Preparation of protein extracts for western blot analysis 
The cells were washed once with cold PBS before addition of cold lysis buffer 
containing protease and phosphatase inhibitors (100μl/well in a 6 well plate). The 
plates were incubated on ice and shaken for 10min before scraping and transferring 
contents into a sterile tube. Samples were then incubated on ice for 30 min, after 
which the cell lysates were cleared by centrifugation at 12,000g for 15 min at 4ºC. 
Supernatants were transferred to a fresh tube and kept at -20°C. The protein 
concentration was determined by means of a BCA (BicinChoninic Acid) protein 
assay kit (Thermo Scientific) that uses a plate-reader on the absorbance setting from 
540-590 nm. In order to calculate the protein concentration per sample, 10μl of each 
cell lysate was mixed with the working reagent in a 96-well plate according to the 
protocols stipulated by the manufacturer. Each sample was then examined in 
duplicate. A set of BSA standard solutions ranging from 0 to 2000 ng/μl were set up 
within the same plate to generate a standard calibration curve (see an example Figure 
2.4). This calibration curve was in turn used to calculate the protein concentrations of 
samples. The absorbance value of the negative control (the lysis buffer without cells) 
was subtracted from the absorbance value acquired for each protein sample. Equal 
volume of samples containing the desired concentration of protein (typically 10-25μg) 
were then resuspended in 4x SDS loading buffer and boiled at 99ºC for 5min, after 
which they were loaded into the prepared SDS-PAGE gel. 
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Figure 2.4: Determination of protein concentration using a BCA standard 
curve. Measurement of the absorbance of samples with a known concentration 
of diluted BSA (2000 to 125 ng/μl) was used to create the standard curve for 
the assessment of the protein concentration of unknown samples. In the 
equation, ‘x’ is the absorbance of the sample and y is the protein 
concentration.  
 
2.6.4 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE)  
Gel electrophoresis was conducted on large gels using a twin vertical electrophoresis 
system (Galileo, Bioscience). The resolving gel (8%, 10%, 12%) was prepared with 
9.9 ml H2O, 12.0 ml 30% Acrylamide, 7.5 ml 1.5 M Tris (pH8.8), with the addition 
of 300µl 10% SDS, 300µl of 10% APS and 12µl of TEMED. Once the resolving gel 
was poured into the glass plates, it was covered with isopropanol. After 
polymerisation, the isopropanol was then discarded and 5% stacking gels were 
prepared with 6.8 ml H2O, 1.7 ml 30% Acrylamide mix, 1.25 ml 1.0M Tris (pH 6.8), 
with 100µl 10% SDS, 300µl 10% APS and 10µl TEMED. The stacking gel was laid 
over the resolving gel and a comb was placed within the stacking gel. After 
polymerisation, the protein ladder and samples were loaded on the gel and 
electrophoresis then performed at 100-120 Volt for 2-3 hours. 
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2.6.5 Western blot 
The resolved proteins were transferred to PVDF membranes (Millipore), using a wet 
transfer apparatus (Bio-Rad, UK). A PVDF membrane was soaked with methanol for 
30 seconds and then equilibrated in cold transfer buffer together with the gel. Four 
pieces of filter paper (Whatman Ltd, UK) and two pads were also immersed in the 
transfer buffer, after which they were packed in the 'transfer sandwich’, making sure 
to remove of air bubbles. The gel cassettes were placed in the apparatus and the 
transfer was performed at 100 Volt for 2-4 hours at 4°C. The blotted membrane was 
then incubated in a 5% milk blocking buffer at room temperature for 1-2 hours 
followed by incubation with the primary antibody (5-15 ml of 2% skimmed milk 
dissolved in TBS-T buffer). For antibody dilution and time of incubation, see Table 
2.16). The membrane was then washed twice for 5 min each with TBS-T buffer to 
remove excess unbound antibodies. Incubation with the secondary HRP-conjugated 
antibodies took place over 2 hours, diluted in 2% skimmed milk dissolved TBS-T 
buffer. The membranes were washed 3 times with TBS-T buffer for 15min.  
2.6.6 Enhanced Chemiluminescence (ECL) based detection 
The blotted proteins were detected using the ECL Western blotting detection system 
(GE Healthcare, UK), according to the manufacturer’s instructions. Equal volumes of 
the two chemiluminescent substrates were mixed together and then incubated with 
the blot, which has bound HRP-conjugated secondary antibodies. The 
chemiluminescence is based on horseradish peroxidise (HRP) catalyzing the 
oxidation of luminol by peroxide, resulting in light emission. The membranes were 
exposed to Fuji Medical X-Ray film (Fujifilm Europe GmbH) for different time 




Materials and Methods Chapter 2 
89 
 
2.7 Bioinformatics analysis 
2.7.1 Microarray experiment and data analysis 
For the microarray experiment reported in this thesis, Marie Craigon (Division of 
Pathway Medicine (University of Edinburgh, UK)) processed the RNA samples 
following a standard Affymetrix protocol and then hybridised the cDNAs to 14 
GeneChip® Mouse Gene 1.0 ST Arrays. The hybridised chips produced raw probe-
level data saved in CEL files. The CEL files were imported into the Partek Genomics 
Suite (MO, USA), where the data (background subtraction, log2 transformation, 
normalisation, and summarisation) was processed using of the Robust Multiarray 
Average (RMA) algorithms. The gene or transcript-level summarization was 
performed using the mean of all probes within the probeset to produce the gene or 
transcript level expression data for 28,853 mouse genes. In addition to the 28,853 
interrogation probeset, the chip includes 6702 control probes, (5222 negative and 
1480 positive). The expression data were then exported into Excel to apply a further 
cut-off based on the value of the median + 2*median average deviation (MAD) 
generated from the 5222 negative probes within each Chip. Those genes passing the 
cut-off criterion were re-imported into the Partek Genomics Suite software to 
calculate the mean values across the technical replicates (3 GeneChips for each 
untreated and miR-199-3p mimic samples and 4 Genechips for each RISC-free and 
miR-199-3p inhibitor transfected samples). The differential expression across two 
biological conditions was performed in Partek software using the ANOVA model 
and false discovery rate (FDR) multiple test correction. Annotation data for the genes 
were automatically obtained from Partek, which provides links to the NetAffx 
database (http://www.affymetrix.com/analysis/index.affy). The final expression data 
were exported in Excel format containing the mean normalised expression value, 
fold changes, corrected P values, and gene annotation. The data quality was also 
assessed for non-normalised and normalized expression data in Partek and Madmax. 
The data was visualized using boxplots, Principle Component Analysis (PCA) and 
sample histograms. The Partek software analysis was performed at the Division of 
Pathway Medicine (University of Edinburgh, UK), while the subscription to 
Madmax was supplied by Dr. Philip De Groot.  
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2.7.2 Ingenuity Pathway Analysis (IPA) 
The Ingenuity Pathway Analysis program (IPA version 8.0, Ingenuity Systems Inc, 
California, USA. www.ingenuity.com) was utilised in order to obtain a deeper 
understanding of the significantly altered canonical pathways and biological 
functions associated with the miR-199-3p dysregulated genes that had been produced 
by the microarray experiment. IPA also creates networks where the uploaded 
differential regulated genes can be connected in either direct or indirect interactions, 
based on published interactions. This approach offers the advantage of highlighting 
unknown relationships that do not exist in the classical canonical pathways. The 
significance of the association between the miR-199-3p regulated genes and 
canonical pathways was assessed based on two measures: 1) a ratio of the number of 
genes from the list that are involved in a given canonical pathway divided by the 
total number of the genes present in this pathway; and 2) A P-value demonstrating 
the likelihood that the assembly of the genes in the dataset within the canonical 
pathway could be interpreted by random chance alone, based on right-tailed Fisher’s 
exact test. The Fisher’s exact test was also used by IPA to determine the significance 
of each biological function assigned to that dataset.  
2.7.3 Genomatix Software Suite 
2.7.3.1 Gene2Promoter 
Gene2Promoter is a bioinformatic program within the Genomatix Package 
(http://www.genomatix.de/) that accesses or predicts the promoter sequences of all 
genes, as well as comparing promoter sequences across various species from flies to 
humans. Two characteristic features are used by Gene2Promoter to determine the 
putative proximal promoter regions: the detection of over-represented transcription 
factor binding sites within the sequence  and the potential protein–protein interaction 
between these transcription factors; as well as an experimentally mapped 
transcriptional start region (TSR) that refers to the transcriptional start sites (TSSs) of 
each transcript. The experimental evidence of TSR was derived from a combination 
of the sequencing of the 5′ termini of the full-length cDNAs and the count of Cap 
Analysis Gene Expression (CAGE) tags for each individual transcript. CAGE is a 
technique used to profile the transcriptional starting sites by means of sequencing all 
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the 5′ termini of capped RNA, which are provided in CAGE Basic Databases 
(http://fantom3.gsc.riken.jp/) (Kawaji et al. 2006). The program then assigns a 
confidence level to each transcript based on the counts of CAGE tags having a 
minimum of 3 CAGE tags in a distance up to 3bp around the TSS (upstream or 
downstream). The analysis was applied using the genomatix optimised length for 
promoter sequence (500bp upstream from the first TSS and 100bp downstream of the 
last TSS).  
2.7.3.2 MatInspector  
Genomatix MatInspector is a program that employs a library of matrix descriptions 
for transcription factor binding sites in order to identify potential matches in the 
promoter sequences (Quandt et al. 1995; Cartharius et al. 2005). The MatInspector 
prediction search is based on a number of parameters by which candidate protein-
binding sites can be recognised. Examples of these parameters include the default 
optimized matrix threshold for individual binding factor and a user-defined core and 
matrix similarities. The quantified values of the ‘core and matrix’ similarities are 
computed within the program based on the nucleotide weight matrices (NWM) of TF 
binding sites and the matches identified in the promoter sequence. The NMM 
designates all the possible nucleotide distributions for each individual position within 
the binding motif, thereby enabling the proportional quantification of the similarities. 
These weight matrices are present within the current MatInspector’s library (Version 
8.4, June 2011), which has been built using the best available research knowledge.  
2.7.4 SylArray  
SylArray is a computational method that can be applied to genome-wide expression 
data in order to determine the effect of miRNA through the search for the over- or 
under-represented target sequences in a sorted gene list 
(http://www.ebi.ac.uk/enright/sylarray) (Bartonicek and Enright 2010). SylArray 
uses Sylamer algorithms to assess the significance of an enriched or depleted target 
sequence for a given miRNA in 3′UTR sequences (Dongen et al. 2009), in addition 
to having a curated database for 3′UTRs in a large number of species.  
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2.7.5 Quantification of chemiluminescent and radioactive signals from 
Western and Northern blots.  
GEL files produced by Phosphorimager, Typhoon and X-ray films were converted 
into16-bit PNG image files. These files were then imported into TotalLab Quant 
Software v11.4 for further analysis. First, lanes were created for all bands within a 
gel. Second, the average intensity of an area where no band is present on the gel is 
taken as the background intensity. The background subtraction method was then 
applied simultaneously to all bands of a gel. Third, the software quantifies the 
intensity of each band in the gel. Fourth, the intensity value of the target was 
normalised to the intensity of the loading control.  
2.7.6 Statistical analysis 
Standard calculations (background subtraction and normalisation) were performed in 
MS Excel 2007. GraphPad Prism software was used to assess statistical 
significances, as well as to plot the graphs (Version6; GraphPad Prism software In). 
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3 Regulation of miR-199a/214 Cluster Expression in 
CMV Infections 
3.1 Introduction  
3.1.1 miRNA genes  
Genes that encode for miRNAs can exist within the introns or exons of annotated 
genes or can reside in the intergenic regions of the DNA with both sense and 
antisense orientations. It is believed that the sense-oriented intronic miRNAs are 
transcribed in parallel with the precursor messenger RNA (pre-mRNA) of their 
parent genes, with the result that the intronic miRNAs depend on parent gene 
promoters for their transcription (Bartel 2004). Consistent with this, a high degree of 
correlation was found between the expression profiles of miRNAs and their parent 
mRNAs (Baskerville and Bartel 2005). However, certain studies have also shown 
instances of poor correlation between intronic miRNAs and their parent gene 
(Baskerville and Bartel, 2005; Liang, 2007; Mi et al., 2007). Although transcript 
stabilities and post-transcriptional regulation may explain this poor correlation, 
promoter prediction studies suggest that some intronic miRNAs may be transcribed 
from independent promoters (Ozsolak et al., 2008; Wang et al., 2009; Monteys et al., 
2010). In contrast, the antisense-oriented miRNAs and intergenic miRNAs are 
believed to be transcribed independent of the parent gene. 
3.1.2 miR-199a/214 cluster  
The miR-199a/214 cluster is an antisense-oriented miRNA cluster. Two precursor 
miRNAs, miR-199a-2 and miR-214 reside in a dicistronic cluster on the opposite 
strand of an intron (intron-14 in mouse and intron-7 in human) of the Dynamin-III 
(DNMIII) gene (Figure 3.1). The dicistronic cluster therefore transcribes in the 
opposite orientation (3′ to 5′) with respect to the DNMIII gene, which is microtubule-
binding GTPase and important regulator of clathrin-mediated endocytosis (Reviewed 
in Hinshaw, 2000). This transcription results in a long primary transcript harbouring 
the two precursors, miR-199a-2 and miR-214. This primary transcript is processed 
into four mature miRNAs, miR-199a-3p, miR-199a-5p, miR-214-5p and miR-214-
3p. miR-214-5p is expressed at a low level hence it was not studied in this work. 
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However, detailed analysis of the expression properties of primary transcript miR-
199a/214 and its parent DNMIII gene across embryo and adult tissues showed that 
they were not completely identical (Loebel et al. 2005). It is also important to note 
that two other miR-199 isoforms, miR-199b and miR-199a-1 are encoded within the 
antisense strand opposite to introns of DNMI and DNMII genes, respectively. This 
means that miR-199 is transcribed from three different genes. At least in the human 
genome, miR-3154 is clustered with miR-199b in DNMI. In addition, other miRNAs 
are embedded within the sense strand of these genes such as the intronic miR-3120 
present within DNMIII and transcribed with its parent-gene precursor mRNA (Scott 
et al. 2012). Also, miR-638 exists within the first intronic region of DNMII while 
miR-4748 is in its fifth intron. As described in the introduction, RNA Pol II 
transcribes most miRNA genes, suggesting the same elements directing the Pol II 
transcription of protein coding genes also regulate miRNA transcription (Woods et 
al, 2007). Furthermore, pri-miRNA transcripts have the characteristic properties of 
mRNAs, with 5′caps and poly(A) tails (Lee et al. 2004). 
3.1.3 The transcriptional regulation of miR-199a/214 cluster  
The dysregulation of miR-199a/214 expression has been shown to be associated with 
various biological processes and diseases (discussed below in 4.1.2). Therefore, 
several studies have been focused on the transcriptional regulation of this cluster. 
First study on the regulation of this cluster reported a correlation between the 
expression of the pri-miR-199a/214 transcript and the basic helix-loop-helix 
transcription factor TWIST-1 during mouse development (Loebel, et al. 2005). Lee 
et al. (2009) predicted the miR-199a/214 promoter sequence, isolated it from mouse 
genomic DNA, and generated a wild type and a deletion mutant promoter that lacked 
TWIST-1 E-box motif, which displayed a decrease in its promoter activity in 
fibroblast cells. The deletion was not limited to the E-box motif but was also 
extended to the flanking sequences (~275bp), which disrupt the interaction of other 
transcription factors with their sites in the promoter sequence. Knocking down 
TWIST-1 in mouse embryonic fibroblasts or human epithelial ovarian cancer stem 
cells, resulted in a reduction in the expression of miR-199-5p, miR-199-3p and miR-
214 (Lee et al., 2009; Yin et al., 2010). However, a detailed comparison of 
expression of TWIST-1 and the pri-miR-199a/214 transcript in the mouse embryo 
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suggests that TWIST-1 is unlikely to be the sole regulator of expression of this 
primary transcript (Loebel et al. 2005). Zinc finger E-box-binding homeobox 1 
(ZEB1) is another transcription factor that induce expression of miR-199a/214 
cluster through a direct interaction with the E-box motif in the uterus of pregnant 
mice (Williams et al. 2012). As ZEB1 and TWIST-1 both bind to E-boxes and have 
several overlapping functions (Peinado et al. 2007), Williams et al. (2012) proposed 
that ZEB1 might co-ordinately induce miR-199a/214 expression (Figure 3.1). Early 
growth response factor-1 (EGR-1), another transcription factor, was also shown to 
drive the transcription of miR-199a/214 through a direct binding to its promoter in 
cancer cell lines (Figure 3.1) (Sakurai et al. 2011). Altered miRNA expression profile 
in smooth muscle cells in which the transcription factor, serum response element 
(SRF), is knocked down showed a decrease in the expression of miR-199-3p, miR-
199-5p, and miR-214 (Park et al. 2011). In consistent with this, Zhang et al. (2011) 
utilised two distinct transgenic mouse models with cardiac-specific overexpression or 
inhibition of SRF in order to demonstrate its regulatory role over the cardiac miRNA 
expression. They observed that SRF regulates the expression of pri-miR-199a/214 
transcript and thereby affecting its mature products (Figure 3.1). Another miRNA 
expression profile in signal transducer and activator of transcription 3 (STAT3)-
knockout mice identified cardiac upregulation of the primary transcript and mature 
miR-199-5p, however, no difference in the expression of mature miR-199-3p and 
miR-214 were detected in these cardiomyocytes (Figure 3.1) (Haghikia et al. 2011). 
Recent work linked expression of miR-199a/214 cluster with the stress response. For 
example, the increased expression of the whole cluster was demonstrated in response 
to the cardiac stress (Rooij et al. 2006). One interpretation for this increase is the 
transcription factor SRF, which is a positive regulator of cardiac growth and failure 
as well as miR-199a/214 expression (Park et al. 2011; Zhang et al. 2011). Another 
speculation made by the authors is the existence of nuclear factor of activated T-cells 
(NFAT) or myocyte enhancer factor-2 or (MEF2) response elements within the 
promoter region of this cluster (Rooij et al. 2006). NFAT and MEFs have been 
shown to be involved in the transcription of several cardiac genes in response to 
stress stimuli (Molkentin et al. 1998; Zhang et al. 2002). In agreement with this, the 
work in this thesis identified five potential sites for NFAT and one site for MEF2 
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within the promoter sequence of miR-199a/214 based on the bioinformatic prediction 
of the potential transcription factor binding sites (TFBS) (3.2.5 and Appendix 4). The 
low expression of miR-199a/214 cluster was found to be associated with the 
endoplasmic reticulum (ER) stress in hepatocellular carcinoma cells and the 
transcription factor NF-κB contributed to the regulation of this cluster in response to 
ER stress (Figure 3.1) (Duan et al. 2012). In addition to the role of transcription 
factors in regulating the expression of miR-199a/214, the promoter of miR-199a/214 
can be epigenetically modulated leading to transcriptional down-regulation or shut 
off.  An important example of the epigenetic regulation is hypermethylation of miR-
199a/214 promoter, which was demonstrated in several cancer cells (Kim et al. 2008; 
Cheung et al. 2011). This hypermethylation results in the transcriptional silencing of 
miRNA-199a/214. In ovarian cancer,  reactive oxygen species (ROS), was shown to 
inhibit miR-199-5p repression through increasing its promoter methylation by DNA 
methyltransferase 1 (DNMT1) (He et al. 2012). However, He et al. (2012) has 
focused on miR-199-5p and has not claimed a similar inhibition in the expression of 
miR-199-3p and miR-214. Based on the previous data, the transcriptional regulation 
of miR-199a/214 is not only controlled by the expression of the transcription factors 
such as TWIST-1, ZEB1, EGR-1, SRF, and NF-κB, but is also subjected to 
modulation by epigenetic mechanisms specifically, DNA methylation, 
 
Figure 3.1: A schematic diagram of human DNM3 gene showing the 
complementary strand within its intron encodes a pri-miR-199a/214 
transcript (DNM3os gene). The inset f igure shows the pri-miR-199a/214 
transcript encodes miR-199a-2 and miR-214 and those transcription factors 
known to regulate its promoter and drive the transcription. 
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3.1.4 Background and rational for studying the regulation of miR-
199a/214 cluster in CMV infections  
A recent report presented a global miRNA profiling of murine and human fibroblasts 
infected with MCMV and HCMV, respectively (Santhakumar et al. 2010). This 
study showed that all the mature members of the miR-199a/214 cluster (miR-199-3p, 
miR-199-5p, and miR-214) displayed a reduction in expression in both CMV 
infections at 24 hours. A functional screen of MCMV and HCMV infected cells 
identified two mature members of the cluster, miR-199-3p and miR-214 that exhibit 
antiviral properties upon the over-expression of these miRNAs in fibroblast cells. 
The antiviral properties of miR-199-3p reported in CMV (β-herpes viruses) extend to 
the other two herpes viruses subfamilies (α and γ-herpes viruses), whereas miR-214 
was only shown to have antiviral properties in one subfamily (γ-herpes viruses) 
(Santhakumar et al. 2010). For this reason, miR-199-3p seems to have the broadest 
antiviral activity.  
3.1.5 Aims 
The work reported in this chapter investigates the molecular mechanisms involved in 
the down-regulation of all the mature members of the miR-199a/214 cluster during 
CMV infection in vitro. The kinetics of the down-regulation of mature miRNAs over 
the course of CMV infections were first examined. The expression of the pri-miRNA 
transcript was then measured to indicate whether the mechanism involved in the 
repression of mature miRNA expression during infection is transcriptional or post-
transcriptional. There was also an attempt to explore cellular regulatory elements 
responsible for miR-199a/214 suppression during infection. The requirement of viral 
gene expression was also addressed with regards to regulation of the expression of 
the cluster.  
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3.2 Results   
3.2.1 Kinetics of expression of the primary miR-199a/214 transcript and 
the mature miRNAs during MCMV infection 
The expression levels of the miRNAs derived from the miR-199a/214 cluster have 
previously been shown to be down regulated by 24 hours post infection of cells with 
MCMV (Santhakumar et al. 2010). The regulation of these miRNAs during viral 
infection could be exerted at different levels, including transcriptional regulation, pri- 
or pre-miRNA processing and mature miRNA stability/turnover. Given that all 
mature members derived from the miR-199a/214 cluster are down-regulated, it 
seems likely that the regulation occurs at the primary transcript level, rather than a 
downstream processing step. It was therefore hypothesised that the miR-199a/214 
cluster is transcriptionally regulated during infection, and this then leads to the 
observed reduction in mature miRNAs.  
In order to test this hypothesis, the expression kinetics of both the pri-miR-199a/214 
transcript and its processed mature products were examined over a time course of 
MCMV infection in the NIH-3T3 cell line. This cell line was used based on the 
following considerations: these are fibroblasts, a cell type infected in vivo by 
MCMV, they are fully permissive to MCMV infection, and miR-199-5p, miR-199-
3p, and miR-214 are abundantly expressed. NIH-3T3 fibroblasts were mock infected 
or infected with MCMV at an MOI of 5 and total RNA was harvested at 4, 8, 12, 16, 
24, 36, 48 hours post infection (hpi). The expression levels of the pri-miR-199a/214 
and its mature miRNAs, miR-199-3p, miR-199-5p and miR-214, were quantified by 
qRT-PCR and expression levels were normalised to endogenous miR-16, as its 
expression is unchanged between mock infected and infected cells. The non-coding 
RNA U6 was also used as an additional control (Santhakumar et al. 2010). As 
expected, no difference was observed in miR-16 or U6 expression between 
uninfected or infected cells. As shown in Figure 3.2a, the levels of mature miR-199-
5p, miR-199-3p, and miR-214 were reduced by 1.4 fold at 16 hpi and 3.4 fold at 48 
hpi, with a steady decline in expression between these time points. For confirmation, 
the expression levels of the mature miR-199 and miR-214 were also examined using 
Northern blot analysis. The results indicated a decrease in the mature miRNAs by 16 
Results Chapter 3 
99 
 
hpi, in agreement with the results of qRT-PCR analysis (Figure 3.2b). It is important 
to note that the decrease in all three miRNAs showed similar kinetics, consistent with 
the hypothesis that viral regulation of mature miR-199a/214 is likely to be dependent 
on the down-regulation of the pri-miRNA transcript. In order to address this 
hypothesis the expression level of the pri-miRNA transcript was examined by qRT-
PCR from the same samples described above. The housekeeping genes GAPDH and 
18S ribosomal RNA were used as internal controls. Neither GAPDH mRNA nor 18S 
rRNA expression levels changed during infection. Whereas infection resulted in a 2 
fold decrease in pri-miR-199a/214 expression within 4 hpi, which remained until 
approximately 16 hpi and further declined to give a 7 and 12 fold decrease at 24 and 
48 hpi, respectively (Figure 3.2c).  
In conclusion, MCMV infection causes a significant reduction in the pri-miR-
199a/214 transcript, which happens earlier than the reduction in the mature miRNAs.  
It seems possible, therefore, that the decrease of mature miRNA occurs in response 
to the repression of pri-miR-199a/214 transcript. This repression in the primary 
transcript may result from a decrease in the rate of transcription and/or transcript 
degradation. To investigate the first possibility, an in silico examination of the 
promoter of miR-199a/214 transcript was carried out to identify transcription factors 
that might be involved in controlling its transcription.  
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Figure 3.2: The expression kinetics of pri-miR-199a/214 and its mature 
miRNAs over the time course of MCMV infection . A) Down-regulation of 
mature miR-199-3p, miR-199-5p, and miR-214 expression in MCMV infected 
cells by 16 hours compared to mock infected cells. NIH-3T3 cells were mock 
infected or infected with MCMV at an MOI=5 for the indicated times. The 
expression levels of mature miRNAs were quantif ied by qRT-PCR and 
normalised to miR-16. U6 snRNA was included as a negative control. Mock 
infected cells from the different t ime points (0, 24 and 48 hours) were averaged 
and compared to infected cells at each time point. Data presented are the 
mean fold change ± S.D. of two independent experiments (n=6). *P<0.05 , 
**P<0.01, and ***P<0.001 compared to mock infected cells as determined by a 
repeated measures one-way ANOVA with Sidak’s post-test for multiple 
comparisons. B) Northern blot analysis of mature miRNAs during MCMV 
infection. Total RNA was harvested from NIH-3T3 cells mock infected or 
infected as in A. 5µg of RNA was loaded per lane and membrane was 
hybridised with 
32
P-labeled probes. miR-16 probe was used as a loading control 
(lower panel), followed by densitometric analysis. The densitometric value for 
the mock infected was set as 1 and values for other t ime points post infection 
were expressed relative to the mock value. C) Down-regulation of pri-miR-
199a/214 expression in MCMV infected cells by 4 hours compared to mock 
infected cells. Total RNA was quanti f ied by qRT-PCR and normalized to 
GAPDH level. 18S rRNA was included as a negative control. Mock infected 
cells from the different time points were averaged and compared to infected 
cells at each time point. Data presented are the mean fold change ± S.D. o f 
two independent experiments (n=6). *P<0.05, **P<0.01, and ***P<0.001 
compared to mock infected cells as determined by a repeated measures one -
way ANOVA with Sidak’s post -test for multiple comparisons.  
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3.2.2 In silico sequence analysis of DNM3os proximal promoter 
The results presented in the section above suggested that the expression of 
miR-199a/214 during MCMV infection is modulated at the transcriptional level.  It is 
anticipated that the miR-199a/214 cluster might therefore be subject to differential 
regulation by specific transcription factors during infection. To identify the 
transcription factors potentially involved in the regulation of miR-199a/214 
promoter, three lines of investigation were carried out: 1) in silico analysis for the 
prediction of TFs in the miR-199a/214 promoter sequence; 2) functional 
characterisation of the predicted promoter; and 3) examination of the promoter 
activity in cells infected with MCMV.  
Two reports  have previously documented the 5′-flanking DNA sequence upstream 
of the human or mouse miR-199a/214 gene (known as dynamin 3, opposite strand 
(DNM3os) in the National Center for Biotechnology Information (NCBI)) and 
considered these sequences to be bona fide promoters (Kim et al. 2008; Lee et al. 
2009). However, to date, no reports have provided a detailed characterisation of 
either the mouse or human miR-199a/214 promoter sequence nor have they shown 
the minimal promoter sequence required for basal expression, transcription start 
site(s), conservation among species or the full set of potential transcription factor 
binding sites. Therefore, in order to further characterize the promoter sequence, a 
combination of bioinformatic and experimental strategies were used. 
3.2.2.1 The murine DNM3os gene promoters 
There are 8 transcripts for murine DNM3os gene annotated by Ensembl (Transcript 
IDs: ENSMUST00000104989, ENSMUST00000104988) and NCBI (Transcript IDs: 
NR_002870, AK020051, AK134411, AK053654, AK164873, AK051872) (For more 
details see Appendix 1). Three of these transcripts contain one or both precursor 
sequences of miR-199a-2 and miR-214: 1) one pri-miRNA transcript includes both 
pre-miR-199a and pre-miR-214; 2) two transcripts contain either pre-miR-199a or 
pre-miR-214; 3) an additional five distinct transcripts contain neither pre-miR-199a 
nor pre-miR-214 (Figure 3.3).  
In order to extract the promoter sequence of DNM3os, the GeneID in NCBI 
(474332) was uploaded to Gene2Promoter Release 5.3 (April 2012) in the 
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Genomatix package, with the analysis utilising the Genomatix optimised length for 
promoter sequences (500bp upstream from the first TSS and 100bp downstream of 
the last TSS). As outlined in Appendix 1 and shown in Figure 3.3, this analysis 
identified four specific promoters: one upstream of the DNM3os gene and the 
remaining three embedded within the DNM3os genomic sequence. As the DNM3os 
encodes 8 distinct transcripts, promoters were designated relative to the 
experimentally verified TSSs of the corresponding transcripts. The evidence for these 
promoters was derived from a combination of existing data on 5′ termini of full-
length cDNAs and the count of cap analysis gene expression tags (CAGE) (described 
in 2.7.3.1). The upstream promoter sequence of pri-miR-199a/214 was therefore 
predicted to span 696 bp, from -596 nt upstream of the first TSS to +100 nt 
downstream of the last of TSS.  The primary transcript appears to have two 
alternative TSSs, each of which are supported by 2 CAGE tags. However, 
Genomatix states that 2 CAGE tags are insufficient to confirm the 5′ end of the 
transcript and the TSS(s), a crucial component in the prediction of the promoter. 
Therefore TSS or TSSs remain to be verified for the pri-miR-199a/214 transcript.  
Figure 3.3: Schematic diagram of potential promoter sites for DNM3os 
gene. Four promoters can potentially drive the expression of eight different 
DNM3os transcripts  (shown as yellow boxes). Each promoter was predicted 
relevant to the TSSs for the annotated transcripts. TSS represents the potential 
starts of the mapped transcripts (shown as red lines). A blue dotted line was 
drawn from the end of the promoter to the start of the transcripts. Only three 
transcripts hold both or either miR-199a and miR-214 sequence (labelled with 
gray stars). Adapted from http://www.genomatix.de/.  
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3.2.2.2 Determination of the transcription start site of the pri-miR-
199a/214 transcript 
In order to experimentally determine the TSS(s) of the primary transcript, primer 
extension analysis was used with total RNA isolated from mouse liver. Two 
extension primers were used; the first was 35bp downstream of the first TSS and the 
second oligonucleotide was 148bp and 99bp downstream of the first and second TSS, 
respectively. Therefore, two bands of 55bp and 168bp were expected for the first 
TSS and a single band of 119bp for the second TSS. Two extension products were 
observed: a minor product was sized at ~50 bp with the first primer and a major 
product at ~160bp using the second oligonucleotide primer (see Figure 3.4). These 
results reveal the presence of a single TSS of pri-miR-199a/214, starting from 5′-
TGCAAATGTG-------3′. While the data presented herein are preliminary and 
therefore still require reproduction, they nevertheless support the first predicted TSS 
and lend confidence to the prediction of the promoter sequence.  
 
Figure 3.4: Primer extension analysis of the transcription start sites for 
pri-miR-199a/214 yields >50nt and >150nt long extension products.  
Approximately 20µg of total RNA isolated f rom mouse liver samples was used. 
Primer extension was performed using two different [γ -32P] ATP 5′-end-labeled 
oligonucleotides. The products were analyzed on a 15% UREA-TBE gel. 
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3.2.2.3 Comparative analysis of the promoter of pri-miR-199a/214 
in human and mouse.  
The mature miR-199-3p, miR-199-5p and miR-214 sequences are 100% conserved 
between mouse and human, with this cluster exhibiting the same down-modulation 
upon CMV infection in both species (see below 3.2.9). It seems likely that the 
mechanisms surrounding the transcriptional regulation of these miRNAs are also 
conserved. For this reason, the promoter region(s) for human DNM3os was also 
predicted and compared to the mouse sequence to explore conserved sites and 
regulatory elements.  
3.2.2.3.1 In silico prediction of human DNM3os promoters  
In contrast to the mouse DNM3os gene, the human DNM3os gene is annotated to 
encode three transcripts: 1) one transcript that contains both miR-199a-2 and miR-
214 (NCBI transcript ID: NR_038397); 2) another transcript that contains only miR-
199a-2 (Ensembl transcript ID ENST00000417354); and 3) a third transcript has 
neither miR-199 nor miR-214 (NCBI transcript ID: AK021543) (For more details see 
Appendix 2). As the pri-miR-199a/214 transcript is unavailable in the human 
genome database in the Genomatix Suite, the program will not predict its promoter 
sequence. Despite this, analysis was conducted on the other two transcripts of human 
DNM3os because the 5′ end of pri-miR-199a-2 transcript and pri-miR-199a/214 are 
located 5nt apart, suggesting that both transcripts may share the same promoter 
sequence. The predicted promoter is 601bp in length, spanning -501 to +100 relative 












Figure 3.5: Schematic diagram of the two putative promoters of the human 
DNM3os gene. The promoters schematised in the figure can produce three 
different transcripts: one transcript includes both m iR-199a and miR-214 
precursors, another spliced transcript has only miR-199, and another has 
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3.2.2.3.2 Conservation of the mouse and human promoter sequences.  
The predicted promoter sequences for pri-miR-199a/214 revealed a high degree of 
conservation between mouse and human. Nucleotide sequence from mouse: 40-591 
(552 bps) and human: 5-549 (545 bps) were conserved, with 89.67% matches 
(495/552), 8.51% mismatches (47/552), and 1.81% gapped nucleotides (Figure 3.6 
and Appendix 3).  
 
Figure 3.6: Alignment of mouse and human DNM3os gene promoter. The 
online software mVISTA was used to compare sequences in the mouse and 
human promoters. VISTA plot in A represents comparison between human and 
mouse DNM3os promoter and gene. The promoter region is zoomed in B to 
display the 600bp promoter region. The Y axis shows the percent identity 
ranging from 50 to 100% across the DNA genomic sequence.  The X axis 
represents the genomic sequence. Regions having greater than 75% 
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3.2.3 Functional characterization of the murine proximal promoter of 
the pri-miR-199a/214 transcript  
Following the in silico prediction of mouse promoter sequence (section 3.2.2), the 
full-length promoter sequence, consisting of a 696bp fragments, was cloned into a 
reporter plasmid, pGL4.10-basic to enable functional studies. This vector lacks 
promoter and enhancer sequences upstream of its reporter luciferase gene. In 
addition, several other constructs were made in parallel for comparison: one having 
1000bp upstream of TSS and three deletion constructs where sequences from -421 to 
+100, -272, +100 and -128 to +100 were cloned.  
Each reporter plasmid was co-transfected with a vector that expresses Renilla 
luciferase into NIH-3T3 cells, to enable normalisation of transfection efficiency. Cell 
viability post-transfection was also assessed in order to control for toxicity of the 
transfection procedure (in all experiments, cells were found to be >80% viable, see 
Figure 3.7a).  
The construct containing the full-length predicted promoter (696bp) resulted in a 
~15-fold increase in luciferase expression when transfected into NIH-3T3 cells, in 
comparison to the promoter-less vector (Figure 3.7b). Increasing the length of the 
promoter sequence to 1000 nucleotides upstream of the TSS did not increase the 
luciferase expression, which suggests that the sequence upstream of position + 596 
does not contribute to the promoter activity in this cell line. The construct containing 
a deletion in the region −596 to -422 showed a 15.9% reduction in promoter activity 
compared to full-length promoter, while the construct missing the region -596 to 
-273 gave a 70.7% decrease in the transcriptional activity of the promoter. The 
shortest construct (−128/+100) showed no significant luciferase expression over the 
background.  
These results suggest that the region spanning −596 to +100 contains the minimal 
promoter sequence of the pri-miR-199a/214 transcript and that the fragment (-421 to 
-273) is critical for the promoter activity. 
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Figure 3.7: Effect of serial 5′-deletions of the mouse pri-miR-199a/214 
promoter on its transcriptional activity.  A) Effect of transfection on NIH-3T3 
cell viabil ity. NIH-3T3 cells were transfected with 1100bp, 696 (full length), or 3 
sequential deletions of the pri-miR-199a/214 promoter sequence for 48 hours. 
Cell viabil ity was determined based on the cell t itre blue assay. The 
background fluorescence of the culture medium was subtracted from the 
fluorescence values of the untreated and transfected cells. Data presented are 
the mean fold change ± S.D. of two independent experiments (n=8).  No 
signif icance compared to untreated cells as determined by unpaired Student's t  
test. B) The functional analysis of miR-199a/214 promoter. The promoter 
constructs was transfected as in A. The promoter activity was measured as the 
firefly luciferase values, which were normalised to Renilla luciferase from the 
co-transfected vector. The firefly/Renilla ratio for promoter constructs was 
compared to the promoter-less vector ratio. Data presented are the mean fold 
change ± S.D. of three independent experiments (n=12). *P<0.05 and **P<0.01 
compared to promoter-less vector as determined by unpaired Student's t test. 
C) Schematic diagram of the promoter sequence with quantif ication of the 
contribution of dif ferent fragments to promoter activity. The full -length promoter 
(-596, +100) was set to 100%. The red-dashed bars show the deleted sequence 
from the promoter. The percentage of contribution was evaluated based on the 
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3.2.4 MCMV infection suppresses the transcriptional activity of the 
miR-199a/214 promoter in fibroblasts. 
Based on the inhibition of pri-miR-199a/214 expression upon MCMV infection 
(results in section 3.2.1), it was anticipated that MCMV may inhibit transcription of 
the pri-miR-199a/214. In silico analysis and functional characterisation of the miR-
199a/214 promoter as described above (3.2.2 and 3.2.3) identified the minimal 
promoter sequence and a fragment critical for promoter activity. It was therefore 
important to test the effect of MCMV infection on the promoter construct.  
NIH-3T3 cells were transfected with the luciferase reporter vector that contains the 
full length promoter sequence (-596, + 100) of miR-199a/214 (described above). 
Cells were either mock infected or infected with MCMV at an MOI of 5. At the 
indicated time points post infection the cells were lysed and luminescence measured. 
As shown in Figure 3.8, a significant down-regulation of promoter activity occurred 
by 4 hours post infection, which then steadily decreased until 48 hours post infection 
(~15 fold repression).  
To summarise, these data provide evidence that MCMV infection reduces 
miR-199a/214 proximal promoter activity, which correlates with the down regulation 
of the pri-miR-199a/214 transcript. 
 
   
 




Figure 3.8: Effect of MCMV on the promoter activity of miR-199a/214. 
NIH-3T3 cells were transfected with full - length promoter construct ( -596, +100) 
for 48 hours. Cells were mock infected or infected with MCMV at an MOI=5 for 
the indicated times. The promoter activity was measured as the firef ly 
luciferase values, which were normalised to Renilla luciferase from the co-
transfected vector. The firefly/Renilla ratio for promoter constructs was 
compared to the promoter-less vector ratio. Data presented are the mean fold 
change ± S.D. (n=5) and are representative of three independen t experiments. 
**P<0.01, ***P<0.001, and ****P<0.0001 compared to mock infected ratios in 
each time point as determined by a repeated measures two-way ANOVA with 
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3.2.5 Analysis of conserved regulatory elements in the proximal 
promoter of miR-199a/214. 
Results presented in the previous section (3.2.4) demonstrated that MCMV infection 
suppresses the promoter activity of the pri-miR-199a/214 transcript. To examine 
whether this regulation occurs via specific cellular transcription factors a 
bioinformatic approach was used. ‘Genomatix MatInspector’ software was applied to 
define the potential transcription factor binding sites within the murine miR-
199a/214 promoter. The MatInspector similarity parameters were set to >0.90 for the 
core and >0.85 for the matrix, whereas the optimized matrix threshold was left at the 
default level (the parameters are described in 2.7.3.2). 
A total of 95 putative binding sites were predicted that corresponded to 59 families 
of transcription factors in either strand of the miR-199a/214 promoter sequence 
(Appendix 4), most transcription factor binding sites can occur in both orientations in 
a promoter or enhancer sequence. Conservation between mouse and human 
sequences was applied as a further filter criterion to the murine transcription-factor 
binding sites.  Of the 95 putative sites, 53 were conserved between mouse and human 
miR-199a/214 promoters (Appendix 5). Given that the previous analysis of deletion 
constructs (3.2.3) had demonstrated the sequence from -421 to -273 as being 
critically important for miR-199a/214 promoter function, it was expected that the 
crucial transcription sites would be localised within this fragment. A total of 11 
conserved sites assigned to 9 families of transcription factors (NFAT, SRF, ETS, 
FKHD, CIZF, RUSH, PLZF, OCT1, and HOMF) were found between nucleotides -
421 and -273. Four of these families, RUSH, PLZF, OCT1 and HOMF were 
excluded as their expression was not detected in the microarray analysis of global 
gene expression in murine NIH-3T3 cells (described in Chapter 4 section 4.2). The 
remaining five conserved transcription factor families were predicted to bind to 
seven sites within -421 to -273 promoter sequence, which denote two sites for both 
NFAT and SRF, with a single site for each of ETS, FKHD, and CIZF.  
As discussed above in 3.1.3, the knockdown of TWIST-1 and SRF have been shown 
to suppress the pri-miR-199a/214 and subsequent production of miR-199a/214 
cluster. The data presented here identifying conserved sites for some of these TF 
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within the apparently critical fragment of 421 to -273 of the full-length promoter 
appears to be in agreement with these reports. 
3.2.5.1  Identification of Putative SRE within the miR-199a/214 
promoter 
As illustrated in Figure 3.9, two SRF recognition sites (CArG boxes) and a DNA-
binding ETS-domain (5’-GGAA-3′) were identified between -322 and -288 of the 
miR-199a/214 promoter. Serum response element (SRE) is defined as containing two 
sites for SRF, in addition to a site for a transcription factor from the ETS family, 
specifically the ternary complex factors (TCF) subclass. SRF is known to interact 
with TCFs, which include three main ETS-transcription factors: ELK-1, ELK-3 
(NET/ERP/ SAP-2), and ELK-4 (SAP-1). Thus, the promoter sequence that confers 
the highest transcriptional activity (-421, -273) contains a potential SRE element, that 
includes ELK and SRF sites.  
 
Figure 3.9: Schematic diagram of the serum response element (SRE) and 
TWIST-1 transcription factor located at -421 to -273 and -234 to -228, 
respectively, relative to the transcription start site.  Conserved transcription 
factor sites, SRF, ETSF, and TWIST-1 were predicted by MatInspector. Zoomed 
view of -322 to -288 shows the potential serum response element (SRE), which 
is composed of two overlapping CArG motifs for SRF and a site for Ets protein. 
A site for SRF at -316 and another for ETS at -300 are within the opposite 
strand, where the primary transcript encoded. Zoomed view of -234 to -228 
shows the TWIST-1-family basic helix- loop-helix (bHLH) transcription factors .  
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The detailed analysis of the miR-199a/214 promoter suggests that the region 
spanning nucleotides from -421 to -273 from the TSS is important for the regulation 
of this miRNA cluster.  Analysis of the sequence in this region revealed potential 
SRF and ELK-1 sites. To examine whether these TFs regulate miR-199a/214, the 
promoter activity of the miR-199a/214 locus and expression levels of the mature 
miRNAs were examined in cells in which SRF and ELK-1 were knocked-down 
using specific siRNAs. TWIST-1 and STAT3 were included as controls in these 
experiments, as TWIST-1 siRNA has been shown to down-modulate 
pri-miR-199a/214 expression and STAT3 siRNA has been reported to up-regulate 
the promoter of miR-199a (Haghikia et al. 2011; Lee et al. 2009). 
3.2.5.2 SRF and ELK-1 siRNAs interfere with the transcriptional 
regulation of miR-199a/214 promoter  
To investigate whether knocking down SRF or ELK-1 affects the promoter activity 
of miR-199a/214, it was important to first assess the silencing efficiencies of the 
siRNAs in these experiments. NIH-3T3 cells were transfected with negative control 
siRNA (RISC-free siRNA), TWIST-1, STAT3, SRF, or ELK-1 siRNAs for 48 hours. 
Total RNA was then isolated from the transfected cells to measure the expression 
level of each target mRNA using qRT-PCR analysis. The expression levels of 
TWIST-1, STAT3, SRF, and ELK-1 were normalised to GAPDH expression and the 
quantification of knockdown was based on comparison to cells transfected with the 
control siRNA. 
The data showed 65%, 53%, 63%, and 57% silencing efficiency at the mRNA level 
for TWIST-1, STAT3, SRF, and ELK-1 mRNA, respectively. In addition, no 
obvious change was observed in the expression of these mRNAs between RISC-free 
siRNA treated samples and untreated samples, indicating that any observed 
difference was specific to the siRNA rather than the transfection procedure (Figure 
3.10a).  
After confirming knockdown of these genes, the miR-199a/214 promoter activity 
was measured in cells in which TWIST-1, STAT3, SRF, or ELK-1 were knocked 
down. NIH-3T3 cells were co-transfected with a specific-target siRNA or control 
siRNA and one of the following: 1) the promoter-less vector; 2) the full-length 
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promoter (-596,+100) vector; or 3) the truncated promoter vector (-128,+100). The 
truncated promoter construct was used as a control to ensure that the results were not 
due to sequences present in the backbone of the plasmid. In addition, the viability of 
NIH-3T3 cells was monitored at 48 hours post transfection (>80% of cells were 
viable under all conditions) (Figure 3.10b). There was 12 fold induction of luciferase 
expression driven by the full-length promoter of miR-199a/214 in cells transfected 
with control siRNA (Figure 3.10c). The luciferase expression was used as a baseline 
(100% activity) for comparison of the promoter activities in cells where each 
transcription factor was knocked down.  As shown in Figure 3.10c, knock-down of 
TWIST-1 resulted in a 55% repression in promoter activity. There was no observed 
change in the luciferase expression in cells where STAT3 was knocked down, in 
contrast to prior observations reporting upregulation (Haghikia et al. 2011). 
Luciferase expression in cells transfected with SRF or ELK-1 siRNAs showed 
significant 2.3 and 4 fold decreases, respectively.  
Furthermore, the short promoter construct (-128, +100) showed the least expression 
of luciferase signal (~2 fold) in cells transfected with control siRNA and no 
significant change in this construct was observed across all the samples treated with 
TWIST-1, STAT3, SRF, or ELK-1 siRNAs. This suggests that the observed 
reduction in promoter activity when knocking down SRF and ELK-1 involves 
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Figure 3.10: TWIST-1, SRF and ELK-1 regulate miR-199a/214 promoter 
activity. A) The silencing efficiency of TWIST-1, STAT3, SRF, and ELK-1 
siRNAs. NIH-3T3 cells were untreated or transfected with 25nM of each siRNA 
and control RISC-free siRNA for 48 hours. The expression levels of TWIST-1, 
STAT3, SRF, and ELK-1 were quantif ied by qRT-PCR and normalised to 
GAPDH. Data presented are the mean fold change ± S.D. (n=3) and are 
representative of two independent experiments. *P<0.05 and **P<0.01 
compared to untreated cells as determined by two-tailed Student's t test. B) 
Effect of transfection on NIH-3T3 cell viabil ity. NIH-3T3 cells were transfected 
with control RISC-free siRNA or specif ic siRNA along with one of promoter 
constructs, full-length promoter (-596, +100) and the deletion construct (-128, 
+100) for 48 hours. Cell viability was determined based on the cell titre blue 
assay. The background fluorescence of the culture medium was subtracted 
from the fluorescence values of the untreated and transfected cells. Data 
presented are the mean fold change ± S.D. of two independent experiments 
(n=8). No signif icance compared to untreated cells as determined by unpaired 
Student's t test. C) Reduction in the miR-199a/214 promoter activity in cells 
transfected with SRF, ELK-1, and TWIST-1 siRNA. The cells were transfected 
as in B. The promoter activity was measured as the firefly luciferase values, 
which were normalised to Renilla luciferase from the co-transfected vector. The 
firefly/Renilla ratio for promoter constructs was compared to the promoter -less 
vector ratio. Data presented are the mean fold change ± S.D. (n=4) and are 
representative of 3 independent experiments. *P<0.05, **P<0.01, and 
***P<0.001 compared to RISC-free siRNA transfected cells as determined by 
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3.2.5.3 Inhibition of miR-199a and miR-214 expression by SRF and 
ELK-1 siRNAs  
The next step was to examine whether the silencing of SRF and ELK-1 could 
decrease the expression of mature miRNAs. Expression levels of miR-199-5p, 
miR-199-3p and miR-214 were determined by northern blot and qRT-PCR using 
samples collected under knock-down conditions. For all three members of the 
miR-199a/214 cluster, a significant reduction in expression level (~2.5 fold) was 
observed in the SRF or ELK-1 siRNA treated samples (Figure 3.11a).  
It was previously reported that knockdown of TWIST-1 suppresses miR-199-5p, 
miR-199-3p and miR-214 expression levels (Lee et al. 2009) and the results 
presented here are consistent with this (Figure 3.11a). In this experiment, knockdown 
of STAT3 had no significant effect on the expression levels of miR-199-3p or miR-
214 and did not affect the promoter activity of the primary transcript. This is in 
contrast to a previous report, which showed induction in promoter activity and miR-
199-5p expression  (Haghikia et al. 2011). The northern blot results corroborate the 
qRT-PCR data for TWIST-1, STAT3 and SRF, however, knockdown of ELK-1 did 
not result in a significant change in the miRNA expression levels in northern blots, 
whereas a 2.5 fold reduction was observed by qRT-PCR. However, these results 
should be repeated as it noted that the loading of the RNA assessed by the control 
















Figure 3.11: Regulation of mature miRNAs, miR-199-3p, miR-199-5p, and 
miR-214 by TWIST-1, SRF, and ELK-1. A) NIH-3T3 cells were transfected with 
either RISC-free control, TWIST-1, STAT3, SRF, or ELK-1 for 48 hours. The 
expression level of mature miRNAs was quantif ied by qRT -PCR and normalised 
to miR-16. Data presented are the mean fold change ± S.D. (n=3) and are a 
representative experiment (out of  two independent experiments). *P<0.05 and 
**P<0.01 compared to untreated cells as determined by two-tailed Student's t  
test. B) Northern blot analysis of miR-199-3p and miR-214 in cells transfected 
with TWIST-1, STAT3, SRF, ELK-1 or RISC-free siRNA. Total RNA was 
harvested from transfected cells as in A. 5µg of RNA was loaded per lane and 
membrane was hybridised with 
32
P-labeled probes. miR-16 probe was used as 
a loading control ( lower panel), followed by densitometric analysis. The  
densitometric value for the RISC-free transfected cells was set as 1 and values 
for other transfected cells were expressed relative to the mock value.  
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3.2.6 TWIST-1 regulates miR-199a/214 expression and is reduced in 
MCMV infection  
3.2.6.1 TWIST-1 mRNA and protein are down-regulated upon 
MCMV infection  
The data presented above suggests that TWIST-1, SRF, and ELK-1 regulate 
miR-199a/214 expression by controlling its promoter activity. To determine whether 
the down-regulation of miR-199a/214 caused by MCMV involves TWIST-1, its 
expression was examined in uninfected and infected cells.  
NIH-3T3 cells were mock infected or infected with MCMV at a MOI of 5. RNA was 
then harvested at various time points post infection and qRT-PCR used to determine 
the kinetics of TWIST-1 mRNA expression over the time-course of MCMV 
infection. 
As shown in Figure 3.12a, there is no significant change in the expression of 
TWIST-1 mRNA up to 16 hpi. However, by 24 and 48 hpi, there is a 2 fold and 3.5 
fold decreases in the mRNA level. In comparison to the level of TWIST-1 mRNA in 
infected cells at 24 hours, a significant 3 fold increase in the TWIST-1 level was 
noted in the mock infected cells at 48 hours. This correlated with 2 fold increase in 
the expression levels of primary transcript and mature miR-199-5p, miR-199-3p, and 
miR-214 at 48 hours, supporting the assertion that miR-199a/214 responds to the 
expression of TWIST-1 (Figure 3.12b). The protein level of TWIST-1 was then 
examined at 24, 48, and 72 hpi under the same conditions. Based on western blot 
analysis, a decrease in TWIST-1 protein in infected cells was observed at 48 and 72 
hpi, while no decrease was detected at 24 hpi (Figure. 3.13a). In mock infected cells, 
a substantial increase was observed in the protein level of TWIST-1 at 48 and 72 
hours by comparison with that seen at 24 hours.  
To determine whether the observed increase in TWIST-1 in mock infected cells over 
time is a natural phenomenon of cultured cells it was important to test certain 
conditions, including cell densities and the effect of serum in the media. Cells were 









) per well in 6-well plates and allowed to 
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grow to higher densities for 24 and 48 hours. As can be seen in Figure 3.13b, 
TWIST-1 expression is reduced at lower seeding densities. No difference in 
TWIST-1 expression was detected in NIH-3T3 cultured in media with or without 
10% calf serum. TWIST-1 expression also increases from 24 to 48 hours post 





 cells/well, but was not clear at 3x10
5 
cells/well possibly due to 
the saturation of TWIST-1 signal on the blot film. 
In conclusion, the level of TWIST-1 mRNA decreases by 24 hpi with MCMV 
infection, while its protein level remains unaffected at 24 hpi but is reduced at 48 hpi. 
Initial studies on the relationship between TWIST-1 and cell confluency suggests 
that TWIST-1 expression, and thereby miR-199a/214 expression, may be linked to 




















Figure 3.12: The expression of TWIST-1 mRNA during MCMV infection.  A) 
Down-regulation of TWIST-1 expression in MCMV infected cells by 24 hours 
compared to mock infected cells. NIH-3T3 cells were mock infected or infected 
with MCMV at an MOI=5 for the indicated times. The expression level of 
TWIST-1 mRNA was quantif ied by qRT-PCR and normalised to GAPDH. Mock 
infected cells from the different t ime points were averaged and compared to 
infected cells at each time point. Data presented are the mean fold change ± 
S.D. of two independent experiments (n=6). *P<0.05 and **P<0.01 compared to 
mock infected cells as determined by a repeated measures one-way ANOVA 
with Sidak’s post-test for multiple comparisons. B) The correlation between the 
expression of TWIST-1 mRNA and the pri-miRNA transcript and mature 
miR-199-3p, miR-199-5p, and miR-214, in mock infected cells at 48 hours 
versus 24 hours. The expression levels were quantif ied by qRT -PCR and 
normalised to GAPDH (in case of TWIST-1 and pri-miR-199a/214) or miR-16 (in 
case of mature miRNAs). Data presented are the mean fold change ± S.D. and 
are representative of two independent experiments.*p < 0.05, **p < 0.01 and 
***, p < 0.001 compared to cells at 24 hours as determined by two -tailed 
Student's t test.  





Figure 3.13: The expression of TWIST-1 protein in MCMV infected cells.  A) 
Western blot showing reduction in TWIST-1 at 48 and 72 hours post MCMV 
infection. Whole cell lysates were harvested from NIH-3T3 cells mock infected 
or infected with MCMV at an MOI of 5 for the indicated times. 20µg of protein 
was loaded per lane and membrane was immunoblotted with primary antibodies 
against either TWIST-1 or β-ACTIN as a loading control. Blots were then 
quantif ied by densitometry and normalized to the corresponding β -ACTIN. The 
mock infected at 24 hours was set as 1 and values for other t ime points were 
expressed relative to this mock value. B) Western blot showing the expression 
of TWIST-1 in different densit ies or in serum-free medium. Cells were seeded 
either in various densit ies for 24 and 48 hours or in 10% serum and serum-free 
media. 20µg of cell lysates was loaded per lane and membrane was 
immunoblotted with primary antibodies against either TWIST -1 or β-ACTIN as a 
loading control. Blots were then quantif ied by densitometry and  normalized to 
the corresponding β-ACTIN. Cells at density of 3x10
5
 were set as 1 and values 
for cells with other densit ies or those grown in 10% serum or serum -free media 
were expressed relative to 3x10
5
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3.2.6.2 MCMV infection may regulate the expression of miR-
199a/214 through TWIST-1 at 24 hours 
While the data presented above demonstrates the novel link between MCMV 
infection and TWIST-1 expression, the down-regulation of TWIST-1 expression at 
48 hours does not correlate with the down-regulation of the primary transcript that 
occurs much earlier by 4 hpi. This could suggest another transcription factor(s) is 
involved. However, it is possible that TWIST-1 is still involved, but its activity, 
rather than expression level, is regulated. For example, it is known that efficient 
binding of TWIST-1 to DNA requires phosphorylation and dimerisation with another 
basic helix-loop-helix (bHLH) transcription factor. A rapid disruption in TWIST-1 
activity could occur upon infection and thereby affecting the transcription of miR-
199a/214, even though its expression level does not change until 48 hpi. 
To examine this in more depth, TWIST-1 was knockdown and mature miR-199-5p, 
miR-199-5p, and miR-214 expression levels compared in uninfected and infected 
cell. This was expected to show whether TWIST-1 knockdown recapitulates the 
reduction in miR-199a/214 transcript levels observed during infection, or whether 
there are additional effects of the virus that are independent of TWIST-1. NIH-3T3 
cells were mock or transfected with RISC-free and TWIST-1 siRNA for 48 hours. 
Cells were then infected with MCMV at MOI of 5 for 24 and 48 hours. Total RNA 
and cell lysates were prepared and analysed by qRT-PCR and Western blotting. NIH-
3T3 cells were mock or transfected with RISC-free and TWIST-1 siRNA for 48 
hours post transfection. Cells were then infected with MCMV at MOI of 5 for 24 and 
48 hours. Total RNA and cell lysates were prepared and analysed by qRT-PCR and 
Western blotting.  
Western blot analysis confirmed that the expression of TWIST-1 protein in mock 
cells is unchanged at 24 hpi (see Figure 3.14a) and that TWIST-1 protein was 
knocked down by the siRNA in both mock infected and infected cells. Consistent 
with the previous results, the expression level of the miR-199a/214 transcript was 
reduced in infected compared to uninfected cells at 24 hpi (Figure 3.14b), even 
though TWIST-1 protein expression was unchanged at this time point. A significant 
decrease was detected in the level of the miR-199a/214 transcript in both uninfected 
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and infected cells in which TWIST-1 was knocked down in these cells. As the 
decrease was comparable regardless of infection status, it would appear that at 24 
hpi, MCMV has no capacity to further down-regulate the cluster expression in 
TWIST-1 silenced cells.  
As seen in Figure 3.14d, a reduction in miR-199a/214 comparable to that at 24 hours 
was found in cells in which TWIST-1 was knocked down and infected cell with 
MCMV for 48 hours. Interestingly, MCMV infection resulted in an significant 
additional inhibitory effect on the cluster expression in cells knocked down for 
TWIST-1 compared to mock infected cells. However, at 48 hpi the effect of TWIST-
1 siRNA appeared to decline in mock infected cells, as compared to 24 hours. Such a 
decline was not obvious in the infected cells, suggesting that MCMV infection has 
down-regulated TWIST-1 protein by 48 hours. It is possible that the reduced effect 
of siRNA in uninfected cells is due to transient transfection, whereas in infected cells 
infected MCMV knocks down TWIST-1 (Figure 3.14c).  
Taken together, these results show that, TWIST-1 may largely be involved in the 
regulation of miR-199a/214 at 24 hpi, but its protein expression is unchanged, by the 
virus siRNA knock down. Therefore, the effect of MCMV infection on TWIST-1 
phosphorylation should be examined at early times of infection prior to 24 hours.  
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Figure 3.14: MCMV induces more robust inhibition of miR-199a/214 
expression than observed for TWIST-1 knockdown at 48 but not 24 hpi.  A 
and C) NIH-3T3 cells were untreated or transfected with either control RISC-
free or TWIST-1 siRNA for 48 hours. Cells were then mock infected or infected 
with MCMV an MOI=5 for 24 hours (A) and 48 hours (c). The expression levels 
of mature miRNAs was quantif ied by qRT-PCR and normalised to miR-16. Data 
presented are the mean fold change ± S.D. and are representative of two 
independent experiments.*p < 0.05, **p < 0.01, ***, p < 0.001 and ****P<0.0001 
compared to RISC-free siRNA transfected cells at 24 hours or 48 hours as 
determined by a repeated measures two-way ANOVA with Sidak’s post-test for 
multiple comparisons. B and D) Western blot confirming the knockdown of 
TWIST-1 and MCMV effect on its protein expression at 24 hours (B) and 48 
hours (D). Whole cell lysates were harvested from cells transfected and then 
infected as in A and C. 20µg of cell lysates was loaded per lane and membrane  
was immunoblotted with primary antibodies against either TWIST -1 or β-ACTIN 
as a loading control. Blots were then quantif ied by densitometry and 
normalized to the corresponding β -ACTIN. The untreated (mock infected) was 
set as 1 and values for other conditions were expressed relative to this 
untreated value.  
.   
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3.2.7 Immediate early gene 3 (IE3) and de novo viral gene expression 
are essential for the transcriptional suppression of pri-miR-
199a/214 in MCMV-infected NIH-3T3 cells 
As shown previously, MCMV infection results in a decrease in the promoter activity 
of miR-199a/214. In order to examine whether this requires de-novo viral gene 
expression, the IE3 deletion mutant virus (MCMVdie3), which lacks the fifth exon 
region of the IE1/IE3 gene, was used (see Figure 2.1 for genomic map). This virus 
can enter cells but viral gene expression is restricted to IE1 and IE2 genes and the 
virus cannot replicate. Replication of this mutant can be rescued by growing the virus 
on a complementary stable cell line (NIH-3T3-Bam25) expressing both IE1 and IE3.  
3.2.7.1 Infection of cells with IE3 deletion mutant virus does not 
cause a reduction in expression of the pri-miR-199a/214 transcript 
or mature miRNAs  
The expression of pri-miR-199a/214 transcript was examined in cells infected with 
MCMV and MCMVdie3. NIH-3T3 cells were mock infected or infected with either 
MCMV or MCMVdie3 at MOI of 5. Total RNA was harvested at several time points 
during infection, and qRT-PCR was used to measure the expression level of primary 
transcript, which was normalised to GAPDH, which maintains constitutive 
expression during MCMV and MCMVdie3 infection. 18S rRNA was used as an 
additional control.  
As previously shown, MCMV infection leads to a significant decrease in the 
expression of pri-miR-199a/214 transcript, by 2 fold and 15 fold at 4 and 48 hpi, 
respectively (Figure 3.2). However, infection with MCMVdie3, did not significantly 
altered the level of pri-miR-199a/214 transcript at 2, 4, 8, or 24 hpi, though a 1.5 fold 
decrease was observed at 48 hpi. These results demonstrate a clear difference in the 
ability of MCMV and MCMVdie3 viruses to down-regulate the pri-miR-199a/214 
transcript (Figure 3.15a). To determine whether this translated to differences in 
expression levels of mature miRNAs, a comparison of mature miR-199-5p, miR-
199-3p, and miR-214 expression in cells infected with MCMV and MCMVdie3 was 
carried out using Northern blot analysis. As shown in Figure 3.15b, the expression 
levels of the mature miRNAs were down-regulated in NIH-3T3 cells infected with 
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MCMV, although no change was seen in MCMVdie3 infected cells relative to mock 
infected cells. 
To investigate whether the differences observed between MCMV and MCMVdie3 
mutant virus are specifically due to IE1/IE3 genes, experiments were also carried out 
in the complementary cell line, NIH-3T3-BAM25, which expresses IE1/IE3. 
NIH-3T3-BAM25 cells were infected with MCMVdie3 at MOI of 5 for 24 hours. 
NIH-3T3 cells also were infected in parallel with MCMV and MCMVdie3 with MOI 
of 5. While the infection of NIH-3T3 cells with MCMVdie3 resulted in no change in 
the primary transcript at 24 hpi, the infection of NIH-3T3-Bam25 cells yielded a 2.5-
fold reduction in the primary transcript expression. However, this reduction was not 
as significant as the reduction observed with MCMV at 24 hpi (Figure 3.15c).  
Taken together these results suggest that primary transcript and miR-199a/214 
expression is inhibited in MCMV infected cells, and this is at least partly dependent 
on the activity of IE3, which is required for inducing viral gene expression and 
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Figure 3.15: MCMVdie3 does not inhibit the pri-miR-199a/214 and mature 
miRNA.  A) pri-miR-199a/214 expression in MCMV versus MCMVdie3 infected 
cells compared to mock infected cells. NIH-3T3 cells were mock infected or 
infected with either MCMV or MCMVdie3 at an MOI=5 for the indicated times. 
The expression level of pri-miRNA was quantif ied by qRT-PCR and normalised 
to GAPDH. 18S rRNA was included as a negative control. Mock infected cells 
from the different t ime points (0hr, 24hr and 48hr) were averaged and 
compared to infected cells at each time point. Data presented are the mean 
fold change ± S.D. of two independent experiments (n=6). *P<0.05, **P<0.01, 
***P<0.001, and ****P<0.0001 compared to mock infected cells as determined 
by a repeated measures one-way ANOVA with Sidak’s post -test for multiple 
comparisons. B) MCMVdie3 inhibits pri -miR-199a/214 expression in NIH-3T3-
BAM25 cells. NIH-3T3 cells were mock infected or infected with either MCMV 
or MCMVdie3 at an MOI=5 for 24 hours. Whereas, NIH-3T3-BAM25 cells were 
also mock infected or infected with only MCMVdie3 at an MOI=5 for 24 hours . 
The expression level of pri-miRNA was quantif ied by qRT-PCR and normalised 
to GAPDH. Data presented are the mean fold change ± S.D. of two independent 
experiments (n=6). **p < 0.01 and ***, p < 0.001 compared to mock infected 
cells as determined by two-tailed Student's t test. C) Northern blot analysis of 
mature miR-199-5p, miR-199-3p, and miR-214 from mock infected and infected 
cells at B. 5µg of RNA was loaded per lane and membrane was hybridised with 
32
P-labeled probes. miR-16 probe was used as a loading control ( lower panel), 
followed by densitometric analysis. The densitometric value for the NIH -3T3 
mock infected was set as 1 and values for other infected cells were expressed 
relative to the mock value.  
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3.2.7.2 Pri-miR-199a/214 expression is regulated in NIH-3T3-
BAM25 cells expressing both IE1 and IE3 genes  
It was demonstrated that IE1 and/or IE3 are required for the down-regulation of miR-
199a/214 expression. To examine the possibility that immediate early genes IE1/IE-3 
are involved in the regulation of miR-199a/214, the expression of primary transcript 
was measured in NIH-3T3-BAM25 cells (a NIH-3T3 cell line in which IE1/IE3 
locus is constitutively expressed). Total RNA was harvested from NIH-3T3-BAM25 
and NIH-3T3 cells for qRT-PCR analysis. The expression of pri-miR-199a/214 was 
reduced 2-fold in NIH-3T3-Bam25 compared to NIH-3T3 cells whereas the 18S 
rRNA expressed at the same levels in both cell lines (Figure 3.16). This indicates that 
the expression of IE3 gene product has a direct or indirect effect on the transcription 
of the primary transcript.  
As IE1 expression was detected in MCMVdie3 infected cells to equivalent levels to 
MCMV infected cells (Angulo et al. 2000) and MCMVdie3 is incapable of 
repressing the expression of the pri-transcript. Therefore, it is unlikely that IE1 
expression in NIH-3T3-Bam25 complementing cell line is involved in the down-
regulation of pri-miR-199a/214 compared to NIH-3T3 cells. Based on these findings, 
the expression of immediate early viral protein (IE3) is required for the down-
regulation of miR-199a/214 that occurs upon infection. The mechanism by which 
this viral protein influences the expression of these miRNAs remains to be 
determined. 
  





Figure 3.16: The expression of IE1 and/or IE3 down-regulates the pri-miR-
199a/214 expression in NIH-3T3-Bam25 cells compared to NIH-3T3 cells.  
Total RNA was harvested from untreated NIH-3T3 and NIH-3T3-BAM25 cell 
l ines. The expression level of pri -miRNA was quantif ied by qRT-PCR and 
normalised to GAPDH. 18S rRNA was included as a negative control. Data 
presented are the mean fold change ± S.D. o f two independent experiments 
(n=6). *p < 0.05 compared to NIH -3T3 untreated cells as determined by two-
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3.2.7.3 MCMVdie3 regulates the activity of the miR-199a/214 
promoter in infected fibroblasts.  
In order to further examine whether the transcriptional regulation of 
pri-miR-199a/214 requires IE1/IE3 gene expression, miR-199a/214 promoter activity 
was measured in MCMVdie3 versus MCMV infected cells.  
Cells were co-transfected with Renilla plasmid for normalisation and the full-length 
promoter construct for 48 hours prior to infection with MCMV or MCMVdie3 at 
MOI of 5. Cells were harvested and lysed at 30min, 2, 4, 8, 24, 48 hpi and 
bioluminescence readings were measured. Consistent with previous results, the 
luciferase expression controlled by the miR-199a/214 promoter decreased steadily in 
MCMV infected cells from 2 to 48 hpi (Figure 3.17).  In contrast, higher levels of 
luciferase expression were observed upon infection with the MCMVdie3 virus from 
2 to 8 hpi. However, a 1.3 and 1.7 fold decrease was detected in the luciferase signals 
by 24 and 48 hpi, respectively (Figure 3.17). These results nicely correlate with 
effects of MCMV and MCMVdie3 on pri-miR-199a/214 levels (Figure 3.15a,b). 
Taken together, these results further confirm that immediate early gene expression is 

















Figure 3.17: The effect of MCMVdie3 on the promoter activity of miR-
199a/214. NIH-3T3 cells were transfected with the full - length promoter 
construct (-596, +100) for 48 hours. Cells were then mock infected or infected 
with either MCMV or MVMVdie3 at  MOI=5 for the indicated times. The activity 
of promoter constructs was measured as the firefly luciferase values, which 
were normalised to Renilla luciferase from the co-transfected vector. The 
firefly/Renilla ratio for promoter constructs was compared to the promoter -less 
vector ratio. Data presented are the mean fold change ± S.D. (n=5)  and are 
representative of two independent experiments. *P<0.05, **P<0.01, ***P<0.001, 
and ****P<0.0001 compared to mock infected ratios in each time point as 
determined by a repeated measures two-way ANOVA with Sidak’s post -test for 
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3.2.8 The regulation of pri-miR-199a/214 and the mature miRNAs 
during HCMV infection.  
MCMV and HCMV infection share roughly half of their encoded open-reading 
frames (ORFs) (Brocchieri et al. 2005; Rawlinson et al. 1996). As a result, there are 
similarities between MCMV and HCMV infections related to events during acute, 
latent, reactivation phase (Adler and Sinzger 2009). However, other conserved viral 
events for modulation of host responses are mediated through different underlying 
mechanisms (Mocarski 2004). We have reported a conserved down-modulation of 
miR-199-5p, miR-199-3p, and miR-214 in HCMV and MCMV infection 
(Santhakumar et al. 2010), it was therefore important to determine whether this 
occurred through similar mechanism. Therefore experiments similar to those 
described for MCMV were carried out using human CMV. Specifically, three 
questions were examined: 1) Does HCMV regulate the pri-miR-199a/214 and its 
mature products? 2) Does this regulation occur at the promoter level? and 3) Is 
TWIST-1 involved in miR-199a/214 regulation in HCMV infection? 
3.2.8.1 Down-regulation of the miR-199a/214 primary transcript 
and mature miRNAs during HCMV infection  
The kinetics of primary transcription and mature miR-199a/214 expression were 
examined in HCMV infected cells. The human lung fibroblast (MRC-5) cell line was 
mock infected or infected with HCMV at MOI of 5. Total RNA and cell lysates were 
harvested at various time points post infection and subjected to qRT-PCR and 
Northern blot analysis.  
As with MCMV, no significant change was observed in the expression of mature 
miR-199-5p, miR-199-3p and miR-214 at early time points, up to 16hpi (Figure 
3.18a). However, a gradual down-regulation occurred between 24 – 72 hpi (1.8 fold 
at 24 hpi to 4 fold at 72 hpi). Consistent with these results, Northern blot analysis 
confirmed the reduction in the mature miR-199-3p, miR-199-5p, and miR-214 at 24, 
48, and 72 hpi; tRNA and miR-16 were measured in parallel as loading controls 
(Figure 3.18b).  
To examine whether the reduction in mature miRNAs resulted from a decrease in 
pri-miR-199a/214 transcript level, the expression of primary transcript was measured 
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in the same time course experiment. As observed in MCMV infection, the expression 
of the pri-miR-199a/214 transcript decreased 1.5 fold within 4 hpi, with a continued 
gradual decrease to 12 fold at 72hpi. The 18S rRNA control showed no change in 
expression at the different time points post HCMV infection (Figure 3.18c). 
Therefore, both MCMV and HCMV reduce the expression of pri-miR-199a/214 
transcript by 4 hpi.   
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Figure 3.18: The expression kinetics of pri -miR-199a/214 and its mature 
miRNAs over the time course of HCMV infection.  A) Down-regulation of 
mature miR-199-3p, miR-199-5p, and miR-214 expression in HCMV infected 
cells by 24 hours compared to mock infected cells. MRC-5 cells were mock 
infected or infected with HCMV at an MOI=5 for the indicated times. The 
expression levels of mature miRNAs were quantif ied by qRT -PCR and 
normalised to miR-16. U6 snRNA was included as a negative control. Mock 
infected cells from the different t ime points (0, 24, 48, 72 hours) were averaged 
and compared to infected cells at each time point. Data presented are the 
mean fold change ± S.D. of two independent experiments (n=6). *P<0.05 and  
**P<0.01 compared to mock infected cells as determined by a repeated 
measures one-way ANOVA with Sidak’s post -test for multiple comparisons.  B) 
Northern blot analysis of mature miRNAs during HCMV infection. Total RNA 
was harvested from MRC-5 cells mock infected or infected as in A. 5µg of RNA 
was loaded per lane and membrane was hybridised with 
32
P-labeled probes. 
miR-16 and tRNA (Gly) probes were used as a loading control ( lower panels), 
followed by densitometric analysis. The densitometric value for the  mock 
infected was set as 1 and values for other time points post infection were 
expressed relative to the mock value. C) Down-regulation of pri-miR-199a/214 
expression in HCMV infected cells by 4 hours compared to mock infected cells. 
Total RNA from A was quantif ied by qRT-PCR and normalized to GAPDH level. 
18S rRNA was included as a negative control. Mock infected cells from the 
different t ime points were averaged and compared to infected cells at each 
time point. Data presented are the mean fold change ±  S.D. of two independent 
experiments (n=6). *P<0.05, **P<0.01, and ***P<0.001 compared to mock 
infected cells as determined by a repeated measures one-way ANOVA with 
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3.2.8.2 HCMV regulates the murine miR-199a/214 promoter in 
infected cells.  
As shown previously (3.2.2.3), there is a high degree of sequence conservation 
between the mouse and human promoters of miR-199a/214. Therefore, the mouse 
promoter construct described above was used to examine whether HCMV affects 
promoter activity.  
The luciferase reporter containing the full-length mouse promoter (-596, +100) was 
co-transfected into MRC-5 cells with a Renilla vector (used for normalisation). 48 
hours after, the cells were then either mock infected or infected with HCMV at MOI 
of 5 for 24 hours. All cells were then lysed and luminescence measured.  
As illustrated in Figure 3.19, the mouse promoter is functional in human cells and 
able to significantly drive luciferase expression by more than 16 fold, relative to the 
promoter-less control construct. This promoter activity in MRC-5 cells was 
comparable to that observed in mouse NIH-3T3 cells. The luciferase expression 
decreased 9-fold in cells infected with HCMV (24 hpi), suggesting that HCMV, like 
MCMV, regulates the pri-miR-199a/214 at the promoter level.   
  




Figure 3.19: Effect of HCMV on the promoter activity of miR-199a/214. 
MRC-5 cells were transfected with murine full - length promoter construct (-596, 
+100) for 48 hours. Cells were mock infected or infected with HCMV at an 
MOI=5 for 24 hours. The promoter activity was measured as the firefly 
luciferase values, which were normalised to Renilla luciferase from the co-
transfected vector. The firefly/Renilla ratio for promoter constructs was 
compared to the promoter-less vector ratio. Data presented are the mean fold 
change ± S.D. of two independent experiments (n=8). **P<0.01, compared to 




Results Chapter 3 
144 
 
3.2.8.3 HCMV down-regulates the expression of TWIST-1 mRNA 
and protein 
The results presented in section 3.2.7, showed that TWIST-1 is downregulated in 
MCMV infection, which at least partially regulates the transcription of 
miR-199a/214. Therefore, the effect of HCMV infection on TWIST-1 expression 
was examined. TWIST-1 mRNA levels were measured using qRT-PCR with total 
RNA isolated from cells mock infected or HCMV infected at MOI of 5. As shown in 
Figure 3.20a, HCMV significantly suppressed the expression of TWIST-1 mRNA 
(from 1.5 fold at 8 hours to a 5 fold decrease by day 3 of infection).  
To further examine whether the regulation occurred at the protein level, cell lysates 
from mock infected and infected cells at 24 and 48 hours were analysed using 
Western blotting. A significant reduction was observed in TWIST-1 protein 
expression was observed at 24 and 48 hours post HCMV infection (Figure 3.20b).  
In conclusion, human TWIST-1 mRNA and protein were downregulated in HCMV 
infection by 8 and 24 hpi, respectively. It should be noted that down-regulation at the 
TWIST-1 protein level in both HCMV and MCMV is not significant until 24 or 48 
hours in HCMV or MCMV infection, respectively. Therefore, the early effect(s) of 
the virus (by 4 hours) on the miR-199a/214 promoter is not explained by changes in 
TWIST-1 protein expression upon infection.  
 
  




Figure 3.20: The expression of TWIST-1 mRNA and protein in HCMV 
infected cells.  A) Down-regulation of TWIST-1 mRNA in HCMV infected cells 
by 2 hours compared to mock infected cells. MRC-5 cells were mock infected or 
infected with HCMV at an MOI=5 for the indicated times. The expression level 
of TWIST-1 was quantif ied by qRT-PCR and normalised to GAPDH. Mock 
infected cells from the different t ime points (0, 24, 48, 72 hours) were averaged 
and compared to infected cells at each time point. Data presented are the 
mean fold change ± S.D. of two independent experiments (n=6). *P<0.05, 
**P<0.01, ****P<0.0001 compared to mock infected cells as determined by a 
repeated measures one-way ANOVA with Sidak’s post-test for multiple 
comparisons. B) Western blot showing reduction in TWIST-1 at 24 and 48 
hours post HCMV infection. Whole cell lysates were harvested from MRC-5 
cells mock infected or infected with HCMV at an MOI of 5 for 24 and 48 hours. 
20µg of protein was loaded per lane and membrane was immunoblotted with 
primary antibodies against either TWIST-1 or β-ACTIN as a loading control. 
Blots were then quantif ied by densitometry and normalized to the 
corresponding β-ACTIN. The mock infected at 24 hours was set as 1 and 
values for other t ime points were expressed relative to the mock value.   
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3.2.8.4 TWIST-1 regulates miR-199-5p, miR-199-3p and miR-214  
The effect of TWIST-1 knock down on the expression of miR-199a/214 was 
examined in MRC-5 cells either mock infected or infected with HCMV. Cells were 
transfected with TWIST-1 siRNA or control siRNA (RISC-free siRNA) for 48 hours 
prior to infection for 24 hours, after which total RNA was harvested and subjected to 
qRT-PCR and Northern blot analyses. 
Transfection of the TWIST-1 siRNA reduced the expression of TWIST-1 mRNA in 
MRC-5 cells by 90%. The knock down of TWIST-1 significantly decreased the 
expression of the mature members of miR-199a/214 cluster by 1.5 fold. HCMV 
infection of cells in which TWIST-1 was knocked down caused a further 2.5 to 3 
fold reduction of the expression of miR-199-5p, miR-199-3p, and miR-214 (Figure 
3.21a). Northern blot analysis of mature members of miR-199a/214 cluster 
confirmed the down-regulation of the mature cluster in cells in which TWIST-1 
siRNA was knocked down as well as a more pronounced down-regulation of these 
miRNAs in infected cells (Figure 3.21b).  
To summarise, the human TWIST-1 is involved in the down-regulation of miR-
199a/214 cluster during HCMV infection. However, since the protein is not regulated 
as early as the pri-miR-199a/214, clearly other factors are involved.  
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Figure 3.21: HCMV induces more robust inhibition of miR-199a/214 
expression than observed for TWIST-1 knockdown at 24 hpi. A) MRC-5 cells 
were transfected with either control RISC-free or TWIST-1 siRNA for 48 hours. 
Cells were then mock infected or infected with HCMV of an MOI=5 for 24 hours.  
The expression level of TWIST-1 and mature miRNAs were quantif ied by qRT-
PCR, normalised to GAPDH and U6 snRNA, respectively. Data presented are 
the mean fold change ± S.D. (n=3) and are representative of two independent 
experiments. *P<0.05 and **P<0.01 compared to mock infected cells as 
determined by a repeated measures two-way ANOVA with Sidak’s post-test for 
multiple comparisons. B) Northern blot analysis of mature miRNAs from 
experiment A. 5µg of RNA was loaded per lane and membrane was hybridised 
with 
32
P-labeled probes. miR-16 and tRNA (Gly) probes were used as a loading 
control ( lower panels), followed by densitometric analysis. The densitometric 
value for the RISC-free siRNA (mock infected) was set as 1 and values for 
other conditions were expressed relative to the mock value.  
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3.4 Discussion   
Increasing evidence suggests that the regulation of cellular miRNA can influence the 
outcome of a viral infection. miRNA expression can be regulated at the level of 
transcription, processing of the pri- or pre-miRNA, and/or degradation of the mature 
miRNA. To date, only one mechanism of cellular miRNA regulation by MCMV has 
been reported: the degradation of cellular miR-27a and miR-27b through the 
expression of a viral transcript, which acts as specific inhibitor of the mature miR-27. 
The mechanism for inhibiting miR-27 expression does not seem to be conserved in 
HCMV infection (Santhakumar et al. 2010; Libri et al. 2012; Marcinowski et al. 
2012). However, three cellular miRNAs derived from the pri-miR-199a/214, are 
down-regulated in both MCMV and HCMV acute infections (Santhakumar et al. 
2010). The mechanism(s) underlying the regulation of miR-199a/214 expression in 
murine and human CMV infections were previously unknown. The work presented 
in this chapter addresses four questions regarding the down-regulation of miR-199-
5p, miR-199-3p, and miR-214 levels during MCMV infection: 1) During which stage 
of miRNA biogenesis, can the expression of these mature miRNAs be regulated in 
infection?; 2) are cellular factors involved in the regulation of these miRNAs during 
infection?; 3) is the down-regulation of miR-199a/214 cluster dependent on viral 
gene expression?; and 4) is the mechanism by which MCMV and HCMV regulate 
the expression of miR-199a/214 conserved?  
3.4.1 Regulation of miR-199a/214 transcription during MCMV infection 
The data presented in sections 3.2.1 and 3.2.4 demonstrates that MCMV infection 
inhibits the transcriptional regulation of the miR-199a/214 cluster, thereby revealing 
another mode of MCMV interference with miRNA biogenesis. The expression of the 
primary transcript of miR-199a/214 cluster is reduced by 4 hpi in MCMV, which is 
earlier than the reduction of mature miRNAs observed at 24 hpi. It is expected that 
the difference in timing of pri-miRNA versus mature miRNA reduction relates to the 
fact that these mature miRNAs are relatively stable (data not shown). There are two 
levels of regulation for pri-miRNA transcript: one at the transcriptional level 
involving promoter regulation and another at the processing level. An example of 
regulation at the processing level would be the editing of pri-miR-142 resulting in 
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inhibition of its processing and reduction of its stability, followed by its degradation 
(Yang et al. 2006). Therefore, the first step was to examine whether or not the 
transcription of pri-miR-199a/214 was altered in MCMV-infected cells. 
Interestingly, the promoter activity of miR-199a/214 decreased with similar kinetics 
to the expression of the primary transcript during MCMV infection, strongly 
indicating that the down-regulation of miR-199a/214 occurs at the transcriptional 
level. This correlates with the short half-life pri-miR-199a/214 transcript (Data not 
shown). Nonetheless, this does not rule out the possibility that additional post-
transcriptional mechanisms also contribute to the down-regulation of these miRNAs 
during infection. In addition to the primary transcript of miR-199a/214, two 
additional transcripts have been found to be produced from the same gene that 
include the precursor sequence of either miR-199a or miR-214, but are expected to 
be under the control of different promoters (Figure 3.3). The expression and 
regulation of these transcripts, pri-miR-199a and pri-miR-214, were not examined in 
infected cells, however, their regulation can contribute to the mature miRNA levels.  
The suppression of miR-199a/214 promoter in uninfected and infected cells could be 
mediated through various mechanisms, including cellular or viral transcription 
elements and epigenetic factors such as DNA methylation and histone modifications. 
Kim et al (2008) previously showed that miR-199a/214 expression is silenced in 
several human cancer cell lines (e.g. A549 and Hela) and epithelial cells (MCF10A 
and PWR-1E) due to heavy methylation of the miR-199a/214 promoter. He et al. 
(2012) reported that reactive oxygen species (ROS) induced DNMT1 activity to 
mediate miR-199a/214 promoter hypermethylation in ovarian cancer. It was reported 
that HCMV is able to induce the generation of ROS within minutes of infection as 
these ROS are critical for the transactivation of MIEP (Speir et al. 1996). It would 
therefore be useful to examine whether the methylation status in the promoter region 
of miR-199a/214 is altered upon infection with MCMV. However, this was beyond 
the scope of this investigation.  
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3.4.2 The regulation of miR-199a/214 expression by TWIST-1, SRF, and 
ELK-1 but not by STAT3 in fibroblasts  
The results presented provide some characterisation of the mouse miR-199a/214 
promoter, which shows ~89.7% conservation with the human promoter. A single 
transcriptional start site was identified in pri-miR-199a/214 transcript using primer 
extension analysis. To determine the minimal promoter sequence, several reporter 
constructs were constructed within the pri-miR-199a/214 promoter, which span from 
-596 to +100 of the relative TSS. The experiment identified a specific region (-
596,+100) as the minimal promoter sequence required for basal promoter activity 
and localized the most functional region (-421,-273) for promoter activity, which 
seems to contain positive regulatory element(s). Three conserved transcription factor 
sites were found within the critical region (-421,-273): the SRF dimer and ELK-1. 
Based on gene-knockdown experiments, these transcription factors were found to 
regulate the basal expression of miR-199-5p, miR-199-3p, and miR-214 under 
normal conditions (uninfected) (Figure 3.11). In accordance with these results, a 
previous report showed that overexpression or inhibition of SRF in transgenic mice 
altered the expression of a number of miRNAs, including miR-199-3p, miR-199-5p, 
miR-214 and the primary transcript (Zhang et al. 2011). It has been reported that 
HCMV stimulates the formation of a complex containing the phosphorylated ELK-1 
and SRF protein shortly after infection (Caposio et al. 2010). SRF and ELK-1 are 
required to mediate the activation of HCMV major immediate early promoter 
(MIEP), and that mutagenesis in SRF and/or ELK-1 binding sites in the MIEP 
impairs the efficient transcription of viral IE genes and replication of recombinant 
HCMV in fibroblasts (Chan et al. 1996; Caposio et al. 2010). Given that the 
competition of viral promoters and enhancers for cellular transcription factors is a 
possible scenario during infection, for example, Wu et al (1998) showed that the 
HCMV IE2 protein can alter the DNA binding activity of a cellular transcription 
factor SP1, thereby activating the expression of genes associated with HCMV 
productive infection such as viral DNA polymerase gene promoter. Therefore, the 
down-regulation of miR-199a/214 promoter may be due to the competitive binding 
of ELK-1 and SRF to the viral promoter(s) rather than cellular promoters including 
miR-199a/214 promoter. Another possible scenario is that SRF and/or ELK-1 are not 
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involved in the down-regulation of miR-199a/214 transcription during infection. 
However, the role of SRF-ELK-1 complex was studied in HCMV and it is not clear 
if this complex is regulated in the same way during MCMV infection. Indeed, 
modulation of miR-199a/214 by both CMV viruses may be mediated by different 
proteins.  
In agreement with previous studies (Yin et al. 2010; Lee et al. 2009), it was shown 
here that TWIST-1 regulates the transcription of miR-199a/214 cluster expression. In 
contrast, STAT3 was not found to regulate the miR-199a-2 promoter or miR-199-5p 
expression in this work (Figure 3.11), which contradicts published data showing an 
increase in miR-199-5p level in heart tissue from STAT3-KO mice and an increase 
in miR-199a-2 promoter activity in neonatal rat cardiomyocyte transduced with anti-
STAT3-shRNA (Haghikia et al. 2011). This may be due to the inherent differences in 
cell types or organisms.  
3.4.3 The transcriptional regulation of miR-199a/214 cluster involves 
TWIST-1 
Infection of cells with MCMV led to a significant decrease in the level of TWIST-1 
mRNA at 24 hours, whereas its protein level was only reduced at 48 hours. The 
delayed reduction in TWIST-1 protein level may be due to the half-life of this 
protein and suggests that the regulation of pri-miR-199a/214 transcript at 4, 8, 12, 16, 
24 hpi cannot be attributed to the reduction in TWIST-1. Therefore, TWIST-1 
inhibition seems to contribute to the decrease in pri-miR-199a/214 transcript at 48 
hours post MCMV infection but this does not explain the early reduction of the 
pri-miRNA between 4 and 24 hpi. It is possible that the activity, rather than 
expression, of TWIST-1 might be altered earlier in infection. There are several 
mechanisms by which the activity of TWIST-1 can be regulated, either through 
phosphorylation state or dimerization with a partner to form bHLH complex 
(Vichalkovski et al. 2010; Firulli and Conway 2008; Firulli et al. 2008). MCMV 
could post-translationally regulate TWIST-1 dimerization with bHLH factor and/or 
its phosphorylation, thereby resulting in decreasing the transcription of pri-miR-
199a/214 transcript at early time points during infection. It is tempting to speculate 
that in order to achieve a rapid down-regulation in pri-miR-199a/214 transcript in 
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host cells, MCMV deactivates the biological function of the existing TWIST-1 
protein. However, to create a prolonged down-regulation of the pri-miRNA 
transcript, TWIST-1 expression is regulated at the levels of both transcription and 
translation. Further work should be conducted in order to determine whether 
infection affects the activity of TWIST-1 by phosphorylation or its ability to 
dimerize with bHLH factor, which could explain the down-regulation of the pri-miR-
199a/214 transcript between 4 to 24 hours post MCMV infection. The observed 
findings (shown in Figure 3.14a) illustrate that the MCMV infection of cells in which 
TWIST-1 was knocked down was incapable of causing further reduction of miR-
199-5p, miR-199-3p and miR-214 expression at 24 hpi. These results may suggest 
that the reduction of miR-199-5p, miR-199-3p, and miR-214 expression is largely 
dependent on TWIST-1 at 24 hours.  
3.4.4 The expression of immediate early viral gene (IE3) is required for 
significant down-regulation of mature miR-199-5p, miR-199-3p, 
miR-214 and their primary transcript.  
The most commonly used procedure to examine the importance of viral products on 
infection processes is the comparison of active and UV-inactivated virus. 
UV-inactivation damages viral DNA, making viruses incapable of gene expression 
and replication. Another tool in the case of MCMV is the use of IE3 mutant strains 
(MCMVdie3), which does not express IE3 gene product. IE3 gene encodes the 
transcriptional transactivator IE3 protein whose expression is essential for the 
expression of early genes and virus replication. The use of the MCMVdie3 mutant 
virus instead of UV-inactivation offers the advantage of a phenotype reversal as the 
replication cycle of the MCMVdie3 mutant can be restored in NIH-3T3-BAM25 
cells, which express the viral IE1 and IE3 genes (Angulo et al. 2000). The data 
presented shows that in fibroblasts infected with MCMVdie3 the expression of miR-
199a/214 is not down-regulated. There was an observable trend towards increasing 
the pri-miR-199a/214 level at 2, 4, and 8, as well as a small reduction at 48 hours 
following MCMVdie3 infection, which was markedly less than that seen in MCMV 
infected cells at 48 hpi (Figure 3.15). These changes may result from the ability of 
the MCMVdie3 mutant virus to trigger cellular cascades during the initial attachment 
to host cells, the release of different tegument proteins during entry, and/or the 
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expression of considerably attenuated levels of viral gene expression downstream of 
IE1/IE2 (Angulo et al. 2000; Lacaze et al. 2011). More importantly, the replicative 
capacity of the MCMVdie3 mutant is restored by the complementary host cell line 
NIH-3T3-BAM25 cells, and as expected the pri-miR-199a/214 is down-regulated 
under these conditions. The inhibition of the primary transcript in MCMVdie3 
infected NIH-3T3-BAM25 cells (~2.5-fold) was not as drastic as that seen in wild 
type MCMV infection of NIH-3T3 cells (~15-fold). This reduced effect could a 
result from attenuated restoration of viral replication in NIH-3T3-BAM25 cells in 
contrast, with the MCMV (Angulo et al. 2000). More interestingly, the level of 
primary transcript in NIH-3T3-Bam25 where IE3 is expressed was inhibited in 
comparison to the parental NIH-3T3 cell line (Figure 3.16). This suggests that IE3 
may play a direct role in the transcriptional regulation of miR-199a/214 or that it 
may play an indirect role through a cellular transcription factor. Further experiments 
are required to explore this hypothesis. 
3.4.5 HCMV uses a conserved mechanism to regulate miR-199a/214 
expression  
In spite of the similarities between MCMV and HCMV (described in section 1.2.4), 
differences still exist between the viruses and must be considered. These viruses only 
share ~80 homologous ORFs, about 40% of the estimated number of ORFs encoded by 
these viruses (Rawlinson et al. 1996; Brocchieri et al. 2005). There are also functional 
differences between homologous MCMV and HCMV proteins, such as the HCMV 
IE1 protein, shown to bind chromatin, whereas this is not the case for the MCMV 
IE1 homolog (Maul and Negorev 2008). Therefore, the viruses have evolved different 
mechanisms for targeting the same signaling pathways in host cells.  
While the overall reduction in mature miR-199-5p, miR-199-3p and miR-214 
expression occurs in both infections, this does not necessarily indicate that similar 
mechanisms are involved. As shown in Figure 3.18, HCMV infection resulted in a 
clear reduction of the pri-miR-199a/214 by 4 hpi that occurred at the promoter level 
(Figure 3.19). TWIST-1 protein was also found to play a part in this regulation, at 
least by 24 hpi (Figure 3.20). The reduction of the human TWIST-1 mRNA and 
protein by HCMV occurs faster than for MCMV infection, either indicating the 
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involvement of different viral factors or differences in the cell lines used. As found 
with MCMV, HCMV infection of cells in which TWIST-1 was knocked down, 
resulted in an additive effect on the suppression of miR-199-5p, miR-199-3p and 
miR-214 (Figure 3.21), implying the involvement of other factors or mechanisms 
besides TWIST-1 in this regulation.  
Overall, the results presented in this chapter demonstrate that the down-regulation of 
the primary transcript encoding miR-199a-2 and miR-214 in MCMV and HCMV 
infected fibroblast cells occurs at the transcriptional level. Additionally, this down-
regulation occurs at early times post infection starting at 4 hours and seems to be 
dependent on the expression of IE3 and/or de novo viral gene expression. It was 
further shown that SRF and ELK-1 regulate the basal transcription level of miR-
199a/214 cluster in uninfected cells and that TWIST-1 has a role in regulating the 
expression of miR-199a/214 and is down-regulated in both infections. Finally, the 
characterisation of the miR-199a/214 promoter described in this work is likely to be 
a useful tool for further studies that examine the transcription factors responsible for 
the regulation of miR-199-5p, miR-199-3p, and miR-214 expression in response to 
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4 A proposed Model for the Antiviral Function of 
miR-199-3p in CMV Infections  
4.1 Introduction  
It has previously been shown that MCMV and HCMV mediate down-regulation in 
expression of the miRNA cluster miR-199/214 that encodes miR-199-5p, miR-199-
3p and miR-214. In vitro overexpression of miR-199-3p and miR-214 can 
significantly inhibit the growth of these viruses. The antiviral properties of miR-199-
3p also extend to other herpesviruses belonging to different subfamilies such as 
HSV-1 (Alphaherpesvirinae) and mouse γ-herpes virus (Gammaherpesvirinae) 
(Santhakumar et al. 2010). Therefore, the work presented in this chapter focuses on 
miR-199-3p since it harbours the broadest antiviral properties against herpes viruses. 
This chapter addresses the question of whether miR-199-3p is able to regulate host 
signaling pathways by targeting multiple transcripts, and if these regulated pathways 
are known to play an important role during the CMV life cycle.  
4.1.1 Functions of miR-199-3p in cells 
So far, a role for miR-199-3p has been implicated in several cancers, viral infections, 
as well as a wide range of biological processes.  
 Cancer  
Dysregulation of miR-199-3p has been found to be associated with several human 
cancers (Table 1.5). However, its significance has only been studied in some of 
these. Expression of miR-199-3p has been shown to be downregulated in 
hepatocellular carcinoma, epithelial ovarian cancer and osteocarcinoma cells, 
whereas it is upregulated in ovarian and breast cancers. The overexpression of miR-
199-3p attenuates cell proliferation, survival and invasiveness in hepatocellular 
carcinoma as well as osteocarcinoma cells (Fornari et al. 2010; Henry et al. 2010; 
Yin et al. 2010; Duan et al. 2011; Hou et al. 2011; Cheng et al. 2012). In contrast, it 
induces the same biological processes in the case of breast cancer (Shatseva et al. 
2011). A number of validated targets of miR-199-3p are associated with its above 
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mentioned role in cancer cells (Table 4.1). These are mainly involved in MET and 
mTOR signaling.   
 Cardiac proliferation and regeneration  
Functional screening identifies miR-199-3p as a proliferative miRNA in 
cardiomyocytes. The overexpression of miR-199-3p in neonatal and adult 
cardiomyocytes results in increased levels of cyclin genes that correlate with 
enhanced proliferative capacity of these cells in vivo. The exogenous administration 
of miR-199-3p into the infarcted heart also has a positive effect on minimising the 
infarct mass and improving cardiac function, consistent with the impact of promoting 
the proliferation of cardiomyocytes. miR-199-3p regulates cardiomyocyte 
proliferation via targeting its calcium signaling (Eulalio et al. 2012) (Table 4.1). 
 Chondrogenesis  
A bone morphogenic protein 2 (BMP2), which triggers chondrogenesis, was reported 
to inhibit the expression of miR-199-3p. miR-199-3p was found to repress the 
chondrogenesis via direct targeting of the SMAD1 transcription factor. The 
overexpression of miR-199-3p reduces expression of marker genes for 
chondrogenesis such as cartilage oligomeric matrix protein (COMP), type II 
collagen, and Sox9 (Lin et al. 2009) (Table 4.1).  
 Inflammation  
miR-199-3p was reported to be involved in the mechanism regulating the 
implantation and quiescence of the myometrium during pregnancy as well as its 
transition into a contractile state during labour (Chakrabarty et al. 2007; Williams et 
al. 2012). miR-199-3p was up-regulated in pregnant mouse myometrium and down-
regulated during labour, thereby correlating with the differential regulation of the 
inflammatory gene PTGS2 (COX-2) and the production of prostaglandin and TNF-α 
Down-regulation of miR-199-3p also contributes to inflammation of joints in patients 
with osteoarthritis via PTGS2 (COX-2) and prostaglandin production (Akhtar and 
Haqqi 2012) (Table 4.1).  
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 Viral infection  
miR-199-3p has been reported to significantly inhibit viral function in a range of 
virus families (Flaviviridae “HCV”, Hepadnavirus “HBV”,  Togaviridae “SFV”, and 
Herpesviridae “CMV – HSV-1 – MHV-68”) (Murakami et al. 2009; Santhakumar et 
al. 2010; Zhang et al. 2010). Although these viruses have distinct replication 
processes, it is possible that they employ similar host proteins or signaling to support 
their life cycle. Therefore, it is possible that miR-199-3p targets factor(s) or signaling 
cascades that are shared amongst all these viruses and are crucial for their respective 
life cycle. However, miR-199-3p was shown to target the HCV and HBV RNAs 
during infections (Murakami et al. 2009; Zhang et al. 2010) (Table 4.1).  
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Table 4.1: List of miR-199-3p-regulated functions and target genes.   
 
4.1.2 Aims  
Given that miR-199-3p has antiviral properties in a range of viruses, this may relate 
to targeting host genes, rather than to direct interactions with viral factors. For this 
reason, work in this chapter is aimed at understanding the role of miR-199-3p in host 
cells during infection. In order to address this, expression profiling was carried out 
comparing cells transfected with miR-199-3p mimics versus inhibitors. Following 
analysis of transcriptoma profile, the targets of miR-199-3p were selected on the 
basis of genes that were regulated by the expression of miR-199-3p and contained 
seed match sites in their 3′UTRs. The modulated biological functions and signaling 
pathways associated with these potential targets were then inferred using the 
Ingenuity Pathway Analysis (IPA). Literature studies were then used to determine 
the pathways implicated in the modulation of viral infection. 
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4.2 Results  
4.2.1 Experimental design of whole genome gene expression study  
For investigation into the cellular targets of miR-199-3p, the mRNA profile was 
examined in NIH-3T3 fibroblasts in which miR-199-3p was over-expressed by 
mimics or knocked down by inhibitors. The mRNA expression was analysed using 
transcriptome microarrays from Affymetrix as miRNA are believed to primarily 
transcriptionally suppress the target and lead to mRNA degradation.  
Cells were untreated or transfected with miR-199-3p mimic, inhibitor, or control 
siRNA (RISC-free siRNA) for 72 hours. RISC-free siRNA is RNA duplex that is 
chemically modified to impede the incorporation into RISC complex, however, it is 
used to control for non-specific effects of transfection. miRNA mimics are 
chemically modified double-stranded RNAs that mimic endogenous mature 
miRNAs, in here one strand is preferentially incorporated into RISC. miRNA 
inhibitors are chemically modified single-stranded RNAs that act as a ‘fake’ target 
and inhibit the endogenous miRNA. Total RNA was harvested from 3 replicates of 
untreated or miR-199-3p mimic transfected cells as well as from 4 samples of control 
siRNA or miR-199-3p inhibitor transfected cells. Prior to the microarray experiment, 
the transfection efficiency and RNA integrity were assessed. All 14 RNA samples 
had a RIN (RNA Integrity Number) value of  ≥ 9.10, which meets the required RNA 
integrity for microarray analysis (Jones et al. 2006).  The extent of over-expression 
or inhibition of miR-199-3p in these samples was assessed by qRT-PCR. 
Transfection of miR-199-3p inhibitor into NIH-3T3 cells resulted in at least a 2 fold 
knockdown whereas transfection with an miR-199-3p mimic gave a 22.8 fold 
increase relative to control RISC-free siRNA or untreated samples (Figure 4.1). 
These RNA samples were then subjected to the experimental preparation according 
to manufacturer's protocol and hybridized onto GeneChip Mouse Gene 1.0 ST Array 
(Affymetrix), which was performed by Marie Craigon at the Division of Pathway 
Medicine, The University of Edinburgh, UK.  
 




Figure 4.1: The quantification of miR-199-3p levels following transfection 
of its mimic and inhibitor.  Up-regulation of miR-199-3p in cells transfected 
with miR-199-3p mimic (A) and inhibition in miR-199-3p in cells transfected 
with miR-199-3p inhibitor (B) compared to untreated cells. NIH-3T3 cells were 
untreated or transfected with 25nM control RISC-free siRNA, miR-199-3p mimic 
(A) or miR-199-3p inhibitor (B) for 72 hours. The expression level of miR-199-
3p was quantif ied by qRT-PCR and normalised to miR-16. Data presented are 
the mean fold change ± S.D (n=5). **p < 0.01 and ****, p < 0.0001 compared to 
untreated cells determined by two-tailed Student's t test.  
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4.2.2 Array quality control (QC) metrics 
Several statistical methods were used to determine the quality of the array 
experiment, including both platform specific and sample specific controls, as 
outlined below.  
4.2.2.1 Affymetrix GeneChip Built in Controls 
The GeneChip mouse Gene 1.0 ST ArrayChip has four built-in controls designed to 
assess the quality of the array experiment including cDNA preparation, labelling, 
hybridisation, and resultant signal intensities.  
1- 5,222 probe sets were defined as negative controls to estimate the background 
signal.  
2- 1,324 probe sets were used as positive controls to indicate the overall quality 
of the cDNA sample.   
3- 4 spike-in hybridisation controls of increasing concentrations were selected to 
examine the hybridisation efficiency.   
4- 4 spike-in Poly-A controls were used to assess the success of the cDNA 
preparation, in particular the reverse transcription step.  
1 and 2) Negative and positive controls  
The signal obtained from the negative probes of each GeneChip is expected to be an 
artefact of the imaging system background, non-specific binding or cross-
hybridisation. The median signal that was produced from these negative probes 
defined the background (~ 3.35 arbitrary unit (a.u.)) whereas the median deviation 
(MAD) of the probes determined the noise in the array (~0.88 a.u.) as illustrated in 
Table 4.2. These values were then used to establish the limits of detection within the 
array, so that genes with expression values below the negative could be discarded. 
The median intensity values obtained from the positive control on the GeneChips 
was ~6.4 compared to the median of the intensities of the negative probes. However, 
the median values of the expression intensities of negative and positive probe sets 
within each array chip were comparable between chips. The intensity values for 
positive probe sets were also found to be stronger relative to the negatives, which 
reflects the background level (see Figure 4.2a).  
Results Chapter 4 
162 
 
3) PolyA unlabeled spikes: in order to monitor the quality of experimental 
preparation of the samples, four polyA-mRNAs of Bacillus subtilis (lys, phe, thr, and 
dap) were spiked into each RNA sample at various concentrations (1, 2, 4, and 15 
fgrams (fg)) respectively, in accordance with the manufacturer's instructions. As can 
be seen in Figure 4.2b, the lowest signal intensities for all the 14 chips were for lys 
mRNA, which subtly increased in phe and thr. The strongest intensity values were 
found in the dap transcript, as it was spiked at a higher concentration of 15fg. This 
suggests that the processed samples were of sufficient quality to produce informative 
results. 
4) Hybridisation labelled spikes: BioB, BioC, BioD and CreX transcripts were 
biotinylated and spiked into the hybridization buffer in various concentrations by the 
manufacturer. These transcripts served as controls for the efficiency of hybridization. 
As illustrated by Figure 4.2c, the biotin-labelled spike in transcripts exhibited a 
similar pattern of signal intensities among all 14 GeneChips. The increase in the 
intensities of the control transcripts was found to correlate with the concentration of 
biotinylated transcripts, which is an indication of successful and uniform 











Table 4.2: The background signal of each GeneChip.  The intensity values of 
5,222 probe sets, acting as negative built- in controls, were used to estimate 
the background signal of each GeneChip. The obtained background value was 
calculated for each chip based on the median value of the negative intensit ies 
and the median absolute deviation. The median absolute deviation (MAD) was 




















Untreated _1 3.39498 0.9078 4.30278 




RISC-free siRNA transfected_1 
3.38342 0.89364 
4. 27706 
RISC-free siRNA transfected_2 3.3185 0.8567 4.27706 
RISC-free siRNA transfected_3 
3.38534 0.88864 
4.27398 
RISC-free siRNA transfected_4 
3.36806 0.8987 
4. .26676 
miR-199-3p mimic transfected_1 
3.35568 0.8848 
4. 24048 
miR-199-3p mimic transfected_2 3.33461 0.87006 4. 20467 
miR-199-3p mimic transfected_3 
3.33031 0.8828 
4. 21311 
miR-199-3p inhibitor  transfected_1 
3.38186 0.88278 
4. 26464 
miR-199-3p inhibitor  transfected_2 
3.33506 0.8691 
4. 20416 
miR-199-3p inhibitor  transfected_3 3.28884 0.8312 4. 12004 
miR-199-3p inhibitor transfected_4 
3.34047 0.85412 
4. 19459 






Figure 4.2: Summary of Affymetrix microarray quality control data.  A) The 
median of the negative and posit ive controls for each GeneChip. B) Four poly-A 
RNA controls were added to the RNA samples in different concentrations in 
order to assess the labelling efficiency and processing of RNA samples. C) 
Four hybridisation controls are spiked into the hybridisation buffer used in this 
experiment at increasing concentrations (1.5 pM BioB, 5 pM Bio C, 25 pM BioD, 
and 100 pM Cre). 
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4.2.3 Pre-processing of data 
Pre-processing is a preliminary step applied to the unprocessed raw data prior to the 
differential expression analysis. This process involves three steps: 1) produce 
background corrected and log-2 transformed values for probe intensities, 2) 
normalise probe intensities between the different GeneChips by means of quantile 
normalisation, and 3) summarise all the related probes into a signal expression value. 
The pre-processing steps were conducted using a robust multi-array average (RMA) 
within the Partek program and Madmax pipeline https://madmax.bioinformatics.nl.  
Box plot of log2 intensities  
The box plots of the log2 intensity distribution are plotted for the 14 GeneChips 
(Figure 4.3a). The distributions of raw log-intensities do not show dramatic 
differences between the chips, however these differences in log-intensities were 
corrected by RMA to make the distributions most comparable. 
Principle component analysis (PCA)  
PCA is a statistical method used to summarise complex datasets into a compact 
principle components. This method was performed on RMA pre-processed values for 
all the GeneChips and the results plotted in Figure 4.3b. An obvious correlation can 
be seen between the expression profiles of the biological replicates in miR-199-3p 
mimic, inhibitor and untreated cells, as these replicates clustered closely to each 
other. The biological replicates in the RISC-free treated samples do not seem to 
cluster together and this is an indication of variability within the expression profile in 
these samples, which warrants caution in using them as controls.  
Clustering analysis  
Clustering analysis is a mathematical approach that assigns GeneChips into groups 
based on the similarity/dissimilarity of the expression profiles of these samples. This 
data was then analysed using Partek’s default measures, Elucidean distance and 
average linkage and plotted as a hierarchical tree (dendrogram). GeneChips were 
closely clustered to the corresponding biological treatment, except that two of four 
RISC-free samples were clustered with different groups, either untreated or miR-
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199-3p inhibitor (Figure 4.3c). Irrespective of the results of the PCA and clustering 
technique, all four chips of RISC-free siRNA were included in the subsequent 
analysis. 
Overall, these primary quality control measures and pre-processing methods showed 
that the GeneChips used were of satisfactory standard, allowing for the differential 









Figure 4.3: Normalisation and comparisons of the expression data 
between GeneChips.  A) Box plots representation of log-intensity distributions 
of raw and normalised data, which was corrected using RMA method. B) A 
principle component analysis (PCA) was performed on the expression data of 
all the 14 array chips. The points represent the different chips and are coloured 
based on the biological treatment and ellipsoid (circle) are drawn around the 
biological replicates of each biological treatment. PCA shows a variance of  
52%. C) A hierarchical cluster analys is based on the similar expression profile 
between the various samples. The Y-axis represents the distance between any 
two samples measured by the correlation distance method (Elucidean). The 
distance between the samples was computed using the average linkage method 
and then plotted in Madmax pipeline.  
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4.2.4 Identification of differentially expressed transcripts in miR-199-3p 
mimic versus inhibitor transfected NIH-3T3 cells 
The next step involved the identification of the differentially regulated genes in 
response to miR-199-3p mimic and miR-199-3p inhibitor at the genome-wide level. 
The data were filtered in two steps: the first discarded the probeset intensities that 
were not expressed above the background; the second selected only the transcripts 
with differential expression levels.  
The background signal of each GeneChip was produced from the background and 
noise measurements, which were calculated from the signal intensities generated 
from the built-in negative controls (5,222 probe sets), as previously demonstrated in 
Table 4.2. The signal intensities that were equal to or lower than the background 
signals were discarded. As a result, of 28,853 transcript clusters, only 12,207 
transcripts, corresponding to 10,652 genes, were expressed over background and 
therefore included in the analysis.  
In the next filtering step, the list of 12,207 transcript intensities were imported into 
Partek’s analysis program in order to calculate the differential expression between the 
mean values of two different treatments, as well as the statistical significance (p-values) 
using ANOVA. Several comparisons were conducted for the detection of 
differentially expressed transcripts: 1) the data from miR-199-3p mimic or inhibitor 
were compared to RISC-free siRNA; 2) the data from miR-199-3p inhibitor were 
compared to miR-199-3p mimic; and 3) the data of untreated samples was compared 
to RISC-free siRNA. A fold change of ≤1.2 down in miR-199-3p mimic or ≥1.2 up 
in miR-199-3p inhibitor relative to RISC-free siRNA treatment and FDR p-value 
below 0.05 were used as  cut offs. The fold change and FDR p-value cut offs resulted 
in 190 down-regulated genes in response to miR-199-3p mimic and 198 up-regulated 
genes for inhibitor transfection (Appendix 6). 12 genes were found to be intersected 
between the down and upregulated gene lists. Another method for determining 
differential expression of genes in response to miR-199-3p was direct comparison of 
the miR-199-3p mimic versus inhibitor data. The fold change and significance cut-
offs were set at ≤1.4 and FDR p-value < 0.05, which identified 198 down-regulated 
genes by miR-199-3p mimic versus miR-199-3p inhibitor. In order to ensure that the 
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differential expression was not based on transfection, RISC-free siRNA and 
untreated cells were subjected to the above analysis. A total of 28 up-regulated and 
16 down-regulated genes were found, with a fold difference of (≥,≤) 1.2 and FDR p-
value < 0.05. Since these genes change as a result of the transfection protocol, their 
differential expression in miR-199-3p transfected cells was considered as a false 
positive. However, the transfection procedure and RISC-free siRNA did not affect 
the gene expression profile of most of the genes indicating it is reliable system.   
4.2.5 SylArray analysis for the enrichment of miR-199-3p seed site 
across the 3′UTRs of miR-199-3p regulated genes  
For the purpose of assessing whether differences in gene expression data could result 
from direct regulation of genes by miR-199-3p, a computational analysis was 
performed using SylArray. The list of 12207 transcripts was ranked based on the 
differential expression in mimic samples compared with inhibitor samples (from the 
most down-regulated to most up-regulated transcripts) regardless of the statistical 
significance and then uploaded to SylArray program. The 3′UTR sequences were 
retrieved from the SylArray database and submitted to the ranked list. The SylArray 
analysis identified a significant overrepresentation of the conserved miR-199-3p seed 
words [the first 2–7 followed by an 'A' or 2–8 nucleotides of miR-199-3p] across the 
ranked list of 3′UTRs. The other miRNA seed sequences were not enriched in the 
3’UTRs changing in this dataset. The enrichment curve of miR-199-3p peaks in the 
left of the plot, which indicates a direct effect of miR-199-3p, as more targets are 
present within the most down-regulated part of this plot (Figure 4.4). This was also 
the case when evaluating mimic dataset individually, relative to the RISC-free 
siRNA control. Figure 4.4 also shows an unexpected depletion of miR-29a seed 
sequences across the most up-regulated transcripts in the miR-199-3p ranked list, 
which has not been examined.   
It can be concluded that the changes in gene expression observed in response to miR-
199-3p are at least partly mediated by direct interaction with elements in the 3′UTRs 
of host genes. 





Figure 4.4: SylArray plot analysis for the seed-match for miR-199-3p in the 
expression profile of cells transfected with miR-199-3p mimic versus 
inhibitor. The X-axis denotes all the annotated 3′UTR sequences in the ranked 
list of genes  downregulated in cells treated with miR-199a-3p mimic versus 
upregulated in cells treated with miR-199-3p inhibitor (left to right). The Y-axis 
represents log10- transformed P values for enrichment of seed site. The dotted 
black line denotes the Bonferroni-corrected P value s ignif icance cut-off of 0.01. 
This f igure il lustrates the words of length 7mer for miR-199-3p, 7-
mer(1A)=CTACTGA and 7-mer(2)=ACTACTG, which are highlighted in red and 
orange. Also, 7-mer(1A)=GGTGCTA and 7-mer(2)=TGGTGCT for miR-29a are 
coloured in blue and green, respectively.  
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4.2.6 The prediction of miR-199-3p targets using TargetScan    
The expression profile of down-regulated genes in miR-199-3p mimic transfected 
samples compared to miR-199-3p inhibitor could be a result of both direct and 
indirect regulation of gene expression by this miRNA. As shown by the SylArray 
plot, there is clearly a global enrichment for miR-199-3p seed sites in the genes that 
are down-regulated. To more specifically examine these sites, TargetScan algorithms 
were applied.  A list of candidates of direct miR-199-3p targets was produced: out of 
the 198 down-regulated genes, 30 putative targets conserved between human and 
mouse were predicted using TargetScan, based on the requirement that their 3′ UTRs 
have at least one seed target site for miR-199-3p (Table 4.3). Another 20 down-
regulated genes were predicted to be targets of miR-199-3p in only the mouse 
genome while seven other genes were only predicted in the human genome. Three of 
the down-regulated genes, PTGS2, CD44, and MET are previously validated targets 
of miR-199-3p, (Chakrabarty et al. 2007; Kim et al. 2008; Henry et al 2010), 
supporting the validity of our approach.  
Target gene  Target sites in 
mouse 3′UTR 




ANKRD13C 3 sites 1 site -1.94 
CD151 4 sites 1 site -4.9757 
CD2AP 1 site 2 sites -1.41428 
CD44 1 site 1 site -1.734 
CEP55 1 site 1 site -1.52784 
CNOT7 2 sites 1 site -1.41417 
CYB5B 1 site 1 site -1.76464 
DUSP5 1 site 1 site -1.75294 
FAM60A 1 site 1 site -1.51947 
FGF7 1 site 1 site -1.96465 
FKTN 3 sites 1 site -1.42653 
G3BP2 1 site 1 site -1.67028 
GALNT7 3 sites 3 sites -1.64384 
GNPTAB 1 site 1 site -1.4333 
ITGA3 1 site 1 site -2.61409 
ITGA6 1 site 1 site -1.56552 
MAPRE1 1 site 1 site -1.53862 
MSN 1 site 1 site -1.40409 
NET1 1 site 1 site -1.67275 




Table 4.3: TargetScan identified 30 targets conserved between mouse and 
human in the genes regulated by miR-199-3p. Prediction of miR-199 direct 
targets among 198 genes found to be down regulated in miR-199-3p mimic 
transfected cells versus miR-199-3p inhibitor cel ls. The list of genes were 
analysed using TargetScan (http://www.targetscan.org/) to search for  the 
genes harbouring at least a site for the miR-199-3p seed sequence in the 
3′UTR sequence of each gene. 8mer (ACTACTGA), 7-mer(1A)=CTACTGA, 
7mer-8m=ACTACTG, and  3′compensatory interaction. The table also contained 
the official gene symbols for these conserved targets of miR-199-3p between 













NUTF2 1 site 1 site -1.50017 
OSTM1 1 site 1 site -1.49464 
OTUD6B 2 sites 1 site -1.99201 
PIK3CB 2 sites 2 sites -1.6513 
PLEKHA3 1 site 1 site -1.57282 
PON2 1 site 1 site -1.84996 
PPP2R5E 2 sites 2 sites -1.47809 
SLC39A10 1 site 1 site -1.54734 
TMSB4X 1 site 1 site -1.54004 
VAMP3 2 sites 2 sites -2.12268 
YWHAE 1 site 1 site -1.48533 
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4.2.7 Pathway and functional analysis of miR-199-3p regulated genes  
In order to understand the signaling pathways and functions of miR-199-3p regulated 
genes, functional and pathway analyses on the 198 genes down-regulated in miR-
199-3p mimic transfected versus inhibitor transfected cells, was carried out in 
Ingenuity pathway analysis programme (IPA) (http://www.ingenuity.com/).  
4.2.7.1 The analysis of canonical pathways  
A canonical pathway is defined as “a core pathway established for a given molecule 
in the cell, in which molecular interactions occur in a linear and stepwise 
manner”(Chung et al. 2011). The IPA library of canonical pathways identified 
statistically significant enriched canonical pathways associated with the 198 genes 
regulated by miR-199-3p. Ten canonical pathways met the p-value cut off of (P < 
0.001). This analysis suggests that miR-199-3p may modulate a number of cellular 
pathways, which are associated with eicosanoid synthesis, PI3k-AKT signaling, 
MAP Kinase cascade, and IGF response. Various cancer-related pathways were also 
present, such as the role of tissue factor in cancer glioma and ovarian cancer (Table 
4.4).  
4.2.7.2 Functional analysis of miR-199-3p regulated genes 
Further analysis was also conducted in IPA to understand the enriched and 
significant biological functions of genes identified in this dataset. A total of 21 
significantly enriched molecular/cellular functions were identified by means of this 
analysis, using a p-value threshold of 0.001. Among them, the p-value significance 
was shown to be higher for functions associated with cellular movement, survival, 
cellular growth, development and proliferation (Table 4.5). These top functions 
appear to be linked with cancer, which was supported by the presence of canonical 
cancer pathways and cancer-related pathways, such as impairment in PI3K-AKT 
functions, IGF signaling, and MAP-kinase activation (Zhu et al. 2011). 
  






P value Ratio Molecules 
Glioma Invasiveness 
Signaling 
3.08E-06 0.117 RRAS2, F2R, TIMP1, CD44, 
PLAUR, PIK3CB, PLAU 
Role of Tissue Factor in 
Cancer  
3.46E-06 0.0789 CTGF, RRAS2, ITGA6, PLAUR, 
HBEGF, PIK3CB, ITGA3, 
CYR61, EIF4E 
PI3K/AKT Signaling  5.13E-05 0.0576 RRAS2,YWHAE, PIK3CB, 
PTGS2, PPP2R5E, ITGA3, 
CCND1, EIF4E 
Eicosanoid Signaling 5.27E-05 0.0759 PLA2G4A, PTGFR, PTGS1, 
PTGS2, PLA2G7, PRDX6 
ERK/MAPK Signaling 2.18E-04 0.0441 PLA2G4A, RRAS2, DUSP1, 
DUSP6, PIK3CB, PPP2R5E, 
ITGA3, PPP1R14B, EIF4E 
Oncostatin M Signaling 5.28E-04 0.114 RRAS2, MT2A, PLAU, CHI3L1 
Coagulation System 5.91E-04 0.105 F2R, PLAUR, PLAU, SERPINE1 
Ovarian Cancer Signaling 6.83E-04 0.0493 GJA1, RRAS2, PTGS1, CD44, 
PIK3CB, PTGS2, CCND1 
Role of MAPK Signaling in 
the Pathogenesis of 
Influenza 
7.37E-04 0.0735 PLA2G4A, RRAS2, PTGS2, 
PLA2G7, PRDX6 
IGF-1 Signaling 7.83E-04 0.0566 CTGF, RRAS2, YWHAE, SOCS6, 
PIK3CB, CYR61 
 
Table 4.4: The top ranked miR-199-3p regulated canonical pathways based 
on  Ingenuity Pathway Analysis (IPA).  P value for inclusion here is ≤ .001. P -
value is calculated using Fischer's exact test indicates the probability of the 
involvement of the genes in the dataset in a given pathway. Ratios represent 
the number of molecules in the dataset that are found in a  given pathway, 
divided by total number of molecules that make up that pathway. Molecules are 
shown in the dataset (≥1.4  decrease and p ≤ 0.05), Potential target genes of 
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Molecular/Cellular functions Number of 
molecules 
P value 
Cellular Movement 68 6.05E-15-3.87E-04 
Cellular Growth and Proliferation 92 1.11E-12-3.48E-04 
Cell Death 83 4.87E-12-3.56E-04 
Cellular Development 76 4.12E-11-3.48E-04 
Carbohydrate Metabolism 41 3.00E-10-3.67E-04 
DNA Replication, Recombination, and 
Repair 
22 3.13E-09-3.13E-04 
Cell-To-Cell Signaling and Interaction 52 8.01E-09-3.87E-04 
Cell Morphology 58 1.84E-08-3.90E-04 
Antigen Presentation 37 4.10E-08-2.46E-04 
Lipid Metabolism 30 6.24E-08-3.66E-04 
Molecular Transport 44 6.24E-08-2.66E-04 
Small Molecule Biochemistry 47 6.24E-08-3.87E-04 
Cellular Assembly and Organization 41 8.76E-08-2.82E-04 
Cellular Function and Maintenance 70 8.76E-08-2.82E-04 
Cell Cycle 32 2.42E-06-1.53E-04 
Energy production 3 5.36E-06-3.66E-04 
Protein synthesis 20 6.39E-06-2.66E-04 
Free Radical Scavenging 17 1.29E-05-2.88E-04 
Cell Signaling 24 4.88E-05-2.50E-04 
Vitamin and Mineral Metabolism 16 4.88E-05-4.88E-04 
Cellular Compromise 2 1.23E-05-1.23E-04 
 
Table 4.5: Enrichment of biological functions in the miR-199-3p 
disregulated genes from Ingenuity Pathway Analysis (IPA).  A p-value of 
inclusion is ≤ .001.  
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4.2.8 The interpretation of the miR-199-3p data in the context of viral 
infection pathways 
To understand the antiviral role of miR-199-3p in HCMV virus infection, a study of 
the current literature was conducted in order to determine whether any of the miR-
199-3p regulated pathways and candidates targets are already known to be important 
for CMV infection. Below is a list of putative miR-199-3p targets with links to 
infection.1) ITGA6, a cellular integrin α-subunit was identified to be down-regulated 
in miR-199-3p dataset. It has been shown that HCMV utilizes ITGA6 and other 
integrins as coreceptors during the entry pathway to host cells, most probably at the 
viral internalisation step. It was also suggested that the activation of integrins trigger 
the focal adhesion kinase (FAK) and the cytoskeletal rearrangement in HCMV 
infected fibroblasts (Feire et al. 2004) that is important for cellular signaling events 
associated with HCMV infection. 2) PIK3CB was found to be down regulated by 
miR-199-3p. Interestingly, PIK3CB is a lipid kinase having a critical role in 
initiating the PI3K signaling cascade, which starts from the phosphorylation of 
phosphatidylinositol 4,5-bisphosphate (PIP2) to the recruitment and phosphorylation 
of AKT, which has a number of downstream substrates that contribute to 
proliferation, survival, growth, cellular metabolism, angiogenesis, migration, and 
cross talk with other signaling pathways, (reviewed by Manning and Cantley 2007). 
Importantly, PI3K-AKT signaling  is known to have an important role in different 
stages of HCMV infection, from replication to viral spread and persistence (Yu and 
Alwine 2002; Johnson et al. 2001b; Smith et al. 2007). Moreover, previous studies 
have shown that a PI3K inhibitor caused reduction in both viral titers and DNA 
replication in HCMV infection of fibroblast cells (Yu and Alwine 2002; Johnson et 
al. 2001b; Smith et al. 2007). 3) MAP kinase and its downstream regulated kinase 
(ERK1/2) is another signaling pathway regulated by miR-199-3p. It has been shown 
previously that MAPK/ERK kinase can be activated at immediate early times of 
infection via the binding of the HCMV envelope glycoprotein gB to host cell 
receptors. The use of U0126, a selective inhibitor of MAPK/ERK kinase had a 
significantly inhibitory effect on the early viral protein products UL44 and UL84 and 
the late protein UL94. In addition the phosphorylation of IE1 and IE2 was reduced. 
Thus, MAPK/ERK kinase is required for viral DNA replication (Johnson et al. 
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2001a; Boyle et al. 1999). 4) PTGS2 (COX-2) is reported to be a direct miR-199-3p 
target in human and mouse cells (Chakrabarty et al. 2007; Williams et al. 2012).This 
gene was found in the microarray study (Results 4.2.4) to be regulated by miR-199-
3p expression. The eicosanoid pathway is responsible for prostaglandin production 
induced upon HCMV infection through the increase in PTGS2 (COX-2). Importantly 
PTGS2 inhibitors interfere with the accumulation of IE2 and reduce viral replication 
in cultured fibroblasts (Zhu et al. 2002). In addition, drugs which antagonise 
prostaglandin synthesis through its receptors and PTGS2 (COX-2) can also block the 
direct spread of HCMV from cell to cell (Schröer and Shenk 2008). Collectively, the 
attenuation of infection induced signaling cascades such as integrin coreceptor, 
PI3K-AKT, ERK-MAP kinase and prostaglandin synthesis (any or all) is expected to 
impact the infection process (Figure 4.5). These pathways appear to be regulated 
through direct miR-199-3p target genes. It should be noted that these targets are only 
those already linked to infection, but it is expected that additional miR-199-3p targets 
could also be important in this context.  
 
  






Figure 4.5: A graphical representation for miR-199-3p regulated signaling 
pathways in context of CMV infection.  Predicted conserved and non-
conserved targets between human and mouse are shown in blue and green 
boxes, respectively. Validated non-conserved miR-199-3p target is denoted by 
shaded green box. Genes which were found to be regulated by miR-199 
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4.2.9 Network analysis for the potential targets of miR-199a-3p  
As discussed in section 4.2.6, 30 putative targets of miR-199-3p have been identified 
in this study. In addition, based on IPA analysis, several pathways including PI3K-
AKT, ERK-MAP kinase, IGF, and prostaglandin signaling are regulated by this 
miRNA. It was therefore decided to examine whether the 30 targets of miR-199-3p 
are directly or indirectly associated with the regulated pathways. The 30 conserved 
potential target genes of miR-199-3p were uploaded into IPA to explore the 
molecular relationships between the targets and AKT, ERK, IGF, and PTGS, which 
are the core components in the PI3K-AKT, ERK-MAP kinase, IGF and 
prostaglandin signaling pathways. 9 putative targets were shown to have a regulatory 
role in the activation of AKT, while 5 regulated ERK (Figure 4.6). Only PRDX6 was 
linked with prostaglandin production and the other two targets (PIK3CB and 
YWHAE) appeared to be involved in insulin-like growth factors (IGF). On the basis 
of these results, several miR-199-3p target genes appear to be associated with PI3K-
AKT and ERK-MAP kinase. 
 
Figure 4.6: A sub-network of a network analysis preformed in IPA using a 
list of 30 conserved putative targets of miR-199-3p.  The interactions 
between AKT and miR-199-3p potential targets are shown in blue arrows while 
ERK1/2 and miR-199-3p targets interactions are linked with green arrows, Dash 
lines denote indirect interactions and solid ones represent direct relationships.   
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4.2.10 AKT phosphorylation but not ERK1/2 phosphorylation is 
modulated in miR-199-3p transfected cells 
ERK1/2 and AKT signaling are signaling pathways identified in the miR-199-3p 
dataset, however, ERK1/2 and AKT genes was not found to have sites that match the 
miR-199-3p seed. Rather, ERK1/2 and AKT interact with a number of miR-199-3p 
target genes and it was thus hypothesised that miR-199-3p regulates the activities, 
rather than expression levels, of ERK1/2 and/or AKT proteins through potential 
target(s) of miR-199-3p that are upstream of either and both ERK1/2 and AKT. In 
order to determine whether miR-199-3p has an effect on AKT and/or ERK1/2 
activation, the phosphorylation of AKT at Ser473 and ERK1/2 at Thr-202 and Tyr-
204 were examined in cells transfected with miR-199-3p as these are the main 
phosphorylation sites in both AKT and ERK1/2. MRC-5 cells were cultured for 48 
hours; untreated or transfected with RISC-free siRNA, miR-199-3p mimic or 
inhibitor. Cell lysates were then harvested and subjected to western blot analysis. As 
can be seen in Figure 4.7, a small but reproducible reduction in independent 
experiments was evident in the phosphorylation of Ser473 and Thr308 in AKT but 
not at Thr-202 and Tyr-204 in ERK1/2 in cells transfected with miR-199-3p mimic 
when compared to the untreated or control transfected samples. No effect was 
observed on the phosphorylation of AKT or ERK in cells transfected with 
miR-199-3p inhibitor. 
Based on these results, the IPA identification of AKT regulation but not ERK1/2 was 
confirmed by examining the down-regulation of phosphorylated (Ser473 and 
Thr308) in AKT. It appears the activation level of AKT, at least as far as can be 












Figure 4.7: miR-199-3p regulates the phosphorylation of AKT but not 
ERK1/2. Western blot showing a reduction in the phosphorylation of AKT at 
serine 473 (Ser473) and theronine (Thr 308) residues and no change in ERK1/2 
phosphorylation at theronine (Thr202) and tyrosine (Tyr204) residues.  MRC-5 
cells were untreated or transfected with control RISC-free siRNA, miR-199-3p 
mimic, or miR-199-3p inhibitor for 48 hours. 20µg of protein was loaded per 
lane and membrane was immunoblotted with primary antibodies against either 
phospho-AKT (ser473), phospho-AKT (Thr308), Phospho-ERK1/2 
(Thr202/Tyr204), and β -ACTIN. Blots were then quantif ied by densitometry and 
normalized to the corresponding β -ACTIN. The untreated was set as 1 and 
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4.2.11 Hypothesised model for the regulation of AKT signaling by miR-
199-3p  
The goal in this chapter was to develop a model for how miR-199-3p exerts its 
antiviral function. Based on the results described above (4.2.7 to 4.2.10), it appears 
that miR-199-3p targets upstream regulator(s) of AKT phosphorylation and 
subsequently inhibits its activation and downstream functions, which could be 
hypothesized as resulting in the antiviral effects of miR-199-3p against CMV. The 
IPA’s sub-network shown in Figure 4.6 suggested the presence of 9 upstream 
interactions between potential or validated miR-199-3p targets and AKT. CD44 and 
5 other potential targets of miR-199-3p, PIK3CB, ITGA3, ITGA6, CD151, and 
FGF7 were included in the hypothesised model (see Figure 4.8).  
Figure 4.8: Suggested model for miR-199-3p regulation of AKT activation.  
PIK3CB is an isoform of PI3-Kinase complex, the critical regulator of AKT 
phosphoregulation. CD44, CD151 and intergrins are adhesion molecules known 
to induce the activation of PI3-kinase and AKT. Fibroblast growth factor-7 
(FGF-7) can bind to it receptor and trigger PI3K-AKT cascades. Red arrows 
indicate miR-199-3p targets.  
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4.2.12 Initial validation of miR-199-3p targets from the microarray 
analysis, PIK3CB, ITGA3, ITGA6, CD151, and FGF7.  
PIK3CB, ITGA3, ITGA6, CD151, and FGF7 were found to be regulated by 
miR-199-3p in the microarray analysis shown in section 4.2.4 and at least one 
conserved miR-199-3p binding site was found in their 3′-untranslated regions 
(3′UTR). In order to validate the microarray data, the expression levels of these 
putative targets were measured using qRT-PCR analysis. As miR-199-3p has 
antiviral function against MCMV and HCMV infections, it was hypothesised that the 
targets of miR-199-3p are likely to be conserved in both mouse and human cells. 
Therefore, mouse NIH-3T3 and human MRC-5 cell lines were mock-transfected or 
transfected with miR-199-3p mimic or inhibitor. Controls included cells transfected 
with RISC-free siRNA, C. elegans mimic, or C. elegans inhibitor. Indeed the 
expression of the 5 candidate targets was unaffected in cells transfected with 
negative controls, RISC-free siRNA, C. elegans mimic, or C. elegans inhibitor in 
both NIH-3T3 and MRC-5 cell lines. By comparison the expression of all five 
candidate targets was upregulated with miR-199-3p inhibitor treatment. Up 
regulation was significant in NIH-3T3 cells, however, in MRC-5 increases were not 
significantly different from controls. In the presence of miR-199-3p mimic all 
candidate targets showed a significant decrease in expression in MRC-5 and NIH-
3T3, except mouse ITGA6 which was decreased but not significantly. 18S rRNA 
was included as a negative control and did not show any significant change in the 
presence of miR-199-3p mimic or inhibitor in comparison to transfected controls or 
untreated cells (Figure 4.9f). In mouse cells, the expression levels of PIK3CB, 
ITGA3, CD151 and FGF7 mRNAs were significantly down-regulated by 
miR-199-3p mimic and upregulated by miR-199-3p inhibitor (Figure 4.9a,b,c,e). For 
ITGA6, upregulation was only found in cells transfected with miR-199-3p inhibitor, 
while no significant change was noted upon mimic transfection (Figure 4.9d). In 
human cells PIK3CB, ITGA3, ITGA6, CD151, and FGF7 mRNAs were reduced in 
cells transfected with miR-199-3p mimic and no obvious regulation occurred in miR-
199-3p inhibitor transfected cells (Figure 4.9a,b,c,d,e).  
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To conclude, the results from the initial experiment to validate the microarray data 
suggest that miR-199-3p regulates PIK3CB, ITGA3, ITGA6, CD151, and FGF7 in 
human and mouse cells.   
B 
A 












Figure 4.9: qRT-PCR validation of predicted mRNA targets of miR-199-3p.  
NIH-3T3 and MRC-5 cells were transfected with 25nM of each RISC-free 
siRNA, C. elegans  mimic, C. elegans  inhibitor, miR-199-3p mimic or miR-199-
3p inhibitor for 48 hours. The expression levels of PIK3CB (A), CD151 (B), 
ITGA3 (C), ITGA6 (D), FGF7 (E) were quantif ied by qRT-PCR and normalised 
to GAPDH level. β-ACTIN (F) was included as a negative control. Data 
presented are the mean fold change ± S.D (n=4). and are representative of 
three independent experiments.*p < 0.05, **p < 0.01, ***p < 0.001 , and 
****P<0.0001 compared to RISC-free siRNA transfected cells as determined by 















A key objective of this study was to identify the genes regulated by miR-199-3p that 
might contribute to its antiviral properties. Target prediction is an important step in 
understanding the functional regulation of miR-199-3p and its consequent antiviral 
properties. Given that the antiviral role of miR-199-3p has been observed in three 
distinct herpes viruses (CMV, HSV-1 and MHV-68) and also against SFV 
(Santhakumar et al., 2010), the antiviral role of miR-199-3p is expected to be caused 
by regulation of host genes by this miRNA instead of direct interaction with the 
virus. Despite this, it is difficult to exclude the existence of miR-199-3p-virus 
interactions, indeed two different studies have shown direct effects of miR-199-3p on 
hepatitis B virus transcripts (HBsAg and HBeAg) and on the 5′UTR of the hepatitis 
C virus genome (Zhang et al. 2010; Murakami et al. 2009). While this direct 
regulation of viral genes by miR-199-3p has a negative impact on HBV and HCV 
replication, the existence of cellular targets of miR-199-3p might also support its 
antiviral properties in these infections. 
4.3.1 Experimental and computational identification of miR-199-3p 
targets 
Two methods were employed for the purpose of identifying the cellular targets of 
miR-199-3p. The first of these was the use of gene expression profiles comparing 
miR-199-3p overexpression or inhibition experiments. The other method was 
computational analysis of the miR-199-3p seed complement sequences in the 3′ 
untranslated regions of the regulated genes. However, there are several caveats to 
consider in this approach. First, the microarray experiment does not identify miRNA 
targets that are only regulated at the translational level, however, miRNAs can 
regulate on average 100-200 mRNA targets (Krek et al. 2005; Lim et al. 2005). 
Secondly, microarray analysis is unable to discriminate direct targets from those 
genes that are secondarily regulated by the direct targets.  To address this, the target 
prediction program (TargetScan 5.0) was used to identify direct targets on the basis 
of miR-199-3p target sites in the 3′UTR. Thirdly the prediction program (TargetScan 
5.0) predicts false positive targets besides being unable to predict non-canonical 
miRNA-target interactions such as bulge and centred sites (Shin et al. 2010; Chi et 
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al. 2012). A recent transcriptome-wide study of cellular targets for miR-155 has 
shown that miRNA-mRNA interactions can occur both canonically (perfect seed 
match) and non-canonically (without perfect match). Loeb et al. (2012) suggests that 
both types of interactions are important to ultimately confer a bigger picture as to 
how miR-155 regulates overall gene expression.  
4.3.2 Functional and pathway analysis of miR-199-3p regulated genes  
The next step was to gain insight into the biology of differentially regulated genes by 
miR-199-3p, which was identified in the microarray analysis. IPA functional analysis 
identified several host pathways that are required if not essential for CMV replication 
and infection process, such as prostaglandin production, ERK/MAPK and PI3K/AKT 
signaling (Figure 4.5 and Table 4.3). The enrichment for ERK/MAP kinase and 
prostaglandin synthesis is consistent with previous reports that have shown that 
miR-199-3p targets MET and its downstream effector ERK2 (Kim et al. 2008). miR-
199-3p has also been found to target PTGS2 (COX-2), which is the key enzyme in 
prostaglandin biosynthesis (Chakrabarty et al. 2007). In addition to the 3 altered 
cancer canonical pathways in miR-199-3p dataset, the most significant functions 
including proliferation, apoptosis and movement (Table 4.6) suggest a link between 
this miRNA and cancer. Consistent with these results, the regulation of miR-199a-3p 
expression has been reported in several cancers (Table 1.5). miR-199-3p expression 
has also been found to reduce or enhance the survival and proliferation as well as the 
motility and invasion of tumour cells (Table 4.1).  
There are two main possibilities that could explain the dual function of miR-199-3p. 
First, as the gene expression profile is not identical between different cells, the 
targets of miR-199-3p can differ from one cell type to another, with the result that 
miR-199-3p manifests different or opposing functions in the different cell types. 
Second, an individual gene may have opposing functions in different or same cell 
types, which suggests that the role of miR-199-3p can change based on the target role 
in this cell type or at specific stage in the life of a cell. For example CD44, a direct 
target of miR-199-3p, is implicated in both tumor progression and suppression of 
breast cancers (Reviewed in Louderbough and Schroeder 2011). As the observed 
antiviral effect of miR-199-3p was found in both human and mouse infections, it 
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seems more likely that targets of relevance will be those conserved between the two 
species. Therefore, non-conserved targets were excluded. However, it is also possible 
that the non-conserved targets could contribute to the outcome of miR-199-3p on 
viral infection or that miR-199-3p could exert its antiviral function in HCMV and 
MCMV infections through different sets of non-conserved targets.  
In an attempt to better understand the role of the 30 conserved targets, the IPA 
network analysis revealed that 9 of these targets are indirectly connected with AKT 
and 5 of the targets are linked to ERK (Figure 4.6). While the pathway and network 
analysis showed regulation of AKT and ERK by miR-199-3p, neither AKT nor ERK 
expression are altered in the miR-199-3p dataset and neither has a seed site for miR-
199-3p in its 3′UTR. It was therefore of interest to examine whether miR-199-3p 
disrupts the activity of either of these genes, rather than their expression levels. This 
may be important for understanding the role of miR-199-3p in infection, as both of 
these proteins have been previously shown to be essential for HCMV gene 
expression and infection (Johnson et al. 2001a; 2001b; Yu and Alwine 2002).  
4.3.3  miR-199-3p negatively regulates the activation of AKT  
Overexpression or inhibition of miR-199-3p in human fibroblasts had no observed 
effect on the regulation of ERK1/2 phosphorylation, which is contradictory to the 
previous reported data by Kim and colleagues. They reported that the overexpression 
of miR-199-3p caused a down-regulation of ERK2 protein in non-starved A549 cells 
(human lung adenocarcinoma epithelial cell line), however, this effect was extremely 
subtle on starved A549 cells. The authors concluded that serum starvation may 
potentially affect the level of ERK2 down-regulation. Additionally, the mechanism 
by which miR-199-3p affects ERK2 protein level was not elucidated (Kim et al. 
2008). However, miR-199a-3p overexpression did result in a significant reduction in 
the expression of phosphorylated serine and theronine in AKT. The inhibition of 
miR-199-3p activity in human MRC-5 cell lines did not promote the activation of 
AKT, which may be due to unsuccessful inhibition of miR-199-3p or to the low 
endogenous levels of miR-199-3p in this cell line The finding here that miR-199-3p 
regulates AKT signaling led to the search for candidate targets of miR-199-3p to 
understand how miR-199-3p regulates AKT. It is important to note that the upstream 
Results Chapter 4 
190 
 
components activating AKT signaling during HCMV infection have yet to be 
elucidated. However, 6 targets of miR-199-3p were chosen from the dataset for 
further validation and investigation based on the results of network analysis, which 
linked them to AKT function.  
4.3.4 Validation of PIK3CB, ITGA3, ITGA6, CD151, and FGF7 as targets 
of miR-199-3p  
PIK3CB is a member of the Phosphatidyl-3-kinases (PI3K), which are primarily 
involved in the regulation of AKT activation. It also harbours two conserved 
potential binding sites for miR-199-3p in its 3′UTR, making it one of the most 
promising candidates for regulation of AKT signaling.  
CD151 has been reported to form a functional complex with some integrin subunits, 
such as ITGA3 and ITGA6. These integrins and CD151 are all predicted to be targets 
of miR-199-3p and each contains one conserved site in their 3′UTRs for this miRNA. 
The integrin α3β1 complex regulates cell-cell adhesion, cytoskeleton organisation 
and the production of matrix metalloproteinase 2 (MMP-2) (Shigeta et al. 2003; 
Chattopadhyay et al. 2003; Sugiura and Berditchevski 1999). CD151 has also been 
shown to determine the molecular distribution of integrin α6 on the cell membrane, 
which affects morphological and functional aspects of cells, such as migration, 
invasion and adhesion signaling (Yang et al. 2008). The involvement of CD151, 
integrin α3 and integrin α6 in HGF-MET signaling  has been shown to reduce AKT 
phosphorylation in cells in which either CD151, integrin α3 or integrin α6 were 
knocked down (Klosek et al. 2009). Importantly, several studies have reported 
various viruses exploiting integrins for the purpose of mediating their attachment, 
internalisation and/or to trigger signaling cascades in host cells that are required for 
infection (Stewart and Nemerow 2007). HCMV gB glycoprotein, which is required 
for viral attachment and entry into the host cells, contains a dis-integrin sequence that 
is conserved in β and γ-herpes viruses but not α-herpes viruses. Several cellular 
integrins, αvβ1, α6β1 and αvβ3, were reported to facilitate HCMV entry and 
signaling (Wang et al. 2005; Feire et al. 2004). HSV-1 entry is associated with αvβ3 
while human herpes virus-8 (HHV-8) requires α3β1 (Parry et al. 2005; Akula et al. 
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2002). The decision was therefore made that the integrins and CD151 complex 
would be included for further validation in this work.  
The adhesion molecule CD44 has been found to be upregulated in fibroblasts 
infected with HCMV and a direct target of miR-199-3p (Ito et al. 1995; Henry et al. 
2010). CD44 has also been reported to promote the proliferation, survival and 
migration through the activation of PI3K and AKT in colon carcinoma cells (Park et 
al., 2011; Subramaniam et al. 2007).  
FGF7, also known as keratinocyte growth factor (KGF), the production of which is 
restricted to fibroblasts and epithelial cells, has broad biological functions including 
proliferation and survival through activation of the PI3-Kinase/AKT signaling 
pathway (Bao et al. 2005; Zhang et al. 2010; Chang et al. 2009). However, no 
investigations have studied the expression or role of FGF7 in HCMV or other herpes 
viral infections.  
qRT-PCR was used for the initial experimental validation of the response of 
PIK3CB, ITGA3, ITGA6, CD151, and FGF7 genes to manipulation of miR-199-3p. 
In mouse NIH-3T3 transfected with miR-199-3p inhibitor, the PIK3CB, ITGA3, 
ITGA6, CD151 and FGF7 transcripts were all up-regulated, whereas in the cells 
transfected with miR-199-3p mimic, PIK3CB, ITGA3 and CD151 mRNAs were all 
down-regulated. Human MRC-5 transfected with miR-199-3p mimic showed a 
pronounced reduction in transcript for each candidate (PIK3CB, ITGA3, ITGA6, 
CD151 and FGF7). Unlike with the miR-199-3p mimic, no reverse effect was found 
in terms of the expression of these target transcripts in MRC-5 transfected with miR-
199-3p inhibitor. As discussed previously, endogenous expression of miR-199-3p 
may be low in MRC-5 or this miRNA may not be inhibited successfully (Figure 4.9). 
In support of this, the antiviral effect of miR-199-3p mimic in HCMV infected 
MRC-5 was extremely pronounced, whereas the proviral impact of miR-199-3p 
inhibitor in infected MRC-5 was very subtle (Santhakumar et al. 2010). However, 
this validation does not distinguish between the direct and indirect targets of miR-
199-3p.  
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In conclusion, the work in this chapter aimed to characterise the effect of 
miR-199-3p disregulation on cellular pathways and to identify target genes of 
miR-199-3p that could be linked to a role in CMV infection in fibroblasts. The 
genome-wide expression analysis demonstrated a large number of regulated genes 
(198 gene) that contains 30 direct genes with at least one conserved target site for 
miR-199-3p. This single host-encoded miRNA regulates multiple pathways required 
and/or activated by CMV, including PI3K/AKT and ERK/MAPK signaling and 
prostaglandin synthesis. Evidence was also provided that shows AKT 
phosphorylation is down-regulated by the overexpression of miR-199-3p in human 
fibroblasts. The regulation of AKT activation occurred indirectly, therefore, CD44 
and the 5 other conserved predicted targets of miR-199-3p previously linked with the 
regulation of AKT activation were chosen for further analysis. The initial validation 
for PIK3CB, ITGA3, ITGA6, CD151 and FGF7 show that these targets were 
regulated at the transcriptional levels in NIH-3T3 and MRC-5 cells transfected with 
either miR-199-3p mimic or inhibitor. In the next chapter, data from a more in depth 
investigation of AKT activation during the HCMV infection in MRC-5 cells is 
presented. New questions will be asked in an attempt to discern whether these genes 
are direct targets of miR-199-3p and whether their regulation influences HCMV 
growth specifically through AKT activation. 
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5 The Antiviral Properties of miR-199-3p May Be 
Associated with Suppression of AKT 
Phosphorylation 
 
5.1 Introduction  
5.1.1 The phosphoinositide 3-kinase (PI3K)/ protein kinase B 
(PKB/AKT) pathway  
PI3K-AKT is a signaling pathway that mediates a broad range of cellular functions in 
response to extracellular signals. PI3Ks are lipid kinases composed of two subunits, 
one regulatory and one catalytic subunit. The regulatory subunits include five 
isoforms, three alternative splicing of the PIK3R1 gene yields three isoforms (p85α, 
p55α, p50α), PIK3R2 (p85β), and PIK3R3 (p55γ) and three isoforms of catalytic 
subunits, PIK3CA (p110 α), PIK3CB (p110β), and PIK3CD (p110δ) (Figure 5.1). 
The regulatory subunits are associated with recruitment and stabilisation of the 
catalytic subunit to avert its rapid degradation. The PI3k (p110) catalytic subunit 
primarily phosphorylates constitutive phosphatidylinositol-4,5-bisphosphate (PIP2) 
on the plasma membrane to produce the major product phosphatidylinositol 3,4,5-
triphosphate (PIP3), which recruits protein kinase B (PKB/AKT). Upon recruitment 
to the plasma membrane AKT is phosphorylated at two critical residues, threonine 
308 (Thr308) and serine (Ser473) to fully activate its kinase activity. 3'-
phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates AKT at 
Thr308, whereas mTORC2 complex phosphorylates AKT at Ser473. The 
phosphorylated AKT then translocates from the plasma membrane to other cell 
compartments to phosphorylate its numerous downstream targets that regulate 
several cellular processes including cell survival, proliferation, protein synthesis, 
glucose metabolism, and others (Reviewed in Hennessy et al. 2005; Vanhaesebroeck 
et al. 2012).  
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Figure 5.1: Schematic diagram of the structure of catalytic and regulatory 
subunits of the phosphatidylinositol 3-kinase (PI3K). (A) Each regulatory 
isoform contains two highly conserved SRC Homology 2 (SH2) domains that 
mediate binding to phosphotyrosine residues and one p110-binding domain. 
The longer isoforms PIK3R1 (p85α) and PIK3R2 (p85β) possess two additional 
domains in the N-terminal region: one SRC homology 3 (SH3) domain and 
RAC-binding domain, which can interact to members of the Rac and CDC42 
GTPases. p85α , p55α , and p50α are alternative protein products of a single 
gene (PIK3R1). (B) Each catalytic subunit contains a Ras-associating domain 
and a C2 domain (Calcium binding motif) in addition to the kinase domain and 
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Figure 5.2: Schematic diagram of the phosphatidylinositol 3-kinase 
(PI3K)/AKT signaling pathway. Activation of growth factor receptor tyrosine 
kinases leads to the recruitment of the regulatory subunit (PIK3R) directly or 
indirectly through an adaptor. This recruitment results in activation of the 
catalytic subunit (p110) and then phosphorylation of phosphatidylinositol-4,5-
biphosphate (PIP2) to generate the second messenger phosphatidylinositol -
3,4,5-tr iphosphate (PIP3). PIP3 recruits AKT kinase and results in consequent 
double phosphorylation of AKT. Once phosphorylated, Akt mediates the 
activation and inhibit ion of several targets involved in apoptosis, growth, 
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5.1.2 The contribution of PI3K-AKT signaling in viral infection  
Activation of PI3k-AKT modulates critical cellular processes involved in viral 
infection: 1) PI3K-AKT signaling regulates the cytoskeleton remodelling, thereby 
assisting the endocytosis and trafficking of viruses into the nucleus; 2) it is required 
for viral gene expression and replication of a small number of viruses; 3) it supports 
cell survival, which aids efficient virus replication and propagation. This also allows 
for long-term persistence of virus in host cells; 4) the oncogenic viruses induce 
PI3K-AKT, which promotes tumour growth, angiogensis, and cellular migration; and 
5) it enhances glucose uptake and overall metabolism. In spite of several viruses 
depending on PI3K-AKT activation for efficient infection, PI3K-AKT is also 
involved in the antiviral immune response in host cells. PI3K has reported to activate 
some transcription factors, like IRF3 and IRF7, leading to the expression of 
interferon-associated genes (Reviewed in Ji and Liu 2008).  
5.1.3 Regulation of PI3K-AKT cascades in viral infection  
Several viruses are known to up-regulate PI3K-AKT signaling during infection 
through viral elements. For example, PI3K-AKT cascades are induced by the HBx 
protein of HBV, the major immediate early protein (MIEP) of HCMV, the NS5A 
protein of HCV (Street et al. 2005; Guo et al. 2007), the NS1 protein of H1N1 (Hale 
et al. 2006; Shin et al. 2007), and the K1 protein of KSHV (Tomlinson and Damania 
2004). Other viruses possess more than one viral protein that can activate the PI3K-
AKT pathway including EBV (Portis and Longnecker 2004; Mei et al. 2007), HIV-1 
(Deregibus et al. 2002; Linnemann et al. 2002), Human papillomavirus-16 (HPV16) 
(Menges et al. 2006; Kim et al. 2006; Spangle and Münger 2010), respiratory 
syncytical virus (RSV) (Bitko et al. 2007), and simian virus 40 (SV40) (Yuan et al. 
2002; Yu and Alwine 2008). In contrast, there are a limited number of cases in which 
viral proteins suppress AKT signaling, but an example includes the VP1 protein in 
foot-and-mouth disease virus (FMDV) infection (Peng et al. 2004). It must be noted, 
however, that the activation of PI3K-AKT signal is differently regulated in various 
stages of the same infection. For example, HCV transiently stimulates the maximal 
activation of AKT during the early stage of infection and becomes undetectable at 24 
and 48 hours post infection. This is to facilitate the viral entry into the host cells (Liu 
et al. 2012). HCMV infection contributes to the development of cardiovascular 
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diseases, including atherosclerosis (Söderberg-Nauclér 2006). HCMV promotes an 
important event in atherosclerosis, which is the reduction in endothelial nitric oxide 
synthase (eNOS) phosphorylation and activation in human aortic endothelial cells. 
This is likely to occur through inhibiting eNOS upstream signaling, AKT 
phosphorylation (Shen et al. 2006).  
5.1.4 HCMV activates PI3K-AKT signaling during infection 
HCMV infection induces phosphorylation of AKT at the Ser473 residue in a PI3K-
dependent manner (Johnson et al. 2001; Yu and Alwine 2002). The activation of 
AKT is mediated via at least two mechanisms. Firstly, through transient induction, 
following HCMV binding to host cell receptors (Johnson et al. 2001b), though the 
actual cellular receptors used to enter the host cells and trigger PI3K-AKT are 
controversial (Isaacson et al. 2007). Second, persistent activation is a consequence of 
the expression of HCMV proteins (Johnson et al. 2001b; Yu and Alwine 2002; 
Kudchodkar et al. 2006), as experiments showed that transfection of either IE1 or 
IE2 promoted the activation of AKT (Yu and Alwine 2002). The activation of 
phosphorylated AKT results in the phosphorylation of its downstream targets the 
eukaryotic initiation factor-4E binding protein (4E-BP), ribosomal S6 Kinase (S6K), 
and transcription factor NF-ᴋB (Johnson et al. 2001b; Kudchodkar et al. 2004). The 
inhibition of PI3-kinase activity using the inhibitor LY294002 impedes the 
expression of viral genes IE1 and IE2 and subsequent DNA replication. In contrast, 
treatment with LY294002 inhibitor in the presence of  PIP3 rescues activation of 
AKT and the expression of viral proteins IE1 or IE2 (Johnson et al. 2001b). These 
results indicate that PI3K-AKT activation is an integral part of expression of the viral 
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Figure 5.3: phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway in 
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5.1.5 Rational for studying the role of miR-199-3p in targeting 
PI3K/AKT signalling in HCMV infection 
Given that PI3K-AKT activation is required for HCMV infection and that 
miR-199-3p negatively influences the phosphorylation of AKT (Figure 4.7), it was 
hypothesised that the antiviral role of miR-199-3p occurs through a molecular 
mechanism involving the regulation of PI3K-AKT signaling cascades. In particular, 
several predicted targets of miR-199-3p can mediate PI3K-AKT activation including 
not only the catalytic subunit PIK3CB, which forms the heterodimeric kinase PI3K, 
but also cellular receptors such as ITGA3, ITGA6, integrin-associated CD151, and 
CD44. In addition, the broad roles of PI3K-AKT in various aspects of viral infection 
may provide an explanation of the broad antiviral properties of miR-199-3p.  
5.1.6 Aims  
The objective of the work presented in this chapter is to validate targets of miR-199-
3p that are associated with PI3K-AKT signaling. The correlation between the down-
regulation of miR-199-3p and its targets during HCMV infection was further studied. 
Moreover, the functional small interfering RNA (siRNA)-mediated knockdown of 
the targets of miR-199-3p was used to investigate whether these targets can 
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5.2 Results  
5.2.1 The experimental validation of predicated miR-199-3p targets in 
NIH-3T3 cells 
As described in chapter 4, a microarray experiment was conducted to identify the 
cellular genes and biological pathways that are regulated by miR-199-3p. AKT 
signalling was identified in the IPA database as a significant regulated pathway in the 
miR-199-3p dataset and this was experimentally validated (see Figure 4.7). Based on 
the IPA database, eight of the miR-199-3p predicted targets (PPP2R5E, WYHAE, 
CD2AP, PIK3CB, ITGA3, ITGA6, CD151, and FGF7) as well as the validated miR-
199-3p target, CD44, are linked to AKT regulation. Based on the literature, the most 
relevant targets for PI3K-AKT signalling, PIK3CB, ITGA3, ITGA6, and CD151, 
were chosen for further validation. In order to examine PIK3CB, ITGA3, ITGA6, 
and CD151 in more detail, qRT-PCR analysis was carried out on these gene 
transcripts using RNA extracted from cells that were transfected with miR-199-3p 
mimic or inhibitor. The data showed a decrease in the levels of target mRNAs in 
human and mouse cells transfected with miR-199-3p mimic and an increase in 
mouse cells transfected with the inhibitor. However, these experiments did not 
examine whether the regulation was through direct interaction between miR-199-3p 
and the targets, versus secondary effects from miR-199-3p regulation of other genes.  
For this reason, a luciferase reporter assay was used to investigate the functional link 
between miR-199-3p and the 3′UTRs of the murine PIK3CB (~1.3 Kb), ITGA3 
(~1.1Kb), ITGA6 (~0.9 Kb), and CD151 (~0.8 Kb) genes containing the predicted 
binding sites for miR-199-3p were cloned downstream of the Renilla luciferase gene 
of the psiCHECK-2 vector (Refer to Appendix 7 for results of sequence alignment). 
The cloning of PIK3CB and CD151 3′UTRs was performed by MSc student Laura 
Kelly under the supervision of Nouf Laqtom. To create a positive control, a miR-
199-3p sensor containing a perfectly complementary mature miR-199-3p sequence 
was constructed. The expression vector (psiCHECK-2) also includes a second 
reporter gene, firefly luciferase, which serves as an internal control for transfection 
efficiency and variation in cell count.  
                                                                                                                        Results Chapter 5                                                                     
                                                                                                                                 
201 
 
Next, co-transfection experiments were carried out to measure the ability of miR-
199-3p to regulate the expression of the luciferase gene bearing the 3′UTR of each 
target, NIH-3T3 cells were left untreated or transfected with either: psiCHECK-2 
(empty vector); psiCHECK-2-miR-199-3p sensor; psiCHECK-2-PIK3CB 3′UTR; 
psiCHECK-2-ITGA3 3′UTR; psiCHECK-2-ITGA6 3′UTR; psiCHECK-2-CD151 
3′UTR along with miR-199-3p mimic, inhibitor, or RISC-free siRNA. As before, C. 
elegans mimic, C. elegans inhibitor or RISC-free siRNA were included as controls. 
psiCHECK-2 harbouring a single target 3′UTR were also transfected alone to 
measure the effect of the endogenous population of miRNAs on the regulation of 
luciferase expression. Cells were lysed 48 hours post-transfection and measurements 
were taken of the expression of firefly and Renilla luciferases.  
5.2.1.1 miRNAs does not interfere with the expression of Renilla 
luciferase from the psiCHECK-2 (empty vector)  
The psiCHECK-2 (empty vector) was transfected in all experiments to measure the 
non-specific effect of the co-transfected RISC-free siRNA, mimics or inhibitors of C. 
elegans miRNA and miR-199-3p on the regulation of luciferase expression. The 
luciferase expression of psiCHECK-2 (empty vector), which has no inserted 3′UTR 
downstream of its Renilla sequence, showed no significant differences in the ratio of 
Renilla to firefly luciferase activity when co-transfected with either C. elegans 
mimic, C. elegans inhibitor, miR-199-3p mimic, miR-199-3p inhibitor, or RISC-free 
siRNA (Figure 5.4, 5.6, 5.7, 5.8a). This suggests that there is no non-specific effect 
on luciferase expression associated with the co-transfection of mimics or inhibitors.  
5.2.1.2 Functional validation of miR-199-3p sensor  
A significant inhibition ~30 fold was observed in the ratio of luciferase activity of 
psiCHECK-miR-199-3p sensor (positive control) in cells transfected with 
psiCHECK-miR-199-3p sensor alone. This inhibition most likely occurs as a result 
of regulation by endogenous miR-199-3p in NIH-3T3 cells (figure 5.5). Moreover, 
the co-transfection of psiCHECK-miR-199-3p sensor with miR-199-3p mimic results 
in a greater than 90-fold reduction in the ratio of luciferase activity (Figure 5.4a), in 
comparison to the co-transfection with miR-199-3p inhibitor, which led to ~500 fold 
upregulation in luciferase expression relative to the control C. elegans inhibitor 
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(Figure 5.4b). This shows that the miR-199-3p sensor plasmid serves as a control for 
miR-199-3p activity in the luciferase activity. The psiCHECK-2 (empty vector) and 
psiCHECK-miR-199-3p sensor (positive control) were included in all experiments to 
identify experimental non-specific effects and support the functionality of miR-199-
3p activity.   
Figure 5.4: Validation of psiCHECK-2-miR-199-3p sensor.  Luciferase 
reporter plasmids, either psiCHECK-2 or psiCHECK-2-miR-199-3p sensor were 
co-transfected into NIH-3T3 cells with either RISC-free siRNA or mimic (A) or 
inhibitor (B) for both C. elegans  miRNA (Cel-miR-67) and miR-199-3p. Cells 
were lysed and luciferase expression was measured at 48  hours post 
transfection. The low background luciferase activity of the untreated cells was 
subtracted from the luciferase activity of transfected cells. The luciferase 
activity of Renilla were normalised to second firefly control luciferase activity to 
correct the variations in transfection efficiency and cell count. Data presented 
are the mean fold change ± S.D. (n=4) of the ratio between Renilla  luciferase 
and firefly control luciferase activit ies and are representative of three  
independent experiments. ****P<0.0001 compared to RISC-free siRNA 
transfected cells as determined by unpaired Student’s t  test.  
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5.2.1.3 Endogenous miRNAs regulate the Renilla luciferase expression 
harbouring the 3′UTR of PIK3CB, ITGA3, ITGA6, or CD151 
mRNAs  
The ratio of Renilla to firefly luciferase activity of cells transfected psiCHECK-2-
miR-199-3p, psiCHECK-2-PIK3CB 3′UTR, psiCHECK-2-ITGA6 3′UTR, 
psiCHECK-2-ITGA3 3′UTR, or psiCHECK-2-CD151 3′UTR alone was reduced in 
comparison to psiCHECK-2 transfected cells (Figure 5.5). This reduction likely 
indicates that the endogenously expressed miRNA is capable of regulating that 
3′UTR that cloned downstream of the Renilla gene.  
Figure 5.5: The influence of endogenous miRNAs on the Renilla luciferase 
expression containing target 3’UTRs. Luciferase reporter plasmids, either 
psiCHECK-2 (empty vector), psiCHECK-2-miR-199-3p sensor, psiCHECK-2-
PIK3CB 3′UTR, psiCHECK-2-ITGA6 3′UTR, psiCHECK-2-ITGA3 3′UTR, or 
psiCHECK-2 CD151 3′UTR were transfected into NIH-3T3 cells. Cells were 
lysed and luciferase expression was measured at 48 hours post transfection. 
The low background luciferase activity of the untreated cells was subtracted 
from the luciferase activity of transfected cells.  The luciferase activity of 
Renilla were normalised to second f irefly control luciferase activity to correct 
the variations in transfection efficiency and cell count. Data presented are the 
mean fold change ± S.D. (n=4) of the ratio between Renilla luciferase and 
firefly control luciferase activities  and are representative of three independent 
experiments. **P<0.01, ***P<0.001, and ****P<0.0001 compared to psiCHECK-
2 (empty vector) transfected cells as determined by unpaired S tudent’s t  test. 
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5.2.1.4 ITGA3 and CD151 are direct targets of miR-199-3p  
The luciferase experiment was then carried out to examine the functional relationship 
between miR-199-3p levels and the Renilla luciferase gene harbouring the 3′UTR of 
either ITGA3 or CD151 mRNAs. In cells transfected with psiCHECK-2-CD151 
3′UTR or psiCHECK-2-ITGA3 3′UTR in the presence of miR-199a-3p mimic, a 
decrease in the luciferase ratios was observed (2.5 fold and 1.7 fold, respectively) 
(Figure 5.6a,b). Whereas in the presence of miR-199-3p inhibitor, a significant 
increases (2.8 fold and 1.5 fold) in the luciferase ratios were observed (Figure 
5.6a,b). As expected, the luciferase ratios of psiCHECK-2-CD151 3′UTR and 
psiCHECK-2-ITGA3 3′UTR were unchanged in cells co-transfected with either the 
C. elegans mimics or inhibitors or RISC-free siRNA (Figure 5.6a,b). The results 
obtained strongly suggest ITGA3 and CD151 are directly regulated by miR-199-3p 
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Figure 5.6: ITGA3 and CD151 are direct target of miR-199-3p. Luciferase 
reporter plasmids, either psiCHECK-2-ITGA3 3 ′UTR (A) or psiCHECK-2-CD151 
3 ′UTR (B) were co-transfected into NIH-3T3 cells with either RISC-free siRNA 
or mimic or inhibitor for both C. elegans  miRNA (Cel-miR-67) and miR-199-3p. 
Cells were lysed and luciferase expression was measured at 48 hours post 
transfection. The low background luciferase activity of the untreated cells was 
subtracted from the luciferase activity of transfected cells.  The luciferase of 
Renilla were normalised to second f irefly control luciferase activity to correct 
the variations in transfection efficiency and cell count. Data presented are the 
mean fold change ± S.D. (n=4) of the ratio between Renilla luciferase and 
firefly control luciferase activities  and are representative of three independent 
experiments. **P<0.01 compared to RISC-free siRNA transfected cells as 
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5.2.1.5 miR-199-3p does not regulate ITGA6 through its 3′UTR   
The same experiments were preformed with the Renilla gene construct containing the 
ITGA6 3′UTR in the presence of either miR-199-3p mimic or inhibitor. However, 
there was no significant change in the luciferase ratios in the presence of miR-199-3p 
mimic or inhibitor compared to RISC-free siRNA (Figure 5.7). The transfection of 
control C. elegans mimic or inhibitor was also found to have no discernible effect on 
the luciferase expression of psiCHECK-2-ITGA6 3′UTR relative to RISC-free 
siRNA. The results presented here indicate that the ITGA6 3′UTR is not involved in 
the regulation of ITGA6 by miR-199-3p, at least in murine cells.  
 
Figure 5.7: miR-199-3p does not regulate murine ITGA6 through its 3′ UTR.  
Luciferase reporter plasmid, psiCHECK-2-ITGA6 was co-transfected into NIH-
3T3 cells with either RISC-free siRNA or mimic or inhibitor for both C. elegans  
miRNA (Cel-miR-67) and miR-199-3p. Cells were lysed and luciferase 
expression was measured at 48 hours post transfection. The low background 
luciferase activity of the untreated cells was subtracted from the luciferase 
activity of transfected cells.  The luciferase of Renilla were normalised to 
second f irefly control luciferase activity to correct the variations in transfection 
efficiency and cell count. Data presented are the mean fold change ± S.D. 
(n=4) of the ratio between Renilla luciferase and firefly control luciferase 
activit ies and are representative of three independent experiments . ns (for non-
signif icance) compared to RISC-free siRNA transfected cells as determined by 
unpaired Student’s t  test.  
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5.2.1.6 miR-199-3p targets PIK3CB 3′UTR through two functional 
binding sites 
PIK3CB 3′UTR containing two conserved binding sites for miR-199-3p was also 
examined in the presence of miR-199-3p mimic or inhibitor. miR-199-3p resulted in 
a significant reduction of ~2.2 fold in the luciferase ratios of psiCHECK-2-PIK3CB 
3′UTR construct compared to the luciferase level in cells transfected with control 
RISC-free siRNA. In cell co-transfected with miR-199-3p inhibitor, there was an 
increase in the luciferase ratios by ~3.7 fold relative to RISC-free siRNA (Figure 
5.8a). No effect was observed on the luciferase expression in cells co-transfected 
with either C. elegans mimic or inhibitor. These results suggest that PIK3CB is 
directly regulated by miR-199-3p through its 3′UTR.  
To further test whether the direct effect of miR-199-3p on the PIK3CB 3′UTR 
reporter construct occurred through the predicted binding sites, a 3 base-pair 
mutation in the seed sequence match was introduced in one or both miR-199-3p 
binding sites in the PIK3CB 3′UTR, resulting in three mutant constructs: 
psiCHECK-2-MUT1-PIK3CB 3′UTR, psiCHECK-2-MUT2-PIK3CB 3′UTR, and 
psiCHECK-2-MUT1/2-PIK3CB 3′UTR (Figure 5.8b). The mutations in the miR-
199-3p binding sites were in nucleotides predicted to pair at nucleotides 2-4 in miR-
199-3p (within the seed site).  
The reporter containing a mutation in the first site (1097nt at the PIK3CB 3′UTR) 
resulted in a 1.4 fold decrease in luciferase ratios in cells co-transfected with miR-
199-3p mimic, whereas the second mutant site (1139nt at the PIK3CB 3′UTR) 
resulted in a 2 fold decrease. In contrast, the luciferase expression in the cells co-
transfected with the miR-199-3p inhibitor showed an approximate increase of 1.7 
fold in the first mutant and 2 fold in the second mutant (Figure 5.8c).  
Remarkably, the double mutant construct resulted in no significant difference in 
luciferase expression when cells were co-transfected with miR-199-3p mimic or 
inhibitor as compared to the luciferase expression in RISC-free control transfected 
cells. Therefore, we conclude that the single mutation only attenuates the effect of 
miR-199-3p on PIK3CB, while the mutation of both miR-199-3p sites was able to 
completely abolish the effect. These results indicate that miR-199-3p targets PIK3CB 
                                                                                                                        Results Chapter 5                                                                     
                                                                                                                                 
208 
 
3′UTR directly, through two functional binding sites. In conclusion, these results 
demonstrated that miR-199-3p has a combinatorial effect to suppress the expression 
of PIK3CB as the double mutations in the two target sites rather than the individual 
mutation eliminated the repression from miR-199-3p.  
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Figure 5.8: PIK3CB is a direct target of miR-199-3p through two binding 
sites in its 3′UTR.  (A) Luciferase reporter plasmid, psiCHECK-2-PIK3CB 
3′UTR was co-transfected into NIH-3T3 cells with either RISC-free siRNA or 
mimic or inhibitor for both C. elegans  miRNA (Cel-miR-67) and miR-199-3p. 
Cells were lysed and luciferase expression was measured at 48 hours post 
transfection. The low background luciferase activity of the untreated cells was 
subtracted from the luciferase activity of transfected cells. The l uciferase of 
Renilla were normalised to second f irefly control luciferase activity to correct 
the variations in transfection efficiency and cell count. Data presented are the 
mean fold change ± S.D. (n=4) of the ratio between Renilla luciferase and 
firefly control luciferase activities and are representative of three independent 
experiments. **P<0.01 and ***P<0.001 compared to RISC-free siRNA 
transfected cells as determined by unpaired Student’s t test. (B) Schematic 
diagram representing the location and mutation of the putative miR-199-3p 
binding sites within the 3′UTR of PIK3CB mRNA. Mutated regions are shown in 
A1097/1139T, C1098/1140G, and T1099/1141A in PIK3CB 3′UTR. Red -colored 
nucleotides indicate the seed match in the PIK3CB 3′UTR and starts (*) 
represent the sites of the point mutation. (C) Luciferase reporter plasmid, 
psiCHECK-2-PIK3CB 3′UTR, psiCHECK-2-MUT1-PIK3CB 3′UTR, psiCHECK-2-
MUT2-PIK3CB 3′UTR, or psiCHECK-2-MUT1/2-PIK3CB 3′UTR was co-
transfected into NIH-3T3 cells with either RISC-free siRNA or mimic or inhibitor  
for miR-199-3p. Cells were lysed and luciferase expression was measured  as I 
in A. Data presented are the mean fold change ± S.D. (n=4) of the ratio 
between Renilla luciferase and firefly control luciferase activit ies and are 
representative of three independent experiments. ns (for non-signif icance), 
*P<0.05, **P<0.01 and ***P<0.001 compared to RISC-free siRNA transfected 
cells as determined by unpaired Student’s t  test. 
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5.2.2 PIK3CB and ITGA6 are regulated by miR-199-3p at the protein 
level 
Although the luciferase reporter assay evidence that the gene is indeed regulated by 
the miRNA, there are caveats of using this assay: 1) the luciferase reporter is 
dependent on the region selected for cloning from the target gene; 2) the Renilla and 
firefly luciferase genes are controlled by different promoters within the psi-CHECK-
2 construct. Theoretically, the transcriptional activity of any of these promoters can 
be affected by overexpression or inhibition of miRNA 3) the overlap in the emission 
spectra ranges can cause bleed-through of the firefly into Renilla during the 
sequential measurements. In order to further examine miR-199-3p regulation of its 
targets, the expression of human PIK3CB and ITGA6 protein was examined in 
fibroblast cell lines, namely MRC-5 and HEFs. The human cells were selected 
because human antibodies were available.  
MRC-5 and HEFs were either untreated or transfected with RISC-free siRNA, miR-
199-3p mimic or inhibitor. Cell lysates were subsequently collected at 48 hours post 
transfection, for quantification of the protein levels by Western analysis. 
As can be seen in Figure 5.9, the protein levels of PIK3CB and ITGA6 were lower in 
those cells transfected with miR-199-3p in comparison to the level in untreated cells 
or cells transfected with RISC-free siRNA. This was seen in both HEF and MRC-5 
cells. As is consistent with the qRT-PCR data presented in the previous chapter 
(Figure 4.9a,d), no significant upregulation was found in PIK3CB and ITGA6 levels 
in miR-199-3p inhibitor transfected MRC-5 cells. Commercial antibody for ITGA3 
was not available and CD151 was not suitable for Western blots as it generates 
strong and multiple nonspecific bands.  
In conclusion, miR-199-3p was found to regulate the expression of Renilla reporter 
gene bearing the 3′UTR of ITGA3 or CD151, suggesting that these genes are direct 
targets of this miRNA. No difference in reporter gene expression was observed when 
it contained the 3′UTR sequence of ITGA6 under the same conditions. This is 
despite the fact that qRT-PCR and Western blot analysis showed down-regulation of 
mRNA and the protein levels of ITGA6 in response to miR-199-3p mimic. 
Therefore, it seems to be the case that ITGA6 is regulated by miR-199-3p but 
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perhaps not through its 3′UTR. All the data strongly suggest that PIK3CB is a direct 
target of miR-199-3p through two sites of interaction. 
 
Figure 5.9: miR-199-3p regulates PIK3CB and ITGA6 protein levels in HEF 
and MRC-5 cell lines.  MRC-5 and HEFs were either untreated or transfected 
with RISC-free siRNA, miR-199-3p mimic or inhibitor. Cell lysates were then 
harvested at 48 hours after transfection. 25µg of cell lysates was loaded per 
lane and membrane was immunoblotted with primary antibodies against 
PIK3CB, ITGA6, or β-ACTIN as a loading control. Blots were then quantif ied by 
densitometry and normalized to the corresponding β -ACTIN. For the upper and 
lower panels, the untreated was set as 1 whereas the RISC-free was 1 for the 
middle panel. Other values were expressed relative to the untreated value (the 
upper and lower panels) or RISC-free siRNA (the middle panel).  
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5.2.3 Regulation of miR-199-3p targets in HCMV infection   
The expression of miR-199-3p is down-regulated during both HCMV and MCMV 
infections (Chapter 3) and several of its cellular targets have been identified (Chapter 
4) and validated (Chapter 5). However, an important question is whether the down-
regulation of miR-199-3p during infection actually influences the target genes under 
physiological conditions (rather than transfection with synthetic reagents). The 
hypothesis is that miR-199-3p targets are up-regulated following infection, to 
correlate with miR199 down-regulation (which occurs between 24 to 72 hpi). In 
order to examine this hypothesis, it was necessary to first serum starve MRC-5 
fibroblast cells before infection. Serum starvation is a common procedure that 
eliminates growth factors and hormones in culture media in order to reduce cell 
signalling to basal levels. This culture condition was used when investigating AKT 
signalling (below) and in all experiments where reproducibly, uniform culture 
conditions were necessary. Following serum starvation, MRC-5 cells were then 
mock infected or infected with HCMV at MOI of 5. Total RNA and cell lysates were 
harvested from infected cells at the following times, 30min, 2, 4, 8, 12, 24, 36, 48, 
and 72 hpi.  
Total RNA was analysed using qRT-PCR and Northern blot and cell lysates were 
analysed by Western blot. The qRT-PCR detected expression levels of miR-199-3p 
and target mRNAs were normalised to U6 snRNA and GAPDH mRNA, respectively. 
U6 snRNA and GAPDH were found to maintain a stable expression level during the 
infection.  
As described previously in this thesis (Result 3.2.9), mature miR-199-3p levels 
decrease at 24 hpi and this is maintained until 72 hpi during HCMV infection. In the 
experiment presented here, PIK3CB mRNA was found to increase by ~8 fold at 24 
hpi and ~30 fold at 72 hpi (Figure 5.10a). Similarly, ITGA6 increased ~14 fold at 24 
hpi and reached ~25 fold at 72 hpi compared with control cells (Figure 5.10b). 
ITGA3 was also up-regulated, with a ~2 to 3 fold increase in its mRNA level 
observed at 24 and 48 hpi (Figure 5.10c). The upregulation of ITGA3 was less 
pronounced than that observed for PIK3CB and ITGA6, but still significantly 
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increased as compared to controls.  By contrast, the level of CD151 mRNA gradually 
reduced at 24 and 72 hpi by ~2 to 4 fold respectively (Figure 5.10d). In addition to 
this, CD44, a validated target of miR-199-3p (Henry et al., 2010), was found to have 
a ~5 fold induction in the expression of its mRNA within 30 min of HCMV 
infection, with a peak of ~6 fold at 2 hours, after which it began to decrease leading 
to ~8 fold decrease in mRNA level at 24 and 72 hpi, respectively (Figure 5.10e).  
Northern blot results verified the down-regulation of miR-199-3p expression within 
24 hpi under these experimental conditions (Figure 5.11a). Western blot analysis was 
also used to confirm the up-regulation of PIK3CB and ITGA6 at the protein level in 
infected cells at 24 to 72 hpi. These results show that the increase in the mRNA 
levels of the target genes, PIK3CB and of ITGA6 is indeed reflected in their protein 
levels in HCMV infection. CD44 protein expression was also found to correlate with 
its mRNA level, showing a rapid up-regulation during the first 8 hours of HCMV 
infection and a decrease from 24 hours onward (Figure 5.11b). As mentioned above, 
the other proteins have not been included in this Western blot analysis due to 
unavailability of suitable antibodies.  
In conclusion, an inverse correlation was identified between the expression of 
miR-199-3p and several of its targets (PIK3CB, ITGA6 and ITGA3) during 
infection. Therefore, it is possible that the suppressive effect of HCMV infection on 
miR-199-3p expression directly contributes to the upregulated expression levels of 
these targets, PIK3CB, ITGA6 and ITGA3. However, additional factors, such as 
transcriptional regulation could also contribute to their up-regulation during 
infection. The expression of CD44 and CD151 transcripts did not show an inverse 
correlation with miR-199-3p expression, and rather these genes were down-regulated 
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Figure 5.10: The expression kinetics of miR-199-3p and its target mRNAs, 
PIK3CB, ITGA6, ITGA3, CD151, and CD44 during HCMV infection.  MRC-5 
cells were serum starved for 48 hours and either mock infected or infected with 
HCMV at an MOI=5 for the indicated times. The expression level of miR -199-3p 
and its target mRNAs were quantif ied by qRT -PCR. The first was normalised to 
miR-16 and the later to GAPDH mRNA. Mock infected cells from the different 
time points (0hr, 24hr  and 48hr) were averaged and compared to infected cells 
at each time point. Data presented are the mean fold change ± S.D. of two 
independent experiments in tr iplicates (n=6). *P<0.05 compared to mock 
infected cells as determined by a repeated measures one-way ANOVA with 
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Figure 5.11: The expression of miR-199-3p and its target protein, PIK3CB, 
ITGA6, and CD44 during HCMV infection.  MRC-5 cells were serum starved 
for 48 hours and either mock infected or infected with HCMV at an MOI=5 for 
the indicated times. (A)  Northern blot analysis of miR-199-3p during HCMV 
infection. Total RNA was harvested from MRC-5 cells mock infected or infected 
as described above. 7µg of total RNA was loaded per lane and membrane was 
hybridised with 32P-labeled probes. miR-16 probe was used as a loading 
control ( lower panel), followed by densitometric analysis. The densitometric 
value for the mock infected was set as 1 and values for other t ime points post 
infection were expressed relative to the mock value. (B) Western blot showing 
the protein expression of PIK3CB, ITGA6 and CD44 during HCMV infection. 
Whole cell lysates were harvested from MRC-5 cells mock infected or infected 
as described above. 20µg of cell lysates was loaded per lane and membrane 
was immunoblotted with primary antibodies against PIK3CB, ITGA6, CD44 or β -
ACTIN as a loading control. Blots were then quantif ied by densitometry and 
normalized to the corresponding β-ACTIN. The mock infected was set as 1 and 
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5.2.4 AKT is activated in HCMV infected MRC-5 fibroblasts   
The detailed kinetics of the phosphorylation of AKT have been studied previously in 
human embryonic lung fibroblast cells (HELs) infected with HCMV. A biphasic 
activation was observed; a rapid phosphorylation of AKT appeared at 15-30 min, 
which was then followed by a sustained phosphorylation that continued to increase 
from 4 to 48 hours post HCMV infection (Johnson et al. 2001b). In the study 
presented here, it was found that miR-199-3p regulates AKT phosphorylation. Based 
on IPA computational analysis (Chapter 4), AKT is linked to several miR-199-3p 
targets including PIK3CB, ITGA6, ITGA3, CD151, and CD44. 
The aim in this section was therefore to analyse AKT activation during HCMV 
infection of MRC-5 cells and to determine if this could result from the regulation of 
its targets. For maximal kinase activation AKT can be phosphorylated at two sites, at 
threonine 308 (Thr308) and serine 473 (Ser473) residues, both phosphorylation sites 
were examined.  
As can be seen in Figure 5.12, both Ser473 and Thr308 sites of AKT were highly 
phosphorylated within 30 min and up to 2 hpi. Levels of phosphorylation at both 
sites returned to the basal level at 4 hpi and were undetectable thereafter. This shows 
a rapid AKT phosphorylation during the first two hours of HCMV infection of MRC-
5 fibroblasts and down-regulation of phosphorylation afterwards. However, these 
results of AKT phosphorylation in HCMV infected MRC-5 were not consistent with 
the kinetics shown in HCMV infected HELs by Johnson and colleagues (Johnson et 
al. 2001b), where increasing phosphoryation was observed at later time points.   
According to these results, AKT phosphorylation in HCMV infected MRC-5 
fibroblasts did not correlate with miR-199-3p expression, which decreased from 24 
hpi. The increase in AKT phosphorylation at 2 hours preceded miR-199-3p down-
regulation during infection, which indicates that miR-199-3p is unlikely to be 
involved in AKT phosphorylation under these conditions.  
 
 
                                                                                                                        Results Chapter 5                                                                     




Figure 5.12: The kinetics of AKT phosphorylation during HCMV infection.  
MRC-5 cells were serum starved for 48 hours and then either mock infected or 
infected with HCMV at an MOI=5 for the indicated times. 20µg of cell lysates 
was loaded per lane and membrane was immunoblot ted with primary antibodies 
against the phosphorylated-Ser473 and phosphorylated-Thr308, total AKT, β-
ACTIN, or GAPDH as a loading control. Blots were then quantif ied by 
densitometry and normalized to the corresponding GAPDH. The mock infected 
was set as 1 and values for other time points were expressed relative to this 
mock infected value. 
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5.2.5 Over-expression of miR-199-3p reduces AKT phosphorylation at 
early time points post infection 
The results in section 4.2.10 demonstrate that the expression of miR-199-3p has a 
negative effect on AKT phosphorylation at both phosphorylation sites, Ser473 and 
Thr308. It was thus hypothesised that the pre-transfection of miR-199-3p into cells 
would reduce the level of HCMV induced AKT phosphorylation at 30 min and 2 hpi.  
To examine this hypothesis, AKT phosphorylation was assessed in cells transfected 
with miR-199-3p and subsequently infected with HCMV for 30 min and 2 hours. In 
more details, MRC-5 cells were untreated or transfected with control RISC-free 
siRNA or miR-199-3p mimic for 24 hours. Cells were then serum starved for a 
further 24 hours and either mock infected or infected with HCMV at MOI of 5. Cell 
lysates were harvested at 30 min and 2 hpi and subjected to Western blotting. 
As can be seen in Figure 5.13, the overexpression of miR-199-3p reduced the 
phosphorylation at the Ser473 site while the level of total AKT is comparable 
between the conditions. The results suggest that miR-199-3p reduces the 
phosphorylation of AKT without affecting the translational regulation of AKT itself, 
suggesting that this is mediated by miR-199-3p targets that involved in regulation of 
AKT phosphorylation such as PI3KCB.  
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Figure 5.13: The AKT phosphorylation following HCMV infection is 
repressed by miR-199-3. MRC-5 cells were transfected with miR-199-3p or 
control RISC-free siRNA for 24 hours prior to serum-starvation. 24 hours 
following the starvation, cells were either mock infected or infected with HCMV 
at an MOI=5 for the indicated times. 20µg of cell lysates was loaded per lane 
and membrane was immunoblotted with primary antibodies against the 
phosphorylated-Ser473, total AKT, or GAPDH as a loading control.  Blots were 
then quantif ied by densitometry and normalized to the corresponding GAPDH. 
The mock infected was set as 1 and values for other t ime points were 
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5.2.6 The rapid activation of AKT is PI3K dependent and may required 
for HCMV infected MRC-5 fibroblasts   
It has previously been shown that inhibition of AKT phosphorylation suppress 
HCMV replication (Johnson et al. 2001b). In the previous section (5.2.5), it was 
demonstrated that the HCMV infection of cells transfected with miR-199-3p reduces 
the phosphorylation levels of AKT. It was therefore hypothesised that this effect is 
responsible for antiviral activity of miR-199-3p. 
Cells were seeded for 24 hours and then treated with LY294002, a specific inhibitor 
of PI3-Kinase for 30 min prior to HCMV infection. LY294002 is an ATP-competitor 
that targets the active ATP binding site of PI3K kinase. It should be noted that the 
PI3-Kinase inhibitor, LY294002, can inhibit the phosphorylation of AKT as well as 
other PI3K-related enzymes such as the DNA-dependent protein kinase (DNA-PK 
and ATM) (Rosenzweig et al. 1997; Izzard et al. 1999). Control cells were treated 
with DMSO as LY294002 is prepared in DMSO. Ly294002 can be used at a 
concentration of 50μM according to the manufacturer’s instructions (Cell Signalling 
Technology). However, this concentration caused a marked reduction in the viability 
of cultured cells after 24 hours. Therefore, two other concentrations of Ly294002, 10 
and 25μM, were examined for their effects on cell viability and PI3K activity. The 
treatment with 25μM of Ly294002 does not lead to cellular death and has a stronger 
inhibitory effect on PI3K activity and AKT phosphorylation in the MRC-5 cell line 
than 10μM of Ly294002 (data not shown). To assess viral growth, LY294002-treated 
and DMSO-treated control cells were infected at MOI of 0.5 with HCMV that 
expresses GFP under control of the UL127 promoter or were mock infected (HCMV-
GFP). Viral growth was assessed by measuring the GFP signal twice/day from 0 to 
156 hours (Day 7 of infection) using Varioskan Flash Multimode Reader (excitation 
wave length of 485 nm and emission of 520 nm).  
A significant reduction was observed in viral growth in LY294002-treated cells in 
comparison to the control DMSO-treated or mock infected cells. The reduction was 
more pronounced in cells treated with 25µM LY294002 than in 10µM LY294002-
treated cells (Figure 5.14).  
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In conclusion, the viral growth of HCMV was suppressed by LY294002 in a dose-
dependent manner, which is likely due to the inhibition of AKT phosphorylation. 
This, in turn suggests that PI3K-AKT signalling has important at the early stage of 
HCMV life cycle.  
 
 
Figure 5.14: Blocking AKT phosphorylation in MRC-5 cells results in 
reduced viral growth.  MRC-5 cells were either untreated or treated with 
DMSO, 10µM and 25µM Ly294002. After 30 min of treatment, MRC-5 were then 
mock infected or infected with HCMV-GFP at an MOI= 0.5. The growth curve of 
GFP virus in infected untreated or treated MRC-5 cells with control DMSO or 
Ly294002. The fluorescent signal of mock infected cells is considered as a 
background. Data presented are the mean normalized f luorescence ± S.D. 
(n=3) and are representative of 3 independent experiments. *P<0.05, **P<0.01, 
and ****P<0.0001 compared to DMSO treated and infected cells as determined 
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5.2.7 miR-199-3p targets, PIK3CB, ITGA6, and ITGA3 may not be 
associated with the antiviral properties of miR-199-3p in HCMV 
infection  
The data presented here show that miR-199-3p regulates the phosphorylation of 
AKT, and that inhibition of this phosphorylation reduces viral growth, likely because 
AKT is required early in the life cycle. However, these results do not address the 
functional significance of the natural down-regulation of miR-199-3p during 
infection, which occurs at 24 hpi. It is not clear if this influence AKT phospho-
regulation, since this was not observed in vitro (Fig. 5.12).  
The data presented in section 5.2.3 shows that cellular genes PIK3CB, ITGA6 and 
ITGA3 are up-regulated when miR-199-3p is down-regulated from 24 to 72 hpi. A 
hypothesis, therefore, is that the down-regulation of miR-199-3p during HCMV 
infection contributes to the upregulation of these genes and that these genes have a 
direct role in promoting viral growth. It should be noted that while the induced 
expression of PIK3CB, ITGA6 and ITGA3 occurs concomitant with miR-199-3p 
suppression in HCMV infection, this alone is insufficient evidence  to conclude that 
miR-199-3p is alone responsible for their up-regulation or that these targets can be 
associated with the antiviral function of miR-199-3p. Experiments were therefore 
designed to investigate whether these targets of miR-199-3p play a role in HCMV 
infection.  
5.2.7.1 The functional significance of PIK3CB, ITGA6 and ITGA3 in 
HCMV infection  
In this section the question whether PIK3CB, ITGA6, and ITGA3 play a role in 
HCMV infection was examined. Therefore, HCMV viral growth was monitored in 
cells in which PIK3CB, ITGA6, and ITGA3 were knocked down by siRNA. Since 
these genes are up-regulated during infection, their silencing should be an effective 
strategy to examine whether or not they are necessary to the viral growth. 
MRC-5 cells were transfected with control RISC-free siRNA, a specific target 
siRNAs for ITGA6 or ITGA3, or two different siRNAs for PIK3CB for 48 and 72 
hours. Total RNA was then isolated in order to test whether the siRNAs were 
effective in gene silencing by measuring the mRNA levels using qRT-PCR. Cell 
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lysates were also harvested to check protein levels using available antibodies. 
Relative to cells transfected with control RISC-free siRNA, the knockdown observed 
for each gene at 48 and 72 hours post transfection was: PIK3CB 1 (5.5 and 12-fold) ; 
PIK3CB 2 ( 11 and 7-fold); ITGA6 (9.5 and 13.5-fold); and ITGA3 (4 and 5.5-fold) 
(Figure 5.15a). The protein levels of PIK3CB were also examined following the 
knock down and showed more than 50% decrease using either siRNA (Figure 5.15b).  
MRC-5 cells were either untreated or transfected for 48 hours with RISC-free 
siRNA, C. elegans mimic, miR-199-3p mimic, e-GFP siRNA, ITGA6, ITGA3, or 
two different siRNAs for PIK3CB. Following transfection, cells were mock infected 
or infected with HCMV-GFP at MOI of 0.5. Viral growth was then monitored in 
transfected cells infected cells by measuring GFP expression over a 6 day time 
course of infection. In parallel, the cell viability was measured prior to infection. All 
transfected cells showed a viability value of >90% (Figure 5.16). 
Viral growth was similar in untreated cells or cells transfected with the control C. 
elegans mimic (Figure 5.17). This demonstrates that the transfection procedure did 
not affect viral growth. The viral growth in cells transfected with RISC-free siRNA 
was attenuated in comparison to untreated and control mimic, implicating non-
specific effects of RISC-free siRNA (Figure 5.17). However, this was statistically 
significance only at day 7.  An siRNA directed at the viral GFP gene expression (e-
GFP siRNA) serve as a control for transfection efficiency, however, it was able to 
decrease the expression of GFP-protein from the HCMV-GFP by ~2.3 fold at 96 hpi, 
~5 fold at 120 hpi and ~2 fold at 168 hpi (Figure 5.17). Cells transfected with 
miR-199-3p mimic showed a ~1.7 fold, ~3 fold, and ~1.4 fold decrease in the 
fluorescence signal at 96, 120, and 168 hpi respectively, indicating that miR-199-3p 
had a negative effect on viral growth. It is therefore possible to conclude that the 
transfection procedure was successful and that miR-199-3p has antiviral properties as 
expected (Figure 5.17).  
The growth rate of HCMV-GFP was also evaluated in cells in which the expression 
of ITGA6, ITGA3, and PIK3CB genes was knocked down. No significant difference 
was observed in the growth rate of HCMV-GFP in MRC-5 cells transfected with 
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ITGA6 siRNA relative to the control RISC-free transfected cells or untreated cells 
over the chosen time course (Figure 5.18a). The knock down of ITGA3 and PIK3CB 
resulted in an increase in the fluorescence signal observed relative to the GFP signal 
emitted by infected RISC-free transfected cells at day 6 and 7, whereas no significant 
change was detected in the growth of HCMV-GFP in those cells compared to 
untreated cells (Figure 5.18a,b).  
As the silencing of gene expression can be incomplete (not 100% efficient) for most 
proteins, a small amount of expression of these proteins can still be sufficient to exert 
their potential functions. Therefore, an experimental complementation of other 
approaches (i.e. the pharmacological inhibition, stable knock down or knock out 
animal or cell line) can support and provide more rigorous conclusions. It has been 
recently described the pharmacological inhibition of the kinase activity of PIK3CB 
with the new drug TGX-221 (Jackson et al. 2005), it was therefore decided to use 
this approach to further evaluate the involvement of the PIK3CB kinase function in 
HCMV infection. It should be noted that PIK3CB siRNA is able to affect the kinase 
dependent and independent function of PIK3CB, whereas the drug TGX-221 
selectively blocks the kinase function of PIK3CB.  
Cells were either untreated or treated with 50 nM TGX-221 or control DMSO for 2 
hours prior to infection. The concentrations to be used in order to block the kinase 
activity of PIK3CB are in a range of 5-50 nM according to the manufacturer’s 
instructions (Cayman Chemical). These concentrations do not affect the kinase 
activity of other PI3K isoforms, i.e. PIK3CA and PIK3CD. In addition, 50 nM does 
not result in a significant change in the proliferation or survival of cultured cells 
(data not shown). As a positive control, cells were treated for 2 hours with 25µM 
Ly294002, which has an antiviral effect (as shown in Figure 5.14). Treated cells 
were then infected with HCMV-GFP at MOI of 0.5 and the viral growth monitored 
based on its fluorescent signal. No change in viral growth was observed in TGX-221 
treated cells in comparison to control DMSO treated cells or the untreated cells over 
the time course of the HCMV infection (Figure 5.19). In contrast, a significant 
inhibition in viral growth was seen in Ly294002 treated cells (Figure 5.19).  
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Overall, the negative control, RISC-free siRNA causes nonspecific effects on viral 
growth or its GFP expression compared to untreated cells or C. elegans mimic 
transfected cells, therefore the results from siRNA experiments can be hard to 
interpret. The knock down of PIK3CB and ITGA3 showed proviral effects relative to 
control RISC-free transfected cells but no significant effect was observed relative to 
untreated cells. Moreover, the knock down of ITGA6 has no effect on the viral 
growth when compared to that in untreated or control RISC-free transfected cells. 
Comparative analysis of PIK3CB knock down experiments was performed using 
pharmacological inhibitor TGX-221 to examine the role of kinase-dependent 
functions of PIK3CB in HCMV infection. Specific blockade of PIK3CB kinase 
function did not influence viral growth. It may therefore be the case that the antiviral 
function of miR-199-3p is not associated with any of these target genes.  
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Figure 5.15: The Knock down of PIK3CB, ITGA6, and ITGA3 using siRNAs.  
A) Reduction in the mRNA levels of PIK3CB, ITGA6, and ITGA3 in  cells 
transfected for 48 and 72 hours with siRNAs directed against each gene. The 
expression levels of target genes were quantif ied by qRT-PCR and normalised 
to GAPDH and compared to cells transfected with RISC-free siRNA. Data 
presented are the mean fold change ± S.D. (n=3) and are representative of two 
independent experiments. **P<0.01, ***P<0.001, and ****P<0.0001 compared to 
RISC-free siRNA transfected cells as determined by unpaired Student’s t test.  
B) Western blot showing reduction in PIK3CB protein in cells transfected with 
either PIK3CB siRNAs. MRC-5 cells were untreated or transfected with either 
RISC-free or PIK3CB siRNAs for 48 hours. 20µg of cell lysates was loaded per 
lane and membrane was immunoblotted with primary antibodies against the 
PIK3CB or β-ACTIN as a loading control . Blots were then quantif ied by 
densitometry and normalized to the corresponding β -ACTIN. The untreated was 
set as 1 and values for transfected cells were expressed relative to the 
untreated value. 
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Figure 5.16: Effects of PIK3CB, ITGA6, and ITGA3 knockdown on cell 
viability. The measurement of cell viabil ity was performed using cell titer blue 
assay. The background fluorescence of the culture medium was subtracted 
from the fluorescence values of the cel ls. The values above the background 
were compared to untreated samples. Data presented are the mean fold 
change ± S.D. (n=4) of one representative experiment (out of two independent 
experiments).  
 
Figure 5.17: HCMV-GFP growth curve in MRC-5 cells transfected with 
miR-199-3p, C. elegans mimic, control RISC-free and e-GFP siRNA.  
Transfected cells were infected with HCMV-GFP at MOI=0.5. The graph 
displays growth curves of HCMV-GFP, which was monitored over 168 hours 
post infection. The fluorescent signal of mock infected cells is considered as a 
background. Data presented are the mean normalized f luorescence ± S.D. 
(n=3) and are representative of 3 independent experiments. *P<0.05, **P<0.01,  
***P<0.001 and ****P<0.0001 compared to RISC-free transfected and infected 
cells or untreated infected cells as determined by a repeated measures two-
way ANOVA with Sidak’s post -test for multiple comparisons.  
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Figure 5.18: Growth curves of HCMV-GFP in transfected MRC-5 cells with 
controls and target siRNAs.  HCMV-GFP growth curves in cells in which 
ITGA6, ITGA3 (A) or PIK3CB (B) were knocked down in MRC-5 cells. 
Transfected cells were mock infected or infected with HCMV-GFP at MOI=0.5. 
The graph displays growth curves of HCMV-GFP, which was monitored over 
168 hours post infection. The fluorescent signal of mock infected cells is 
considered as a background.  Data presented are the mean normalized 
fluorescence ± S.D. (n=3) and are representative of three independent 
experiments. **P<0.01 compared to RISC-free transfected and infected cells as 
determined by a repeated measures two-way ANOVA with Sidak’s post -test for 
multiple comparisons.  
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Figure 5.19: HCMV-GFP growth curves of MRC-5 cells treated with TGX-
221. HCMV-GFP growth curves in cells untreated or treated with 50nM TGX-
221, or 25µM Ly294002. Untreated and treated cells were infected with HCMV-
GFP at MOIO=0.5. The graph displays growth curves of HCMV-GFP, which was 
monitored over 168 hours post infection. The fluorescent signal of mock 
infected cells is considered as a background. Data presented are the mean 
normalized fluorescence ± S.D. (n=3) and are representati ve of three 
independent experiments. *P<0.05, **P<0.01, and ****P<0.0001 compared to 
DMSO treated and infected cells as determined by a repeated measures two-
way ANOVA with Sidak’s post -test for multiple comparisons.  
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5.3 Discussion  
miRNAs have an important role in regulating intracellular signaling cascades, which 
ultimately result in modification of diverse cell functions. As mentioned in the 
previous chapter, miR-199-3p was found to modulate PI3K-AKT signalling based on 
the reduced level of phosphorylation of AKT at key sites in cells transfected with 
miR-199-3p mimic. In addition to this, in silico analysis using IPA and TargetScan 
5.0 software suggest a number of targets of miR-199-3p that are associated with the 
regulation of AKT, such as PIK3CB, ITGA6, ITGA3, CD151, and CD44. Of these 
six targets, only CD44 has been previously shown to be a direct target of miR-199-3p 
(Henry et al., 2010). Given the above findings, the role of miR-199-3p in regulating 
AKT and targets of miR-199-3p linked to AKT were selected for the further 
functional studies presented in this chapter.   
5.3.1 The validation of miR-199-3p targets using a luciferase reporter 
system and Western blot analysis.  
To date, the most specific method for validating miRNA target sites is based on 
reporter assays where the 3′UTR with target site is cloned downstream of a luciferase 
gene. The luminescence should be altered in the event that the target sequence is 
regulated by miRNA and this can be tested with mutation of target site. In addition, 
an inhibition of luminescence can be observed through the introduction of a 
regulatory miRNA mimic or induction of luminescence is seen when the endogenous 
level of this regulatory miRNA is knocked down. Importantly, the reporter has an 
internal control for transfection efficiency and cell count. A caveat to using miRNA 
overexpression in this assay is that the miRNA could be at non-physiological 
concentrations and therefore have non-physiological interactions. Here, it was shown 
that miR-199-3p targets ITGA3 and CD151 through binding to their 3′UTRs, as well 
as targeting PIK3CB through two conserved sequences within the PIK3CB 3′UTR 
(Figure 5.8). The only candidate target of miR-199-3p that did not respond to either 
the overexpression or inhibition of miR-199-3p was ITGA6, though ITGA6 mRNA 
and protein were down-regulated by miR-199-3p mimic in human cells (Figure 4.9 
and 5.9). However, changes in expression level does not prove a direct interaction 
with miRNA, therefore it is possible that ITGA6 might be an indirect target of 
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miR-199-3p. There are a number of other possible explanations for why  ITGA6 is 
regulated by miR-199-3p but not validated as a direct target with luciferase assay: 1) 
there could be a non-canonical binding site(s) for miR-199-3p within ITGA6 5’UTR 
or ORF (Ørom et al. 2008; Stark et al. 2007) (only the 3′UTR is examined in the 
above luciferase assay); and 2) it is possible that the mouse and human 3′UTRs of 
ITGA6 respond differently to miR-199-3p (this experiment used mouse 3′UTR). The 
mouse and human ITGA6 3′UTRs are 75% conserved, including a conserved 
miR-199-3p binding site. But it is possible that the mouse and human 3′UTRs have 
different RNA structural features, which could interfere with target-site accessibility 
and the mRNA:miRNA interaction.  
5.3.2 The inverse correlation between miR-199-3p and its targets for 
during infection 
It was hypothesised that the reduction of miR-199-3p in CMV infection at 24 to 72 
hours resulted in, or contributed to, the upregulation of target genes, and this is 
expected to be beneficial to the virus. Therefore, the correlation between the miRNA 
and target mRNAs was examined in the context of infection. Upon HCMV infection, 
PIK3CB and ITGA6 were induced at the mRNA and protein levels while ITGA3 
showed less pronounced upregulation. As it is generally believed that miRNAs exert 
subtle effects on their target genes, additional mechanisms may be involved in 
regulating these genes during infection, which could work in concert with miR-199-
3p.  
With regards to CD151 and CD44, these targets were markedly down-regulated 
when miR-199-3p was repressed during HCMV infection. While this does not 
exclude the possibility that these genes are regulated by miR-199-3p, it seems less 
likely that their regulation by miR-199-3p would have a large effect on their levels 
during infection. On this basis, these two genes were not analysed further in this 
study.  
5.3.3 Regulation of AKT phosphorylation in cells upon HCMV infection 
The main hypothesis addressed in this chapter is whether the viral modulation of 
miR-199-3p altered AKT phosphorylation during HCMV infection. In order to 
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answer that question, the kinetics of AKT phosphorylation were examined in MRC-5 
fibroblasts. Surprisingly, phosphorylated AKT, a protein kinase crucial for the 
regulation of a range of cellular functions, was completely dephosphorylated at 4 hpi. 
However, it was strongly phosphorylated within 30 min and 2 hpi, potentially 
indicating that AKT signalling is required during the first stages of infection, such as 
viral entry, internalisation and trafficking into the nucleus. Johnson and colleagues 
(2010b) showed that HCMV infection leads to the phosphorylation of AKT at the 
serine residue in a PI3K dependent manner at 30 min and then from 4 to 48 hpi. This 
phosphorylation and activation of AKT required for the expression of immediate 
early genes (IE1 and IE2) and early genes such as UL44 and UL84, which are 
involved in the initiation of viral DNA replication (Johnson et al. 2001b). It is not 
clear why the AKT phosphorylation was not observed at late time points as was 
published (Johnson et al. 2001b). One possible explanation is that it results from the 
use of two different laboratory strains. Johnson (2001b) used human cytomegalovirus 
strain Towne while this study uses the AD169 strain. It should be noted that Towne 
and AD169 share approximately 90% of their nucleotide sequences (Pritchett 1980). 
Another possibility is that a mutation occurred during the laboratory passage, such as 
deletion or rearrangement of viral DNA sequence (Cha et al. 1996). It is also 
important to mention the use of different cell lines, although both MRC-5 and HELs 
are fibroblasts. However, according to the data presented here, the phosphorylation 
of AKT, which happens at 30 min to 2 hpi is not caused by the down-regulation of 
miR-199-3p, which happens at 24 to 72 hpi. As the experimental procedure used to 
elucidate the role of miR-199-3p in HCMV infection was based on the transfection 
of miR-199-3p mimic prior to infection, the miR-199-3p mimic could exert a 
negative regulation of AKT phosphorylation during the first two hours of infection. 
In other words, the transfection of miR-199-3p creates a cellular environment that is 
less conducive to early stages of infection. The pharmacological inhibition of AKT 
phosphorylation using PI3K inhibitor (LY294002) showed that AKT appears to be 
required for HCMV infection and therefore, the reduced AKT phosphorylation in 
miR-199-3p transfected cells could lead to antiviral effect. As LY294002 can also 
block other PI3K-related enzymes, a further experiment is needed to confirm the role 
of AKT protein during HCMV infection using more specific methods to inactivate 
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AKT (i.e. cells expressing dominant negative forms of AKT (kinase dead) and/or 
PI3K). However the natural function of miR-199-3p in regulating PI3K-AKT 
signalling at later times post infection remains unclear.  
5.3.4 PIK3CB, ITGA6, and ITGA3 do not appear to be involved in the 
antiviral function of miR-199-3p  
As the expression levels of PIK3CB, ITGA6, and ITGA3 are correlated with the 
down-regulation of miR-199-3p during HCMV infection, it was decided to examine 
their functional properties during infection. In order to investigate the functional role 
of PIK3CB, ITGA6 and ITGA3 genes in HCMV infection, it was decided to use the 
knock down of ITGA6, ITGA3, and PIK3CB as well as the pharmacological 
inhibition of PIK3CB kinase function. As PIK3CB can function as a protein kinase 
or independent of its kinase activity, the use of siRNA would therefore affect both 
functions, whereas TGX-221 selectively blocks the kinase function of PIK3CB (Jia 
et al., 2008). Neither PIK3CB siRNAs nor TGX-221 negatively impacted the growth 
of HCMV-GFP reporter virus. It is important to note that as the knock down of 
PIK3CB at the protein level was incomplete, the remaining level expressed after 
knock down may enough for its function during the infection. However further 
studies are required in order to properly determine the function of PIK3CB through 
utilisation of more efficient method of silencing. It is also important to mention that 
there is two isoforms of PI3K catalytic subunits, PIK3CA and PIK3CB, which have 
functional redundancy as well as the distinct roles inside cells (Foukas et al. 2006; Bi 
et al. 2002; Chaussade et al. 2007). It is possible that functional loss of PIK3CB 
could be compensated for by the expression of PIK3CA in this cell type. In regard to 
ITGA6 and ITGA3, either these do not influence or the partial knock down was 
insufficient to see an effect. Feire and collegues used integrin blocking antibodies to 
identify different α and β subunits of integrin receptors that are engaged in the entry 
pathway of HCMV into NHDF fibroblasts. Important roles were revealed for integrin 
subunits α2, α6, αV, β1 and β3 in supporting virus entry, however, this is not the case 
for α3. It has been suggested that HCMV apparently engages multiple integrin 
subunits to perform redundant functions (Feire et al. 2004). Consequently, the knock 
down of α6 may not inhibit viral infection. HCMV is also known to have a broad 
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tissue tropism, suggesting that either HCMV exploits a combination of viral 
envelope glycoproteins (Isaacson and Compton 2009; Mach et al. 2000; Kinzler and 
Compton 2005; Britt 1984) and cellular receptors to infect a range of different cells 
or that a universal cellular receptor mediates the interaction between the different 
host cells and viral envelope protein(s). The research question posed for this thesis 
‘to identify the targets of miR-199-3p that are responsible for its antiviral properties’ 
still needs further examination. However, this is exceptionally challenging largely 
due to the fact that individual miRNAs can target multiple cellular and viral genes.  
In conclusion, the first evidence has been provided to show that PIK3CB, CD151, 
ITGA3 are direct targets of miR-199-3p through their 3′UTRs. ITGA6 is also 
regulated by miR-199-3p, although it remains unclear whether this involves a direct 
interaction with the miRNA. It has also been indentified that PIK3CB, ITGA6, and 
ITGA3 are up-regulated by HCMV at 24 to 72 hours post infection, in concert with 
the viral repression of miR-199-3p, however,  this does not appear to be the case for 
CD151, or CD44. While the silencing of these target genes PIK3CB, ITGA3 or 
ITGA6 does not appear to influence viral growth, these results are still insufficient to 
conclude that these genes are not associated with the antiviral role of miR-199-3p. 
However, further experiments should be conducted in order to elucidate their roles 
during HCMV infection. This study has shown for the first time that miR-199-3p 
induces the impairment of AKT phosphorylation in HCMV infected fibroblasts. In 
addition, the phosphoregulation of AKT was demonstrated to occur in early infection 
(2 hours) while the viral down-regulation of miR-199-3p later in infection (24- 72 
hours) is therefore after AKT phosphorylation that occurs in the first two hours. 
Finally, the down-regulation of AKT phosphorylation as result of the pre-transfection 
of miR-199-3p seems to have a negative effect on viral infection. The antiviral role 
of reducing AKT phosphorylation requires more specific experiments for 
confirmation.  
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6 Discussion  
6.1 Rational and objectives of the study  
Besides HCMV infection is a significant cause of fatal and childhood developmental 
abnormalities such as neurologic sequelae and deafness, and also establishes a latent 
infection accompanied by an inherent risk of reactivation and corresponding risk of 
life-threatening diseases, as is in the case of immunocompromised hosts, particularly 
in transplant recipients and AIDS patients. In the United States The Committee to 
Study Priorities for Vaccine Development for the 21
st
 Century has ranked HCMV as 
one of the top priorities for vaccine research in an attempt to prevent the prenatal 
infection and other complications encountered by immunocompromised patients 
(Stratton et al. 2001). Therefore, the development of a vaccine or reliable anti-virals 
for the prevention of the initial infection, super-infection or HCMV recurrences is of 
critical importance. A greater understanding of ‘HCMV Biology and Pathology’ at 
the molecular, cellular and systemic levels is essential for this. A new class of 
molecules small non-coding RNA (miRNAs), are now appreciated to play important 
roles in virus-host interactions since the discovery of a host miR-122, which is 
capable of modulating the replication of HCV (Jopling et al. 2005). 
The functional significance of miRNAs in the context of viral infections is supported 
by a number of key findings in the last nine years: 1) certain viruses, including 
members of Herpesviridae, encode miRNAs indicating the significance of this mode 
of gene regulation to the viral life cycle; 2) certain host-encoded miRNAs have 
positive or negative effects in acute, latent and reactivated phases of infections, either 
in a direct or indirect manner; 3) host miRNAs play a role in the regulation of 
antiviral immune responses, as well as in the maintenance of basic cellular functions, 
such as proliferation, apoptosis, and metabolism; and 4) viruses have evolved 
numerous strategies for the manipulation of the expression of host-encoded miRNAs. 
The significance of miRNAs as therapeutic targets is now widely recognised. For 
example, miR-122 antagonists were administered to chimpanzees chronically 
infected with HCV, which led to a significant decrease in HCV RNA in serum 
(Lanford et al. 2010). miR-122 antagonists are currently being assessed in Phase II 
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clinical trials. In addition, a few miRNAs are in pre-clinical developmental stages, 
such as miR-34 and let-7 mimics. These have been shown to prevent tumour growth 
in mouse models for lung and prostate cancer (Wiggins et al. 2010; Liu et al. 2011) 
and the latter also in lung cancer mouse model (Trang et al. 2010).   
The expression levels of cellular miRNAs has been characterised in MCMV and 
HCMV infection and initial insights into the functional role of these miRNAs have 
been reported (Wang et al. 2008; Santhakumar et al. 2010). Santhakumar and 
colleagues showed the broad antiviral properties of miR-199-3p in DNA viruses 
corresponding to three subfamilies of Herpesviridae (α, β, γ-Herpesviruses) 
including HCMV, MCMV, HSV-1 and MHV-68 and also SFV, a positive-stranded 
RNA virus of Togaviridae. Despite the fact that Herpesviridae and Togaviridae are 
not evolutionarily conserved, it is possible that these viruses use similar host proteins 
or signalling cascades to support their infections. A deeper understanding of the 
antiviral functional of miR-199-3p may define valuable targets for HCMV therapies 
and/or other viruses. In addition, while a significant inhibition of this antiviral 
miRNA occurs at 24 hours of HCMV infection, the mechanism of this inhibition had 
not been previously defined. This project examined the mechanisms by which miR-
199a-3p is down-regulated in HCMV infection, and examined possible targets of the 
miRNA that could mediate its antiviral function.  
The main objectives of this study were to: 
1. Identify the level of regulation by which miR-199-3p expression is reduced 
upon infection with CMV.  
2. Determine the functional role of miR-199-3p in the modulation of cellular 
signalling pathways in the context of CMV infections.  
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6.2 Overview of Thesis Results’ Chapters  
Chapter 3: Regulation of miR-199a/214 cluster expression in CMV 
infection 
Chapter 3 examines three core objectives regarding the down-regulation of miR-199-
3p expression in MCMV and HCMV infections. The first of these objectives 
examined whether CMV regulates miR-199-3p biogenesis at the transcriptional or 
post-transcriptional level. As described, miR-199-3p comes from a cluster, the other 
members in this cluster, including miR-199-5p and miR-214 were also down-
regulated during infection, suggesting that regulation of the the primary transcript 
could occur. Therefore, the level of the pri-miR-199a/214 transcript encoding miR-
199a-3p, miR-199a-5p, and miR-214 was assessed in a time course of infection. This 
revealed that in both MCMV and HCMV infections, the pri-miR-199a/214 transcript 
is downregulated by 4 hpi. As this down-regulation of the primary transcript could 
result from a change in promoter activity, the activation of the miR-199a/214 
promoter was measured during MCMV infection. The infection is able to suppress 
the promoter activity by 4 hpi, which is consistent with the down-regulation of pri-
miR-199a/214 transcript in infected cells at 4 hours.  
The second objective was to determine the transcriptional factor(s) involved in the 
regulation of miR-199a/214 cluster during infection. A bioinformatic approach 
coupled with a functional characterisation of the promoter sequence was employed in 
order to determine the sequences critical to miR-199a/214 promoter function and to 
identify those transcription factors with binding sites within this critical sequence. 
The minimal promoter sequence was identified, which spans 696nt, and the sequence 
spanning -421 to -273 was shown to play the most critical contribution to the 
promoter activity based on 5′ deletion constructs of the miR-199a/214 promoter.  
This sequence contains conserved sites for several transcription factors, including 
SRF and ELK-1. Both of these transcription factors were shown to be important for 
the basal activation of miR-199/214 promoter and subsequent their expression levels. 
However, it is now known that SRF is a transcription factor critical for the regulation 
of miR-199a/214 expression in smooth or cardiac muscles. However, it remains 
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unclear whether this regulation is based on a direct interaction with miR-199a/214 
promoter or an indirect result of SRF binding to another gene (Park et al. 2011; 
Zhang et al. 2011). As for ELK-1, no work has been conducted yet to examine 
whether this transcription factor regulates miR-199a/214 promoter either directly or 
indirectly.  
In addition, their regulation needs to be examined during CMV infection. Another 
transcription factor, TWIST-1 was examined as it has been reported that the 
expression of the primary transcript of miR-199a/214 and its mature cluster is 
regulated by TWIST-1 suggesting that regulation occurs at the transcriptional level 
(Lee et al. 2009). It was found that TWIST-1 protein is down-regulated in MCMV 
infection by 48 hours and this also occurs in HCMV infection, but at an earlier time 
point of 24 hours. However, the timing of the down-regulation of TWIST-1 protein 
does not correlate with the down-regulation of the primary transcript, which occurs 
by 4 hpi. Therefore, the change in TWIST-1 levels during infection does not 
contribute to the early down-regulation of the pri-miR-199a/214 transcript. It is 
possible that this protein may still play a role as in other systems, TWIST-1 can be 
regulated at the post-translational level, which could potentially interfere with its 
functional properties (Vichalkovski et al. 2010; Firulli and Conway 2008; Firulli et 
al. 2008). Therefore, further examination of the phosphoregulation of TWIST-1 in 
infected cells may be worthwhile to find out whether it plays any role in the down-
regulation of miR-199a/214 expression. 
The third objective was to examine whether viral gene expression is required for the 
transcriptional down-regulation of miR-199a/214 cluster. Therefore, the IE3 deletion 
mutant MCMVdie3 was examined in comparison to wild type MCMV regarding its 
capacity to regulate the promoter activity as well as the expression of the primary 
transcript and mature members of miR-199a/214 cluster.  
It was showed in cells infected with MCMVdie3, the level of pri-miR-199a/214 
transcript is not down-regulated by 4 hpi and only slightly by 24 hpi. In contrast 
infection of cells expressing IE3, the NIH-3T3-BAM25 with MCMVdie3 was able to 
complement the expression defects of IE3 in the mutant virus and partially rescue the 
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phenotype towards the wild-type MCMV phenotype, which suggests that the 
expression of the IE3 gene is essential in the regulation of miR-199a/214 by MCMV 
infection. Based on all the results in this chapter, it is concluded that the down-
regulation of miR-199-5p, miR-199-3p and miR-214 is primarily controlled at the 
transcriptional level in both MCMV and HCMV infections. This down-modulation 
may involve TWIST-1 and other transcription factors during CMV infections. The 
expression of the viral gene IE3 is crucial for the transcriptional down-regulation of 
miR-199a/214 by MCMV.  
Chapter 4: A proposed model for the antiviral function of miR-199-3p 
in MCMV infection  
This chapter focused on building a model for the possible functions of miR-199-3p 
during infection. One of the important mechanisms of miRNA functional regulation 
is the induction of mRNA degradation. For this reason, an mRNA microarray study 
was conducted to identify mRNAs regulated in response to over-expression or 
inhibition of miR-199-3p. In an attempt to distinguish the direct targets of miR-199-
3p from all the regulated mRNAs, computational target prediction software 
(TargetScan 5.0) was used to identify direct target sites of miR-199-3p within the 
3’UTR of each individual mRNA. In addition to the mRNA expression profile, 
pathway analysis of miR-199-3p regulated genes was also carried out. This showed 
that miR-199-3p modulates multiple pathways required for and/or induced in CMV 
infection, including PI3K-AKT and ERK-MAPK signaling, and prostaglandin 
production.  
These results suggest that miR-199-3p may regulate PI3K-AKT signalling. 
Consequently, the phosphoregulation of AKT, which has been reported to be 
required for the productive infection of HCMV, was examined in response to miR-
199-3p over-expression or inhibition. The suppression of AKT phosphorylation was 
demonstrated at Ser473 and Thr308 in cells transfected with miR-199-3pmimic. This 
would be expected to disrupt the AKT signalling cascade, with a resultant negative 
effect on viral infection. Nine potential targets of miR-199-3p are associated with 
AKT. Four targets were validated using qRT-PCR analysis and selected for further 
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studies, PIK3CB, ITGA6, ITGA3, and CD151. CD44, a validated target of 
miR-199-3p, was also included to examine its regulation in infected cells. 
Chapter 5: The antiviral properties of miR-199-3p may associated with 
suppressed AKT phosphorylation 
The aim in Chapter 5 was to validate the target genes of miR-199-3p and to examine 
which of these are responsible for the observed antiviral function of miR-199-3p. 
Three questions were pursued: 1) Are PIK3CB, ITGA6, ITGA3, and CD151, which 
are associated with AKT, direct targets of miR-199-3p; 2) Is the expression of these 
target genes and the phosphorylation of AKT enhanced when miR-199-3p is down-
regulated during HCMV infection; 3) Do the expression of these targets and AKT 
phosphorylation influence viral growth?  
The work reported in Chapter 5 provides evidence that PIK3CB, ITGA3, and CD151 
are novel direct targets of miR-199-3p. In addition, the site-directed mutagenesis of 
the PIK3CB 3’UTR revealed that miR-199-3p regulates PIK3CB by interacting with 
two sites in its 3′UTR. While ITGA6 expression (mRNA and protein) is regulated in 
cells transfected with miR-199-3p mimic, the luciferase reporter harbouring the 
ITGA6 3’UTR was not affected by miR-199-3p transfection. Therefore, ITGA6 
appears to be regulated by miR-199-3p but not through a target site in its 3’UTR. 
The effect of HCMV infection on endogenous PIK3CB, ITGA6, ITGA3, CD151, 
and CD44 expression was investigated. Only the levels of PIK3CB, ITGA6, and 
ITGA3 increased in HCMV infection, from 24 hours onward, correlating with the 
decrease in miR-199-3p. The phosphorylation of AKT was induced at the initiation 
of infection and disappeared after 4 hours, demonstrating that miR-199-3p inhibition 
at 24, 48, 72 hours of HCMV infection does not increase the level of phosphorylated 
AKT, as it was found to be completely dephosphorylated at these times. These 
observations suggest that the inhibition of miR-199-3p at 24, 48 and 72 hours post 
HCMV infection contributes to the upregulation of its targets, namely PIK3CB, 
ITGA6 and ITGA3. However, it is not clear whether these targets contribute to the 
antiviral properties of miR-199-3p. Therefore, the functional significance of 
PIK3CB, ITGA6, and ITGA3 was evaluated during viral infection based on siRNA 
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knock-down. The results suggested that ITGA6 and ITGA3 do not have negative 
influence the growth of HCMV. In addition, combined approaches demonstrated that 
neither the pharmacologic inhibition of PIK3CB kinase activity nor its knock-down 
had any inhibitory effect on viral growth. Although the above experiments do not 
explain the physiological function of miR-199-3p down-regulation during infection, 
it was still of interest to explain its antiviral properties.  
Overexpression of miR-199-3p mimic prevented the complete phosphorylation of 
AKT during the early stage of HCMV infection (2 hours). The pharmacological 
inhibition of AKT phosphorylation with Ly294002 (PI3-Kinase inhibitor) was also 
found to reduce the growth of HCMV. This suggests that the transfection of 
miR-199-3p into cells affects the phosphorylation of AKT, which may explain at 
least in part its antiviral properties. Because LY294002 is not exclusively selective 
for AKT but all PI3K-related enzymes, more experiments are required. However, the 
direct target(s) of miR-199-3p mediating the phosphorylation step of AKT remain to 
be determined. The functional importance of phosphorylated AKT within the first 
two hours of infection also remains unknown.  
6.3 Conclusion 
The dysregulation of miRNAs in infection and disease necessitates an improved 
understanding of the transcriptional and post-transcriptional mechanisms controlling 
these miRNAs. Previous reports have shown that miRNAs are often transcribed from 
RNA polymerase II promoters, which are also responsible for the transcription of 
cellular mRNAs (Bortolin-Cavaillé et al. 2009; Lee et al. 2004). This allows for a 
similar set of molecular and computational tools to be applied in the study of 
miRNAs promoters. In this thesis, an initial characterisation of the promoter 
sequence of miR-199a/214 was carried out, which also included the identification of 
the transcription start site, the minimal promoter sequence needed for basal 
transcriptional activation, and several putative transcription factor binding sites 
within the promoter. The search for transcription factor binding sites resulted in 
identification of a serum response element (SRE) that contains SRF and ETS sites. It 
will be important to examine whether these transcription factors are recruited to the 
promoter by making use of the point mutations in the core sequences recognized by 
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the transcription factors, ELK-1 and/or SRF, such a mutation can affect the binding 
of these transcription factors and subsequently, the promoter activity. In addition to 
that, the interaction between transcription factors and the promoter sequence should 
be validated.  
The results obtained so far suggest a requirement for ELK-1 and SRF in the basal 
expression of the pri-miR-199a/214 transcript, however, the relative contribution of 
these transcription factors to the suppression of expression upon infection is not 
clear. An important consideration in this context is that both the expression and 
activity (e.g. phosphorylation and dimerisation) of these transcription factors could 
be regulated by the virus. The promoter results presented in this thesis are based on 
studies of the murine promoter, which is highly conserved in sequence (89%) to the 
promoter in human. This indicates that a similar mechanism of transcriptional 
regulation may occur in both mouse and human, however, these results should be 
confirmed in the human cells.    
Continued investigation of the transcriptional mechanism controlling the expression 
of miR-199a/214 may lead to the development of a novel approach to manipulate the 
expression of this cluster in infections or diseases in which the miR-199a/214 levels 
are disregulated. The attenuated, inactivated or non-productive virus is generally 
used to evaluate the requirement of de novo viral proteins (e.g. those not tegument 
proteins) in a cellular process. The UV-radiation of the virus particles is an efficient 
method for damaging viral DNA, meaning that the virus is incapable of gene 
expression and DNA replication. Several studies have used UV-radiation with 
MCMV to create UV-irradiated virus particles (Budt et al. 2009; Bale et al. 1985; 
Wang and Chen 2009; Wiebusch et al. 2008). In the work presented in this thesis, the 
use of MCMVdie3, which has a deletion mutation disrupting the product of the IE3 
gene, was a preferred approach rather than using UV-radiation of MCMV. The use of 
MCMVdie3 overcomes certain technical difficulties regarding the use of UV-
irradiated MCMV, such as the variation between UV-irradiated batches. MCMVdie3 
is able to expresses IE1 and IE2 at attenuated levels and is unable to produce IE3 and 
those genes downstream of it. An advantage of using MCMVdie3 as a tool is that the 
IE3 protein can be restored when grown in NIH-3T3-Bam25 cells.   
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The experimental results from infection with the mutant virus suggest that the down-
regulation of the primary transcript of miR-199a/214 at 4 hours is dependent on viral 
de novo expression, of most likely IE3 and/or early viral proteins, which are 
expressed during these hours. Therefore, IE1, IE2, tegument proteins, and the 
cellular proteins regulated during viral entry are not sufficient to down-regulate the 
pri-miR-199a/214 transcript since these proteins present in both MCMVdie3 and 
MCMV infections. The decrease in miR-199-3p at 24 hours may influence various 
aspects of the viral life cycle, such as the expression of late viral genes, viral 
assembly, egress from infected cells, and/or cell-cell spread or disregulated cellular 
processes required for virus and/or host cell survival, cell cycle, and/or metabolism. 
Since the transcriptional regulation of miR-199a/214 cluster occurs in both MCMV 
and HCMV infections, and that there is high degree of conservation between MCMV 
IE3 and HCMV IE2, it seems likely that the regulation also requires IE2 in HCMV. 
One of the most challenging aims in the miRNA field is to understand how an 
miRNA exerts its functional properties in a particular cell, given the large number of 
potential targets. Therefore, understanding the biological role of miR-199-3p in 
HCMV infection requires the identification of all its host cell or viral gene targets. 
Given that miR-199-3p is inhibited at 24, 48, and 72 hpi, it is expected that the miR-
199-3p targets that contribute to its function would be upregulated at these times. 
In the context of this thesis, there are three limitations that need to be acknowledged 
and addressed: first, it is assumed that that the functional consequences of miR-199-
3p relate to the targeting of host genes, rather than direct interactions with viral 
transcripts. Therefore, the viral targets of miR-199-3p were excluded based on the 
observation that the antiviral functions of miR-199-3p extended to evolutionary 
unrelated viruses such as herpesviruses and SFV. Indeed, the direct regulation by 
miR-199-3p of the HBV and HCV genes, which belong to unrelated groups of DNA 
and RNA viruses, suggest that miRNA-virus interaction could occur. It is not 
impossible that both host and viral targets of miR-199-3p influence HCMV and 
MCMV infections. More importantly, the role of miR-199-3p in HBV and HCV 
infections supports the argument that miR-199-3p is broad antiviral miRNA acting 
against several DNA and RNA enveloped viruses. Second, it is assumed all effects 
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will be detected at transcriptional level, therefore, microarray was used to produce a 
large and unbiased dataset that identified differences between transfected and control 
cells, the observations are also made at the transcriptional level, which can be 
misleading as it does not necessarily reflect protein level. This method therefore, 
fails to identify target genes that are regulated primarily at the translational level or 
to distinguish between genes that are direct and genes that are regulated indirectly. A 
high-throughput technique (AGO2-CRAC) is now available to the group, which is 
based on the precipitation of miRNA and its target mRNA within the RISC 
complexes, the effectors of which are Argonaute (Ago) proteins (Libri et al. 2012). 
This approach would improve the overall scope of this study by determining the 
direct targets through indication of the interaction sites between the miRNA and its 
target mRNA, even for those targets with unpredicted and non-canonical binding 
sites. It is likely that this would make the interpretation of the antiviral function of 
miR-199-3p less challenging, although still relatively complex as an miRNA can 
target hundreds of genes, with each gene being implicated in distinct cellular 
functions and subsequently having a range of effects upon viral infection. This 
suggests that the list of miR-199-3p target genes may include antiviral, proviral, and 
neutral targets, however, the net influence on the infection is antiviral. Importantly, 
the elucidation of an miRNA function appears to be more complicated than limiting 
it to one or two targets, which seems to be the case in the majority of published 
studies.  
A third assumption was that miR-199-3p targets multiple components of a pathway 
to effectively modulate its signalling cascade to interfere with the viral life cycle. 
The results of pathway analysis suggest that miR-199-3p modulates several 
pathways, ERK-MAPK, PI3K-AKT signalling and prostaglandin synthesis, which 
are all associated with viral gene expression, DNA replication, and spread of HCMV 
infection. Given that an miRNA can regulate numerous targets (several hundred 
targets) simultaneously, miR-199-3p might regulate several genes within a particular 
signalling pathway leading to pronounced modulation in its signalling cascades. This 
miRNA could also subtlety influence several biological pathways simultaneously. 
This thesis investigated the phosphoregulation of two signalling proteins, ERK and 
AKT in response to miR-199-3p over-expression and found a suppression of AKT 
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phosphorylation but not ERK by miR-199-3p. The hypothesis was therefore, that 
miR-199-3p reduces the phosphoregulation of AKT and the subsequent activation of 
its cascade, and this inhibits HCMV infection. 
A major concern in functional studies of miR-199-3p is that inhibition of its 
endogenous level does not result in a significant increase in the level of expression of 
targets or a high level of phosphorylated AKT. The qRT-PCR data showed 
successful inhibition of the endogenous level of miR-199-3p in MRC-5 and HEF 
cells (2.5-fold and 3.5-fold). It is important to note that the observed modest level of 
miRNA inhibition as shown by qRT-PCR could be due to the technical caveat. 
miRNA inhibitors are designed to act through irreversible interactions with their 
target miRNA forming antimiR:miR heteroduplexes without causing miRNA 
degradation. This creates a problem when levels of miRNA are quantified by qRT-
PCR. During the initial denaturation step of reverse transcription antimiR:miR 
duplexs dissociate and now single stranded miRNAs can be polyadenylated and 
quantified by PCR which will result in an underestimated level of inhibition. Taken 
together, due to the possible technical caveat, these results should be taken with 
caution. Indeed, the degree of miR-199-3p inhibition in cells transfected with the 
inhibitor is comparable to its level in cells infected with HCMV. Therefore, more 
evidence is required to demonstrate that the decrease in miR-199-3p during HCMV 
infection significantly contribute to the upregulation of its targets.  
HCMV infection leads to rapid increase in AKT phosphorylation at both Ser473 and 
Thr308 residues within 30 min to 2 hours, followed by dephosphorylation at the 
same residues between 4 and 72 hours. This increased phosphorylation during the 
initial 2 hpi does not correlate with the down-regulation of miR-199-3p, which 
occurs between 24 and 72 hpi. Although the ideal scenario is to observe an increase 
in AKT phosphorylation when miR-199-3p is downregulated, it is essential to keep 
in mind that AKT is a central protein to several cellular processes and therefore, 
expected to be regulated through a highly complex network of genes. It is important 
to note that these experiments were conducted using high MOI (5 PFU per cell), 
which typically result in a single round of viral replication. It might be at low MOIs 
(0.01 to 1 PFU per cell), which result in multiple rounds of viral infection and re-
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infection, phosphorylated AKT is present at the initiation of each round of infection 
and here the viral down-regulation of miR-199-3p would assist the re-infection step 
through enhancing the level of phosphorylated AKT in infected cells. 
 
Despite the expression of PIK3CB, ITGA6 and ITGA3 correlating with miR-199-3p 
expression during infection, no antiviral effect was shown in the knock down studies. 
The HCMV-GFP virus was used in these studies to measure the growth of the virus 
following the transfection with siRNA or TGX-221. Although GFP expression is 
correlated with viral growth, there is a possibility that the treatment affected the GFP 
signal and not viral growth. Therefore, plaque assay based growth curves should be 
conducted to confirm the results. 
It is especially noteworthy that, despite being derived from the same primary 
transcript, miR-199-3p and miR-214 are reported to exert opposite effects on AKT 
regulation. It has been reported that miR-214 up-regulates phosphorylated AKT 
through targeting of phosphatase and tensin homolog (PTEN), which acts as the main 
negative regulator of the PI3-kinase (Yang et al. 2008). miR-199-3p down-regulates 
the level of phosphorylated AKT by targeting of PIK3CB or unknown targets and 
therefore this cluster could balance levels of AKT phosphorylation within the cells. 
However, it is even more complex as these miRNAs probably function in concert 
with other genes to result in a pronounced effect on AKT phosphoregulation.  
Further investigation of both miR-199-3p and its target PI3K-AKT signalling 
pathway is required to improve our understanding of the underlying mechanism by 
which miR-199-3p regulates this signalling pathway. It is not a surprise that the 
broad antiviral properties of miR-199-3p are consistent with the important role of 
PI3K-AKT cascades in a wide range of viral infections. Therefore, the role of miR-
199-3p in regulating AKT could likely be extended to other virus-host interactions. 
Finally, the role of miR-199-3p in regulating this central pathway may form the basis 
for future treatments for several viral infections and cancers.  
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6.4 Significance of the thesis  
It is evident that cellular miRNAs are an important part of viral–host interactions, 
and viruses have evolved mechanisms to regulate miRNA expression and 
subsequently their activities to control cellular processes and/or the viral life cycle. 
To date, rather little is known about the mechanisms by which miRNAs are regulated 
during viral infection. Here it was shown that all mature members of miR-199a/214 
cluster, miR-199-3p, miR-199-5p and miR-214 are down-regulated with a similar 
kinetics in both MCMV and HCMV infections. This down-regulation occurs at the 
transcriptional level and requires viral gene products. This thesis also provides 
insight into the role of miR-199-3p during infection. The central model that was 
examined is whether miR-199-3p down-regulates host signalling pathways required 
for HCMV life cycle, which would explain its antiviral activity.  By employing a 
strategy that integrates molecular, biochemical and bioinformatic approaches, it was 
identified that miR-199-3p regulates the PI3K-AKT signalling pathway by reducing 
AKT phosphorylation. Several targets of miR-199-3p including PIK3CB, ITGA6, 
ITGA3 and CD151 were validated which are known to be associated with AKT 
phosphorylation. Consistent with these results, published targets of miR-199-3p 
include CD44, MET and mTOR, all of which are known to activate AKT signalling 
cascades. It is important to examine whether these targets are regulated by miR-199-
3p to modulate AKT phosphorylation and its subsequent functions. AKT is a central 
protein involved in several cancers and viral infections and this work may further the 
understanding of why miR-199-3p has anti-oncogenic functions and broad antiviral 
properties. 
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6.5 Future considerations 
The findings from this study suggest a number of potentially important avenues for 
future investigation, specifically with regards to obtaining a better understanding of 
the mechanisms involved in the regulation of miR-199-3p and the targets that 
mediate antiviral properties. 
1. Is miR-199-3p implicated the innate immune response against viral 
infection? 
2. At which stage does miR-199-3p interfere with the viral life cycle? 
3. What is the mechanism for the transcriptional down-modulation of miR-
199a and miR-214 during CMV infection?  
 Is IE3 directly involved in the regulation of miR-199a/214 
transcription?  
 Is TWIST-1 activity involved in the early regulation of miR-199a/214 
transcription, and if so, is it by a viral mechanism?  
 Are SRF and ELK-1 involved in the transcriptional regulation of 
miR-199a/214 during infection? 
 What is the DNA methylation status of the miR-199a/214 promoter 
upon infection? 
 Can miR-199a and miR-214 be transcriptionally regulated 
independently of one another?  
4. Which targets of miR-199-3p mediate its effect on AKT 
phosphorylation?  
5. Does miR-199-3p target viral transcripts in addition to the cellular 
targets?  
6. Are these target transcripts responsible for miR-199-3p antiviral 
properties?
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7 Appendices  
 Appendix 1 
 Genomatix ID Start End Length CAGE Analysis 
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Transcription start site TSR_605435 164149138 164149169 32 bp 2 CAGE 
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Appendix 1: Multiple putative promoters in the mouse DNM3os gene were extracted from Genomatix promoter database 
using Gene2promoter program. This prediction is based on an optimised length of genomic sequences spanning 500 
nucleotides (nt) upstream and 100 nt downstream of the candidate start sites of each transcript.  Each promoter region was given 
an ID starting with ‘GXP’. In addition to its  genomic location, length, and the transcripts that potentially can be expressed from 
each promoter. Similarly, some of the information about the transcript is l isted like the accession ID, the genomic location,  and 
length. The transcriptional start regions (TSR), which are supported by experimental evidence from the sequencing of full - length 
cDNA clones and 5’ CAGE tags count is the most crucial parameter of promoter predictions. However, if the distance between the 
TSSs are within or less than 40 nt, these TSSs were grouped together and considered as a unique TSR.    
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Appendix 2: Two promoters in the human DNM3os gene was predicted using Gene2promoter (Genomatix). 
 Genomatix ID Start End Length CAGE Analysis 
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 Appendix 3 
   
 
 
  Mouse      ACAAGAAAACAAAGTATCGCAGGAAAGTTAAAAAAAAAAAAAAAGGCCTCGAAGTTTGC-   
              |              ||                     |||||||  || || |  ||    
Human      GC--------------TC---------------------AAAAAGGTTTCCAAATGAGCT   
Mouse      CTGCTTAACAGTGTTTGACTTTCTGCTTACTGCTTTGTCATCTTTCTATCTTTAAATTAC   
           |||| |  |||||||  |||||||| |||||  ||  ||  |  |||||||| |||||||   
Human      CTGCCTTCCAGTGTTCAACTTTCTGTTTACTATTTCATCTACCCTCTATCTTCAAATTAC   
 
Mouse      TTCTTCAGCCCAGATCAGGCAACAAATTTGTACTTCTACTCTCAACTCACTTTCGGTTGG   
           ||||  ||||  | |||| ||  |||||||||||||||| || ||||||||||| |||||   
Human      TTCTCTAGCCTGGGTCAGACAGTAAATTTGTACTTCTACACT-AACTCACTTTCAGTTGG   
 
Mouse      CCACAGCAGAACTGTACATCTTGCCTTTTTTTTTTTTTTTTACAGCTTTTCCATACTGGG   
           ||||||| ||||||||||||||| || ||||||||||    |||||||||||||||||||   
Human      CCACAGCCGAACTGTACATCTTGACTCTTTTTTTTTT----ACAGCTTTTCCATACTGGG   
 
Mouse      GCCCCACTTCCTGCCCAGTTGAGGGAAAAAATCTGGCCTGAAGATGAAATGACTGCTTAA   
           |||| ||||||||||||||||||| |||||||||||||||||||||||||||||||||||   
Human      GCCC-ACTTCCTGCCCAGTTGAGGAAAAAAATCTGGCCTGAAGATGAAATGACTGCTTAA   
 
Mouse      CATTACACGAAAACATCTGGTACCATTTTATGCACAGACCCATGTCTGAGAGCAGGCGAT   
           | |||||| |||||||||||||||||||||||||||||||||||||||||||||||||||   
Human      CGTTACACTAAAACATCTGGTACCATTTTATGCACAGACCCATGTCTGAGAGCAGGCGAT   
 
Mouse      TCTAGCGGTCTCTCCAGCGGCACAGCGCATACCCAAACCTCCCCAGGGTGACATCATCCC   
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||   
Human      TCTAGCGGTCTCTCCAGCGGCACAGCGCATACCCAAACCTCCCCAGGGTGACATCATCCC   
 
Mouse      ATATATGGACTCTCCAGCCCAGCCCTCCCCCTTTTCCTGGTCCTAAATTCATTGCCAGTT   
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||   
Human      ATATATGGACTCTCCAGCCCAGCCCTCCCCCTTTTCCTGGTCCTAAATTCATTGCCAGTT   
 
Mouse      CCCTAGTCTGCTGCAAATGTGCCACGTCAAGACTGGAAATCACAGCCCTTTAGTGTGTCT   
           ||| ||||||| |||||||||||||||||||||||||||||||||||||| |||||||||   
Human      CCCCAGTCTGCAGCAAATGTGCCACGTCAAGACTGGAAATCACAGCCCTTGAGTGTGTCT   
 
Mouse      CAGTCGATGCAGCAGACAGGGTTCAGGGGGGAA-GCTGAACA-AGCCCCTGGTGCAGGAA   
           |||||   ||||||||     |||||||||||| ||||||   | |||||||||||       
Human      CAGTCAGCGCAGCAGA----ATTCAGGGGGGAAAGCTGAATGCAACCCCTGGTGCA----   
 
Mouse      GACAGGCTCTCCCCAGCCCCGGGACAGGATTTTCCACACACCGATGGAA   
 
  Human      -------------------------------------------------   
 
 
Appendix 3: sequence alignment of miR-199a/214 promoter showing 89.7% 
conservation among the mouse and human. 
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V$BARB V$BARBIE.01 0.88 2 16 + 0.886 1 aaagAAAGgggggag 
V$ZF02 V$ZNF219.01 0.91 2 24 - 0.925 1 agttggggctCCCCcctttcttt 
V$ZF02 V$ZBP89.01 0.93 5 27 - 0.942 1 ataagttggggctCCCCcctttc 
V$PLAG V$PLAG1.02 0.97 7 29 + 1 1 aaGGGGggagccccaacttatct 
V$NFKB V$NFKAPPAB50.01 0.83 9 23 + 0.944 1 gggGGGAgccccaac 
V$MZF1 V$MZF1.01 0.99 9 19 + 0.996 1 ggGGGGagccc 
V$RXRF V$PXR_RXR.01 0.8 15 39 - 0.902 1 tagtgaGGTCagataagttggggct 
V$RORA V$REV-ERBA.01 0.88 20 42 - 0.891 1 ccttagtgagGTCAgataagttg 
V$GATA V$GATA1.03 0.95 20 32 - 0.992 1 gtcaGATAagttg 
V$FKHD V$ILF1.01 0.98 50 66 + 0.989 1 tacaagaaAACAaagta 
V$LEFF V$LEF1.01 0.86 53 69 + 0.877 1 aagaaaaCAAAgtatcg 
V$SORY V$SOX4.01 0.91 54 78 + 0.952 1 agaaaACAAagtatcgcaggaaagt 
V$HEAT V$HSF1.01 0.84 60 84 + 0.879 0.952 caaagtatcgcaGGAAagttaaaaa 
V$ARID V$JARID2.01 0.89 62 82 - 0.893 0.9 tttaacTTTCctgcgatactt 
V$BTBF V$KAISO.01 0.92 66 76 - 0.996 1 tttcCTGCgat 
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V$NFAT V$NFAT5.02 0.87 69 87 + 0.872 1 gcaGGAAagttaaaaaaaa 
V$MYT1 V$MYT1L.01 0.92 72 84 + 0.967 1 ggaaAGTTaaaaa 
V$MYT1 V$MYT1.02 0.88 99 111 + 0.885 1 tcgAAGTttgcct 
V$SORY V$SOX2.01 0.92 128 152 - 0.924 1 agatgACAAagcagtaagcagaaag 
V$AP1R V$TCF11MAFG.01 0.81 135 155 - 0.924 1 gaaagaTGACaaagcagtaag 
V$EVI1 V$EVI1.07 0.9 142 158 - 0.962 1 atagaAAGAtgacaaag 
V$MEF2 V$SL1.01 0.84 148 170 + 0.898 1 catctttCTATctttaaattact 
V$GATA V$GATA2.02 0.9 151 163 - 0.918 1 taaaGATAgaaag 
V$HOXF V$HOXC6.01 0.85 155 173 - 0.863 1 agaagtAATTtaaagatag 
V$LHXF V$LHX3.02 0.82 159 181 - 0.856 1 tgggctgaagaagTAATttaaag 
V$PCBE V$PREB.01 0.86 179 193 + 0.911 1 ccagaTCAGgcaaca 
V$CART V$ISX.01 0.85 183 203 - 0.882 1 agtacaAATTtgttgcctgat 
V$CART V$ISX.01 0.85 188 208 + 0.875 1 gcaacaAATTtgtacttctac 
V$RUSH V$SMARCA3.02 0.98 197 207 + 0.994 1 ttgtACTTcta 
V$IRFF V$ISGF3G.01 0.82 213 233 - 0.877 1 gtggccaaccGAAAgtgagtt 
V$PLZF V$PLZF.01 0.86 234 248 - 0.927 1 atgTACAgttctgct 
V$FKHD V$HNF3B.03 0.87 261 277 - 0.896 1 aagctgTAAAaaaaaaa 
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V$NFAT V$NFAT5.02 0.87 266 284 - 0.872 1 tatGGAAaagctgtaaaaa 
V$OCT1 V$OCT1.04 0.8 272 286 - 0.852 1 agTATGgaaaagctg 
V$SrfF V$Srf.04 0.86 275 293 - 0.866 1 gggccccagTATGgaaaag 
V$SrfF V$Srf.02 0.84 276 294 + 0.852 1 ttttcCATActggggcccc 
V$HOMF V$HMX3.01 0.89 288 306 - 0.898 1 tgggcaggAAGTggggccc 
V$ETSF V$ETS1.01 0.92 288 308 - 1 1 actgggcaGGAAgtggggccc 
V$STAT V$STAT.01 0.87 304 322 + 0.905 1 ccagttgagGGAAaaaatc 
V$NFAT V$NFAT5.01 0.83 310 328 + 0.892 1 gagGGAAaaaatctggcct 
V$CIZF V$NMP4.01 0.97 313 323 + 0.99 1 ggAAAAaatct 
V$EVI1 V$MEL1.03 0.95 325 341 + 0.973 1 gcctgaaGATGaaatga 
V$TCFF V$TCF11.01 1 336 342 - 1 1 GTCAttt 
V$HAND V$TAL1BETAE47.01 0.87 355 375 - 0.946 1 atggtacCAGAtgttttcgtg 
V$GREF V$PRE.01 0.84 357 375 - 0.852 1 atggtaccagaTGTTttcg 
V$MYOD V$TCFE2A.02 0.94 358 374 - 0.981 1 tggtaccaGATGttttc 
V$RP58 V$RP58.01 0.84 359 371 + 0.962 1 aaaaCATCtggta 
O$VTBP O$VTATA.02 0.89 368 384 - 0.904 1 gtgcaTAAAatggtacc 
V$RUSH V$SMARCA3.01 0.96 370 380 + 0.961 1 taCCATtttat 
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V$ABDB V$HOXA9.02 0.85 371 387 - 0.853 1 tctgtgcaTAAAatggt 
V$STEM V$OCT3_4.02 0.88 371 389 - 0.928 1 ggtctgtGCATaaaatggt 
V$PARF V$DBP.01 0.84 372 388 + 0.864 1 ccattTTATgcacagac 
V$OCT1 V$POU3F3.01 0.81 373 387 - 0.907 1 tctgtGCATaaaatg 
V$RBP2 V$PLU1_JARID1B.01 0.96 381 389 + 0.972 1 GCACagacc 
V$RBP2 V$PLU1_JARID1B.01 0.96 429 437 + 1 1 GCACagcgc 
V$ZF02 V$ZNF300.01 0.99 437 459 + 0.994 1 catacccaaacctCCCCagggtg 
V$RREB V$RREB1.01 0.8 440 454 + 0.928 1 aCCCAaacctcccca 
V$GLIF V$ZIC2.01 0.89 443 457 + 0.933 1 caaacctCCCCaggg 
V$NOLF V$EBF1.01 0.88 443 465 + 0.977 1 caaaccTCCCcagggtgacatca 
V$ZF05 V$ZFP410.01 0.84 460 474 - 0.941 1 tatatgGGATgatgt 
V$YY1F V$YY1.02 0.94 463 483 + 0.945 1 tcatcCCATatatggactctc 
V$SrfF V$Srf.04 0.86 463 481 - 0.993 1 gagtccataTATGggatga 
V$SrfF V$Srf.04 0.86 464 482 + 0.99 1 catcccataTATGgactct 
V$RUSH V$SMARCA3.01 0.96 466 476 + 0.985 1 tcCCATatatg 
V$PLAG V$PLAG1.02 0.97 480 502 - 1 1 aaGGGGgagggctgggctggaga 
V$ZF02 V$ZBP89.01 0.93 483 505 + 0.974 1 ccagcccagccctCCCCcttttc 
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V$ZF02 V$ZNF219.01 0.91 486 508 + 0.921 1 gcccagccctCCCCcttttcctg 
V$EGRF V$CKROX.01 0.88 488 504 - 0.96 1 aaaaggGGGAgggctgg 
V$ZF07 V$ZNF263.01 0.92 489 503 + 0.944 1 cagccCTCCcccttt 
V$KLFS V$GKLF.01 0.86 492 508 - 0.867 1 caggaaaagggggAGGG 
V$BARB V$BARBIE.01 0.88 493 507 - 0.925 1 aggaAAAGggggagg 
V$STAT V$Stat3.02 0.94 499 517 + 0.962 1 ccttTTCCtggtcctaaat 
V$SORY V$HMGA.01 0.88 505 529 - 0.886 1 aactggcaatgAATTtaggaccagg 
V$ABDB V$HOXB9.01 0.88 505 521 + 0.946 1 cctggtccTAAAttcat 
V$NF1F V$NF1.04 0.87 537 557 + 0.883 1 ctgctgcaaatgtGCCAcgtc 
V$CREB V$ATF6.02 0.85 544 564 - 0.992 1 cagtcttGACGtggcacattt 
V$E4FF V$E4F.01 0.82 547 559 - 0.904 1 ttgACGTggcaca 
V$HIFF V$HRE.01 0.91 547 563 - 0.917 1 agtcttgaCGTGgcaca 
V$CREB V$CREB.02 0.89 547 567 - 0.919 1 ttccagtctTGACgtggcaca 
V$SMAD V$SMAD4.01 0.94 555 565 - 0.941 1 ccaGTCTtgac 
V$GFI1 V$GFI1.01 0.96 564 578 + 0.99 1 ggaAATCacagccct 
O$INRE O$DINR.01 0.94 587 597 + 0.975 1 tcTCAGtcgat 
V$KLFS V$EKLF.01 0.89 598 614 + 0.941 1 gcagcagacaGGGTtca 
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V$ZF02 V$ZBTB7.01 0.9 608 630 - 0.935 1 tgttcagcttcCCCCctgaaccc 
V$ETSF V$SPI1.02 0.96 611 631 + 0.961 1 ttcaggggGGAAgctgaacaa 
V$PLAG V$PLAG1.02 0.97 613 635 + 1 1 caGGGGggaagctgaacaagccc 
V$MZF1 V$MZF1.01 0.99 615 625 + 0.996 1 ggGGGGaagct 
V$ETSF V$ETV1.02 0.96 636 656 + 0.989 1 ctggtgcaGGAAgacaggctc 
V$ZF02 V$ZNF300.01 0.99 645 667 + 0.994 1 gaagacaggctctCCCCagcccc 
V$CP2F V$CP2.01 0.9 647 665 - 0.92 1 ggCTGGggagagcctgtct 
V$KLFS V$KKLF.01 0.91 650 666 - 0.932 1 gggctGGGGagagcctg 
V$SP1F V$SP1.01 0.88 655 671 - 0.896 1 tcccgGGGCtggggaga 
V$NFAT V$NFAT5.02 0.87 667 685 - 0.932 1 tgtGGAAaatcctgtcccg 
V$NFAT V$NFAT.01 0.95 669 687 - 0.96 1 tgtgtGGAAaatcctgtcc 
V$NFKB V$NFKAPPAB65.01 0.87 671 685 + 0.969 1 acaggattTTCCaca 
 
Appendix 4: MatInspector prediction of binding sites in the mouse pri-miR-199a/214 promoter. The factors are listed with the sequence of their 
DNA site (consensus sequence are highlighted in uppercase). The score cut-off was set to ≥0.85 and ≥0.9 for matrix and core similarities, respectively. 
Also, we have just selected the conserved sites between mouse and human. The ‘V$’ prefixes to each family or matrix indicates its name based on the 
vertebrate library. Yellow rows highlight the transcription factors confer the highest transcriptional activity to the miR-199a/214 promoter (-421 to -272). 
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 Appendix 5 
        40        50         60        70        80        90         
Mouse   AAAAAGGCCTCGAAGTTTGC-CTGCTTAACAGTGTTTGACTTTCTGCTTACTGCTTTGTC 
        |||||||::||:||:|::|| ||||:|::|||||||::||||||||:|||||::||::|| 
Human   AAAAAGGTTTCCAAATGAGCTCTGCCTTCCAGTGTTCAACTTTCTGTTTACTATTTCATC 
        10        20        30        40        50        60     
 
 
        100       110       120       130       140       150         
Mouse   ATCTTTCTATCTTTAAATTACTTCTTCAGCCCAGATCAGGCAACAAATTTGTACTTCTAC 
        ::|::||||||||:|||||||||||::||||::|:||||:||::|||||||||||||||| 
Human   TACCCTCTATCTTCAAATTACTTCTCTAGCCTGGGTCAGACAGTAAATTTGTACTTCTAC 
             70        80        90       100       110       120     
 
         
        160       170       180       190       200       210         
Mouse   TCTCAACTCACTTTCGGTTGGCCACAGCAGAACTGTACATCTTGCCTTTTTTTTTTTTTT 
        :|| |||||||||||:||||||||||||:|||||||||||||||:||:||||||||||   
Human   ACT-AACTCACTTTCAGTTGGCCACAGCCGAACTGTACATCTTGACTCTTTTTTTTTT-- 
             130       140       150       160       170       180  
 
 




        220       230       240       250       260       270         
Mouse   TTACAGCTTTTCCATACTGGGGCCCCACTTCCTGCCCAGTTGAGGGAAAAAATCTGGCCT 
          ||||||||||||||||||||||| |||||||||||||||||||:|||||||||||||| 
Human   --ACAGCTTTTCCATACTGGGGCCC-ACTTCCTGCCCAGTTGAGGAAAAAAATCTGGCCT 
                 190       200        210       220       230   
 
       
 
         
         
 
       
        280   290       300       310       320       330         
Mouse   GAAGATGAAATGACTGCTTAACATTACACGAAAACATCTGGTACCATTTTATGCACAGAC 
        ||||||||||||||||||||||:||||||:|||||||||||||||||||||||||||||| 
Human   GAAGATGAAATGACTGCTTAACGTTACACTAAAACATCTGGTACCATTTTATGCACAGAC 
        240       250       260       270       280       290         
 
        
         
        
 340       350       360       370       380       390         
Mouse   CCATGTCTGAGAGCAGGCGATTCTAGCGGTCTCTCCAGCGGCACAGCGCATACCCAAACC 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Human   CCATGTCTGAGAGCAGGCGATTCTAGCGGTCTCTCCAGCGGCACAGCGCATACCCAAACC 










HMOF NFAT SRF 
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        400       410       420       430       440       450         
Mouse   TCCCCAGGGTGACATCATCCCATATATGGACTCTCCAGCCCAGCCCTCCCCCTTTTCCTG 
        |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Human   TCCCCAGGGTGACATCATCCCATATATGGACTCTCCAGCCCAGCCCTCCCCCTTTTCCTG 




      
       
        460       470       480       490       500       510         
Mouse   GTCCTAAATTCATTGCCAGTTCCCTAGTCTGCTGCAAATGTGCCACGTCAAGACTGGAAA 
        ||||||||||||||||||||||||:|||||||:||||||||||||||||||||||||||| 
Human   GTCCTAAATTCATTGCCAGTTCCCCAGTCTGCAGCAAATGTGCCACGTCAAGACTGGAAA 




         
        520       530       540       550       560       570         
Mouse   TCACAGCCCTTTAGTGTGTCTCAGTCGATGCAGCAGACAGGGTTCAGGGGGG-AAGCTGA 
        |||||||||||:||||||||||||||:::||||||||    :|||||||||| ||||||| 
Human   TCACAGCCCTTGAGTGTGTCTCAGTCAGCGCAGCAGA----ATTCAGGGGGGAAAGCTGA 
        480       490       500       510           520       530    
 
 
         580        590                                               
Mouse    ACA-AGCCCCTGGTG 
         |:: |:||||||||| 
Human    ATGCAACCCCTGGTG 
            540                                                       
 
Appendix 5: Evolutionary conserved binding sites in the genomic sequence of mouse 
and human pri-miR-199a/214 promoters. MatInspector (Genomatix) were used to find the 
conserved putative binding elements in the promoter sequences and aligned with human 
promoter. The putative sites are marked with arrows above the DNA sequence. Also, these 
arrows point out the orientation and extension of the binding site. The used threshold for this 
prediction is 0.9 and 0.85 for core and matrix similarities. Potential TATA Box is marked with 





















KLFS INRE GFI1 
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 Appendix 6 
Gene Symbol Ref Seq Fold-Change FDR adjusted P value  
1700029F09RIK BC119032 -1.47796 1.3447E-07 
2810407C02RIK NM_001040396 -1.76231 1.47747E-08 
AHCY NM_016661 -1.55303 5.06164E-08 
AK4 NM_001177602 -1.68752 3.43908E-06 
AKR1B3 NM_009658 -1.77502 1.72508E-06 
ALDH3A1 NM_007436 -1.54204 8.46094E-06 
ALG14 NM_024178 -1.74012 6.07156E-06 
ALG3 NM_145939 -1.44439 6.11195E-05 
ANGPTL4 NM_020581 -2.04532 3.14155E-06 
ANK NM_020332 -1.74956 8.85795E-09 
ANKRD1 NM_013468 -1.53286 1.81714E-08 
ANKRD13C NM_001013806 -1.95331 3.60477E-07 
ARRDC3 NM_001042591 -1.47001 0.000130958 
BNC1 NM_007562 -1.49495 6.83697E-05 
BNIP3 NM_009760 -1.75893 2.99076E-06 
CAPG NM_007599 -1.42639 2.46402E-05 
CASP3 NM_009810 -1.40022 1.93699E-06 
CCL2 NM_011333 -2.17358 2.66214E-08 
CCL7 NM_013654 -2.2755 8.63116E-07 
CCND1 NM_007631 -1.61118 0.000455877 
CCNT1 NM_009833 -1.50185 0.000302526 
CCNYL1 NM_001097644 -1.78677 1.49543E-06 
CD151 NM_009842 -4.93796 1.5166E-12 
CD2AP NM_009847 -1.41062 0.000172628 
CD44 NM_009851 -1.73196 1.10317E-06 
CD55 NM_010016 -1.89187 0.00021562 
CDR2 NM_007672 -1.44745 1.40685E-06 
CEP55 NM_001164362 -1.52857 5.31744E-05 
CHI3L1 NM_007695 -1.4358 0.00107833 
CNIH4 NM_030131 -1.45704 0.000682372 
CNOT7 NM_011135 -1.40966 0.000332731 
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Gene Symbol Ref Seq Fold-Change FDR adjusted P value  
COBLL1 NM_177025 -1.41866 0.00108778 
COQ10B NM_001039710 -1.41411 0.00020181 
CP NM_001042611 -1.49695 8.86904E-05 
CPT1A NM_013495 -1.4613 2.32189E-06 
CTGF NM_010217 -1.51907 0.00037741 
CTHRC1 NM_026778 -1.4659 7.21627E-06 
CXCL5 NM_009141 -1.9934 2.24749E-06 
CYB5B NM_025558 -1.74762 2.3446E-08 
CYCS NM_007808 -1.43036 1.23779E-05 
CYR61 NM_010516 -1.56317 0.000108099 
D030056L22RIK BC020125 -1.67767 2.09558E-07 
D10WSU102E NM_026579 -1.42705 0.000507577 
D17H6S56E-5 L78788 -1.49655 2.39057E-07 
DDAH1 NM_026993 -2.0222 3.03164E-07 
DHFR NM_010049 -1.44426 0.000597181 
DKK3 NM_015814 -1.4254 1.10523E-06 
DOK1 NM_010070 -1.45078 1.25039E-06 
DUSP1 NM_013642 -1.42706 3.5206E-07 
DUSP14 NM_019819 -1.41831 0.00000381 
DUSP5 NM_001085390 -1.74983 9.59739E-07 
DUSP6 NM_026268 -1.97079 1.3818E-06 
EEF1E1 NM_025380 -1.41432 0.000730955 
EIF2B2 NM_145445 -1.51639 9.95125E-06 
EIF4E NM_007917 -1.43021 8.60235E-08 
ENPP1 NM_008813 -1.54937 9.57035E-08 
ENPP3 NM_134005 -1.6313 1.15791E-07 
EPHA2 NM_010139 -1.61001 5.30671E-07 
EPS8 NM_007945 -1.41415 9.41879E-08 
ERCC1 NM_007948 -1.51737 5.30065E-05 
EREG NM_007950 -2.14346 9.30926E-06 
ERRFI1 NM_133753 -2.42044 2.03407E-09 
ETV1 NM_007960 -1.64897 1.30665E-05 
F2R NM_010169 -1.46289 1.21663E-05 
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Gene Symbol Ref Seq Fold-Change FDR adjusted P value  
FAM198B NM_133187 -1.40142 0.00343189 
FAM60A NM_019643 -1.49705 2.0233E-06 
FGF7 NM_008008 -1.9612 9.32754E-08 
FHL2 NM_010212 -1.46813 0.00160295 
FIGNL1 NM_001163359 -1.40162 3.56903E-05 
FKTN NM_139309 -1.43223 1.30538E-05 
FOSL1 NM_010235 -2.15032 1.96678E-06 
FTH1 NM_010239 -1.60975 4.83762E-10 
G3BP2 NM_011816 -1.66335 2.92499E-06 
GALNT7 NM_144731 -1.65901 0.000287219 
GBE1 NM_028803 -1.73676 1.31869E-06 
GEMIN6 NM_026053 -1.41288 7.41889E-05 
GJA1 NM_010288 -1.44478 0.000483414 
GM6644 NR_028277 -1.80654 1.15911E-06 
GNPTAB NM_001004164 -1.4336 1.76738E-06 
GPR149 NM_177346 -1.41348 0.000122706 
GREM2 NM_011825 -1.40238 0.000112603 
GRIK2 NM_010349 -1.93807 9.50799E-07 
GSTO1 NM_010362 -1.73911 7.37015E-06 
GSTO2 NM_026619 -1.74605 6.66188E-07 
HAS2 NM_008216 -1.46653 0.00041128 
HAUS5 NM_027999 -1.51584 7.25432E-05 
HBEGF NM_010415 -1.58978 0.00013898 
HGF NM_010427 -1.46838 0.000264262 
HMGA1 NM_016660 -1.64585 2.66952E-05 
HMGA2 NM_010441 -1.64278 1.49216E-05 
HPRT NM_013556 -1.40571 7.97293E-06 
HRSP12 NM_008287 -1.59351 4.79526E-08 
HSPA1A NM_010479 -1.74463 7.06982E-06 
HYOU1 NM_021395 -1.47716 0.00157838 
IL1RL1 NM_001025602 -1.91541 9.03198E-07 
IL4RA NM_001008700 -1.51981 2.56941E-06 
ITGA3 NM_013565 -2.63318 2.0554E-08 
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Gene Symbol Ref Seq Fold-Change FDR adjusted P value  
ITGA6 NM_008397 -1.55628 5.25789E-06 
LBH NM_029999 -1.54208 6.9417E-06 
LCLAT1 NM_001081071 -1.45479 0.000195678 
LMAN2 NM_025828 -1.4407 0.000133464 
LPCAT3 NM_145130 -1.54999 9.6278E-07 
LRP8 NR_033496 -1.47575 0.000183082 
LY6A NM_010738 -1.48547 0.000123839 
MAK16 NM_026453 -1.42345 0.000353268 
MAPRE1 NM_007896 -1.53249 8.96014E-08 
MARCKSL1 NM_010807 -1.57792 4.41005E-05 
MMD NM_026178 -1.61318 7.28023E-07 
MRPL20 NM_025570 -1.4062 3.71448E-05 
MSLN NM_018857 -1.50677 2.12621E-05 
MSN NM_010833 -1.40196 0.00119516 
MT2 NM_008630 -1.42366 0.000991689 
NAA25 NM_172722 -1.68734 0.000376675 
NACC1 NM_025788 -2.02042 1.39208E-05 
NDUFB7 NM_025843 -1.70403 1.4164E-07 
NET1 NM_019671 -1.67756 3.03659E-06 
NHP2 NM_026631 -1.42995 1.01108E-05 
NIPAL1 NM_001081205 -1.50835 3.74801E-07 
NQO1 NM_008706 -2.00114 7.04287E-05 
NR4A1 NM_010444 -2.48262 6.30722E-07 
NRN1 NM_153529 -1.76588 3.87547E-06 
NUTF2 NM_026532 -1.50356 0.00012034 
NXT2 NM_172782 -1.43783 6.23117E-05 
OAF NM_178644 -1.52895 7.73761E-06 
ORC2 NM_008765 -1.42209 2.25477E-07 
OSTM1 NM_172416 -1.49617 5.28874E-06 
OTUD6B NM_152812 -1.98159 3.68495E-06 
PDCL NM_026176 -1.42818 2.17703E-05 
PFKL NM_008826 -1.78819 6.47225E-07 
PGD NM_001081274 -1.41145 1.29755E-06 
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Gene Symbol Ref Seq Fold-Change FDR adjusted P value  
PHLDA1 NM_009344 -1.48313 0.000284529 
PIK3CB NM_029094 -1.64019 6.97561E-05 
PLA2G4A NM_008869 -1.44995 3.11538E-05 
PLA2G7 NM_013737 -1.43543 1.08871E-05 
PLAU NM_008873 -1.45949 1.53577E-05 
PLAUR NM_011113 -1.56884 0.000234949 
PLEKHA3 NM_031256 -1.56756 4.37545E-07 
POLR1B NM_009086 -1.40511 0.000445411 
PON2 NM_183308 -1.85379 7.09827E-08 
PPP1R14B NM_008889 -1.44446 0.00016005 
PPP2R5E NM_012024 -1.47601 4.89489E-05 
PRDX6 NM_007453 -1.69073 5.37588E-07 
PRL2C3 NM_011118 -3.44125 7.63928E-10 
PRL2C5 NM_181852 -7.19066 8.99114E-09 
PSMD10 NM_016883 -1.76691 5.77087E-10 
PTCD3 NM_027275 -1.45642 3.87367E-05 
PTGFR NM_008966 -1.52193 1.39221E-05 
PTGS1 NM_008969 -1.79867 1.29275E-07 
PTGS2 NM_011198 -3.1678 5.65403E-06 
PTPMT1 NM_025576 -1.4751 2.90195E-05 
RAMP3 NM_019511 -1.43461 2.23778E-05 
RANGRF NM_021329 -1.44513 0.00374417 
RGS2 NM_009061 -1.47057 8.91837E-08 
RRAS2 NM_025846 -1.51847 1.28891E-07 
RRM2 NM_009104 -1.50732 7.94797E-05 
SC5D NM_172769 -1.42257 7.29202E-07 
SCAMP1 NM_029153 -1.43732 2.09414E-06 
SDCCAG1 NM_025441 -1.42925 0.000290392 
SDPR NM_138741 -1.49042 0.000343916 
SERPINE1 NM_008871 -1.98196 0.000208534 
SERTAD4 NM_198247 -1.80483 1.84171E-05 
SFRP1 NM_013834 -1.574 0.000681926 
SGK1 NM_001161845 -1.69265 6.98813E-08 
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Gene Symbol Ref Seq Fold-Change FDR adjusted P value  
SLC16A13 NM_172371 -1.55871 7.64107E-06 
SLC25A13 NM_015829 -1.7932 1.14786E-07 
SLC39A10 NM_172653 -1.54462 0.000116719 
SLCO2A1 NM_033314 -1.70031 1.16237E-05 
SOCS6 NM_018821 -1.4052 3.49774E-06 
SPON2 NM_133903 -3.24746 4.2321E-08 
SPP1 NM_009263 -2.89187 1.4871E-09 
SYNGR2 NM_009304 -1.41049 7.79583E-06 
TDG NM_011561 -1.41238 6.85761E-07 
TES NM_207176 -1.87482 1.58087E-06 
TFB2M NM_008249 -1.45678 2.47201E-06 
TFRC NM_011638 -2.40897 1.12668E-05 
THBS1 NM_011580 -2.07816 6.4052E-08 
THY1 NM_009382 -1.70035 9.52816E-05 
TIMM8A1 NM_013898 -1.51935 1.34026E-05 
TIMP1 NM_001044384 -1.53957 0.000105795 
TIPIN NM_025372 -1.4483 1.2446E-06 
TK1 NM_009387 -1.44598 8.20347E-05 
TMEM30A NM_133718 -1.62202 8.7512E-06 
TMSB4X NM_021278 -1.53573 0.000225598 
TNC NM_011607 -2.71629 4.81097E-06 
TNFRSF12A NM_013749 -1.57746 3.39357E-06 
TNFRSF23 NM_024290 -1.61242 2.9723E-06 
TPBG NM_011627 -1.4517 4.48576E-06 
TRIB2 NM_144551 -1.44386 7.24317E-06 
TWF1 NM_008971 -1.40188 2.49236E-06 
UACA NM_028283 -1.58546 1.50851E-08 
UBE2F NM_026454 -1.46197 4.16773E-05 
UCHL5 NM_019562 -1.45458 1.38511E-05 
VAMP3 NM_009498 -2.10972 2.25175E-09 
VDR NM_009504 -1.50419 0.000777416 
WDR3 NM_175552 -1.42053 0.000815868 
WISP2 NM_016873 -1.52514 3.83123E-05 
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Gene Symbol Ref Seq Fold-Change FDR adjusted P value  
YRDC NM_153566 -1.40902 5.53707E-05 
YWHAE NM_009536 -1.48485 1.20663E-09 
 
Appendix 6: According to Affymetrix microarray analysis of genes regulated by miR-
199-3p mimic versus inhibitor.  
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 Appendix 7 
PIK3CB 3′UTR  
 






ATGCCCACCCTGTGTTCCCGAGCGCTTCCAGGACTCATCGTGAGCAGCAGCATGGAGGCCCCTTCCTGCTGACCTTGCAC       
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ATGCCCACCCTGTGTTCCCGAGCGCTTCCAGGACTCATCGTGAGCAGCAGCATGGAGGCCCCTTCCTGCTGACCTTGCAC 
GCGAGGGATGCTACTAGGGACTGCTGGGGATCTTTTCTTTCTTTCCTTCAGTATTTGGTACTTTACCAGAGAGGTGTACA       
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GCGAGGGATGCTACTAGGGACTGCTGGGGATCTTTTCTTTCTTTCCTTCAGTATTTGGTACTTTACCAGAGAGGTGTACA 
TACTTCTTTTCAGTGTTGTGACCAAGTGCTGCGACTCAGCCAACAACTTACCACATTCGGGGCTGGGAGCTGTTCTAAGA     
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TACTTCTTTTCAGTGTTGTGACCAAGTGCTGCGACTCAGCCAACAACTTACCACATTCGGGGCTGGGAGCTGTTCTAAGA 






TATTGGTGGGGCAAATATAATATATATATAATATATATATATATATATGCTGCATATATATTTATAAAATTTCTAGTGGG    
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TATTGGTGGGGCAAATATAATATATATATAATATATATATATATATATGCTGCATATATATTTATAAAATTTCTAGTGGG 
AGTTCTATATAAAAAGATGTTTCTTTGGTATTCTTCAGCCTGTGTTTTCAAGTTTTACAGAAGCAGAGCTTTTCCCTAAG      
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AGTTCTATATAAAAAGATGTTTCTTTGGTATTCTTCAGCCTGTGTTTTCAAGTTTTACAGAAGCAGAGCTTTTCCCTAAG 
TTCCTCTTCGGTTCACTGTAGATCCAGTTCTTCCAGCCGCTTCAGCACTGAGGCGCCATGAATGCGGTTTCTCTGTGTAG       
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TTCCTCTTCGGTTCACTGTAGATCCAGTTCTTCCAGCCGCTTCAGCACTGAGGCGCCATGAATGCGGTTTCTCTGTGTAG 
CTCTGAGAGTTCGTTTCATAGAACACAACACTTGAGCAGATGCATCCAAGGAGGCGAGCAAATGAAAAGGAATCTATTTA       
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CTCTGAGAGTTCGTTTCATAGAACACAACACTTGAGCAGATGCATCCAAGGAGGCGAGCAAATGAAAAGGAATCTATTTA 






CATATAGCCAGGGTGCTAGGTGATGAGTGGTGTTAGCATGTGCAATAGGAACTACTGGTTTGCTGTGTAAATGGATGTCA       
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CATATAGCCAGGGTGCTAGGTGATGAGTGGTGTTAGCATGTGCAATAGGAACTACTGGTTTGCTGTGTAAATGGATGTCA 
GGATCCAGCAAAACTACTGCTTTCTTCTCCAAAGACATGTGGGAGCCTTCAATCCTCAGTGGCATGGGAAACAGCTGAGT   
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GGATCCAGCAAAACTACTGCTTTCTTCTCCAAAGACATGTGGGAGCCTTCAATCCTCAGTGGCATGGGAAACAGCTGAGT 
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ACTTGCCCCGTGACTTCAGTTTTCTATAGGAATTTTATTAAAGAGTGTTTAATTTTGTTGTCCTTCTTAATGTTCTCAGT      
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ACTTGCCCCGTGACTTCAGTTTTCTATAGGAATTTTATTAAAGAGTGTTTAATTTTGTTGTCCTTCTTAATGTTCTCAGT 
CAAATAAATGGGTGGTTTCATCTGTTTGGGG                   
|||||||||||||||||||||||||||||||                   
CAAATAAATGGGTGGTTTCATCTGTTTGGGG 




GAACACTACTGACCACGATGATGTCAGGCCGGGCGGCCAGCCTTGCACTACTGACCACGATGATGCCAGGCTGGGCGGCC       
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GAACACTACTGACCACGATGATGTCAGGCCGGGCGGCCAGCCTTGCACTACTGACCACGATGATGCCAGGCTGGGCGGCC 
AGCCTTGCACTATGTCCCAGCCCCACTACTGAACACTACTGACTTAGACTGCTGACTGCCAGAGGTAGCTACCCTCATGC      
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AGCCTTGCACTATGTCCCAGCCCCACTACTGAACACTACTGACTTAGACTGCTGACTGCCAGAGGTAGCTACCCTCATGC 
CATCGCCATGACCCCCCCTGGCATGCCACCTCAGGGGCATGCACCTTCAAGTGCCTTTCACTGCACACCAAAGTCCCAAA     
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CATCGCCATGACCCCCCCTGGCATGCCACCTCAGGGGCATGCACCTTCAAGTGCCTTTCACTGCACACCAAAGTCCCAAA 
GCTCGAAGCAGCGTACTTGCCCCAGCATTAAGAAGGGGGGGGGGGGTGGGGGGTTCAAATGCCAGTGTTGGGCTAGGCCT      
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GCTCGAAGCAGCGTACTTGCCCCAGCATTAAGAAGGGGGGGGGGGGTGGGGGGTTCAAATGCCAGTGTTGGGCTAGGCCT 
GGCTAGTAGAATAGGGTTTAGATTATTTGACAGAAGTGCCTCTTATGCAGACTGCTTCCCTTTGGGTAGCTGTGATCTGC       
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GGCTAGTAGAATAGGGTTTAGATTATTTGACAGAAGTGCCTCTTATGCAGACTGCTTCCCTTTGGGTAGCTGTGATCTGC 
AGTAAGTCTGGGGAGAACCTGAGTACACCACTACACGTTGGGTAAAAGCAGGTGGGGCCTTTCTGGTTGGATTAGGCACC       
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AGTAAGTCTGGGGAGAACCTGAGTACACCACTACACGTTGGGTAAAAGCAGGTGGGGCCTTTCTGGTTGGATTAGGCACC 






TGTAAATGCTCCATGTTCCTGTACACTGTCTCCTTTTGGAGCATCTCTGAATGGAGCATGGCTGTTTTCATCTCACTGCT      
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TGTAAATGCTCCATGTTCCTGTACACTGTCTCCTTTTGGAGCATCTCTGAATGGAGCATGGCTGTTTTCATCTCACTGCT 
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TCCCCGACAAACCTTCCGGCGCTCCCTTCCTTCCTATTTATCATAAATTATGACTCCGACAGTCCAAAGGGGGCCACGCC     
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TCCCCGACAAACCTTCCGGCGCTCCCTTCCTTCCTATTTATCATAAATTATGACTCCGACAGTCCAAAGGGGGCCACGCC 
CTTGGCTGGCACCAGCAGGCTCAGGCATCTATCCCTCTTCAGTGCAGGCATGTTTTCTGGGGCCCTGGAATCTCCTTCAA    
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CTTGGCTGGCACCAGCAGGCTCAGGCATCTATCCCTCTTCAGTGCAGGCATGTTTTCTGGGGCCCTGGAATCTCCTTCAA 
GACCTTGCAATGCTGAGCCCAGCACAGCCCTTGCACAGTGGACACACACACAGGGCCTACTGCTAATGGCCTGCTCTGAT      
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GACCTTGCAATGCTGAGCCCAGCACAGCCCTTGCACAGTGGACACACACACAGGGCCTACTGCTAATGGCCTGCTCTGAT 
ATATCATGGAGGGTGCCGTATCCAAGTCTCTGTCTGTGCCAAAACCAAGCCAAAGCGCCTCTACTGGGAGACAGGAGGAA     
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ATATCATGGAGGGTGCCGTATCCAAGTCTCTGTCTGTGCCAAAACCAAGCCAAAGCGCCTCTACTGGGAGACAGGAGGAA 
AAGGTCCCTGATGTGGGGACACGGCTCCTCCACACTGAATCCCCCTTGAGCCATTGTCAATGGATGGAGTTTACTGTCCA     
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AAGGTCCCTGATGTGGGGACACGGCTCCTCCACACTGAATCCCCCTTGAGCCATTGTCAATGGATGGAGTTTACTGTCCA 
GAATAAAACTACTGATGCGGAGGAGACAGTCAGGCTCAGCTGCAATTCCTGCCAGGCACTGGAGCGCAGGGCTACACTAA       
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GAATAAAACTACTGATGCGGAGGAGACAGTCAGGCTCAGCTGCAATTCCTGCCAGGCACTGGAGCGCAGGGCTACACTAA 
AGGCTACCCAGGGGATGTTCTTACGACCTGCGTGCTCAGACGCAAGAGCAATGAACTAGAAAGCAGGTCGCCGGAATGGG       
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AGGCTACCCAGGGGATGTTCTTACGACCTGCGTGCTCAGACGCAAGAGCAATGAACTAGAAAGCAGGTCGCCGGAATGGG 
CTTTATGGGTGCATCTCTAAAATCGTGGCTACAGAGAGAGCTGGCAAGAAACGCAGCCCGAAGGAACAAAGAGAGACCGT      
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CTTTATGGGTGCATCTCTAAAATCGTGGCTACAGAGAGAGCTGGCAAGAAACGCAGCCCGAAGGAACAAAGAGAGACCGT 
GGGCAGCCTGGACGCACACACTGTGCTGGGACTGACCTGGAGCATGGCGGCATCCTTCAGAGAGCAGGGTCCTGGCGCAG      
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GGGCAGCCTGGACGCACACACTGTGCTGGGACTGACCTGGAGCATGGCGGCATCCTTCAGAGAGCAGGGTCCTGGCGCAG 






CTGCTCCCTTGACCACAGAGATGAGATTCTGAGCTGCCTGTGGCTTTCTTCCCCTCCCCCAGGGGCTGCATCCCCATTCT      
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CTGCTCCCTTGACCACAGAGATGAGATTCTGAGCTGCCTGTGGCTTTCTTCCCCTCCCCCAGGGGCTGCATCCCCATTCT 
AGCAGTGGAGGCTGATTTCCCAGGTCCTCTCCCCATCCCGGTCCACAGGCAGGCCCACTCCCCAGCTCTGTCCCCTCCAC       
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AGCAGTGGAGGCTGATTTCCCAGGTCCTCTCCCCATCCCGGTCCACAGGCAGGCCCACTCCCCAGCTCTGTCCCCTCCAC 
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ATGAGAAACACATGGATAACCTCGAAAAAAAACAGTGGATCACCAAGTGGAATGAAAACGAAAGTTACTCATAGAGAGGA       
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ATGAGAAACACATGGATAACCTCGAAAAAAAACAGTGGATCACCAAGTGGAATGAAAACGAAAGTTACTCATAGAGAGGA 
GGGCACAGGAAAGAACACCTCACACTACCCAAAGCCCCCCCTTATTTTTTCCAGCTCAGAAATTCAGGTGGCTTCAAAGC      
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GGGCACAGGAAAGAACACCTCACACTACCCAAAGCCCCCCCTTATTTTTTCCAGCTCAGAAATTCAGGTGGCTTCAAAGC 









CCAGGTCACCTGTGCTAACAGAGTGGCTATCCCAGCCTGCTCCCACAAGCATTCTTCTCATAAGATTGACCTTGGCTCAA       
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CCAGGTCACCTGTGCTAACAGAGTGGCTATCCCAGCCTGCTCCCACAAGCATTCTTCTCATAAGATTGACCTTGGCTCAA 
GACTGCCAATGGATAGCTGTGCCTCTGGTGAAAGTTCTGTCTTAAATGTGCAATAGAAGGTGATGTTACCCTTTGGCCTT       
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GACTGCCAATGGATAGCTGTGCCTCTGGTGAAAGTTCTGTCTTAAATGTGCAATAGAAGGTGATGTTACCCTTTGGCCTT 










Appendix 7: Sequence alignment between Sanger sequencing reads of cloned 3′UTRs 
to reference sequences (from NCBI) using BioEdit software.   
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